Neutralizing Antibodies That Bind To The Zika Virus Domain Iii Envelope Region

Abstract

Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of U.S. patent application Ser. No. 16/603,341, filed Oct. 7, 2019, which is a National Phase of International patent application no. PCT/US2018/026676, filed Apr. 9, 2018, which claims priority to U.S. provisional patent application No. 62/483,001, filed Apr. 7, 2017, the disclosures of each of which are incorporated herein by reference.

SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 6, 2018, is named 076091_00046_SL.txt and is 507,614 bytes in size.

BACKGROUND

[0004] Zika virus (ZIKV) infection typically produces mild symptoms consisting of fever, rash and arthralgia that resolve rapidly, and the infection is also occasionally associated with Guillain-Barre Syndrome (Lessler et al., 2016; Miner and Diamond, 2017). However, when infection occurs during pregnancy, vertical transmission can lead to a spectrum of devastating neurodevelopmental aberrations, collectively referred to as Congenital Zika Syndrome. Although the data are still incomplete, infants born to mothers infected with ZIKV during pregnancy carry an up to 42% risk of developing overt clinical or neuroimaging abnormalities (Brasil et al., 2016; Costa et al., 2016; Franca et al., 2016).

[0005] ZIKV belongs to the Flavivirus genus, which includes yellow fever (YFV), West Nile (WNV), and the 4 serotypes of dengue virus (DENV1-4). These positive-stranded RNA viruses are responsible for considerable morbidity and mortality in the equatorial and subequatorial regions populated by their mosquito vectors (Kramer et al., 2007; Murray et al., 2013; Weaver and Reisen, 2010). Unlike most other flaviviruses, ZIKV can also be transmitted sexually, and on occasion persists for months (Barzon et al., 2016; Foy et al., 2011; Murray et al., 2017; Suy et al., 2016).

[0006] All flaviviruses display a single envelope protein, E, that is highly conserved between different members of this virus family. The E protein ectodomain consists of three structural domains. Domain I (EDI) contains the N-terminus, domain II (EDIT) is an extended finger-like structure that includes the dimerization domain and also a pH-sensitive fusion loop that mediates viral fusion in the lysosomes. Finally, domain III (EDIII) is an immunoglobulin-like domain that mediates attachment to target cells (Barba-Spaeth et al., 2016; Dai et al., 2016; Kostyuchenko et al., 2016; Modis et al., 2003; Mukhopadhyay et al., 2005; Rey et al., 1995; Sirohi et al., 2016; Zhang et al., 2004). Several human neutralizing antibodies targeting different E protein epitopes have been described. Antibodies against the EDIII of flaviviruses are among the most potent neutralizers in this group (Beasley and Barrett, 2002; Crill and Roehrig, 2001; Screaton et al., 2015).

[0007] Due to the conserved structural features of the E protein, antibodies that develop in response to infection by one flavivirus may also recognize others (Heinz and Stiasny, 2017). Cross-reactivity can lead to cross-protection as first documented by Sabin who showed experimentally in humans that exposure to DENV1 could provide short-term protection from subsequent challenge with DENV2. In contrast, immunity to the autologous strain was long lasting (Sabin, 1950). More recently, human monoclonal antibodies to DENV have been shown to cross-neutralize ZIKV, and vice versa (Barba-Spaeth et al., 2016; Stettler et al., 2016; Swanstrom et al., 2016). However, there is concern that cross-reacting antibodies that fail to neutralize the virus may enhance rather than curb subsequent flavivirus infections (Harrison, 2016; Wahala and Silva, 2011). In vitro and in vivo experiments in mice suggest that this phenomenon, commonly referred to as Antibody Dependent Enhancement (ADE), extends to ZIKV (Bardina et al., 2017; Dejnirattisai et al., 2016; Harrison, 2016; Priyamvada et al., 2016). While several human antibodies to ZIKV have been cloned from convalescent individuals by methods utilizing B cell transformation with Epstein-Barr virus (Sapparapu et al., 2016; Stettler et al., 2016), individual donors were not selected for high neutralization titers; whether their antibodies are representative of optimal immune responses, and how these antibodies might relate to previous flavivirus exposure remains unknown.

[0008] Since no approved prophylaxis or treatment exists, there is an ongoing need for compositions and methods that provide robust protection against ZIKV and other flaviviruses (such as DENV1). Because of the risk of ADE, it is preferable that such compositions and methods avoid the generation of antibodies that bind to the virus but are non-neutralizing and potentially enhancing. Passive administration of monoclonal antibodies represents an alternative approach to vaccines, and has the advantage that antibodies can be modified to prevent interaction with cellular receptors that mediate ADE. The present disclosure is pertinent to this need.

BRIEF SUMMARY

[0009] Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals that develop high titers of anti-ZIKV antibodies we screened cohorts in Brazil and Mexico for ZIKV envelope domain III (ZEDIII) binding and neutralization. Sequencing of nearly 300 antibodies showed that donors with high ZIKV neutralizing antibody titers had expanded clones of memory B cells that carried the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-reacted with DENV1, but not other flaviviruses. In particular, a VH3-23/VK1-5 antibody described in detail below as Z004 neutralized both DENV1 and ZIKV, and protected mice against ZIKV challenge. Structural analyses revealed the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing showed that antibodies to this region correlate with serum neutralizing activity to ZIKV, and that reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure was associated with increased ZIKV neutralizing titers after exposure. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1. Accordingly, mice immunization experiments showed that immunization with the EDIII of DENV1 followed by boosting with ZEDIII resulted in higher neutralizing titers against ZIKV than immunization with either component alone. The disclosure takes advantage of these discoveries to provide novel compositions and methods for approaching ZIKV and DENV1 prophylaxis and/or therapy. Furthermore, the present disclosure demonstrates that a combination of two different antibodies that recognize distinct but overlapping epitopes on the EDIII lateral ridge of ZIKV and DENV1 has unique properties. In particular, the antibody described below as Z021 potently neutralized ZIKV and DENV1 in vitro and prevented disease in mice. In macaques, prophylactic co-administration of Z004 with Z021 was protective and suppressed emergence of ZIKV resistant variants. Thus, the present disclosure demonstrates that a combination of two human monoclonal antibodies that recognize distinct but overlapping epitopes on ZIKV EDIII is sufficient to suppress infection and thwart viral escape in macaques, a natural host for ZIKV. It is considered based on these data that similar effects can be elicited in humans.

[0010] In embodiments the disclosure thus provides an isolated or recombinant antibody, or polynucleotides encoding the antibody, comprising a complementarity determining region (CDR) 3 (CDR3) amino acid sequence selected from heavy chain and light chain CDR3 sequences in Table 1 and Table 2. Table 1 also provides variable sequences for numerous antibody heavy and light chain from which CDR1, CDR2 and CDR3 sequences can be determined.

[0011] In certain embodiments the disclosure provides a Z004 antibody comprising a heavy chain comprising: a CDR1 comprising GFTFRDYA (SEQ ID NO:1), a CDR2 comprising YSGIDDST (SEQ ID NO:2), and a CDR3 comprising AKDRGPRGVGELFDS (SEQ ID NO:3) (a Z004 heavy chain); and a light chain comprising: a CDR1 comprising QSISKW (SEQ ID NO:4), a CDR2 comprising TTS, and a CDR3 comprising QHFYSVPWT (SEQ ID NO:5) (a Z004 light chain). In an embodiment the disclosure provides a Z021 antibody comprising a heavy chain comprising: a CDR1 comprising GGSIDTYY (SEQ ID NO:6), a CDR2 comprising FYYSVDN (SEQ ID NO:7), and a CDR3 comprising ARNQPGGRAFDY (SEQ ID NO:8) (a Z021 heavy chain); and a light chain comprising: a CDR1 comprising QSVSNY (SEQ ID NO:9), a CDR2 comprising DTS, and a CDR3 comprising QERNNWPLTWT (SEQ ID NO:10) (a Z021 light chain), or iii) a bispecific antibody comprising the Z004 heavy chain CDR1, CDR2, CDR3, and the Z004 light chain CDR1, CDR2, CDR3, and the Z021 heavy chain CDR1, CDR2, CDR3, and the Z021 light chain CDR1, CDR2, CDR3.

[0012] In embodiments, the Z004 antibody (also referred to herein as MEX18_89) comprises a heavy chain having the sequence:

TABLE-US-00001 (SEQ ID NO: 11) EVQLLESGGGLVQPGGSLRLTCATSGFTFRDYAMSWVRQAPGKGLEWVSS YSGIDDSTYYADSVKGRFTISRDNSKSTLSLHMNSLRAEDSALYFC GQGTLVTVSS

[0013] and a light chain having the sequence:

TABLE-US-00002 (SEQ ID NO: 12) DIQMTQSPSTLSASVGDRVTITCRASQSISKWLAWYQQKPGKAPKWYTTS TLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGT KVEIK

[0014] In this Z004 sequence and Z021 sequence below, the CDR1 is italicized, the CDR2 is bolded and the CDR3 is italicized and bolded.

[0015] In embodiments, the Z021 antibody (also referred to herein as MEX84_p4-23) has a heavy chain having the sequence:

TABLE-US-00003 (SEQ ID NO: 13) QVQLQESGPGLVKPSETLSLTCTVSGGSIDTYYWSWIRQTPGKGLEWIGC FYYSVDNHFNPSLESRVTISVDTSKNQFSLKMTSMTASDTAVYYC WGPGTLVTVSS

[0016] and a light chain having the sequence:

TABLE-US-00004 (SEQ ID NO: 14) EIVLTQSPATLSLSPGQRATLSCRASQSVSNYFAWYQQKPGQAPRLLIYD TSKRATGTPARFSGSGSGTDFTLTISSLEPEDFAVYYC F GLGTKVEIK.

[0017] Any antibody described herein can comprise at least one modification of its constant region. The modification is of any one or more amino acids. The modification can have any of a number of desirable effects. In certain approaches, the modification increases in vivo half-life of the antibody, or alters the ability of the antibody to bind to Fc receptors, or alters the ability of the antibody to cross placenta or to cross a blood-brain barrier or to cross a blood-testes barrier, or inhibits aggregation of the antibodies, or a combination of said modifications, or wherein the antibody is attached to a label or a substrate. In embodiments, the modification improves the manufacturability of the antibody. In embodiments, any antibody or combination thereof described herein can be present in an immunological assay, such as an enzyme-linked immunosorbent assay (ELISA) assay, or an ELISA assay control. The ELISA assay can be any of a direct ELISA assay, an indirect ELISA assay, a sandwich ELISA assay, or a competition ELISA assay.

[0018] In another aspect the disclosure provides a method for prophylaxis or therapy of a viral infection comprising administering to an individual in need thereof an effective amount of at least one antibody or antigen binding fragment thereof. The antibody may comprise at least one modification of the constant region. In embodiments, the composition is administered to an individual who is infected with or is at risk of being infected with a virus selected from the group consisting of Zika virus (ZIKV), dengue 1, 2, 3 or 4 viruses (DENV1-4), yellow fever virus (YFV), West Nile virus (WNV), and combinations thereof. In one approach, at least two antibodies are administered. In an embodiment, administering at least two distinct antibodies suppressed formation of viruses that are resistant to the antibodies. In one embodiment, the Z004 antibody and the Z021 antibody are administered.

[0019] In another aspect the disclosure provides vaccine formulations. In an embodiment a vaccine formulation comprises: i) an isolated or recombinant polypeptide or a polynucleotide encoding the polypeptide, wherein the polypeptide is derived from the ZIKV EDIII protein, wherein the polypeptide comprises a segment of the lateral ridge of ZIKV EDIII (ZEDIII); or ii) an isolated or recombinant polypeptide or a polynucleotide encoding the polypeptide, wherein the polypeptide is derived from the DENV1 EDIII protein, wherein the polypeptide comprises a segment of the lateral ridge of the DENV1 EDIII protein, or a combination of i) and ii).

[0020] In certain implementations, a vaccine formulation comprises a ZEDIII polypeptide which comprises at least one contiguous segment of ZEDIII comprising amino acids 305-311, 333-336, or 350-352, and/or wherein the segment comprises one or more of ZEDIII amino acids L307, S306, T309, K394, A311, E393, T335, G334, A310, and D336, and/or wherein the polypeptide comprises one or more of DENV1 EDIII amino acids M301, V300, T303, E384, T329, K385, S305, E327, G328, and D330. In certain approaches, a ZIKV EDIII epitope and/or a DENV1 EDIII epitope is duplicated in the polypeptide, and/or the polypeptide comprises both ZIKV EDIII and DENV1 EDIII epitopes. In certain approaches, the polypeptide in the vaccine is modified such that it comprises one or more glycans, and/or by addition of amino acids that comprise epitope(s), and/or the polypeptide is stapled, and/or is cyclicized, and/or is multimerized.

[0021] In another approach the disclosure provides a method for prophylaxis or therapy of a viral infection comprising administering to an individual in need thereof an effective amount of at least one vaccine formulation described herein. In certain embodiments, a first vaccination is performed with a polypeptide or a polynucleotide encoding the polypeptide, wherein the polypeptide is derived from the DENV1 EDIII protein, and wherein the polypeptide comprises a segment of the lateral ridge of the DENV1 EDIII. This can be followed by performing a second vaccination with a polypeptide or polynucleotide encoding the polypeptide, wherein the polypeptide is derived from the ZIKV EDIII protein, and wherein the polypeptide comprises a segment of the lateral ridge of ZIKV EDIII (ZEDIII). Such vaccination approaches can stimulate production of neutralizing antibodies in the individual that inhibit infectivity of a virus selected from the group of viruses consisting of Zika virus, dengue 1, 2, 3 or 4 viruses (DENV1-4), yellow fever virus (YFV), West Nile virus (WNV), and combinations thereof.

[0022] In another aspect, a method for detecting antibodies to Zika virus (ZIKV) and/or dengue 1 virus (DENV1) is provided, and comprises: contacting a biological sample with an isolated or recombinant polypeptide derived from ZIKV EDIII protein, wherein the polypeptide comprises a contiguous segment of the ZIKV EDIII protein that includes an epitope that comprises amino acids E393-K394 of the EDIII protein, and/or with an isolated or recombinant polypeptide derived from DENV1 EDIII protein that comprises a contiguous segment of the DENV1 EDIII protein that includes an epitope that comprises amino acids E384-K385 of the DENV1 EDIII protein, and directly or indirectly detecting a complex comprising the polypeptide and the antibodies if the antibodies are present in the biological sample. In embodiments, the method is performed using an ELISA assay, such as a competition ELISA assay. A suitable assays may further comprise contacting the biological sample with the isolated or recombinant polypeptide with added antibodies, wherein the added antibodies are detectably labeled, and wherein the added antibodies compete with antibodies in the biological sample (if present prior to the adding) for binding to the isolated or recombinant polypeptide, and wherein less binding of the added antibodies relative to a control indicates serologic activity against ZIKV and/or DENV1 in the biological sample.

[0023] In another embodiment, a suitable assay further comprises performing a control reaction. The control reaction substitutes a recombinant polypeptide derived from ZIKV EDIII protein with a recombinant polypeptide derived from ZIKV EDIII protein that comprises a mutation of E393 and/or K394, wherein the mutation is optionally a substitution of E and/or K with an alanine, and comparing an antibody binding value from the control reaction with an antibody binding value to characterize serologic activity against ZIKV in the biological sample.

[0024] In another aspect the disclosure provides one or more recombinant expression vectors, and kits comprising the expression vectors. The expression vectors encode the heavy chain and the light chain of any of the antibodies of described herein. Cells comprising the recombinant expression vectors are included, as are methods of making antibodies by culturing cells that comprise expression vectors that express the antibodies, and separating antibodies from the cells. Cell culture media containing such cells and/or antibodies is also included.

BRIEF DESCRIPTION OF THE FIGURES

[0025] FIGS. 1A-1B--Identification of individuals with high ZEDIII binding and neutralization capacity.

[0026] FIG. 1A--Sera from the Brazilian and Mexican cohorts were screened by ELISA for IgG antibodies binding to ZEDIII. Each dot represents an individual donor. Optical densities are normalized to control serum from a flavivirus naive individual vaccinated for YFV. In black are sera selected for neutralization analysis. FIG. 1B--The neutralization capacity of selected sera from Mexico (dark grey) and Brazil (light grey) was determined by a ZIKV luciferase reporter viral particle (RVP) neutralization assay. The reciprocal of the serum dilution that resulted in 50% inhibition compared to RVP alone is reported as the 50% neutralization titer (NT.sub.50). The dotted line indicates the lower limit of dilutions that were examined. The five samples below the dotted line have NT.sub.50 values lower than 10.sup.3. Individuals from whom antibodies were sequenced and cloned are indicated.

[0027] FIGS. 2A-2C--Discovery of ZEDIII-specific antibodies.

[0028] FIG. 2A--Frequency of ZEDIII-specific, IgG.sup.+ memory B cells in peripheral blood of 6 donors. Flow cytometry plots display the percentage of all IgG.sup.+ memory B cells that bind to a fluorescently tagged ZEDIII bait. Flavivirus naive peripheral blood samples are shown alongside as negative controls. FIG. 2B--Pie charts show the distribution of antibody clones that share the same IGHV and IGLV; the width of each colored or shaded slice is proportional to the number of clones sharing a distinct combination of IGHV and IGLV sequences. The total number of antibody clones sequenced from each donor is indicated in the center of the pie chart. VH3-23/VK1-5 clones are in red, while other VH3-23 clones are indicated with different shades of blue. Non VH3-23 clones are shown in shades of grey, and singlets are in white. None of the grey clones are recurrent across individuals. FIG. 2C--V(D)J assignments for the VH3-23/VK1-5 clones. IgBLAST was used to assign the germline (GL) reference sequence for IGHV and IGLV. Red highlights differences in D and J usage in the VH3-23 clones between individuals.

[0029] See also FIG. 8, and Tables 1 and 2.

[0030] FIGS. 3A-3D--Binding of cloned antibodies to EDIII from ZIKV and other flaviviruses.

[0031] FIG. 3A--Binding of human monoclonal antibodies to ZEDIII. Human anti-HIV antibody 10-1074 was used as a negative control (Mouquet et al., 2012). The average half effective concentration (EC.sub.50) from at least two independent experiments is shown. FIG. 3B--Somatic mutations are required for ZEDIII binding. Binding of Z004 (arrow), its predicted germline (GL), and control antibodies to ZEDIII as assessed by ELISA is shown. FIG. 3C--Human monoclonal antibody cross-reactivity by ELISA. Reactivity to the EDIII of the indicated flaviviruses is shown in grey. The list of antibodies is reported on the left of panel A. FIG. 3D--Z004 binds to the EDIII of DENV1. Binding of Z004 (arrow), its predicted germline (GL), and control antibodies to DENV1 EDIII as assessed by ELISA is shown.

[0032] See also FIGS. 9A-C.

[0033] FIGS. 4A-4I--VH3-23/VK1-5 antibodies neutralize ZIKV and DENV1.

[0034] FIG. 4A--Neutralization potency of human monoclonal antibodies by ZIKV luciferase RVP assay. The human anti-HIV antibody 10-1074 serves as a negative control. Average values of the half maximal inhibitory concentration (IC50) from at least two independent experiments are shown. FIG. 4B and FIG. 4C--Z004 neutralizes ZIKV (B) and DENV1 (C) RVPs. Luciferase activity relative to the no antibody control was determined in the presence of increasing concentrations of Z004 (arrow) or of its predicted germline antibody as indicated. Control antibody was tested at a single concentration. Data are represented as mean.+-.SD. FIG. 4D, FIG. 4E, and FIG. 4F--Z004 protects IFNAR1.sup.-/- mice from ZIKV disease. Mice were infected by footpad (f.p.) injection with the Puerto Rican PRVABC59 ZIKV strain and treated intraperitoneally (i.p.) with Z004 (or 10-1074 control) either before (E) or 1 day after (F) infection. Mice were monitored for symptoms and survival. Survival: p<0.0001 (pre-exposure) and p=0.0027 (post-exposure). Symptoms: p<0.0001 (both pre- and post-exposure, Mantel-Cox test). Three independent experiments, of 4 to 7 mice per group, were combined and displayed. FIG. 4G--Amino acid alignment of a portion of the EDIII lateral ridge region for a panel of flaviviruses (SEQ ID NOS 1061-1069, respectively, in order of appearance). The corresponding accession numbers are indicated in parenthesis. FIG. 4H--The K394 residue in the ZEDIII lateral ridge is required for ZIKV neutralization by Z004. Luciferase activity relative to no antibody control was determined for ZIKV wild type or mutant E393A and K394A RVPs. FIG. 4I--Z004 neutralizes both Asian/American and African strains. RVPs bearing Asian/American ZIKV wild type (E393), mutant (Asian/American with E393D) and African strain (D393) E proteins were neutralized by Z004. In H and I data are represented as mean.+-.SD.

[0035] See also FIGS. 10A-10E.

[0036] FIGS. 5A-5F--Structures of Fab complexes with ZIKV and DENV1 EDIII domains.

[0037] FIG. 5A--Superimposition of Z006 Fab-ZEDIII and Z004 Fab-DENV1 EDIII crystal structures after alignment of the EDIII domains. The V.sub.H domain positions differ by a 14.degree. rotation about an axis passing through the center of the interface. Inset: close-up of interactions between the E393.sub.ZIKV-K394.sub.ZIKV/E384.sub.DENV1-K385.sub.DENV1 motif (shown as sticks) within the EDIII lateral ridge and the two Fabs. Fab CDRs are highlighted. FIG. 5B--Overlay of the Z006-ZEDIII complex structure (EDIII in black) with previously solved structures of antibodies in complex with ZIKV and DENV1 EDIII domains. The E393.sub.ZIKV-K394.sub.ZIKV side chains in ZEDIII are shown as spheres. Structures were aligned on the EDIII domains; only ZEDIII is shown for clarity. FIG. 5C--ZEDIII epitope: EDIII residues contacted by Z006 Fab are highlighted on a surface representation of the EDIII structure. Residues making interactions with both V.sub.H and V.sub.L are dark grey. The E393.sub.ZIKV-K394.sub.ZIKV motif is outlined. Contacts between the Z004 Fab and DENV1 EDIII were less extensive than Z006-ZEDIII contacts, in part because of disorder of the CC' loop in DENV1 EDIII (residues 343-349). FIG. 5D to FIG. 5F--Comparison of key antibody-antigen interactions for Z006 Fab-ZEDIII and Z004 Fab-DENV1 EDIII structures. Hydrogen bonds are shown as dotted lines. FIG. 5D--Fab interactions with K394.sub.ZIKV/K385.sub.DENV1. FIG. 5E--Fab interactions with E393.sub.ZIKV/E384.sub.DENV1. FIG. 5F--Y58.sub.HC (germline-encoded in VH3-23) interactions with antigen.

[0038] See also Tables 5 and 6.

[0039] FIGS. 6A-6B--EDIII reactivity over time.

[0040] FIG. 6A--A set (n=63) of paired sera from the Brazilian cohort participants were collected in April and November 2015 and assayed for binding to flavivirus EDIII. Optical densities are normalized as described in FIG. 1A. Paired sera from the same individual are connected by a line. Each value represents the average of two independent measurements. P values were determined with the two-tailed paired t test (n.s., not significant). FIG. 6B--Correlation between DENV1 EDIII reactivity in April and ZEDIII reactivity in November 2015. Circles and plus signs distinguish data from two independent experiments. Pseudo-.rho.=0.48, p<0.001 by univariate analysis.

[0041] FIGS. 7A-7E--EDIII antibodies contribute to the serologic response and ZIKV neutralization capacity.

[0042] FIG. 7A--Competition ELISA shows the increase within individuals of serum antibodies that block biotin-Z004 ZEDIII binding after ZIKV exposure. Each dot represents a serum sample (n=62 at each of the indicated time points). A line connects sera from the same individual obtained at different time points. The p value was determined with the two-tailed paired t test. FIGS. 7B and 7C--The estimated quantity (.mu.g/ml) of Z004 blocking antibodies in the serum obtained after ZIKV introduction (X axes) was plotted with the overall serum binding activity to ZEDIII (Y axis, B), and the change in that individual's serum ZEDIII binding from before to after ZIKV (Y axis, C). Binding activity change was determined by subtracting the pre- from the post-ZIKV ELISA relative optical density value (average of two independent measurements). Each dot represents an individual (n=62, two-tailed Spearman r test). FIGS. 7D and 7E--Serum neutralization potency expressed as NT.sub.50 versus the overall serum binding activity to ZEDIII (D), or Z004 blocking antibody concentrations in sera (E) obtained after ZIKV introduction are plotted. Each dot represents a serum sample from a single donor (n=27, two-tailed Spearman r test). Representative of two independent experiments is shown.

[0043] FIG. 8--Maximum likelihood tree of VH3-23/VK1-5 antibodies. Related to FIGS. 2A-2C and Table 1.

[0044] Antibody amino acid sequences (heavy and light chain combined) are clustered and labeled according to the donor ID (MEX18, MEX105, MEX84, BRA112, BRA12) followed by the clone's unique sequence ID.

[0045] FIGS. 9A-9C--Features of anti-ZIKV antibodies. Related to FIGS. 3A-3D and Table 1.

[0046] FIG. 9A--Dose-dependent binding of recombinant human monoclonal antibodies to ZEDIII as measured by ELISA. Representative non-linear regression curves are shown. FIGS. 9B and 9C--VH3-23/VK1-5 antibodies have low levels of somatic mutation. The number of V gene nucleotide (FIG. 9B) or amino acid (FIG. 9C) mutations at Heavy (H) and Light (L) chain genes are shown for each donor. Each dot represents one individual antibody V gene (n=69). The average number of nucleotide mutations overall is 27.7 within VH3-23 and 17.5 within VK1-5. The average number of amino acid mutations overall is 14.3 at VH3-23 and 10.6 at VK1-5.

[0047] FIGS. 10A-10E--Neutralization and polyreactivity of anti-ZIKV antibodies. Related to FIGS. 4A-4I.

[0048] FIG. 10A--Dose-dependent neutralization of ZIKV RVPs by recombinant human monoclonal antibodies. Luciferase activity relative to no antibody control is determined in the presence of increasing antibody concentrations. Data are represented as mean.+-.SD. FIG. 10B--ZIKV neutralization by Z004 antibody assessed by PRNT assay. FIG. 10C--DENV1 neutralization by Z004 antibody measured by a flow cytometry-based assay. The number of infected cells was determined using the pan-flavivirus monoclonal antibody 4G2. Data are represented as mean.+-.SD. FIG. 10D--Z004 protects IFNAR1.sup.-/- mice from ZIKV infection. Three independent experiments were performed as described in FIG. 4D-F; results were pooled and presented in FIG. 4. FIG. 10E--Low auto- and polyreactivity profile of Z004. ELISA measures Z004 binding over a range of concentrations against the following antigens: single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), lipopolysaccharides (LPS), insulin, and keyhole limpet hemocyanin (KLH).

[0049] FIGS. 11A-11D--Treatment with Z004 antibody alone leads to the emergence of resistant ZIKV in rhesus macaques (Macaca mulatta).

[0050] FIG. 11A--Macaques were administered Z004 (arrows) or remained untreated (black) one day before intravenous inoculation with 10.sup.5 PFU of ZIKV. Graph shows plasma viral RNA levels of ZIKV over time as determined by RT-qPCR. FIG. 11B--Mutations emerging in macaques treated with Z004 alone. An alignment in the region of residues E393/K394 (in bold) is shown at the top (SEQ ID NOS 1061, 1070, 1062, and 1070, respectively, in order of appearance) and chromatograms of the PCR amplicons showing the mutations (indicated by arrows) are shown at the bottom. In macaque 6414, E393D and K394R are on separate viruses, as determined by sequencing of the cloned amplicon. FIG. 11C--Footprint of the Z004-related antibody Z006 onto the EDIII of ZIKV. The E393/K394 residues are highlighted. FIG. 11D--Impaired binding of Z004 to the EDIII escape mutants. ELISA demonstrates impaired binding of Z004 Fab to EDIII.sub.E393D and EDIII.sub.K394R. The positive control antibody Z015 recognizes an epitope that is independent of Z004. Data are represented as mean.+-.SD of triplicates and a representative of two experiments is shown. See also FIGS. 5A-5F.

[0051] FIGS. 12A-12E--Antibody Z021 neutralizes ZIKV in vitro and in mice.

[0052] FIG. 12A--Z021 is effective against ZIKV. ZIKV neutralization was determined by measuring the ability of increasing concentrations of Z021 to reduce the number of plaques in a PRNT assay. Data are represented as mean.+-.SD of two independent experiments. FIG. 12B--Z021 is effective against DENV1. DENV1 neutralization was assessed by measuring the number of 4G2 positive infected cells by flow cytometry. Data are represented as mean.+-.SD of triplicates and a representative of two experiments is shown. In FIGS. 12A and 12B values are relative to control antibody 10-1074 and antibody Z004 is shown alongside for comparison.sup.5. FIGS. 12C-12E--Z021 protects mice from ZIKV disease. FIG. 12C--Ifnar1.sup.-/- mice were treated with Z021 or control 10-1074 antibody 1 day before (FIG. 12D) or 1 day after (FIG. 12E) challenge with ZIKV in the footpad (f.p.). Mice were monitored for symptoms and survival. The graph indicates death or symptoms. Survival: p<0.0001 (pre-exposure) and p=0.0002 (post-exposure). Symptoms: p=0.0002 (pre-exposure) and p=0.0006 (post-exposure; Mantel-Cox test). Data represent two combined experiments.

[0053] FIGS. 13A-13C--Antibodies Z021 and Z004 recognize distinct epitopes.

[0054] FIG. 13A--Residues E393/K394 of ZIKV EDIII are dispensable for Z021 binding. Graphs show ELISA binding to ZIKV EDIII by increasing concentrations of antibody Z004 (left) or Z021 (right) after blocking with wild type EDIII or EDIII.sub.E393A/K394A. FIG. 13B--Residues E393/K394 are dispensable for ZIKV neutralization by Z021. Graphs show neutralization of ZIKV luciferase RVPs by Z021 and Z004 using wild type RVPs (left) or RVPs mutated at the Z004 binding site (E393A/K394A; right). Data are represented as mean.+-.SD of triplicates and a representative of two experiments is plotted. Values are relative to no antibody control. FIG. 13C--The epitopes of Z004 and Z021 are overlapping. ZIKV EDIII antigen was immobilized with either Z021 IgG (left) or Z004 IgG (right) before detection by ELISA with Fragments antigen binding (Fab) of Z021 and Z004. The positive control Z015 Fab recognizes an epitope that is independent of both Z021 and Z004.sup.5. Data are represented as mean.+-.SD from one experiment done in quadruplicate.

[0055] FIGS. 14A-14C--Comparison of Z021 and Z004 Fab binding to the ZIKV and DENV1 EDIII domain.

[0056] FIG. 14A--Superimposition of Z021 Fab-ZIKV and Z021 Fab-DENV1. The E394 and K395 residues of ZIKV are highlighted. FIG. 14B--Superimposition of Z021 Fab-DENV1 EDIII with Z004 Fab-DENV1 (PDB ID: 5VIC). The V.sub.HV.sub.L of Z021 Fab is rotated .about.48.degree. around an axis near CDRH2 compared to the Z004 V.sub.HV.sub.L bound to the same antigen. FIG. 14C--DENV1 EDIII residues within 4 .ANG. of Z021 Fab, Z004 Fab, or both are highlighted on surface representations of the DENV1 EDIII structure. The E384/K385.sub.DENV1 motif is outlined. The two panels are related by a 90.degree. rotation.

[0057] FIG. 15--The combination of Z004 and Z021 protects ZIKV challenged macaques from viral escape.

[0058] Macaques were administered the combination of Z004 and Z021 or their Fc mutant version (Z004-GRLR and Z021-GRLR) one day before intravenous inoculation with high-dose (10.sup.5 PFU) of ZIKV. Graph shows plasma viral RNA levels of ZIKV over time as determined by RT-qPCR. No mutations were detected in the EDIII region of the emerging virus in the combination treated macaques.

[0059] FIG. 16--The combination of Z004-GRLR and Z021-GRLR antibodies fully protects from subcutaneous challenge with 10.sup.3 PFU of ZIKV.

[0060] Macaques were co-administered Z004-GRLR and Z021-GRLR one day before infection. Graph shows plasma viral RNA levels of ZIKV over time, as determined by RT-qPCR.

[0061] FIG. 17--ZIKV mutations in Ifnar1.sup.-/- mice. Related to FIGS. 11A-11D.

[0062] Summary of the analysis of ZIKV EDIII sequences from infected mouse blood at the indicated time points. Empty cell is sequence not determined, grey cell is symptomatic mouse, wt is wild type EDIII sequence. The only identified mutation (K394R) was in a mouse treated with Z004.

[0063] FIGS. 18--Z021 neutralizes ZIKV RVPs corresponding to both the Asian/American and the African strain. Related to FIGS. 12A-12F.

[0064] Neutralization by Z004 is shown alongside for comparison. Data are represented as mean.+-.SD of triplicates.

[0065] FIG. 19--Human IgG levels in macaque plasma over time. Related to FIG. 15.

[0066] The levels of human IgG antibodies were determined by ELISA. The top panel displays human IgGs in individual macaques, the bottom panel shows the mean for each group. Macaques were administered 15 mg/kg of each of the antibodies on day -1. The mean peak antibody levels on the day of infection (day 0) were 334 .mu.g/ml in the Z004+Z021 group and 326 .mu.g/ml in the Z004-GRLR+Z021-GRLR group. The antibody levels on day 15 were 32 .mu.g/ml in the Z004+Z021 group and 34 .mu.g/ml in the Z004-GRLR+Z021-GRLR group, resulting in plasma half-lives of 4.4 days and 4.6 days, respectively.

[0067] FIGS. 20A-20D--Z004 with engineered modifications at the antibody Fc portion that prevent Fc-gamma receptor binding (GRLR mutation;.sup.25,26) and extend the half-life (LS mutation;.sup.27,28) prevents ADE and remains effective against ZIKV. Related to FIG. 15.

[0068] FIG. 20A--ADE of Fc-gamma receptor bearing K562 cells is abrogated with Z004 antibodies bearing GRLR and GRLR/LS substitutions. Data are represented as mean.+-.SD of triplicates. Positive control (+) is wild type Z004 antibody (10 ng/ml). FIG. 20B--Surface plasmon resonance (SPR) binding profile of Z004 bearing the LS and GRLR mutations alone or in combination. FIGS. 20C-20D--Z004 antibodies bearing the LS and GRLR substitutions alone or in combination remain effective against ZIKV RVPs in vitro (FIG. 20C) or ZIKV in vivo (FIG. 20D).

[0069] FIGS. 21A-21C--Z021 with substitutions that prevent Fc-gamma receptor binding (GRLR) and extend the half-life (LS) prevents ADE and remains effective against ZIKV. Related to FIG. 15.

[0070] FIG. 21A--ADE is abrogated with Z021 antibodies bearing GRLR and GRLR/LS substitutions. Data are represented as mean.+-.SD of triplicates. Positive control (+) is wild type Z004 antibody (10 ng/ml). FIGS. 21B-21C--Z021 antibodies bearing the LS and GRLR substitutions remain effective against ZIKV RVPs in vitro (FIG. 21B) or ZIKV in vivo (FIG. 21C).

[0071] FIGS. 22A-22B--Immunizing wild type mice with DENV1 EDIII before ZIKV EDIII enhances the mice neutralizing antibody response against ZIKV.

[0072] FIG. 22A--Sequential immunization with DENV1 followed by ZIKV EDIII proteins improves antibody titers to the ZEDIII lateral ridge. Competition ELISA with the biotinylated antibody Z004 was used to estimate the concentration of antibodies to the lateral ridge of ZIKV. * is p<0.05. FIG. 22B--Sequential immunization with DENV1 followed by ZIKV EDIII proteins induces higher neutralization in more mice. IgG was purified from mouse serum and assayed for neutralization using ZIKV RVPs. IC50 is in .mu.g/ml.

DESCRIPTION OF INVENTION

[0073] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0074] Every numerical range given throughout this specification includes its upper and lower values, as well as every narrower numerical range that falls within it, as if such narrower numerical ranges were all expressly written herein.

[0075] This disclosure includes every nucleotide sequence described herein, and in the tables and figures, and all sequences that are complementary to them, RNA equivalents of DNA sequences, all amino acid sequences described herein, and all polynucleotide sequences encoding the amino acid sequences. Every antibody sequence and functional fragments of them are included. Polynucleotide and amino acid sequences having from 80-99% similarity, inclusive, and including ranges of numbers there between, with the sequences provided here are included in the invention. All of the amino acid sequences described herein can include amino acid substitutions, such as conservative substitutions, that do not adversely affect the function of the protein or polypeptide that comprises the amino acid sequences. It will be recognized that when reference herein is made to an "antibody" it does not necessarily mean a single antibody molecule. For example, "administering an antibody" includes administering a plurality of the same antibodies. Likewise, a composition comprising an "antibody" can comprise a plurality of the same antibodies.

[0076] Those skilled in the art will recognize that representative sequences from specific ZIKV and DENV1 viruses are presented for use in vaccine formulations and diagnostic approaches, but other sequences from different strains of these viruses are encompassed by this disclosure. The disclosure includes polynucleotides encoding antigens and antibodies from which introns present in the genomic DNA have been removed, i.e., cDNA sequences and DNA sequences complementary thereto.

[0077] For amino acid and polynucleotide sequences of this disclosure contiguous segments of the sequences are included, and can range from 2 amino acids, up to full-length viral protein sequences. Polynucleotide sequences encoding such segments are also included.

[0078] The disclosure includes DNA and RNA sequences encoding the antibodies and virus peptides described herein for use in prophylactic and therapeutic approaches as protein or DNA and/or RNA vaccines, which may be formulated and/or delivered according to known approaches, given the benefit of this disclosure.

[0079] From DNA sequences and amino acid sequences presented in the tables of this disclosure antibody complementarity determining region (CDR) sequences can be identified by using publicly available databases, such as IGBLAST (www.ncbi.nlm.nih.gov/igblast) using the germline database.

[0080] The disclosure includes antibodies described herein, which are present in an in vitro complex with a ZIKV or a DENV1 protein.

[0081] In certain approaches compositions and methods of this disclosure may be adapted for use in non-human animals that may be determined to be an actual or potential reservoir or vector for the Zika and/or dengue viruses. Thus, veterinary compositions and methods of administering them are included.

[0082] From the examples and descriptions of this disclosure it will be apparent to those skilled in the art that the instant disclosure can be distinguished from studies that have examined anti-ZIKV antibodies developing in a small number of available individuals (Sapparapu et al., 2016; Stettler et al., 2016; Wang et al., 2016). In contrast, we screened sera from more than 400 donors from ZIKV epidemic areas of Mexico and Brazil to select high responders. Serologic reactivity to ZIKV varied greatly among individuals, with neutralization potencies spanning over more than 2 logs. To better understand this activity we isolated 290 memory B cell antibodies from 6 individuals with high serum neutralizing activity. The sequencing experiments revealed the existence of expanded clones of memory B cells expressing E protein lateral ridge-specific ZIKV and DENV1 neutralizing VH3-23/VK1-5 antibodies in 4 of the 6 individuals.

[0083] Three separate groups have cloned human anti-ZIKV E protein reactive antibodies before the present disclosure (Sapparapu et al., 2016; Stettler et al., 2016; Wang et al., 2016). In all they studied 8 individuals and documented 92 antibodies to the E protein. The great majority of these antibodies (79) were obtained by screening supernatants of Epstein-Barr virus transformed B lymphocytes for binding to ZIKV, and only a minority (15) were directed to the ZEDIII. Among all of these antibodies there was only a single expanded clone containing 3 related VH1-46/VK1-39 antibodies specific for a yet to be determined E epitope. These 3 antibodies were relatively poor neutralizers (3-257 .mu.g/ml) (Wang et al., 2016). There was also a single VH3-23/VK1-5 antibody that targeted the ZEDIII and neutralized ZIKV (ZIKV-116), but this antibody is believed to be different than those of this disclosure because it failed to neutralize the African ZIKV strain (Sapparapu et al., 2016). Thus, there was no prior indication of a potent recurrent neutralizing response to ZIKV.

[0084] We found a total of 69 individual VH3-23/VK1-5 memory B cells antibodies in 5 out of 6 individuals. In addition to recurring V gene segments, VH3-23/VK1-5 antibodies bear the same IGL J gene, and a limited set of IGH D and J genes. These antibodies are closely related and they are potent neutralizers with IC.sub.50 values ranging from 0.7-4.6 ng/ml. This variation in activity is likely due to somatic mutations, since predicted germline versions of the VH3-23/VK1-5 antibodies bind to ZEDIII and neutralize the virus only weakly. Thus, and without intending to be constrained by any particular theory, it is considered that somatic mutations are required for optimal VH3-23/VK1-5 antibody neutralizing activity.

[0085] Recurring antibodies that share the same IGV genes and the same molecular interactions with antigen have not been reported for ZIKV or other flaviviruses before the present disclosure, but they have been described in other viral infections including HIV-1 and influenza. Broadly neutralizing antibodies targeting the CD4 binding site of HIV-1 frequently utilize VH1-2 or VH1-46 genes (Scheid et al., 2011; West et al., 2012), and broadly neutralizing antibodies to Influenza utilize VH1-69 (Laursen and Wilson, 2013; Pappas et al., 2014; Sui et al., 2009; Throsby et al., 2008; Wrammert et al., 2011). However, in both HIV-1 and influenza, the VH genes can be paired with a collection of different VL genes, a finding that was explained by structural analysis showing that many of the essential contacts made by influenza and HIV-1 antibodies involve variable portions of the IGHV (Ekiert et al., 2009; Pappas et al., 2014; Scheid et al., 2011; Wrammert et al., 2011; Zhou et al., 2010).

[0086] Although the Z004 and the related Z006 antibodies have CDRH3s and CDRL3s of different lengths they share a common mode of EDIII binding. Several shared sequence features may be important for this binding mode. The most suggestive of these is R96.sub.HC. This CDRH3 residue appears to derive from N region addition, thus the different VH3-23/VK1-5 clones do not share this residue due to shared germline genes. Examination of a large collection (n=44,270) of VH3-23-derived antibody sequences indicates that only 13% have R at position 100 (Rubelt et al., 2012). However, 68 of 69 of the sequenced VH3-23/VK1-5 clones contain R96. The clones also tend to conserve the germline residues forming the Z004/Z006/EDIII common interactions: Y58.sub.HC, W32.sub.LC, Y91.sub.LC, and S93.sub.LC.

[0087] Without intending to be bound by any particular interpretation, the requirement for conserved IGHV and IGLV genes in VH3-23/VK1-5 antibodies appears to be explained in part by interactions using germline residues. For the light chain, CDRL1 germline residue W32.sub.LC interacts with K394.sub.ZIKV. Few IGLV genes contain W32; the most common of these is VK1-5 (followed by VK1-12, but this gene is several-fold less common than VK1-5). For the heavy chain, residue Y58.sub.HC (present in the VH3-23 germline) makes a contact with EDIII residue 307.sub.ZIKV. Y58.sub.HC is present in .about.50% of VH germlines, potentially explaining a portion of the restriction. Finally, VH3-23 is among the most frequently used VH genes as is VK1-5 (Arnaout et al., 2011; DeKosky et al., 2015). Therefore it is likely that naive B cell precursors carrying DENV1 and ZIKV reactive VH3-23/VK1-5 antibodies would also be common in the pre-immune repertoire making this epitope a particularly attractive vaccine candidate.

[0088] VH3-23/VK1-5 antibodies recognize and neutralize both DENV1 and ZIKV, suggesting that clones of VH3-23/VK1-5 producing B cells originally elicited in response to DENV1 were further expanded in response to ZIKV. This prime-boost, or original antigenic sin hypothesis, is supported by two observations. First, pre-existing antibodies to DENV1 EDIII are associated with a higher antibody response to ZEDIII. Second, at the population level, the introduction of ZIKV correlates with an increase in DENV1 EDIII-reactive antibodies at a time when DENV1 was not circulating. Although DENV1 and ZIKV only share 50% amino acid identity in EDIII, they are structurally very similar, particularly in the lateral ridge region that is recognized by VH3-23/VK1-5 (FIG. 5). Thus, DENV1 EDIII reactive memory B cells have a significant probability of being cross-reactive to ZEDIII. A primary response to DENV1 would increase the frequency of these ZIKV cross-reactive memory B cells and thereby increase their likelihood of undergoing clonal expansion in response to ZIKV. Consistent with this, memory B cells with VH3-23/VK1-5 antibodies represent close to half of all ZEDIII-specific B cell clones in 3 of the 6 individuals examined.

[0089] Infection by DENV1 confers transient protection to infection by DENV2 (Sabin, 1950, 1952). Whether prior DENV1 infection also protects from ZIKV by cross-priming or in other cases enhances infection is unclear (Castanha et al., 2016; Dejnirattisai et al., 2016; Priyamvada et al., 2016; Swanstrom et al., 2016; Wahala and Silva, 2011). However, the existence of human antibodies to DENV that cross-neutralize or enhance ZIKV in vitro indicates that protection by cross-priming is possible (Barba-Spaeth et al., 2016; Dejnirattisai et al., 2016; Harrison, 2016; Pierson and Graham, 2016; Priyamvada et al., 2016; Stettler et al., 2016; Swanstrom et al., 2016).

[0090] ZIKV infection is asymptomatic in most people. Only 20% of ZIKV infected individuals develop symptoms, and in those cases the severity of the disease varies broadly (Miner and Diamond, 2017). Similarly, the spectrum and incidence of developmental sequelae in infants born to women infected with ZIKV during pregnancy differs within and across geographic areas with risk estimates that range from 6-42% (Brasil et al., 2016; Honein et al., 2017). Examples of this disclosure indicate a cellular and molecular explanation for how a history of DENV1 exposure could alter host responses and susceptibility to ZIKV.

[0091] In embodiments, the disclosure provides an isolated or recombinant antibody that binds with specificity to a neutralizing epitope in the lateral ridge of Zika virus (ZIKV) envelope domain III (ZEDIII) protein, wherein the epitope comprises E393-K394 of the ZEDIII protein, and wherein the antibody optionally comprises a modification of the amino acid sequence, including but not limited to a modification of its constant region. Such antibodies can also bind with specificity to a neutralizing epitope of dengue 1 virus (DENV1) EDIII protein. Specific and non-limiting examples of antibodies are provided herein, along with amino acid sequences of pertinent parts of the antibodies, including heavy (H) and light (L) chain sequences.

[0092] All combinations of H and L chains are included. In embodiments, a single antibody of this disclosure may comprise an H+L chain from one antibody, and an H+L chain from another antibody that is described below. In embodiments, the modifications are not coded for in any B cells obtained from an individual, and/or the antibodies are not produced by immune cells in an individual from which a biological sample from the individual is used at least in part to identify and/or generate and/or characterize the antibodies of this disclosure. In embodiments, antibodies provided by this disclosure can be made recombinantly, and can be expressed with a constant region of choice, which may be different from a constant region that was coded for in any sample from which the amino acid sequences of the antibodies were deduced.

[0093] In certain approaches the disclosure provides one or more isolated or recombinant antibodies comprising a complementarity determining region 3 (CDR3) amino acid sequence selected from heavy chain and light chain CDR3 sequences in Table 1 and Table 2, and combinations of said heavy and light chain CDR3 amino acid sequences. In non-limiting embodiments the disclosure includes amino acid sequences encoded by VH3-23/VK1-5 human immunoglobulin genes, but all of the H and L gene segments described herein and the proteins they encode are included in the invention.

[0094] In certain embodiments, the antibodies contain one or more modifications, such as non-naturally occurring mutations, non-limiting examples of which are further described herein. In non-limiting examples, antibodies described herein can be modified according to various approaches that will be apparent to those skilled in the art, given the benefit of this disclosure. In certain approaches the Fc region of the antibodies can be changed, and may be of any isotype, including but not limited to any IgG type, or an IgA type, etc. Antibodies of this disclosure can be modified to improve certain biological properties of the antibody, e.g., to improve stability, to modify effector functions, to improve or prevent interaction with cell-mediated immunity and transfer across tissues (placenta, blood-brain barrier, blood-testes barrier), and for improved recycling, half-life and other effects, such as manufacturability and delivery.

[0095] In embodiments, an antibody of this disclosure can be modified by using techniques known in the art, such as those described in Buchanan, et al., Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression mAbs 5:2, 255-262; March/April 2013, and in Zalevsky J. et al., (2010) Nature Biotechnology, Vol. 28, No. 2, p 157-159, and Ko, S-Y, et al., (2014) Nature, Vol. 514, p 642-647, and Horton, H. et al., Cancer Res 2008; 68: (19), Oct. 1, 2008, from which the descriptions are incorporated herein by reference. In certain embodiments an antibody modification increases in vivo half-life of the antibody (e.g. LS mutations), or alters the ability of the antibody to bind to Fc receptors (e.g. GRLR mutations), or alters the ability to cross the placenta or to cross the blood-brain barrier or to cross the blood-testes barrier. In embodiments bi-specific antibodies are provided by modifying and combining segments of antibodies as described herein, such as by combining heavy and light chain pairs from distinct antibodies into a single antibody. Suitable methods of making bispecific antibodies are known in the art, such as in Kontermann, E. et al., Bispecific antibodies, Drug Discovery Today, Volume 20, Issue 7, July 2015, Pages 838-847, the description of which is incorporated herein by reference.

[0096] In embodiments, any antibody described herein comprises a modified heavy chain, a modified light chain, a modified constant region, or a combination thereof, thus rendering them distinct from antibodies produced by humans. In embodiments, the modification is made in a hypervariable region, and/or in a framework region (FR). In certain embodiments an antibody modification increases in vivo half-life of the antibody and/or alters the ability of the antibody to bind to Fc receptors. In embodiments, the mutations comprise LS or GRLR mutations. In certain embodiments an antibody modification increases in vivo half-life of the antibody by way of LS mutations, or alters the ability of the antibody to bind to Fc receptors by way of GRLR mutations. In embodiments, the mutation(s) can thus comprise a change of G to R, L to R, M to L, or N to S, or any combination thereof.

[0097] In embodiments, mutations to an antibody described herein, including but not limited to the antibodies described below as Z004 and Z021, comprise modifications relative to the antibodies originally produced in humans. Such modifications include but are not necessarily limited to the heavy chain of Z004, which can comprise G241R and/or L333R mutations to prevent binding to Fc gamma receptors, and/or M433L/N439S mutations to increase the antibody half-life.

[0098] In an embodiment, a Z004 IgG1 heavy chain comprises or consists of a contiguous segment or the entire sequence:

TABLE-US-00005 (SEQ ID NO: 15) EVQLLESGGGLVQPGGSLRLTCATSGFTFRDYAMSWVRQAPGKGLEWVSS YSGIDDSTYYADSVKGRFTISRDNSKSTLSLHMNSLRAEDSALYFCAKDR GPRGVGELFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL GPSVFLEPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA PAPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV HEALHSHYTQKSLSLSP G.

In this SEQ ID NO: 15 the variable sequence is bolded, and the remaining sequence comprises Fc sequence which is shown with the G241R and/or L333R mutations to prevent binding to Fc gamma receptors and M433L/N439S mutations to increase the antibody half-life in bold and italics. A C-terminal lysine was removed to reduce micro-heterogeneity (removed lysine not shown).

[0099] In an embodiment, a Z004 light chain comprises or consists of a contiguous segment or the entire sequence:

TABLE-US-00006 (SEQ ID NO: 16) DIQMTQSPSTLSASVGDRVTITCRASQSISKWLAWYQQKPGKAPKWYTTS TLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHFYSVPWTFGQGT KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC.

In this sequence the variable region is shown in bold.

[0100] In an embodiment, a Z021 heavy chain includes an IgG1, with modifications that can include G237R/L329R mutations to prevent binding to Fc gamma receptors, M429L/N435S mutations to increase the antibody half-life, and a C-terminal lysine removed to reduce micro-heterogeneity.

[0101] In an embodiment, a Z021 heavy chain comprises or consists of a contiguous segment or the entire sequence:

TABLE-US-00007 (SEQ ID NO: 17) QVQLQESGPGLVKPSETLSLTCTVSGGSIDTYYWSWIRQTPGKGLEWIGC FYYSVDNHFNPSLESRVTISVDTSKNQFSLKMTSMTASDTAVYYCARNQP GGRAFDYWGPGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL GPSVFLEPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKA PAPIEKTISKAKGQPREPQVY TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSV HEALHSHYTQKSLSLSPG.

In this SEQ ID NO: 17, the variable sequence is bolded, and the remaining sequence comprises Fc sequence which is shown with the G237R/L329R mutations to prevent binding to Fc gamma receptors and M429L/N435S mutations to increase the antibody half-life in bold and italics. A C-terminal lysine was removed to reduce micro-heterogeneity (removed lysine not shown). In an embodiment, the Z021 heavy chain sequence comprises a C50 modification, which may reduce unwanted disulfide bond formation. Thus, in one embodiment, the disclosure comprises a Z021 heavy chain of SEQ ID NO: 17, wherein the C50 is changed, such as to a V, but other amino acid substitutions can also be made provided they do not adversely affect affinity of the antibody for its epitope and/or the antibody's ability to neutralize ZIKV and/or DENV1.

[0102] In an embodiment, a Z021 light chain comprises or consists of a contiguous segment or the entire sequence:

TABLE-US-00008 (SEQ ID NO: 18) EIVLTQSPATLSLSPGQRATLSCRASQSVSNYFAWYQQKPGQAPRLLIYDT SKRATGTPARFSGSGSGTDFTLTISSLEPEDFAVYYCQERNNWPLTWTFGL GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC.

In this sequence the variable region is shown in bold.

[0103] Similar mutations can be made in any antibody of this disclosure.

[0104] In embodiments, antibodies of this disclosure have variable regions that are described herein, and may comprise or consist of any of these sequences, and may include sequences that have from 80-99% similarity, inclusive, and including ranges of numbers there between, with the sequences expressly disclosed herein, provided antibodies that have differing sequences retain the same or similar binding affinity as an antibody with an unmodified sequence. In embodiments, the sequences are at least 95%, 96%, 97%, 98% or 99% similar to an expressly disclosed sequence herein.

[0105] Those skilled in the art will recognize that antibodies of this disclosure are from time to time described using nomenclature that includes a "Z" and a number, and that these are correlated with nomenclature in the tables of this disclosure, such as "MEX" or "BRA" followed by an alphanumeric designation. Those skilled in the art will be able to readily attribute the particular Z number with the MEX and BRA numbers in view of the description and tables presented herein. For example, Z004 is also referred to herein as MEX18 89 and Z021 is referred to as MEX84_p4-23.

[0106] In non-limiting embodiments the disclosure provides antibodies with a CDR3 heavy chain sequence and a CDR3 light chain sequence selected from amino acid sequences in Table 1 or Table 2 having one of the following designations:

[0107] Z001 (MEX18_21), Z006 (MEX105_42), Z010 (MEX105_88), Z012 (MEX105_57), Z014 (MEX18_91), Z015 (MEX84_p2-44), Z018 (MEX84_p2-45), Z024 (MEX84_p4-12), Z028 (MEX84_p4-53), Z031 (BRA112_46), Z035 (BRA112_71), Z037 (BRA112_57), Z038 (BRA12_2), Z039 (BRA12_21), Z041 (BRA138_57), Z042 (BRA138_17), Z043 (BRA138_15), Z002 (MEX18_27), Z003 (MEX18_58), Z005 (MEX18_13), Z007 (MEX105_50), Z008 (MEX105_60), Z009 (MEX105_64), Z011 (MEX105_15), Z013 (MEX18_84), Z016 (MEX84_p2-55), Z017 (MEX84_p2-58), Z019 (MEX84_p4-16), Z020 (MEX84_p4-30), Z032 (BRA112_24), Z034 (BRA112_09), Z036 (BRA112_91), Z040 (BRA12_81), Z044 (BRA138_46), Z045 (BRA12_08), Z048 (BRA112_23), Z050 (BRA138_28), Z051 (BRA138_59), Z052 (BRA138_62), Z053 (BRA138_65), Z054 (BRA138_94), Z055 (MEX84_p4-61), Z056 (MEX84_p2-94), Z057 (MEX84_p4-54), Z058 (MEX84_p2-53), Z059 (MEX84_p4-34), Z060 (BRA12_58), Z061 (BRA112_36), and Z062 (BRA112_70).

[0108] In embodiments an antibody of this disclosure comprises a CDR1 and/or a CDR2 amino acid sequence comprised by IgH and/or IgL amino acid sequences of Table 1.

[0109] Antibodies comprising the following list of variable sequences have been expressed and characterized for at least binding affinity, and as otherwise described herein. Bispecific antibodies comprising distinct heavy and light chain pairs from distinct antibodies listed below are included in the disclosure. In the following sequences, the CDR1 is italicized, the CDR2 is bolded and the CDR3 is italicized and bolded. All of these CDR1, CDR2 and CDR3 sequences are included in this disclosure as separate sequences, apart from the remainder of the disclosed variable/framework sequences that are also disclosed in this list:

TABLE-US-00009 Z004 (MEX18_89) Heavy Chain (HC) (SEQ ID NO: 11) EVQLLESGGGLVQPGGSLRLTCATSGFTFRDYAMSWVRQAPGKGLEWVSSYSGIDD STYYADSVKGRFTISRDNSKSTLSLHMNSLRAEDSALYFC W GQGTLVTVSS Light Chain (LC) (SEQ ID NO: 12) DIQMTQSPSTLSASVGDRVTITCRASQSISKWLAWYQQKPGKAPKLLIYTTSTLKSGV PSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z021 (MEX84_p4-23) Heavy Chain (HC) (SEQ ID NO: 13) QVQLQESGPGLVKPSETLSLTCTVSGGSIDTYYWSWIRQTPGKGLEWIGCFYYSVDNH FNPSLESRVTISVDTSKNQFSLKMTSMTASDTAVYYC WGPGTLV TVSS Light Chain (LC) (SEQ ID NO: 14) EIVLTQSPATLSLSPGQRATLSCRASQSVSNYFAWYQQKPGQAPRLLIYDTSKRATGT PARFSGSGSGTDFTLTISSLEPEDFAVYYC FGLGTKVEIK Z001 (MEX18_21) Heavy Chain (HC) (SEQ ID NO: 19) EVQLLESGGGLVQPGGSRRLSCATSGFSFDTYAMSWLRQAPGKGLEWVSSFSGLDD STYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYC W GQGTLVTVSS Light Chain (LC) (SEQ ID NO: 20) DIQMTQSPSTLSASVGDRVTITCRASQSISRWLAWYQQKPGKAPKLLIYKTSTLKSEV PSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z006 (MEX105_42) Heavy Chain (HC) (SEQ ID NO: 21) EVQLLESGGGLVQPGGSLRLSCAASGFTFKNYAMAWVRQAPGKGLEWVSLLYNSEE STYYADSVKGRFTISRDNSKNTLFLQMNRLRVEDTAVYFC WGR GTLVTVSS Light Chain (LC) (SEQ ID NO: 22) DIQMTQSPSTLSASVGDRVTMTCRASQTISGWLAWYQQKPGKAPKLLIYQASRLESG IPSRFSGSGSGTEFTLTISSLQPDDVATYYC FGLGTKVEIK Z010 (MEX105_88) Heavy Chain (HC) (SEQ ID NO: 23) EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMAWVRQAPGKGLEWVSLIYSGDD STYYADFVKGRFTISRHNSKNTLSLQMNSLRAEDTAIYYC WGQ GTLVTVSS Light Chain (LC) (SEQ ID NO: 24) DIQMTQSPSTLSASVGDRVTITCRASQTISNWLAWYQQKPGKAPKLLIYQASSLESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z012 (MEX105_57) Heavy Chain (HC) (SEQ ID NO: 25) QVQLVQSGAEVKKSGASVKVSCKASGYSFTTNYIHWVRQAPGQGPEWMGIINPRGG STTYAQKFQGRVLMTSDTSTSTVYMELSSLRSEDRAVYYC WGQGTTVTVSS Light Chain (LC) (SEQ ID NO: 26) DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGV PSRFSGSGSGTDFTLTISNLQPEDFATYFC FGQGTKLEIK Z014 (MEX18_91) Heavy Chain (HC) (SEQ ID NO: 27) EVQLLESGGDLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGFDPS TYYADSVRGRFTIARDNSKNTLYLQMKSLRVEDTAIYYC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 28) DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPREVPKLLIYAASTLHSGV PSRFSGSGSGTDFTLTISGLQPEDVATYYC GQGTKVEIK Z015 (MEX84_p2-44) Heavy Chain (HC) (SEQ ID NO: 29) QVQLVQSGAEVKKPGASVKLSCKSSGYSFTSYYMHWVRQAPGQGLEWMGIINPSGV FTSYAQRFQGRVTMTSDTATSTVYMELSSLRSGDTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 30) EIVLTQSPGTLSLSPGERATLSCRASQSVSLSFLAWYQQKPGQAPRLLIYGASNRATGI PDRFSGSGSGTDFTLTISRLEPGDFAVYYC FGPGTKVDIK Z018 (MEX84_p2-45) Heavy Chain (HC) (SEQ ID NO: 31) QVQLVQSGPGVKKPGASVKVSCKASGYIFSDYYILWVRQAPGQGLEYMGWMNPISG FTHYAQNFQGRVTMTRDTSISTAYMELTRLASDDTAVYYC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 32) EIVLTQSPATLSLSPGERATLSCRASQSISTFSLAWYQQKFGQAPRLLIYGASSRATGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYC FGGGTKVEIK Z024 (MEX84_p4-12) Heavy Chain (HC) (SEQ ID NO: 33) EVQLVQSGAEVRKPGESLRISCKTSGYTFTSHWVAWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQISISADKSINTAYLQWSSLKASDTGIYYC WGQGTTVTVSS Light Chain (LC) (SEQ ID NO: 34) DIQLTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPNLLIYAASSLQSGVP SRFSGSGSGTDFTLTISSLQPEDYAIYYC FGQGTKVEIK Z028 (MEX84_p4-53) Heavy Chain (HC) (SEQ ID NO: 35) EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYAMSWVRQAPGKGLEWVSSINGHSDS TYFADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 36) DIQMTQSPSTLSASIGDRVTITCRASQSITPWLAWYQQKPGKAPKFLIYQTSILESGVP SRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z031 (BRA112_46) Heavy Chain (HC) (SEQ ID NO: 37) EVQLLESGGGLVQPGGSLRLSCVASGFTFGSYGMAWVRQAPGKGLEWISSISSIDPST YYADSVKGRFTVSRDNSENTLYLHMSSLKVEDTAVYFC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 38) DIQMTQSPSTLSASVGDSVTITCRASQSISSWLAWYQQKPGKAPKFLIHKASSLESGIP SRFSGSGSGTEFTLTINNLQPDDFATYYC FGQGTKVEIK Z035 (BRA112_71) Heavy Chain (HC) (SEQ ID NO: 39) EVQLLESGGGLIQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGA SDNGASRYYADSVKGRFSISRDNSKNTVYLQMNSLRAEDTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 40) DIQMTQSPSTLAASVGDRVTITCRASQNINSWLAWYQQKPGKAPKFLIYKASTLESG APSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z037 (BRA112_57) Heavy Chain (HC) (SEQ ID NO: 41) QVQLQESGPGLVKPSETLSLTCSVSGYFISSGHYWGWIRQSPGKGLEWIASIYQSGSK FQTGNTYYNPSLESRVTISMDTSKNQFSLKLSSVTAADTAVYFC WGQGILVTVSS Light Chain (LC) (SEQ ID NO: 42) EIVLTQSPGTLSLSPGERATLSCRASQSLSSSFLAWYQQKPGQSPRLLIYGTSSRDTGIP DRFSGSGSGTDFTLTISRLEPEDSAVYYC FGQGTKLEIK Z038 (BRA12_2) Heavy Chain (HC) (SEQ ID NO: 43) EVQLLESGGGLVQPGGSLRLSCEASGFTFSNYAMNWVRQAPGKGLEWVSTLGATDN SGDSTYYVESAKGRFTISRDNSKNTLYLQMNSLRVEDTAVYFC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 44) DIQMTQSPSTLSASVGDRVTITCRASHRISGWLAWYQQKPGKAPKLLIYQASGLESGV PSRFSGSGYGTEFTLTISSLQADDFATYYC FGQGTKVEIK Z039 (BRA12_21) Heavy Chain (HC) (SEQ ID NO: 45) EVQLLESGGGLVQPGGSLRLSCAASGYIFDNYAMSWVRQAPGKGLEWVSYINGGGY GTDYADSVKGRFTISRDNSKRILYLQMNSLRVGDTAVYYC W GQGTLVTVSS Light Chain (LC) (SEQ ID NO: 46) EIVLTQSPGTLSLSPGERATLSCRASQTIFFNYLAWYQKKPGQAPRLLVHGASTRATG IPDRFSGSGSGTDFTLTINSLDPEDFAVYYC FGGGTKVEIK Z041 (BRA138_57) Heavy Chain (HC) (SEQ ID NO: 47) QVQLVQSGAEVKKPGSSVRLSCKASGGSYSTYAISWVRQAPGQGLEWMGRIIPSLGK THLAQKFQGRVTFTADESTTTVYMILSSLKSEDTALYYC WG QGTLVTVSS Light Chain (LC)

(SEQ ID NO: 48) DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSTGYNYLDWYLQKPGQSPQLLIYLGSNR ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC FGPGTKVDIK Z042 (BRA138_17) Heavy Chain (HC) (SEQ ID NO: 49) QVQLQESGPGLVKPSETLSLSCTVSSGSISNYYWNWIRQPPGKGLEWIGYIYYSGSISY NPSLKSRVTISVDTSKNQLSLKLNSVTAADTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 50) EIVMTQSPATLSVSPGERVTLSCRASQSVSYNLAWHQQKPGQAPRLLIYGASTRATGI PARFSGSGSGTEFTLTISNMQSEDFAVYYC FGPGTKVDIK Z043 (BRA138_15) Heavy Chain (HC) (SEQ ID NO: 51) QVQLVQSGAEVKKPGASVKVSCKTSGYTFTSYYMNWVRQAPGQGLEWMGIIKPSDG STNYAQKFQGRVTMTRDTSTSTVYMELRSLRSEDTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 52) QSALTQPASVSGSPGQSITISCAGTSSDVGNYNLVSWYQQHPGKAPKLLIYEVSKRPSG VSNRFSGSKSGNTASLTISGLQAEDEADYYC FGTGTEVTVL Z002 (MEX18_27) Heavy Chain (HC) (SEQ ID NO: 53) EVQLLESGGGLVQPGGSLRLSCATSGFTFSTYAMSWVRQAPGKGLEWVSSFSGVDDS TYYAESVKGRFTISRDNSKNTVYLQMTRLRAEDTAVYYC W GQGTLVTVSS Light Chain (LC) (SEQ ID NO: 54) DIQMTQSPSTLSASVGDRVTMTCRASQSINRWLAWYQQKPGKAPKWYTTSTLKSG VPSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z003 (MEX18_58) Heavy Chain (HC) (SEQ ID NO: 55) EVQLLESGGGLVQPGGSLRLSCATSGFTFTTFAMSWVRQAPGKGLEWVSSISGADDS TYYAASVKGRFTISRDNSRSTLFLQMNSLRAEDTAVYYC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 56) DIQMTQSPSTLSASVGDRVTITCRASQSISKWLAWYQQKPGKAPRLLIYTTSTLKSGV PSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z005 (MEX18_13) Heavy Chain (HC) (SEQ ID NO: 57) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSFSGIDDS TWYADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYC W GRGTLVTVSS Light Chain (LC) (SEQ ID NO: 58) DIQMTQSPSSLSASVGDRVTITCRASQDISKYLAWYQQRPGKVPNLLIYTASTLQSGV PSRFSGSGSGTHFTLTISSLQPEDVATYYC FGQGTKVEIK Z007 (MEX105_50) Heavy Chain (HC) (SEQ ID NO: 59) EVQLLESGGGLVRPGGSLRLSCTASGFTFRRYAMAWVRQAPGKGLEWVSLIYDGDD STYYAKSVKGRFAISRDNSKNTLSLQMNSLRAEDTAVYYC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 60) DIQMTQSPSTLSASVGDRVTITCRASHSISGWLAWYQQKPGKAPKLLIYQASILESGV PSRFSGSGSGTEFTLTIGSLQPEDFATYFC FGQGTKVEIK Z008 (MEX105_60) Heavy Chain (HC) (SEQ ID NO: 61) EVQLLESGGGLVRPGGSLRLSCTASGFTFRRFAMAWVRQAPGKGLEWVSLIWNGDD STYYAESVRGRFTISRDNSHNTLSLQMRSLRAEDTAIYYC WGQ GTLVTVSS Light Chain (LC) (SEQ ID NO: 62) DIQMTQSPSTLSASVGDRVTITCRASQTIGNWLAWYQQKPGKAPKLLIYQASVLESG VPSRFSGSGSGTEFTLTISSLQPEDFATYFC FGQGTKVEIK Z009 (MEX105_64) Heavy Chain (HC) (SEQ ID NO: 63) EVQLLESGGGLVRPGGSLRLSCTASGFTFRRYAMAWVRQAPGKGLEWVSLIYNGDD STYYAESVKGRFTVSRDNSQNTLSLQMNSLRAEDTAIYYC WGQ GTLVTVSS Light Chain (LC) (SEQ ID NO: 64) DIQMTQSPSTLSASVGDRVTITCRASRTIGSWLAWYQQKPGKAPKLLIYQASILEGGV PSRFSGSVSGTEFTLTIRSLQPEDFATYFC FGQGTKVEIK Z011 (MEX105_15) Heavy Chain (HC) (SEQ ID NO: 65) EVQLLESGGGLVQPGGSLRLSCAASGFTFRTYAMSWVRQPPGKGLEWVSSISAREDS TYFAASVRGRFTISRDNSKNTLYLQMNNLRAEDTALYYC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 66) DIQMTQSPSTLSASVGDRVTITCRASQNINSWLAWYQQKPGKAPKLLIYMASSLQSG VPSRFSGSGSGTEFTLTVSSLQPDDFATYYC FGQGTKVEIK Z013 (MEX18_84) Heavy Chain (HC) (SEQ ID NO: 67) EVQLLESGGGLVQPGGSLRLSCAASGFTFTSYAMNWVRQAPGKGLEWVSGIGGRGA IAGDGSIYYADSVKGRFTISRDNSKNIVYLQMNGLRVEDTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 68) DIQMTQSPPTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGV PSRFSGSGSGTEFSLTISSLQPEDFATYYC FGQGTKVEIK Z016 (MEX84_p2-55) Heavy Chain (HC) (SEQ ID NO: 69) QVQLVQSGAEVKKPGASVKLSCKASGYTFTSYYVHWVRQAPGQGLEWMGIINPGNN FVSFAQNFYDRATMTRDTSTNTVYMELTNLQSEDTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 70) EIVLTQSPGTLSLSPGERGTLSCRASQYITTGHFAWYQQKPGRAPRLLIYGASVRATG VPDRFSGSGAETDFTLTISRLDPEDVGVYYC FGPGTKVDIK Z017 (MEX84_p2-58) Heavy Chain (HC) (SEQ ID NO: 71) QVQLVQSGAGMRKPGASVKVSCKASGYSFNDYYIHWVRQAPGQGLEWMGWINPKS GFTNYAQRFQGRVTMTGDTSNSVAYMELTRLTSDDTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 72) EIVLTQSPDTLSLSPGETATLSCRASQSIGSISLGWYQQKFGQAPRLLIYGASTRATGTP DRFSGSGSETDFTLTISRLEPEDSAVYYC FGGGTKVEIK Z019 (MEX84_p4-16) Heavy Chain (HC) (SEQ ID NO: 73) QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYFIHWVRQAPGQGLEWMGIINPNSG STNYAQKIQGRVTMTTDTSASTVYMELSGLRSEDTAVYYC WGQGTMVTVSS Light Chain (LC) (SEQ ID NO: 74) DIQLTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPNLLIFATSSLQSGVP SRFSGSGSGTDFTLTISSLQPEDFATYYC FGGGTKVEIK Z020 (MEX84_p4-30) Heavy Chain (HC) (SEQ ID NO: 75) QVQLQQWGARPLKPSETLSLTCGVNGGSFSGYHWSWIRQPPGKGLEWIGEIDHNGRI NYNPSLKSRVTISIDTFKSQFSLRLTSIIAADTAVYYC WGQGTTVTVSS Light Chain (LC) (SEQ ID NO: 76) EIVLTQSPGTLSLSPGDRATLSCGASQSVSSNYLAWYQQKLGQAPRLLIYAASTRATGI PDRFSGGGSGTDFTLTINKLEAEDFAMYYC FGQGTKVEIK Z032 (BRA112_24) Heavy Chain (HC) (SEQ ID NO: 77) EVQLLESGGRLVQPGGSLTLSCAASGFPFSTYAMSWLRQAPGKGLEWVSGITGDSGS TYYAASVKGRFTISRDNSKNTLYLQMNSLTADDTAVYYC W GQGTLVTVSS Light Chain (LC) (SEQ ID NO: 78) DIQMTQSPSTLSASVGDRVNITCRASQSINQWLAWYQQKPGKAPKFLMYKASTLETG VPSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z034 (BRA112_09) Heavy Chain (HC) (SEQ ID NO: 79) EVQLLESGGGLAQPGGSLRLSCETSGFTFRSYGMGWVRQAPGKGLEWVSSIYISGDS TYYAASVKGRFTISRDNSKSTLYLQMDRLTAEDTAVYYC WG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 80) DIQMTQSPSTLSASVGDRVTMTCRASQSVNKWLAWYQQKPGKAPKLLIYETSILESG VSSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z036 (BRA112_91) Heavy Chain (HC) (SEQ ID NO: 81) EVQLLESGGDLVQPGGSLRLSCAASGFTFSTYGMAWVRQAPGKGLEWLSSISSVDDS KYYAASVKGRFTISRDNSRNTLYLHMNSLRVDDTAVYYC W GQGTLVTVSS

Light Chain (LC) (SEQ ID NO: 82) DIQMTQSPSTLSASVGDRVTITCRASQSISGWLAWYQQKPGKAPRLLMHKASNLYSG VPSRFSGSGSGTEFTLTISSLQPDDFATYYC FGQGTKVEIK Z040 (BRA12_81) Heavy Chain (HC) (SEQ ID NO: 83) EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSAISGSGRS TYYADSVKGRFTISRDNSKNTLYLQMNSLRGEDTAVYYC WGQGTTVTVSS Light Chain (LC) (SEQ ID NO: 84) DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVP SRFSGSGSGTEFTLTISSLQPEDFATYYC FGPGTKVDIK Z044 (BRA138_46) Heavy Chain (HC) (SEQ ID NO: 85) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSTYIHWVRQAPGQGLEWMGIINPSSSN TNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC WGQGTMVTVSS Light Chain (LC) (SEQ ID NO: 86) QSALTQPASVSGSPGQSITISCTGTSSDVGSFNLVSWYQQHPGKAPKLIIYEVSKRPSG VSNRFSGSKSGNTASLTISGLQAEDEVHYYC FGTGTKVTVL Z045 (BRA12_08) Heavy Chain (HC) (SEQ ID NO: 87) EVQLLESGGALVQPGGSLRLSCAASGFTFNYYAMTWVRQAPGRGLEWVSTITDNGG TTYLADSVKGRFTISRDNSQNTQSLQMNNLRADDTAVYFC WGQ GTLVTVSS Light Chain (LC) (SEQ ID NO: 88) EIVLTQSPGTLSLSPGERATLSCRASQSVSGSYLAWYQQKPGQAPRLLIYGASRRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYC FGQGTKLEIK Z048 (BRA112_23) Heavy Chain (HC) (SEQ ID NO: 89) EVQLLESGGGLVKPGGSLRLSCAASGLTFSTYAMSWVRQAPGKGLEWVSAISPGSGD NIYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC WGQG TLVTVSS Light Chain (LC) (SEQ ID NO: 90) EIVLTQSPATLSLSPGERATLSCRASQSVSNYLAWYQQKPGQAPRLLIYDASNMAPGIP ARFSGSGSGTDFTLTISSLEPEDFAVYYC FGGGTKVDIK Z050 (BRA138_28) Heavy Chain (HC) (SEQ ID NO: 91) QVQLVQSGAEVKKPGSSVKVSCKAPGGTFSRYSIAWVRQAPGQGLEWMGGINPTFT TPNYAQKFQGRVTITADESTNTAYLDLSSLRSEDTAVYYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 92) EIVLTQSPATLSLSPGERVTLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIP ARFTGSGSGTDFTLTISSLEPEDFAVYYC FGGGTKVEIK Z051 (BRA138_59) Heavy Chain (HC) (SEQ ID NO: 93) QVQLQESGPGLVKPSQTLSLTCTVSGVSISSGGYYYSWFRQLPGKGLEWIGHIYYTGN THYNPSLRSRLTISVDTSKNQFSLKLSSVTAADTARYYC WG RGTLVTVSS Light Chain (LC) (SEQ ID NO: 94) EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQHKPGQAPRLLIYGASSRAPGIP DRFSGSGSGTDFTLTISRLEPEDFAVYWC FGQGTKLEIK Z052 (BRA138_62) Heavy Chain (HC) (SEQ ID NO: 95) QVQLQESGPGLVKPSQTLSLTCTVSGGSITGGVYYWNWIRHHPGKGLEWIGYMFYSG DTDYNPSLRSRVTISGDTSKNKFSLNLNSVTAADTAVYYC W GQGTLVTVSS Light Chain (LC) (SEQ ID NO: 96) EIVLTQSPATLSLSPGERATLSCRASQSVSSTYLVWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYFC FGQGTKLEIK Z053 (BRA138_65) Heavy Chain (HC) (SEQ ID NO: 97) QLQLQESGPGLVKPSETLSLTCTVSGGSISSYNYYWGWIRQPPGKGLEFIGSIYYTGST YYNPSLRSRVTISVDTSKNQFSLKLTSVTAADTAVYYC WG RGTLVTVSS Light Chain (LC) (SEQ ID NO: 98) EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRAPGIPA RFSGSGSGTDFTLTISSLEPEDFAVYYC FGGGTKVEIK Z054 (BRA138_94) Heavy Chain (HC) (SEQ ID NO: 99) QLQLQESGPRLVKPSETLFLTCTVSGDSISSSSYFWGWIRQPPGKGLEWIGSISYSGST YYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTVVYYC WG PGTLVTVSS Light Chain (LC) (SEQ ID NO: 100) EIVLTQSPATLSLSPGERATLSCRASQSVSIYLAWYQQKPGQAPRLLIYDASSRATGIPA RFSGSGSGTDFTLTISSLEPEDFAVYYC FGQGTKVEIK Z055 (MEX84_p4-61) Heavy Chain (HC) (SEQ ID NO: 101) EVQLVQSGAEVKKPGASVKVSCKASGYTFSGYYIHWLRQAPGQGLEWMGWINSNSG GADSGPRFHGRVTMTRDTSINTAYLELTNLRSDDTAVYYC WGRGTLVTVSS Light Chain (LC) (SEQ ID NO: 102) AIRMTQSPSSLSASVGDRVTITCRASQDIGSYLNWYQQKPGKAPNVLISAASTLQSGV PSRISGIGSGTDFTLTISSLQPEDFATYYC FGQGTKLEIK Z056 (MEX84_p2-94) Heavy Chain (HC) (SEQ ID NO: 103) EVQLVQSGAEVKKPGASVKVSCKASGNTFMGYYFHWVRQAPGQGLEWMGWINPNS GHANIAQTFQGRVTMTRDPSITTAYMELSRLRSDDTAVFYC WGQGTLVTVSS Light Chain (LC) (SEQ ID NO: 104) DIQMTQSPSTLSASVGDRVTITCRASQSISHWLAWYQQRPGEAPKLLIYQASTLESGV PSRFSGSGSGTEFTLSISSLQPDDFATYYC FGQGTKLEIK Z057 (MEX84_p4-54) Heavy Chain (HC) (SEQ ID NO: 105) EVQLVQSGAEVKRPGASVKVSCKASGYTFADYYIHWVRQAPGLGLEWMGWINPKT GFSHYEQTFQGRVTMARDTSIPAAYMELSSLKSDDTAIYYC W GQGSLVTVSS Light Chain (LC) (SEQ ID NO: 106) DIQMTQSPSTLSTFVGDRVTITCRASQTIGDWLAWYQQKPGKAPKLLISKATRLESGV PSRFSGSGSETEFSLTINSLQPDDVAAYYC FGQGTKLEIK Z058 (MEX84_p2-53) Heavy Chain (HC) (SEQ ID NO: 107) EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIIWVRQAPGQGLEWMGGIIPIFGT TNYAQKFRGRVTIATDASKSAAYMDLSSLKSEDTAIYYC QWG QGTLVTVSS Light Chain (LC) (SEQ ID NO: 108) EIVMTQSPATLSVSPGERATLSCRASHSVTSNLAWYQQKPGQAPRLLIYGASTRATGI PARFSGSGSGTEFTLTISSLQSEDSAVYYC FGQGTKLEIK Z059 (MEX84_p4-34) Heavy Chain (HC) (SEQ ID NO: 109) EVQLVQSGAEVKTPGSSVKVSCKTSGGTFSNFAITWVRQAPGQGLEWMGGIIPLFGI TNYTQKFQGRVTITTDESKTTAYMDLSGLRSEDTAVYFCA WGQG TLVTVSS Light Chain (LC) (SEQ ID NO: 110) EIVMTQSPATLSVSPGERATLSCRASQTVNRNLAWYQQKPGQAPRLLIYAASARATG VPARFSGSGSGTEFTLTISSLQSEDFVVYYC FGGGTKLEIK Z060 (BRA12_58) Heavy Chain (HC) (SEQ ID NO: 111) QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGFIYYSGSTNY NPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYC WGQ GTLVTVSS Light Chain (LC) (SEQ ID NO: 112) EIVLTQSPGTLSLSPGERATLSCRASQSVSSSSLAWYQQKPGQAPRLLIYGASNRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYC FGGGTKVEIK Z061 (BRA112_36) Heavy Chain (HC) (SEQ ID NO: 113) EVQLVESGGGVVQPGRSLRLSCAASGFTFSISTIHWVRQAPGKGLEYVVVISHDGNT KYYADSVKGRFIISRDNSKNTVFLQMNSLRPVDTAVYYC WGRGTLV TVSS Light Chain (LC) (SEQ ID NO: 114) EIVLTQSPATLSLSPGERATLSCRASQSVSSFLAWYQQKPGQPPRLLIYDASTRATGIP ARFSGSGSGTDFTLTISSLEPEDFAVYYC FGQGTRLEIK Z062 (BRA112_70) Heavy Chain (HC) (SEQ ID NO: 115) EVQLVESGGGVVQPGRSLRLSCAASGFSFSSHAMYWVRQAPGKGLEWVAIVSYDGS

TKNYADSVKGRFTISRDNSKNTIYLHLNSLRAEDTAVYFC WGQ GTLVTVSS Light Chain (LC) (SEQ ID NO: 116) EIVLTQSPATLSLSPGERATLSCRARQNVRNFLAWYQQKPGQAPRLLIYDASNRATDI PARFSGSGSGTDFTLTISSLEPEDFAVYYC FGQGTRLEIK

[0110] The following Table A table provides a summary of neutralizing and binding properties that pertain to the immediately forgoing 32 antibodies.

TABLE-US-00010 TABLE A ZIKV ZIKV EDIII neutralization binding EC.sub.50 DENV1 DENV2 DENV3 DENV4 YFV WNV Antibody IC.sub.50 (ng/ml) (ng/ml) binding binding binding binding binding binding Z002 1.5 25.2 + - - - - - Z003 1 25.5 + - - - - - Z005 1.3 216.3 + - - - - - Z007 1.5 34.6 + - - - - - Z008 1.7 32.6 + - - - - - Z009 1.4 28.4 + - - - - - Z011 1 38.0 + - - - - - Z013 4.1 >10000 + - - - - - Z016 68.9 72.4 - - - - + + Z017 n.d. >10000 - - - - - + Z019 n.d. >10000 n.d. n.d. n.d. n.d. n.d. n.d. Z020 n.d. >10000 n.d. n.d. n.d. n.d. n.d. n.d. Z032 0.9 19.5 n.d. n.d. n.d. n.d. n.d. n.d. Z034 1.3 23.5 + - - - - - Z036 0.7 17.2 + - - - - - Z040 n.d. >10000 - - - - - - Z044 n.d. >10000 - - - - - - Z045 n.d. >10000 n.d. n.d. n.d. n.d. n.d. n.d. Z048 n.d. >10000 n.d. n.d. n.d. n.d. n.d. n.d. Z050 36.7 30.3 - - - - - + Z051 n.n. 1864.5 - - - - - - Z052 10.9 13.1 - - - - - + Z053 n.n. 1683 - - - - - - Z054 n.n. >10000 - - - - - - Z055 54.4 1878 - - - - + + Z056 36.7 982 - - - - + + Z057 28.8 82.8 - - - - + + Z058 n.n. >10000 n.d. n.d. n.d. n.d. n.d. n.d. Z059 96.0 610.4 - - - - + + Z060 n.d. >10000 n.d. n.d. n.d. n.d. n.d. n.d. Z061 n.d. 311.3 - - - - - - Z062 n.d. 208.2 - - - - - - n.d. = not determined n.n. = non-neutralizing

[0111] In embodiments the disclosure provides neutralizing antibodies. The term "neutralizing antibody" refers to an antibody or a plurality of antibodies that inhibits, reduces or completely prevents viral infection. Whether any particular antibody is a neutralizing antibody can be determined by in vitro assays described in the examples below, and as is otherwise known in the art.

[0112] Antibodies of this disclosure can be provided as intact immunoglobulins, or as fragments of immunoglobulins, including but not necessarily limited to antigen-binding (Fab) fragments, Fab' fragments, (Fab').sub.2 fragments, Fd (N-terminal part of the heavy chain) fragments, Fv fragments (the two variable domains), dAb fragments, single domain fragments or single monomeric variable antibody domains, isolated CDR regions, single-chain variable fragment (scFv), and other antibody fragments that retain virus-binding capability and preferably virus neutralizing activity as further described below.

[0113] Antibodies and peptides or mRNA or DNA vaccines of this disclosure can be provided in pharmaceutical formulations. It is considered that administering a DNA or RNA vaccine encoding any protein (including peptides and polypeptides) antigen described herein is also a method of delivering such peptide antigens to an individual, provided the DNA and RNA are expressed in the individual. Methods of delivering DNA and RNAs encoding proteins are known in the art and can be adapted to deliver the protein antigens, given the benefit of the present disclosure. Similarly, the antibodies of this disclosure can be administered as DNA molecules encoding for such antibodies using any suitable expression vector(s), or as RNA molecules encoding the antibodies.

[0114] Pharmaceutical formulations containing antibodies or viral antigens can be prepared by mixing them with pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers include solvents, dispersion media, isotonic agents and the like. The carrier can be liquid, semi-solid, e.g. pastes, or solid carriers. Examples of carriers include water, saline solutions or other buffers (such as phosphate, citrate buffers), oil, alcohol, proteins (such as serum albumin, gelatin), carbohydrates (such as monosaccharides, disaccharides, and other carbohydrates including glucose, sucrose, trehalose, mannose, mannitol, sorbitol or dextrins), gel, lipids, liposomes, resins, porous matrices, binders, fillers, coatings, stabilizers, preservatives, liposomes, antioxidants, chelating agents such as EDTA; salt forming counter-ions such as sodium; non-ionic surfactants such as TWEEN, PLURONICS or polyethylene glycol (PEG), or combinations thereof. In embodiments, a pharmaceutical/vaccine formulation exhibits an improved activity relative to a control, such as antibodies that are delivered without adding additional agents, or a particular added agent improves the activity of the antibodies.

[0115] The formulation can contain more than one antibody type or antigen, and thus mixtures of antibodies, and mixtures of antigens, and combinations thereof as described herein can be included. These components can be combined with a carrier in any suitable manner, e.g., by admixture, solution, suspension, emulsification, encapsulation, absorption and the like, and can be made in formulations such as tablets, capsules, powder (including lyophilized powder), syrup, suspensions that are suitable for injections, ingestions, infusion, or the like. Sustained-release preparations can also be prepared.

[0116] The antibodies and vaccine components of this disclosure are employed for the treatment and/or prevention of ZIKV and/or DENV1 infection in a subject, as well as for inhibition and/or prevention of their transmission from one individual to another, and in particular in the case of transmission of Zika virus from a mother to a fetus, or from one partner to another during sexual intercourse wherein transmission between the individuals can take place. Accordingly, while embodiments of the disclosure are appropriate for use with any individual who is at risk of, is suspected of having, or has been diagnosed with a Zika virus infection, or a dengue 1 virus infection (or other related viruses), in particular embodiments of the disclosure comprise administering a composition of this invention to a female who is known to be pregnant, intending to become pregnant, suspected of being pregnant, or is engaging in sexual activity which raises a likelihood of pregnancy. Administration soon after delivery is also included, and direct administration to a fetus or to a newborn is also included.

[0117] The term "treatment" of viral infection refers to effective inhibition of the viral infection so as to delay the onset, slow down the progression, reduce viral load, and/or ameliorate the symptoms caused by the infection.

[0118] The term "prevention" of viral infection means the onset of the infection is delayed, and/or the incidence or likelihood of contracting the infection is reduced or eliminated.

[0119] The term "prevention" of viral transmission means the incidence or likelihood of a viral infection being transmitted from one individual to another (e.g., from a ZIKV-positive woman to her child during pregnancy, labor or delivery, or breastfeeding; or between sexual partners) is reduced or eliminated.

[0120] In embodiments, to treat and/or prevent viral infection, a therapeutic amount of an antibody or antigen vaccine disclosed herein is administered to a subject in need. The term "therapeutically effective amount" means the dose required to effect an inhibition of infection so as to treat and/or prevent the infection.

[0121] In embodiments, the disclosure comprises co-administration of a combination of antibodies. In an embodiment, administration of a combination of distinct antibodies suppresses formation of viruses that are resistant to the effects of either one of the antibodies alone. In embodiments, a combination of at least two antibodies includes at least two antibodies that each recognize distinct epitopes on Zika Envelope Domain III (EDIII), non-limiting examples of which are described below. In one non-limiting example, a combination of antibodies described herein as Z004 and Z021 is protective and suppresses emergence of resistant variants and/or fully suppresses virus emergence altogether. Thus, in embodiments, such a co-administration of a combination of at least two distinct antibodies described herein suppresses formation of variant Zika viruses that are resistant to treatment and/or prevents infection. In embodiments, the Z004 and Z021 antibodies can be administered concurrently or sequentially.

[0122] The dosage of an antibody or antigen vaccine depends on the disease state and other clinical factors, such as weight and condition of the subject, the subject's response to the therapy, the type of formulations and the route of administration. The precise dosage to be therapeutically effective and non-detrimental can be determined by those skilled in the art. As a general rule, a suitable dose of an antibody for the administration to adult humans parenterally is in the range of about 0.1 to 20 mg/kg of patient body weight per day, once a week, or even once a month, with the typical initial range used being in the range of about 2 to 10 mg/kg. Since the antibodies will eventually be cleared from the bloodstream, re-administration may be required. Alternatively, implantation or injection of the antibodies provided in a controlled release matrix can be employed.

[0123] The antibodies and/or antigen vaccines (as proteins or polynucleotides encoding the proteins) can be administered to the subject by standard routes, including oral, transdermal, and parenteral (e.g., intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular). In addition, the antibodies and/or the antigen vaccines can be introduced into the body, by injection or by surgical implantation or attachment such that a significant amount of an antibody or the vaccine is able to enter blood stream in a controlled release fashion. In certain embodiments antibodies described herein are incorporated into one or more prophylactic compositions or devices to, for instance, neutralize a virus before it enters cells of the recipient's body. For example, in certain embodiments a composition and/or device comprises a polymeric matrix that may be formed as a gel, and comprises at least one of hydrophilic polymers, hydrophobic polymers, poly(acrylic acids) (PAA), poly(lactic acids) (PLA), carageenans, polystyrene sulfonate, polyamides, polyethylene oxides, cellulose, poly(vinylpyrrolidone) (PVP), poly(vinyl alcohol) (PVA), chitosan, poly(ethylacrylate), methylmethacrylate, chlorotrimethyl ammonium methylmethacrylate, hydroxyapatite, pectin, porcine gastric mucin, poly(sebacic acid) (PSA), hydroxypropyl methylcellulose (HPMC), cellulose acetate phthalate (CAP), magnesium stearate (MS), polyethylene glycol, gum-based polymers and variants thereof, poly (D,L)-lactide (PDLL), polyvinyl acetate and povidone, carboxypolymethylene, and derivatives thereof. In certain aspects the disclosure comprises including antibodies in micro- or nano-particles formed from any suitable biocompatible material, including but not necessarily limited to poly(lactic-co-glycolic acid) (PLGA). Liposomal and microsomal compositions are also included. In certain aspects a gel of this disclosure comprises a carbomer, methylparaben, propylparaben, propylene glycol, sodium carboxymethylcellulose, sorbic acid, dimethicone, a sorbitol solution, or a combination thereof. In embodiments a gel of this disclosure comprises one or a combination of benzoic acid, BHA, mineral oil, peglicol 5 oleate, pegoxol 7 stearate, and purified water, and can include any combination of these compositions.

[0124] The disclosure includes devices and kits that relate to inserting into vagina an intravaginal medicated device comprising antibodies of the disclosure. In certain embodiments the disclosure provides a vaginal tampon, vaginal ring, vaginal cup, vaginal tablet, vaginal sponge, a vaginal bioadhesive tablet, a vaginal lubricant, a condom, or a modified female hygiene or other vaginal health care product, such as prescription and over-the-counter antifungal products that treat and/or cure vaginal yeast infections, or bacterial vaginosis, but that have been adapted to include antibodies of this disclosure. Applicators that are provided with female hygiene or vaginal health care products can be adapted for intravaginal administration of the antibodies. In certain aspects a method of the invention comprises intravaginal insertion of a medicated device antibodies of this disclosure. The delivery composition can be formulated to adhere to and act directly on the vaginal epithelium and/or mucosa. In certain aspects a composition and/or device of this may comprise one or more additional agents known to be suitable for treatment of viral, or other bacterial or parasitic infections. Such compositions include but are not limited to antibiotics and previously known anti-viral agents, and chemical compounds that act as biocides or antiseptic agents, such as benzalkonium chloride. Additional agents include but are not limited to soothing compositions that contain, for example anti-irritant and/or anti-inflammatory agents, such as hydrocortisone or related compounds, or emollients, or anti-hemorrhagic or hemostatic or anti-allergic agents. In embodiments a composition and/or device of this disclosure comprises a contraceptive agent, such as a spermicide or a hormonal or non-hormonal contraceptive drug that is combined with one or more antibodies of this disclosure.

[0125] Antibodies of this disclosure can be produced by utilizing techniques available to those skilled in the art. For example, one or distinct DNA molecules encoding one or both of the H and L chains of the antibodies can be constructed based on the coding sequence using standard molecular cloning techniques. The resulting DNAs can be placed into a variety of suitable expression vectors known in the art, which are then transfected into host cells, which are preferably human cells cultured in vitro, but may include E. coli or yeast cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, and human embryonic kidney 293 cells, etc.

[0126] In certain approaches the invention includes neutralizing antibodies as discussed above, and methods of stimulating the production of such antibodies. Antibodies can be produced from a single, or separate expression vectors, including but not limited to separate vectors for heavy and light chains, and may include separate vectors for kappa and lambda light chains as apporpriate.

[0127] The antibodies may be neutralizing with respect to infectivity by ZIKV, DENV1, and combinations thereof. Neutralization may extend beyond ZIKV and DENV1 to include other viruses of the same genus (such as but not limited to DENV2, DENV3, DENV4, YFV, WNV), given that the EDIII of these viruses shares structural similarities. In this regard, the present disclosure demonstrates that at least some of the antibodies described herein bind to DENV2-4, yellow fever virus (YFV) and West Nile virus (WNV) (see e.g. FIG. 3C). In embodiments antibodies are neutralizing with respect to Asian/American strains of ZIKV, and also to African ZIKV, wherein the African ZIKV comprises an amino acid difference in its EDIII protein relative to the ZIKV Asian/American EDIII protein, and wherein the difference is optionally at position 393 in the African ZIKV EDIII protein, and wherein the difference at position 393 is optionally D393 instead of E393.

[0128] In certain approaches the disclosure includes methods for prophylaxis and/or therapy for a viral infection(s) comprising administering to an individual a vaccine formulation comprising antibodies and/or viral antigens described herein. The compositions can be administered to any individual in need thereof, wherein the individual is infected with or is at risk of being infected with Zika virus and/or dengue 1 virus. In one approach, administration of a vaccine comprising and/or encoding Zika polypeptides described herein is preceded by administering to the individual a composition comprising a DENV1 antigen, which without intending to be bound by any particular theory is believed to be able at least in some instances to enhance protection against Zika virus.

[0129] In certain embodiments the disclosure provides for consecutive or concurrent administration of ZIKV and DENV1 antigens, as well as other EDIII-derived antigens from other structurally similar viruses, including but not limited to DENV2-4, YFV, and WNV. In connection with this, it is contemplated that administering an antigen described herein, or a structurally similar antigen, may provide for stimulating production and/or proliferation of B lymphocytes that express a VH3-23/VK1-5 gene combination, which without intending to be bound by any particular theory, may provide for enhanced neutralizing antibodies against ZIKV, DENV1 and other related viruses.

[0130] An aspect of the disclosure is illustrated in FIG. 22. Data summarized in FIG. 22 show results of immunizing mice using the EDIII of flaviviruses as the immunogen. The antibody response to the EDIII lateral ridge region, which as discussed above is the neutralizing epitope recognized by antibody Z004, is enhanced if the immunization with the ZIKV EDIII is preceded by priming with the EDIII of DENV1 (Panel A). Moreover, this regimen results in antibodies with higher neutralization capacity (Panel B). This result is consistent with the observation that the lateral ridge represents a shared neutralizing epitope for both ZIKV and DENV1, and that individuals exposed to DENV1 are more likely to become high responders to ZIKV.

[0131] In certain implementations the invention includes antigens and segments thereof for use in vaccine formulations and diagnostic approaches. In non-limiting examples the ZEDIII polypeptide for use as antigen in vaccination comprises or consists of all or a contiguous or non-contiguous segment of the ZIKV EDIII sequence:

TABLE-US-00011 i) (SEQ ID NO: 117) VSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLT PVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITMWHRS (ZIKV E protein residues 303-403);

and/or comprises or consists of all or a contiguous or non-contiguous segments of the DENV1 EDIII sequence:

TABLE-US-00012 ii) (SEQ ID NO: 118) MSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQ NGRLITANPIVTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKK (DENV1 E protein residues 297-394),

[0132] or sequences having from 80-99% identity with the sequence of i) and/or ii).

[0133] In embodiments a ZEDIII polypeptide of this disclosure optionally comprises at least one contiguous segment of ZEDIII comprising amino acids 305-311, 333-336, or 350-352 (and combinations thereof), and/or the segment optionally comprises one or more of ZEDIII amino acids L307, S306, T309, K394, A311, E393, T335, G334, A310, and D336, and/or the polypeptide comprises a segment of the DENV1 EDIII that includes an epitope that comprises amino acids M301, V300, T303, E384, T329, K385, S305, E327, G328, D330 DENV1 EDIII protein.

[0134] In certain approaches the disclosure includes vaccinating an individual using a composition described herein, and determining the presence, absence, and/or an amount of neutralizing antibodies produced in response to the vaccination. Thus, methods of determining and monitoring efficacy of a vaccination at least in terms of neutralizing antibody production are included. Determination of the neutralizing antibodies can be performed using any suitable approach, one of which includes a competitive ELISA assay as described herein. In an embodiment, subsequent to determining an absence of neutralizing antibodies, and/or an amount of neutralizing antibodies below a suitable reference value, the invention includes administering a composition disclosed herein to the individual. Subsequent administrations and measurements can be made to track the treatment efficacy and make further adjustments to treatment accordingly. In one embodiment the presence, absence and/or amount of ZIKV and/or DENV1 neutralizing antibodies is determined using a biological sample from a pregnant human female, and the determination of the antibodies is used in estimating risk of fetal complications, including but not necessarily a risk of the fetus developing microcephaly. In one approach, determining an absence of neutralizing antibodies, and/or an amount of neutralizing antibodies below a suitable reference value for a pregnant female is followed by administering a composition described herein for the purpose of inhibiting development of the fetal complications.

[0135] Antibodies and proteins of this disclosure can be detectably labeled and/or attached to a substrate. Any substrate and detectable label conventionally used in immunological assays and/or devices is included. In embodiments the substrate comprises biotin, or a similar agent that binds specifically with another binding partner to facilitate immobilization and/or detection and/or quantification of antibodies and/or viral proteins.

[0136] In embodiments the disclosure comprises immunological assays to, for example, characterize serologic activity against ZIKV or DENV1.

[0137] In embodiments any type of enzyme-linked immunosorbent (ELISA) assay can be used, and can be performed using polypeptides and/or antibodies of this disclosure for diagnostic purposes, and can include direct, indirect, and competitive ELISA assays, and adaptations thereof that will be apparent to those skilled in the art given the benefit of this disclosure.

[0138] In embodiments the disclosure provides for a competition ELISA using, for example, assay plates coated with any ZEDII protein described herein. Upon exposure of a patient sample, such as a blood or serum sample, patient antibodies to the lateral ridge (LR) epitope present on the ZEDII protein (if such patient antibodies are present) will bind to the ZEDII protein. Taking a labeled Z004 antibody as a non-limiting example of a detecting antibody, the presence in serum of antibodies to the LR-epitope will block binding of labeled Z004, whereas absence of (or less) patient antibodies to the LR-epitope will allow binding of labeled Z004, enabling detection. The concentration of Z004 blocking antibodies can then extrapolated from a standard curve.

[0139] In another embodiment an ELISA is conducted after serum blocking is performed. To perform such an assay, patient serum dilutions are incubated (`blocked`) with saturating amounts of either wild type ZEDIII protein or with ZEDIII protein mutated as described herein, such as by alanine at the E393 and K394 residues. (Alternatively, DENV1 proteins can be adapted for similar use, and can include, for example, using DENV1 EDIII protein mutated at the E384 and/or K385 residues). Next, the remaining IgG binding to wild type ZEDIII is measured by ELISA and the BT.sub.50 values (=50% of maximal binding titer, binding titer 50) for the samples blocked with ZEDIII wild type or with ZEDIII mutant proteins are determined. The shift in binding activity between the two blocking can be represented graphically as the .DELTA.BT.sub.50 and is a measure of the amount of LR-epitope specific antibodies in the patient sample.

[0140] Any diagnostic result described herein can be compared to any suitable control. Further, any diagnostic result can be fixed in a tangible medium of expression and communicated to a health care provider, or any other recipient. In one aspect the disclosure comprises diagnosing an individual as infected with ZIKV and/or DENV1 and administering a composition of this invention to the individual.

[0141] In certain embodiments the disclosure includes one or more recombinant expression vectors encoding H and L chains of an antibody of this disclosure, cells and cell cultures comprising the expression vectors, methods comprising culturing such cells and separating antibodies from the cell culture, the cell culture media that comprises the antibodies, antibodies that are separated from the cell culture, and kits comprising the expression vectors encoding an antibody and/or a polypeptide of this disclosure. Products containing the antibodies and/or the polypeptides are provided, wherein the antibodies and/or the polypeptides are provided as a pharmaceutical formulation contained in one or more sealed containers, which may be sterile and arranged in any manner by which such agents would be suitable for administration to a human or non-human subject. The products/kits may further comprise one or more articles for use in administering the compositions.

[0142] The following Examples are intended to illustrate but not limit the invention.

Example 1

[0143] Serologic Responses to ZIKV in Brazil and Mexico

[0144] Individuals infected with pathogens display a spectrum of antibody responses ranging from low levels of non-neutralizing antibodies to high titers of neutralizing antibodies. To determine whether a population infected with ZIKV also displays a range of antibody responses we screened 405 individuals living in ZIKV epidemic areas for serum IgG capable of binding to ZIKV E Domain III (ZEDIII, FIG. 1A).

[0145] Nearly three hundred sera were obtained in November 2015, shortly after ZIKV was introduced in Salvador, Brazil, from participants who were enrolled in a prospective study in 2013 from Pau da Lima, an urban slum community within the city (Cardoso et al., 2015; Felzemburgh et al., 2014; Hagan et al., 2016). An additional 108 sera were from Santa Maria Mixtequilla, a rural town in Oaxaca, Mexico. ZIKV infections were documented by PCR in Santa Maria Mixtequilla at the time of sample collection in April of 2016. Dengue virus (DENV) is endemic at both sites. Sera obtained from the Pau da Lima cohort in 2010 following a DENV outbreak, but before the introduction of ZIKV into Brazil, served as non-ZIKV flavivirus-exposed control for background reactivity against ZIKV (Silva et al., 2016). ZIKV introduction was associated with a broad distribution of serologic reactivity against ZEDIII in both Brazilian and Mexican samples by ELISA (FIG. 1A).

[0146] To determine whether serologic reactivity to ZEDIII is associated with ZIKV neutralizing activity, we assessed the top 31 sera (black symbols in FIG. 1A) for neutralization of luciferase-expressing reporter viral particles (RVP) bearing ZIKV structural proteins (see Methods; FIG. 1B). Neutralizing titers, expressed as the reciprocal of the dilution resulting in a 50% reduction of the luciferase signal achieved in the absence of serum (NT.sub.50), varied by over 2 logs indicating a broad range of humoral immune responses to ZIKV (FIG. 1B).

[0147] Human Monoclonal Antibodies to ZIKV

[0148] To further characterize the antibody response in 6 individuals with high neutralizing titers, 3 from each cohort, we used fluorescently-labeled ZEDIII to identify and purify single memory B cells in the peripheral blood (FIG. 2A). ZEDIII-specific memory B cells were found at frequencies ranging from 0.13-1.98% of all circulating IgG.sup.+ memory B cells (FIG. 2A, see Methods). Although the sample size is limited, the frequency of ZEDIII-specific memory B cells did not appear to correlate with either ZEDIII binding or neutralizing activity (FIG. 1). We conclude that there is significant variability in the frequency of ZEDIII-specific memory B cells in individuals that show serum ZIKV neutralizing activity.

[0149] Antibody heavy (IGH) and light (IGL) chain genes were amplified from single purified ZEDIII binding B cells by RT-PCR and sequenced (Scheid et al., 2009; von Boehmer et al., 2016). Overall, 290 antibodies were identified from the 6 individuals. Nearly one half of all of the antibodies (133) were found in expanded clones that shared the same IGH and IGL variable (IGVH and IGVL) gene segments, and the remaining half were unique (FIG. 2B and Tables 1 and 2).

[0150] Memory B cells expressing antibodies composed of VH3-23 paired with VK1-5 were found in 5 out of the 6 individuals assayed (FIG. 2B, and FIG. 8). Moreover, VH3-23/VK1-5 was present as an expanded clone in 4 individuals, and was the largest expanded clone in 3 out of the 6 individuals. The sequence of the VH3-23/VK1-5 antibodies in the expanded clones was further limited in that the VK1-5 gene segment was always recombined with JK1 (FIG. 2C). In addition to VH3-23/VK1-5 clones we also found expanded clones of memory B cells expressing antibodies composed of VH3-23 paired with other IGL genes (VH3-23/VK1-27, VH3-23/VK3-11 and VH3-23/VK3-20; FIG. 2B). Of the 6 individuals examined, only BRA 138, who exhibited the lowest level of neutralizing activity, did not have any detectable memory B cells expressing VH3-23/VK1-5 antibodies. We conclude that individuals with high serologic neutralizing titers to ZIKV in geographically distinct outbreak areas frequently show clonally expanded ZEDIII-specific memory B cells that express VH3-23/VK1-5 antibodies.

[0151] Cross-Reactivity with Other Flaviviruses

[0152] Nineteen representative antibodies obtained from expanded memory B cell clones from the 6 individuals were expressed for further testing. This antibody panel included 8 different VH3-23/VK1-5 antibodies from 5 separate volunteers. Antibody binding activity to ZEDIII was measured by ELISA, and found to vary broadly even among the closely related VH3-23/VK1-5 antibodies, with EC.sub.50 values ranging from 20 to >4000 ng/ml (FIGS. 3A, 3B, and 9A). Like other human antibodies derived from memory B cells, anti-ZEDIII antibodies showed somatic mutations. For example, the number of IGH V gene mutations in the VH3-23/VK1-5 clones ranged from 12-40 nucleotides (average=27.7, FIG. 9B), which is far lower than that seen in antibodies during chronic HIV-1 infection (Escolano et al., 2017). Nevertheless, the mutations in anti-ZEDIII antibodies are essential to the binding activity of the antibodies since reversion of the mutations to the predicted germline sequence impaired binding to the antigen (FIG. 3B).

[0153] To determine whether the antibodies cloned from our cohorts cross-react to the EDIII proteins of other flaviviruses, we screened for binding to the four DENV serotypes (DENV1-4), YFV (Asibi and 17D strains), and WNV. We observed 5 different patterns of cross-reactivity with other flaviviruses (FIG. 3C). All 8 of the VH3-23/VK1-5 antibodies tested cross-reacted with DENV1, but not with the other flaviviruses in our panel (FIGS. 3C and 3D). Other antibodies showed singular cross-reactivity to WNV, or broader reactivity to DENV1-4, or YF and WNV, and some antibodies were uniquely specific for ZIKV (FIG. 3C). Similar to ZIKV, mutations in the VH3-23/VK1-5 antibodies were required for optimal binding to DENV1 EDIII since reversion to the predicted germline sequence impaired binding to the DENV1 antigen (FIG. 3D). We conclude that anti-ZEDIII VH3-23/VK1-5 antibodies cross-react with DENV1 but not with other flaviviruses.

[0154] Neutralizing Activity In Vitro and In Vivo

[0155] To determine whether the anti-ZEDIII antibodies neutralize ZIKV in vitro we measured their neutralizing activity in the ZIKV luciferase RVP assay described above. Neutralizing activity varied among the different antibodies ranging from sub-nanogram 50% inhibitory concentrations (IC.sub.50) to non-neutralizing (FIGS. 4A, 4B and 10A). The most potent antibody, Z004, a member of one of the VH3-23/VK1-5 clones, displayed an IC.sub.50 of 0.7 ng/ml (FIGS. 4A, 4B). Similar results were obtained by plaque reduction neutralization test (PRNT) using a Puerto Rican strain of ZIKV (IC.sub.50 of 2.2 ng/ml, FIG. 10B). All of the other VH3-23/VK1-5 antibodies tested were also potent neutralizers of ZIKV with IC.sub.50 values ranging from 0.7-4.6 ng/ml (FIG. 4A).

[0156] Z004 is a member of the VH3-23/VK1-5 family that cross-reacts with DENV1. To determine whether Z004 also neutralizes DENV1, we measured its neutralizing activity against DENV1 luciferase RVPs and by flow cytometry using authentic DENV1. We found that Z004 is a potent neutralizer of DENV1 in both assays (IC.sub.50=1.6 ng/ml by luciferase assay, and IC.sub.50=16.4 ng/ml by flow cytometry; FIGS. 4C and 10C). Thus, the VH3-23/VK1-5 antibody Z004 binds and neutralizes both ZIKV and DENV1.

[0157] To determine whether VH3-23/VK1-5 antibodies also neutralize ZIKV in vivo, we passively transferred Z004 to IFNAR1.sup.-/- mice one day before or one day after ZIKV infection (FIG. 4D). In 3 independent pre-exposure experiments, with a total of 14 mice infected with ZIKV in the presence of control antibody, we found that 93% developed clinical symptoms and 79% succumbed to infection. In contrast, pre-exposure prophylaxis with Z004 resulted in a significant reduction in disease symptoms and mortality. Only 12.5% of the Z004 group developed clinical symptoms and none died (p<0.0001 for both disease and survival; FIGS. 4E and 10D). Similar results were also obtained when the antibody was administered one day after infection (p<0.0001 for symptoms, p=0.0027 for survival; FIGS. 4F and 10D). We conclude that Z004 was protective and significantly reduced both symptoms and mortality when administered either before or after infection. Z004 also displayed a suitable profile of low poly- and auto-reactivity (FIG. 10E). Thus, VH3-23/VK1-5 antibodies have the potential for further pre-clinical evaluation.

[0158] VH3-23/VK1-5 Antibodies Recognize the Lateral Ridge of ZEDIII

[0159] There are only 2 contiguous amino acids that are uniquely shared between the EDIIIs of ZIKV and DENV1, and not by DENV2, DENV3, DENV4, WNV or YFV (E393 and K394 in ZIKV, E384 and K385 in DENV1; FIG. 4G). These 2 amino acids are found in the lateral ridge region of the ZEDIII, which is a region that is associated with virus interaction with cellular receptors (Mukhopadhyay et al., 2005). To determine whether these 2 amino acids are essential for interaction between VH3-23/VK1-5 antibodies and ZIKV, we made alanine substitutions in the context of the ZIKV RVPs and tested the recombinant RVPs for sensitivity to Z004-mediated neutralization. Although ZIKV RVPs bearing the E393A substitution remained sensitive to Z004, K394A mutant RVPs were resistant to the antibody (FIG. 4H). African ZIKV strains differ from others at position 393 carrying aspartic acid at this position. Similar to wild type Asian/American ZIKV RVPs, African ZIKV RVPs carrying D393 instead of E393 were sensitive to Z004, and Asian/American ZIKV RVPs with an E393D substitution were also efficiently neutralized (FIGS. 4G and I). Thus a shared epitope in the lateral ridge region could account for the finding that Z004 neutralizes ZIKV and DENV1, but not other flaviviruses.

[0160] Structures of ZIKV Antibodies/EDIII Complexes Reveal a Shared Binding Mode

[0161] To gain additional insights into the molecular basis of ZEDIII recognition by VH3-23/VK1-5 antibodies, we solved crystal structures of complexes of the antigen-binding fragment (Fab) of two antibodies isolated from different donors, Z006 and Z004, with ZIKV and DENV1 EDIII domains, respectively (FIG. 5). The Z006 Fab-ZEDIII and Z004 Fab-DENV1 EDIII structures showed a common mode of antigen recognition, as revealed by similar orientations of Fab V.sub.H and V.sub.L domains when the EDIII domains were superimposed (FIG. 5A). The Z006/Z004 Fab orientation is distinct from orientations in other crystallographically-characterized Fab/ZIKV and Fab/DENV1 EDIII complexes (FIG. 5B). The Z006 epitope extends over much of the EDIII lateral ridge (FIG. 5C): beyond the E393-K394.sub.ZIKV region, the next largest parts of the interface consist of the N-terminal region of EDIII (residues 305-311.sub.ZIKV), CC' loop residues 350-352.sub.ZIKV, and BC loop residues 333-336.sub.ZIKV. The E393-K394.sub.ZIKV (E384-K385.sub.DENV1) motif is central to the interface (FIG. 5C) and contacts residues within the Fab CDRH3, CDRL3, and CDRL1 loops in both structures (FIG. 5A, D-F). Despite the antibodies originating from different donors and binding to two different flavivirus EDIIIs, a number of contact interactions occur in both complexes (Table 6). Specifically, the side chain of residue K394.sub.ZIKV (K385.sub.DENV1) occupies a hydrophobic pocket formed by W32.sub.LC and Y91.sub.LC(Z006)/F91.sub.LC(Z004) and forms an H-bond with the latter residue's backbone oxygen atom (FIG. 5D). The side chain of residue E393.sub.ZIKV (E384.sub.DENV1) interacts with R96.sub.HC, although this interaction differs somewhat in the two structures: in the Z006 structure, E393.sub.ZIKV forms an H-bond with the Y91.sub.LC hydroxyl and an electrostatic interaction with R96.sub.HC, while for Z004, the side chain of residue F91.sub.LC lacks a hydroxyl group to form an H-bond, and instead the side chain of E384.sub.DENV1 forms a salt bridge with R96.sub.HC (FIG. 5E). Other common interactions include the side chain of Y58.sub.HC forming an H-bond to the backbone oxygen of L307.sub.ZIKV (M301.sub.DENV1) (FIG. 5F), and the side chain of T93.sub.LC (Z006)/S93.sub.LC (Z004) forming an H-bond to the backbone N of T335.sub.ZIKV (T329.sub.DENV1). Hence the common mode of recognition involves using equivalent pairwise interactions as well as binding with a similar orientation.

[0162] Pre-Existing DENV1 Reactivity is Associated with Enhanced ZEDIII Antibody Responses

[0163] The existence of VH3-23/VK1-5 antibodies that neutralize both DENV1 and ZIKV and are recurrently found in expanded clones suggests that prior exposure to DENV1 primes the development of protective ZIKV immunity. To examine this possibility, we tested sera obtained at time points before and after introduction of ZIKV in the Pau da Lima community in Salvador, Brazil. Anti-ZEDIII serum IgG reactivity increased significantly between April and November of 2015 (FIG. 6A). Interestingly, a similar increase was seen for DENV1, although there was no documented DENV1 outbreak in this area at this time, with only 5 DENV1 cases reported between September 2014 and July 2016 (FIG. 6A). In contrast, no significant increase in reactivity was observed for DENV2, DENV3, DENV4, YFV, or WNV EDIIIs (FIG. 6A). Consistent with the hypothesis that DENV1 primes the subsequent response to ZIKV, we observed a significant positive correlation between DENV1 EDIII-reactive IgG levels pre-ZIKV, and ZEDIII-reactive IgG levels post-ZIKV (Pseudo-p=0.48, p<0.001, FIG. 6B). Together, these data indicate that the exposure to ZIKV boosted the pre-existing DENV1 antibody response, and that individuals with pre-existing antibodies targeting the DENV1 EDIII are more likely to develop high levels of EDIII antibodies upon ZIKV infection.

[0164] Lateral Ridge Antibodies are Associated with ZIKV Neutralization

[0165] To determine whether antibodies to the lateral ridge region recognized by Z004 contribute to serologic activity against ZIKV in the Pau da Lima cohort, we developed a competition ELISA assay. In this assay we measure inhibition of biotin-Z004 binding to ZEDIII in order to quantify lateral ridge-binding antibodies present in serum (see Methods). Paired samples from April 2015 (before ZIKV) and November 2015 (after ZIKV) showed an increase in lateral ridge reactivity after ZIKV introduction (p=0.0007, FIG. 7A). Levels of antibodies present in the post-ZIKV serum that are capable of blocking Z004 binding to ZEDIII were directly correlated with the overall reactivity of antibodies to ZEDIII (Spearman coefficient, p=0.7319, p<0.0001 FIG. 7B), as well as with the increase in reactivity to ZEDIII from prior to after ZIKV (p=0.8190, p<0.0001, FIG. 7C). Finally, there was also a significant correlation between ZIKV neutralizing activity and total ZEDIII reactivity (p=0.5885, p=0.0012, FIG. 7D), as well as Z004 blocking activity (p=0.6585, p=0.0002, FIG. 7E). We conclude that antibodies that block Z004 binding to the lateral ridge make a measurable contribution to the overall serum neutralizing activity to ZIKV in exposed individuals.

Example 2

[0166] This Example provides a description of materials and methods used to obtain the results discussed above.

Experimental Model and Subjects Details

[0167] Human Subjects

[0168] Samples of peripheral blood were obtained upon consent from community participants of cohort studies in Pau da Lima (Brazil) and Santa Maria Mixtequilla (Mexico) under protocols approved by the ethical committees of the Rockefeller University (IRB DRO-0898), Yale University (IRB HIC 1603017508), FIOCRUZ (CAAE 63343516.1.0000.5028), Hospital Geral Roberto Santos (1.998.103), and National Institute of Respiratory Diseases (C16-16). Information regarding sex and age of study participants can be obtained upon request. Details on the size of the cohorts and time when samples were obtained is listed in the Results section of the manuscript.

[0169] Mice

[0170] IFNAR1.sup.-/- mice were obtained from The Jackson Laboratory and bred and maintained in the AAALAC-certified facility of the Rockefeller University. Mice were specific pathogen free and maintained under a 12 hr light/dark cycle with standard chow diet. Both male and female mice (3-4 week old) were used for all experiments and were equally distributed within experimental and control groups. Animal protocols were in agreement with NIH guidelines and approved by the Rockefeller University Institutional Animal Care and Use Committee (16855-H).

[0171] Cell Lines

[0172] Human embryonic kidney HEK-293-6E suspension cells were cultured at 37.degree. C. in 8% CO.sub.2, shaking at 120 rpm. All other cell lines described below were cultured at 37.degree. C. in 5% CO.sub.2, without shaking. Green monkey VERO cells and human hepatocytes Huh-7.5 cells (Blight et al., 2002) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 1% nonessential amino acids (NEAA) and 5% FBS. Human Lenti-X 293T cells (Clontech) and STAT1.sup.-/-, an SV40 large T antigen immortalized skin fibroblast line (Chapgier et al., 2006), were grown in DMEM 10% FBS.

[0173] Bacteria

[0174] E. coli BL21(DE3) were cultured at 37.degree. C., shaking at 250 rpm. MC1061 cells were cultured in LB medium, with 250 rpm shaking, at 30-37.degree. C. depending on the plasmid.

[0175] Viruses

[0176] Zika virus (ZIKV), 2015 Puerto Rican PRVABC59 strain (Lanciotti et al., 2016), was obtained from the CDC and passaged once in STAT1.sup.-/- fibroblasts (STAT1.sup.-/--ZIKV stock, used in mouse experiments) or twice in Huh-7.5 cells (Huh-7.5-ZIKV stock, used in all other experiments). The Thai human isolate of DENV1 PUO-359 (TVP-1140) was obtained from Robert Tesh and amplified by three passages in C6/36 insect cells.

[0177] Method Details

[0178] Collection of Human Samples

[0179] Samples of peripheral blood for serum or mononuclear cells (PBMCs) isolation were obtained from community participants and donors and frozen at the cohorts' sites. PBMCs were purified using the gradient centrifugation method with Ficoll and cryopreserved in 90% heat-inactivated fetal bovine serum (FBS) supplemented with 10% dimethylsulfoxide (DMSO), prior to shipment to Rockefeller University in liquid nitrogen. Serum aliquots were heat-inactivated at 56.degree. C. for 1 h and stored at 4.degree. C. thereafter.

[0180] Production and Biotinylation of Flavivirus Protein

[0181] The coding sequences for the EDIII portion of flaviviruses were preceded by sequences encoding the human CD5 signal peptide (MPMGSLQPLATLYLLGMLVASCLG (SEQ ID NO: 119)) and followed by a polyhistidine-AviTag (SIH-GLNDIFEAQKIEWHE (SEQ ID NO: 120)). The following flavivirus sequences were used.

TABLE-US-00013 ZIKV (KJ776791): (SEQ ID NO: 121) 5'GTGTCATACTCCTTGTGTACCGCAGCGTTCACATTCACCAAGATCCCGG CTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAG ATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGA CCCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTG AGAACTCTAAGATGATGCTGGAACTTGATCCACCATTTGGGGACTCTTACA TTGTCATAGGAGTCGGGGAGAAGAAGATCACCCACCACTGGCACAGGAGT. DENV1 (codon-optimized based on NC_001477): (SEQ ID NO: 122) 5'ATGTCATATGTGATGTGTACGGGGTCCTTTAAACTTGAAAAGGAGGTGG CAGAAACACAGCACGGAACAGTACTTGTGCAGGTTAAATATGAGGGAACCG ATGCTCCTTGTAAAATACCGTTTTCAAGCCAGGACGAAAAGGGTGTAACAC AAAATGGTCGCCTGATTACAGCCAACCCAATAGTCACTGATAAGGAGAAAC CTGTGAATATCGAGGCAGAGCCACCATTCGGCGAAAGTTATATCGTAGTTG GTGCTGGAGAAAAGGCCCTGAAACTCTCTTGGTTTAAGAAG. DENV2 (NC001474): (SEQ ID NO: 123) 5'ATGTCATACTCTATGTGCACAGGAAAGTTTAAAGTTGTGAAGGAAATAG CAGAAACACAACATGGAACAATAGTTATCAGAGTGCAATATGAAGGGGACG GCTCTCCATGCAAGATCCCTTTTGAGATAATGGATTTGGAAAAAAGACATG TCTTAGGTCGCCTGATTACAGTCAACCCAATTGTGACAGAAAAAGATAGCC CAGTCAACATAGAAGCAGAACCTCCATTCGGAGACAGCTACATCATCATAG GAGTAGAGCCGGGACAACTGAAGCTCAACTGGTTTAAGAAA. DENV3 (codon-optimized based on NC_001475.2): (SEQ ID NO: 124) 5'ATGTCATACGCAATGTGTACGAACACATTCGTTCTTAAAAAAGAGGTAA GTGAAACCCAACATGGTACTATCCTTATAAAAGTTGAGTACAAGGGCGAGG ACGCTCCCTGCAAAATACCGTTTTCCACAGAGGACGGGCAAGGTAAGGCAC ACAATGGGAGACTTATAACCGCCAATCCAGTAGTGACCAAGAAAGAGGAAC CAGTCAACATTGAAGCGGAGCCCCCTTTCGGAGAATCCAACATAGTGATAG GCATTGGGGACAACGCTCTGAAGATCAACTGGTATAAGAAG. DENV4 (codon-optimized based on NC_002640.1): (SEQ ID NO: 125) 5'ATGTCATATACAATGTGTAGCGGTAAATTCAGCATTGATAAAGAAATGG CCGAGACACAGCACGGCACCACCGTGGTAAAAGTGAAATACGAAGGAGCGG GAGCCCCGTGCAAGGTCCCCATCGAAATCAGGGATGTAAACAAAGAGAAGG TCGTTGGTAGAATAATTTCTTCTACACCACTGGCCGAGAACACTAATTCAG TTACGAATATAGAACTTGAGCCCCCCTTTGGTGACAGCTATATAGTTATTG GCGTGGGAAATTCTGCACTGACTCTGCATTGGTTCCGAAAA. YFV (Asibi strain, KF769016): (SEQ ID NO: 126) 5'ACATCCTACAAAATGTGCACTGACAAAATGTCTTTTGTCAAGAACCCAA CTGACACTGGCCATGGCACTGTTGTGATGCAGGTGAAAGTGCCAAAAGGAG CCCCCTGCAAGATTCCAGTGATAGTAGCTGATGATCTTACAGCGGCAATCA ATAAAGGCATTTTGGTTACAGTTAACCCCATCGCCTCAACCAATGATGATG AAGTGCTGATTGAGGTGAACCCACCTTTTGGAGACAGCTACATTATCGTTG GGACAGGAGATTCACGTCTCACTTACCAGTGGCACAAAGAG YFV (17D strain, KF769015): (SEQ ID NO: 127) 5'ACATCCTACAAAATATGCACTGACAAAATGTTTTTTGTCAAGAACCCAA CTGACACTGGCCATGGCACTGTTGTGATGCAGGTGAAAGTGTCAAAAGGAG CCCCCTGCAGGATTCCAGTGATAGTAGCTGATGATCTTACAGCGGCAATCA ATAAAGGCATTTTGGTTACAGTTAACCCCATCGCCTCAACCAATGATGATG AAGTGCTGATTGAGGTGAACCCACCTTTTGGAGACAGCTACATTATCGTTG GGAGAGGAGATTCACGTCTCACTTACCAGTGGCACAAAGAG. WNV (KX547539.1): (SEQ ID NO: 128) 5'ACAACCTATGGCGTCTGTTCAAAGGCTTTCAAGTTTCTTGGGACTCCCG CAGACACAGGTCACGGCACTGTGGTGTTGGAATTGCAGTACACTGGCACGG ATGGACCTTGCAAAGTTCCTATCTCGTCAGTGGCTTCATTGAACGACCTAA CGCCAGTGGGCAGATTGGTCACTGTCAACCCTTTTGTTTCAGTGGCCACGG CCAACGCTAAGGTCCTGATTGAATTGGAACCACCCTTTGGAGACTCATACA TAGTGGTGGGCAGAGGAGAACAACAGATCAATCACCACTGGCACAAGTCT.

[0182] Gene synthesis was by Genscript. The proteins were produced by transient transfection into HEK-293-6E cells using PEI (polyethylenimine, branched). After 7 days of incubation, cell supernatants were cleared by centrifugation and histidine-tagged proteins were purified with Ni Sepharose 6 Fast Flow. Purified ZEDIII was biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer's instructions.

[0183] ELISA Assays

[0184] Serum and Recombinant Antibody

[0185] The binding of serum IgG or recombinant IgG antibodies to the EDIII proteins was measured by standard ELBA. ELISA plates were coated with 250 ng of EDIII protein in PBS per well and stored overnight at room temperature. Plates were then blocked with 1% BSA, 0.1 mM EDTA in PBS-T (PBS with 0.05% Tween20) for 1 h at 37.degree. C. Plates were washed with PBS-T in between each step above. Serum samples were diluted 1:500 with PBS-T and added for 1 h at 37.degree. C. Secondary HRP-conjugated goat anti-human IgG (0.16 .mu.g/ml) was added for 1 h at 37.degree. C., Plates were then developed using ABTS substrate and read at 405 nm. The relative binding affinity of recombinant monoclonal antibodies was determined similarly, using serially diluted samples. The half effective concentration (EC.sub.50) needed for maximal binding was determined by non-linear regression analysis.

[0186] Cross-Reactivity ELISA

[0187] The binding of monoclonal antibodies to the panel of flavivirus EDIII proteins was determined using the standard ELISA setup described above. Antibodies were tested at 10 .mu.g/ml alongside a control serum weakly cross-reactive to all flaviviruses. Samples with a relative optical density ratio of >1 compared to control were deemed reactive.

[0188] Auto- and Poly-Reactivity ELISA

[0189] To determine the auto- and poly-reactivity of recombinant antibodies, ELISA plates were coated with 50 .mu.l PBS containing dsDNA (10 .mu.g/ml), ssDNA (10 .mu.g/ml, obtained by denaturing dsDNA at 95.degree. C. for 30 minutes), LIDS (10 .mu.g/ml), Insulin (5 .mu.g/ml), or keyhole limpet hemocyanin (KLH; 10 .mu.g/ml). After washing with PBS-T, plates were blocked with 1% BSA and 0.5 mM EDTA in 0.05% PBS-T for 2 h at room temperature. Serial dilutions of antibody samples were then incubated for 2 h, also at room temperature. Incubation with secondary antibody and ELISA development were performed as described above. Previously reported antibodies ED38 (Wardemann et al., 2003) and mG053 (Yurasov et at, 2005) were used as positive and negative control, respectively.

[0190] Competition ELISA

[0191] Competition ELISA was performed as described above for serum EDIII binding, with the following modifications. After 1 h of incubation with serum (diluted 1:10 in PBS-T) at room temperature, biotinylated antibody 2004 (biotin-Z004) was added at a final concentration of 0.16 .mu.g/ml to compete for an additional 15 min at room temperature. After washing, streptavidin-HRP was used for detection of bound biotin-Z004. The optimal concentration of biotin-Z004 (0.16 .mu.g/ml) was determined by measuring its binding to ZEDIII over a range of concentrations, and corresponds to 50% of the Observed maximal binding. The concentration of Z004 blocking antibodies in serum was estimated by interpolation with a standard curve generated by competing biotin-Z004 (0.16 .mu.g/ml) with a range of non-biotinylated Z004 concentrations, and using the stats package nls( ) function in R 3.3.2.

[0192] Antibody Discovery and Production

[0193] Isolation of ZEDIII.sup.+ Memory B Cells

[0194] B cell purification, labeling and antibody discovery were performed as previously described in detail (Tiller et al., 2008; von Boehmer et al., 2016), with the following modifications.

[0195] PBMCs were resuscitated and washed in 37.degree. C. RPMI. To enrich for B cells, PBMCs were incubated with CD19 microbeads according to the manufacturer's instructions. Upon washing, B cells were positively selected using LS magnetic columns, washed with PBS 3% FBS, and incubated with anti-CD20-PECy7, anti IgG-APC, and fluorescently-labeled ZEDIII bait at 4.degree. C. for 20 min. The fluorescently-labeled ZEDIII bait was previously prepared by incubating 2-3 .mu.g of biotin-ZEDIII with streptavidin-PE for at least 1 h at 4.degree. C. in the dark. After wash, single CD20.sup.+ZEDIII.sup.+gG.sup.+ memory B cells were sorted into 96-well plates using a FACSAriaII (Becton Dickinson).

[0196] Antibody Sequencing and Production

[0197] RNA from single cells was reverse-transcribed using random primers (von Boehmer et al., 2016), followed by nested PCR amplifications and sequencing using the primers listed in (Tiller et al., 2008). V(D)J gene segment assignment and determination of the CDR3 sequences were with IgBlast (Ye et al., 2013). Sequences that were non-productive, out of frame, or with premature stop codons were excluded. Similarly, sequences for which a matching light or heavy chain sequence was not identifiable were omitted. Cloning for recombinant antibody production was by the Sequence and Ligation-Independent Cloning (SLIC; (Li and Elledge, 2007)) method as detailed in (von Boehmer et al., 2016). Amplicons from the first sequencing PCR reaction were used as template for amplification with the SLIC-adapted primers listed in Table 3, and cloned into IG.gamma.1-, IG.kappa. or IG.lamda.-expression vectors as detailed in (von Boehmer et al., 2016). The recombinantly expressed antibodies correspond to the following antibody sequence IDs (see Tables 1 and 2): Z028 (MEX84_p4-53), Z001 (MEX18_21), Z004 (MEX18_89), Z006 (MEX105_42), Z010 (MEX105_88), Z031 (BRA112_46), Z035 (BRA112_71), Z038 (BRA12_2), Z014 (MEX18_91), Z039 (BRA12_21), Z015 (MEX84_p2-44), Z018 (MEX84_p2-45), Z021 (MEX84_p4-23), Z024 (MEX84_p4-12), Z012 (MEX105_57), Z037 (BRA112_57), Z041 (BRA138_57), Z042 (BRA138_17), Z043 (BRA138_15). The variable portion of the predicted germline antibody Z004-GL was codon-optimized, synthesized by Genscript, and cloned as described above

TABLE-US-00014 (IGH (SEQ ID NO: 129) 5'GAGGTGCAGCTGTTGGAGTCTGGGGGAGGTCTTGTTCAGCCGGGTGGAT CATTGAGACTTTCTTGTGCTGCAAGTGGATTTACTTTCTCTTCCTACGCCA TGTCTTGGGTTCGACAAGCTCCAGGGAAAGGACTCGAATGGGTTAGTGCGA TATCTGGGTCTGGAGGATCTACTTACTACGCAGATTCAGTAAAAGGGCGCT TCACAATATCACGCGATAATTCCAAGAATACGCTCTACCTTCAGATGAACA GTCTTCGGGCAGAGGACACAGCGGTTTATTATTGTGCGAAAGATCGCGGTC CCAGAGGCGTGGGCGAACTGTTCGACTATTGGGGACAAGGCACCCTGGTCA CCGTCTCCTCAG and IGK (SEQ ID NO: 130) 5'GACATCCAGATGACCCAGTCACCGTCTACCTTGTCAGCGTCAGTTGGTG ACCGGGTAACCATTACTTGCCGCGCTAGTCAGAGTATTTCCTCCTGGCTCG CCTGGTATCAACAAAAACCAGGTAAAGCCCCCAAATTGCTGATCTATAAGG CAAGTAGCTTGGAATCAGGAGTTCCCAGCCGCTTCTCTGGCTCAGGGTCCG GTACTGAATTTACATTGACCATCTCTTCTCTCCAGCCAGATGACTTCGCCA CGTACTATTGTCAACAGTATAACTCATATCCCTGGACTTTTGGACAGGGGA CCAAGGTGGAAATCAAAC).

Recombinant antibodies were produced as previously described (Klein et al., 2014). Briefly, HEK-293-6E cells were transiently transfected with equal amounts of immunoglobulin heavy and light chain expression vectors. After 7 days, the supernatant was harvested and antibodies were purified with Protein G Sepharose 4 Fast Flow. For antibody biotinylation, 1.5 mg/ml of Z004 were used with FluoReporter Mini-biotin-XX Protein Labeling Kit as instructed by the manufacturer.

[0198] Mouse Experiments

[0199] All experiments involving mice were performed under protocols approved by the Rockefeller University Institutional Animal Care and Use Committee. 123 .mu.g of monoclonal antibodies in 200 .mu.l of PBS were administered intraperitoneally to 3-4 week old IFNAR1.sup.-/- mice one day prior or after infection with 1.25.times.10.sup.5 PFU ZIKV Puerto Rican strain in 50 .mu.l into the footpad. Mice were monitored for symptoms and survival over time.

[0200] Virus Titration

[0201] Viral titers were measured on VERO cells by plaque assay (PA) for ZIKV virus and focus forming assay (FFA) for DENV-1 strains. For PA, 200 .mu.l of serial 10-fold virus dilutions in OPTI-MEM were used to infect 400,000 cells seeded the day prior in a 6-well format. After 90 minutes adsorption, the cells were overlayed with DMEM containing 2% FBS with 1.2% Avicel and Pen/Strep. Four days later the cells were fixed with 3.5% formaldehyde and stained with crystal violet for plaque enumeration. For FFA, 100 .mu.l of serial 10-fold virus dilutions in OPTI-MEM were used to infect 250,000 cells seeded the day prior in a 12-well format. After 90 minutes, the cells were overlayed as described above for PA. Six to 7 days later the cells were fixed and incubated with 2 .mu.g/ml of antibody Z004 in PBS/5% FBS/0.25% Triton X-100 for 1 h at room temperature. Foci were enumerated after reaction with goat anti-human IgG HRP-conjugated antibodies and TrueBlue HRP substrate, followed by addition of a few drops of DAB buffer solution (DAKO). Experiments with infectious ZIKV and DENV strains were performed in a biosafety level 2 laboratory.

[0202] Plaque Reduction Neutralization Test

[0203] Antibody neutralization activity was measured using a standard plaque reduction neutralization test (PRNT) on VERO cells. Diluent medium consisted of medium 199 (Lonza) supplemented with 1% BSA and Pen/Strep (BA-1 diluent). Briefly, 3- to 10-fold serial human antibody dilutions were added to a constant amount of Huh-7.5-ZIKV stock diluted in BA-1 diluent and incubated for 1 h at 37.degree. C. prior to application to VERO cells seeded at 400,000 cells per 6-well the day prior. After 90 min adsorption at 37.degree. C. the cells were overlayed as per PA protocol above. After 4 days at 37.degree. C., the wells were fixed and stained to enumerate plaques. PRNT.sub.50 values were determined as the antibody concentration that resulted in 50% of the number of plaques obtained with the no antibody control.

[0204] RVP Plasmid Construction West Nile virus (WNV) subgenomic replicon-expressing plasmid pWNVII-Rep-REN-IB (Pierson et al., 2006) and a ZIKV C-prM-E expression plasmid (pZIKV/HPF/CprME) were obtained from Ted Pierson (NIH). Plasmid pWNVII-Rep-REN-IB encodes a Renilla luciferase-expressing WNV replicon RNA while pZIKV/HPF/CprME encodes the structural proteins (C-prM-E) of the ZIKV French Polynesian strain H/PF/2013, both under the control of a CMV promoter. Co-transfection of the two plasmids into permissive cells allows the WNV replicon RNA to replicate, express luciferase and be packaged by the ZIKV H/PF/2013 structural proteins to generate RVPs that can be used for single round infection studies (Mukherjee et al., 2014; Pierson et al., 2006). To facilitate expression of the envelopes of a wide range of ZIKV strains, plasmid pZIKV/HPF/CprME was engineered to have a unique BspHI restriction enzyme site immediately upstream of the envelope region by PCR-based site-directed mutagenesis of two other BspHI restriction sites located in the plasmid backbone. The resulting plasmid, pZIKV/HPF/CprM*E*, has unique BspHI and SacII restriction sites flanking the envelope region, allowing facile manipulation. PCR-based site-directed mutagenesis was used to introduce E393A or K394A mutations into the envelope of H/PF/2013 in pZIKV/HPF/CprM*E*, resulting in plasmids pZIKV/HPF/CprME(E393A) and pZIKV/HPF/CprME(K394A). We generated pZIKV/HPF-CprM/MR766-E by replacing the H/PF/2013 envelope in pZIKV/HPF/CprM*E* with that of the ZIKV African strain, MR766. Because the African strains contain a BspHI site within the E protein coding region, this site was mutated using assembly PCR prior to swapping in the MR766-based BspHI and SacII fragment. To generate pDENV1/PUO-359/CprME, DENV1 (strain PUO-359) virion RNA was isolated by TRIzol extraction (Thermo Fisher Scientific), cDNA generated using Superscript II reverse transcriptase (Thermo Fisher Scientific), and the C-prM-E region amplified by PCR. After PCR assembly with the upstream promoter and vector sequences, the corresponding region of pZIKV/HPF/CprME was replaced using SnaBI/SacII enzymes. PCR reactions utilized either PfuUltra Hotstart DNA Polymerase (Agilent technologies), Phusion High Fidelity DNA polymerase (NEB) or KOD DNA polymerase (Toyobo). All PCR-derived plasmid regions were verified by sequencing. Primer sequences used for assembly PCR and mutagenesis are listed in Table 4.

[0205] RVP Production

[0206] Reporter viral particles (RVPs) were produced in Lenti-X 293T cells, seeded the day before DNA transfection at 1.times.10.sup.6 cells/well in collagen coated 6-well plates. One .mu.g of pWNVII-Rep-REN-IB (WNV replicon expression construct) and 3 .mu.g of the appropriate flavivirus CprME expression construct were co-transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Lipid-DNA complexes were removed after 4-5 h incubation at 37.degree. C. and replaced with DMEM containing 20 mM HEPES and 10% FBS. After incubation for 48-72 h at 34.degree. C., RVP-containing supernatants were harvested, filtered through a 0.45 micron filter and frozen at -80.degree. C. RVPs were titrated on Huh-7.5 cells to determine the dilution to use in the RVP-based neutralization assay to achieve .about.2-5.times.10.sup.6 RLU in the absence of serum/antibody.

[0207] RVP Neutralization Assay

[0208] The day before infection, 96-well plates were seeded with 15,000 Huh-7.5 cells/well in a volume of 100 .mu.l. RVPs were diluted in BA-diluent (ranging from 1:4 to 1:32 depending on the RVP stock) and 100 .mu.l were added to 100 .mu.l of triplicate samples of 3- or 10-fold serially diluted human serum/antibody. After incubation for 1 h at 37.degree. C., 100 .mu.l of the RVP/antibody mixture was added to the cells. After 24 h incubation at 37.degree. C., the medium was removed and cells were lysed in 75 .mu.l lysis buffer and 20 .mu.l used for Renilla luciferase measurement using the Renilla Luciferase Assay System (Promega) according to the manufacturer's instructions using a FLUOstar Omega luminometer (BMG LabTech). Neutralization capacity of the serum/antibody was determined by the percentage of luciferase activity obtained relative to activity from RVPs incubated with BA-diluent alone (no serum/antibody). NT.sub.50 values represented the reciprocal of the serum dilution or the antibody concentration that resulted in 50% inhibition compared to RVP alone.

[0209] Flow Cytometry-Based Neutralization Assay

[0210] The day prior to infection 5,000 VERO cells/well were seeded in 96-well plates. Serial dilutions of antibody were mixed with ZIKV or DENV-1 virus for 1 h at 37.degree. C. and then applied to infect cells, using an MOI of 0.02 for ZIKV and DENV-1. After 3 days, cells were fixed with 2% formaldehyde and permeabilized in PBS containing 1% FBS and 0.5% saponin. Cells were stained with 2 .quadrature.g/ml of the pan flavivirus anti-E protein 4G2 monoclonal antibody (Henchal et al., 1982). After incubation with Alexa Fluor 488-conjugated anti-mouse IgG antibody (Invitrogen) at 1:1,000 dilution, the number of infected cells was determined by flow cytometry. The percentage of infected cells relative to cells infected with virus in the absence of antibody was calculated for each antibody dilution to estimate the 50% reduction.

[0211] Protein Production and Crystallization

[0212] His-tagged Fabs were transiently expressed in HEK-293-6E cells by co-transfecting with appropriate heavy and light chain plasmids. Fabs were purified from the supernatant using Ni-NTA affinity chromatography (GE Healthcare) and size exclusion chromatography (Superdex 200; GE Healthcare) in 20 mM Tris pH 8.0, 150 mM NaCl, 0.02% NaN.sub.3. The Fabs were concentrated to 10-20 mg/mL for crystallography. Untagged constructs of ZEDIII and DENV1 EDIII were expressed in E. coli and refolded from inclusion bodies as previously described (Sapparapu et al., 2016). Briefly, BL21(DE3) E. coli were transformed with an appropriate expression vector encoding ZIKV E protein residues 299-407 (ZIKV EDIII, strain H/PF/2013) or DENV1 E protein residues 297-396 (DENV1 EDIII, strain clone 45AZ5). Cells were grown to mid-log phase and induced with isopropyl .beta.-D-1-thiogalactopyranoside (IPTG) for 4 hours. The cells were lysed and the insoluble fraction containing inclusion bodies was solubilized in buffer containing 6M guanidine hydrochloride and 20 mM .beta.-mercaptoethanol, and then clarified by centrifugation. The solubilized inclusion bodies were refolded using rapid dilution into 400 mM L-arginine, 100 mM Tris-base (pH 8.0), 2 mM EDTA, 0.2 mM phenyl-methylsulfonyl fluoride, and 5 and 0.5 mM reduced and oxidized glutathione at 4.degree. C. The refolded protein was filtered and concentrated, and then purified by size exclusion chromatography (Superdex 75; GE Healthcare) in 20 mM Tris pH 8.0, 150 mM NaCl, 0.02% NaN.sub.3. Antigens were concentrated to 2-15 mg/mL for crystallography. Complexes for crystallization were produced by mixing Fab and antigen at a 1:1 molar ratio and incubating at room temperature for 1-2 hours. Crystals of Z006 Fab-ZEDIII complex (space group H32; a=385.08 .ANG., b=385.08 .ANG., c=56.64 .ANG., .alpha.=90.degree., .beta.=90.degree., .gamma.=120.degree.; two molecules per asymmetric unit) were obtained by combining 0.2 .mu.L of crystallization sample with 0.2 .mu.L of 10% isopropanol, 0.1M sodium citrate tribasic dihydrate pH 5.0, 26% PEG 400 in sitting drops at 22.degree. C. Crystals of Z004 Fab-DENV1 EDIII complex (space group P4.sub.32.sub.12; a=74.23 .ANG., b=74.23 .ANG., c=190.76 .ANG.; one molecule per asymmetric unit) were obtained by combining 0.2 .mu.L of crystallization sample with 0.2 .mu.L of 0.1M sodium acetate trihydrate pH 4.5, 30% w/v PEG 1500 in sitting drops at 22.degree. C.

[0213] Structure Determination and Refinement X-ray diffraction data were collected at Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12-2 using a Dectris Pilatus 6M detector. The data were integrated using Mosflm (Battye et al., 2011) and scaled using CCP4 (Winn et al., 2011) (Table 5). The Z006-ZEDIII complex structure (PDB ID 5VIG) was solved by molecular replacement with a Z006 unbound Fab structure (data not shown) and Zika EDIII (PDB ID SKVG) as the search models using Phaser and Molrep (CCP4) and refined to 3.0 .ANG. using an iterative approach involving (i) refinement in CNS and Phenix applying NCS constraints and (ii) manual rebuilding into electron density maps using 0 and AntibodyDatabase (Jones, 2004; West et al., 2013). The final model (R.sub.work=21.2%; R.sub.free=25.7%) contains 7,892 protein atoms and one citrate ion (12 atoms). 90.8, 7.6, and 1.6% of the residues were in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot (Table 5). Residues 1, 128-133, 214-219, and the 6.times.-His tag of the Z006 heavy chain; residue 214 of the LC; and residues 299-304 and 405-407 were disordered and are not included in the model. The Z004-DENV1 EDIII complex structure (PDB ID 5VIC) was solved by molecular replacement using the V.sub.HV.sub.L (CDR residues removed) and C.sub.HC.sub.L domains from PDB 3 SKJ and DENV1 EDIII from PDB 4L5F as search models in Phenix (Adams et al., 2010). The model was refined to 3.0 .ANG. resolution using an iterative approach involving (i) refinement in Phenix and (ii) manual rebuilding into a simulated annealing composite omit map using Coot (Emsley and Cowtan, 2004). The final model (R.sub.work=23.6%; R.sub.free=28.1%) contains 3,904 protein atoms. 93.0%, 6.8%, and 0.2% of the residues were in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot (Table 5). Residues that were disordered and not included in the model were Fab HC residues 129-132, 215-219, and the 6.times.-His tag; LC residues 212-214; and DENV1 EDIII domain residues 315-317, 341-347, 373-374, and 393-396. Structures were superimposed, rmsd calculations done, and figures were generated using PyMOL. Hydrogen bonds were assigned using the following criteria: a distance of <3.5 .ANG., and an A-D-H angle of >90.degree..

[0214] Statistical Analysis Details

[0215] Unless otherwise noted, statistical analysis was with Prism software. The half effective concentration (EC.sub.50) needed for maximal binding by ELISA was determined by non-linear regression analysis (FIG. 3A). Data are the average of at least two independent experiments. Similarly, luciferase- and flow cytometry-based neutralization assays were performed in triplicate wells, and the serum dilution (NT.sub.50) or antibody concentration (IC.sub.50) that neutralized 50% of the virus or RVP inoculum was calculated by nonlinear, dose-response regression analysis (FIG. 4A). The Mantel-Cox test was applied to analyze disease and survival in mice infection experiments (FIG. 4D-F). The Paired t test was used to analyze changes in sero-reactivity over time (FIGS. 6A and 7A). Univariate associations were assessed between log-relative optical densities of anti-ZEDIII antibodies at t=2 (November 2015) with log-relative optical densities of anti-DENV1 EDIII antibodies at t=1 (April 2015) using proc mixed in SAS v 9.4 (FIG. 6B). An individual-level random intercept was included to account for non-independence of the two replicated measurements. The two-tailed Spearman r test was used for the correlations in FIG. 7B-E.

[0216] References cited for the foregoing description and FIGS. 1-10. This reference listing is not an indication that any of the references are material to patentability of any invention encompassed by this disclosure [0217] Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, L W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica Section D, Biological crystallography 66, 213-221. [0218] Arnaout, R., Lee, W., Cahill, P., Honan, T., Sparrow, T., Weiand, M., Nusbaum, C., Rajewsky, K., and Koralov, S. B. (2011). High-resolution description of antibody heavy-chain repertoires in humans. PloS one 6, e22365. [0219] Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M. C., Medits, I., Sharma, A., Simon-Loriere, E., Sakuntabhai, A., Cao-Lormeau, V. M., Haouz, A., et al. (2016). Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53. [0220] Bardina, S. V., Bunduc, P., Tripathi, S., Duehr, J., Frere, J. J., Brown, J. A., Nachbagauer, R., Foster, G. A., Krysztof, D., Tortorella, D., et al. (2017) Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. [0221] Barzon, L., Pacenti, M., Franchin, E., Lavezzo, E., Trevisan, M., Sgarabotto, D., and Palu, G. (2016). Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro surveillance: bulletin Europeen sur les maladies transmissibles=European communicable disease bulletin 21. [0222] Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R., and Leslie, A. G. (2011). iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta crystallographica Section D, Biological crystallography 67, 271-281. [0223] Beasley, D. W., and Barrett, A. D. (2002). Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. Journal of virology 76, 13097-13100. [0224] Blight, K. J., McKeating, J. A., and Rice, C. M. (2002). Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. Journal of virology 76, 13001-13014. [0225] Brasil, P., Pereira, J. P., Jr., Moreira, M. E., Ribeiro Nogueira, R. M., Damasceno, L., Wakimoto, M., Rabello, R. S., Valderramos, S. G., Halai, U. A., Salles, T. S., et al. (2016). Zika Virus Infection in Pregnant Women in Rio de Janeiro. The New England journal of medicine 375, 2321-2334. [0226] Cardoso, C. W., Paploski, I. A., Kikuti, M., Rodrigues, M. S., Silva, M. M., Campos, G. S., Sardi, S. I., Kitron, U., Reis, M. G., and Ribeiro, G. S. (2015). Outbreak of Exanthematous Illness Associated with Zika, Chikungunya, and Dengue Viruses, Salvador, Brazil. Emerging infectious diseases 21, 2274-2276. [0227] Castanha, P. M., Nascimento, E. J., Cynthia, B., Cordeiro, M. T., de Carvalho, O. V., de Mendonca, L. R., Azevedo, E. A., Franca, R. F., Rafael, D., and Marques, E. T., Jr. (2016). Dengue virus (DENV)-specific antibodies enhance Brazilian Zika virus (ZIKV) infection. The Journal of infectious diseases. [0228] Chapgier, A., Boisson-Dupuis, S., Jouanguy, E., Vogt, G., Feinberg, J., Prochnicka-Chalufour, A., Casrouge, A., Yang, K., Soudais, C., Fieschi, C., et al. (2006). Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS genetics 2, e131. [0229] Costa, F., Sarno, M., Khouri, R., de Paula Freitas, B., Siqueira, I., Ribeiro, G. S., Ribeiro, H. C., Campos, G. S., Alcantara, L. C., Reis, M. G., et al. (2016). Emergence of Congenital Zika Syndrome: Viewpoint From the Front Lines. Annals of internal medicine 164, 689-691. [0230] Crill, W. D., and Roehrig, J. T. (2001). Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. Journal of virology 75, 7769-7773. [0231] Dai, L., Song, J., Lu, X., Deng, Y. Q., Musyoki, A. M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., et al. (2016). Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell host & microbe 19, 696-704. [0232] Dejnirattisai, W., Supasa, P., Wongwiwat, W., Rouvinski, A., Barba-Spaeth, G., Duangchinda, T., Sakuntabhai, A., Cao-Lormeau, V. M., Malasit, P., Rey, F. A., et al. (2016). Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nature immunology 17, 1102-1108. [0233] DeKosky, B. J., Kojima, T., Rodin, A., Charab, W., Ippolito, G. C., Ellington, A. D., and Georgiou, G. (2015). In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nature medicine 21, 86-91. [0234] Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M., Goudsmit, J., and Wilson, I. A. (2009). Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251. [0235] Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta crystallographica Section D, Biological crystallography 60, 2126-2132. [0236] Escolano, A., Dosenovic, P., and Nussenzweig, M. C. (2017). Progress toward active or passive HIV-1 vaccination. The Journal of experimental medicine 214, 3-16. [0237] Felzemburgh, R. D., Ribeiro, G. S., Costa, F., Reis, R. B., Hagan, J. E., Melendez, A. X., Fraga, D., Santana, F. S., Mohr, S., dos Santos, B. L., et al. (2014). Prospective study of leptospirosis transmission in an urban slum community: role of poor environment in repeated exposures to the Leptospira agent. PLoS neglected tropical diseases 8, e2927. [0238] Foy, B. D., Kobylinski, K. C., Chilson Foy, J. L., Blitvich, B. J., Travassos da Rosa, A., Haddow, A. D., Lanciotti, R. S., and Tesh, R. B. (2011). Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerging infectious diseases 17, 880-882. [0239] Franca, G. V., Schuler-Faccini, L., Oliveira, W. K., Henriques, C. M., Carmo, E. H., Pedi, V. D., Nunes, [0240] M. L., Castro, M. C., Serruya, S., Silveira, M. F., et al. (2016). Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation. Lancet 388, 891-897. [0241] Hagan, J. E., Moraga, P., Costa, F., Capian, N., Ribeiro, G. S., Wunder, E. A., Jr., Felzemburgh, R. D., Reis, R. B., Nery, N., Santana, F. S., et al. (2016). Spatiotemporal Determinants of Urban Leptospirosis Transmission: Four-Year Prospective Cohort Study of Slum Residents in Brazil. PLoS neglected tropical diseases 10, e0004275. [0242] Harrison, S. C. (2016). Immunogenic cross-talk between dengue and Zika viruses. Nature immunology 17, 1010-1012. [0243] Heinz, F. X., and Stiasny, K. (2017). The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiology and molecular biology reviews: MMBR 81. [0244] Henchal, E. A., Gentry, M. K., McCown, J. M., and Brandt, W. E. (1982). Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. The American journal of tropical medicine and hygiene 31, 830-836. [0245] Honein, M. A., Dawson, A. L., Petersen, E. E., Jones, A. M., Lee, E. H., Yazdy, M. M., Ahmad, N., Macdonald, J., Evert, N., Bingham, A., et al. (2017). Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. Jama 317, 59-68. [0246] Jones, T. A. (2004). Interactive electron-density map interpretation: from INTER to O. Acta crystallographica Section D, Biological crystallography 60, 2115-2125. [0247] Klein, F., Nogueira, L., Nishimura, Y., Phad, G., West, A. P., Jr., Halper-Stromberg, A., Horwitz, J. A., Gazumyan, A., Liu, C., Eisenreich, T. R., et al. (2014) Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. The Journal of experimental medicine 211, 2361-2372. [0248] Kostyuchenko, V. A., Lim, E. X., Zhang, S., Fibriansah, G., Ng, T. S., Ooi, J. S., Shi, J., and Lok, S. M. (2016). Structure of the thermally stable Zika virus. Nature 533, 425-428. [0249] Kramer, L. D., Li, J., and Shi, P. Y. (2007). West Nile virus. The Lancet Neurology 6, 171-181. [0250] Lanciotti, R. S., Lambert, A. J., Holodniy, M., Saavedra, S., and Signor Ldel, C. (2016). Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerging infectious diseases 22, 933-935. [0251] Laursen, N. S., and Wilson, I. A. (2013). Broadly neutralizing antibodies against influenza viruses. Antiviral research 98, 476-483. [0252] Lessler, J., Chaisson, L. H., Kucirka, L. M., Bi, Q., Grantz, K., Salje, H., Carcelen, A. C., Ott, C. T., Sheffield, J. S., Ferguson, N. M., et al. (2016). Assessing the global threat from Zika virus. Science 353, aaf8160. [0253] Li, M. Z., and Elledge, S. J. (2007). Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nature methods 4, 251-256. [0254] Miner, J. J., and Diamond, M. S. (2017). Zika Virus Pathogenesis and Tissue Tropism. Cell host & microbe 21, 134-142. [0255] Modis, Y., Ogata, S., Clements, D., and Harrison, S. C. (2003). A ligand-binding pocket in the dengue virus envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America 100, 6986-6991. [0256] Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J. F., Halper-Stromberg, A., [0257] Gnanapragasam, P. N., Spencer, D. I., Seaman, M. S., et al. (2012). Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America 109, E3268-3277. [0258] Mukherjee, S., Pierson, T. C., and Dowd, K. A. (2014). Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection. Methods in molecular biology 1138, 75-97. [0259] Mukhopadhyay, S., Kuhn, R. J., and Rossmann, M. G. (2005). A structural perspective of the flavivirus life cycle. Nature reviews Microbiology 3, 13-22. [0260] Murray, K. O., Gorchakov, R., Carlson, A. R., Berry, R., Lai, L., Natrajan, M., Garcia, M. N., Correa, A., Patel, S. M., Aagaard, K., et al. (2017). Prolonged Detection of Zika Virus in Vaginal Secretions and Whole Blood. Emerging infectious diseases 23, 99-101. [0261] Murray, N. E., Quam, M. B., and Wilder-Smith, A. (2013). Epidemiology of dengue: past, present and future prospects. Clinical epidemiology 5, 299-309. [0262] Pappas, L., Foglierini, M., Piccoli, L., Kallewaard, N. L., Turrini, F., Silacci, C., Fernandez-Rodriguez, B., Agatic, G., Giacchetto-Sasselli, I., Pellicciotta, G., et al. (2014). Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516, 418-422. [0263] Pierson, T. C., and Graham, B. S. (2016). Zika Virus: Immunity and Vaccine Development. Cell 167, 625-631. [0264] Pierson, T. C., Sanchez, M. D., Puffer, B. A., Ahmed, A. A., Geiss, B. J., Valentine, L. E., Altamura, L. A., Diamond, M. S., and Doms, R. W. (2006). A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346, 53-65. [0265] Priyamvada, L., Quicke, K. M., Hudson, W. H., Onlamoon, N., Sewatanon, J., Edupuganti, S., Pattanapanyasat, K., Chokephaibulkit, K., Mulligan, M. J., Wilson, P. C., et al. (2016). Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proceedings of the National Academy of Sciences of the United States of America 113, 7852-7857. [0266] Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C., and Harrison, S. C. (1995). The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298. [0267] Rubelt, F., Sievert, V., Knaust, F., Diener, C., Lim, T. S., Skriner, K., Klipp, E., Reinhardt, R., Lehrach, H., and Konthur, Z. (2012). Onset of immune senescence defined by unbiased pyrosequencing of human immunoglobulin mRNA repertoires. PloS one 7, e49774. [0268] Sabin, A. B. (1950). The dengue group of viruses and its family relationships. Bacteriological reviews 14, 225-232. [0269] Sabin, A. B. (1952). Research on dengue during World War II. The American journal of tropical medicine and hygiene 1, 30-50. [0270] Sapparapu, G., Fernandez, E., Kose, N., Bin, C., Fox, J. M., Bombardi, R. G., Zhao, H., Nelson, C. A., Bryan, A. L., Barnes, T., et al. (2016). Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443-447. [0271] Scheid, J. F., Mouquet, H., Feldhahn, N., Walker, B. D., Pereyra, F., Cutrell, E., Seaman, M. S., Mascola, J. R., Wyatt, R. T., Wardemann, H., et al. (2009). A method for identification of HIV gp140 binding memory B cells in human blood. Journal of immunological methods 343, 65-67. [0272] Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637. [0273] Screaton, G., Mongkolsapaya, J., Yacoub, S., and Roberts, C. (2015). New insights into the immunopathology and control of dengue virus infection. Nature reviews Immunology 15, 745-759. [0274] Silva, M. M., Rodrigues, M. S., Paploski, I. A., Kikuti, M., Kasper, A. M., Cruz, J. S., Queiroz, T. L., Tavares, A. S., Santana, P. M., Araujo, J. M., et al. (2016). Accuracy of Dengue Reporting by National Surveillance System, Brazil. Emerging infectious diseases 22, 336-339. [0275] Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T. C., Rossmann, M. G., and Kuhn, R. J. (2016). The 3.8 A resolution cryo-EM structure of Zika virus. Science 352, 467-470. [0276] Stettler, K., Beltramello, M., Espinosa, D. A., Graham, V., Cassotta, A., Bianchi, S., Vanzetta, F., Minola, A., Jaconi, S., Mele, F., et al. (2016). Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823-826. [0277] Sui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L. M., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009). Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature structural & molecular biology 16, 265-273. [0278] Suy, A., Sulleiro, E., Rodo, C., Vazquez, E., Bocanegra, C., Molina, I., Esperalba, J., Sanchez-Seco, M. P., Boix, H., Pumarola, T., et al. (2016). Prolonged Zika Virus Viremia during Pregnancy. The New England journal of medicine 375, 2611-2613. [0279] Swanstrom, J. A., Plante, J. A., Plante, K. S., Young, E. F., McGowan, E., Gallichotte, E. N., Widman, D. G., Heise, M. T., de Silva, A. M., and Baric, R. S. (2016). Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. mBio 7.

[0280] Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L. L., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., et al. (2008). Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PloS one 3, e3942. [0281] Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C., and Wardemann, H. (2008). Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. Journal of immunological methods 329, 112-124. [0282] von Boehmer, L., Liu, C., Ackerman, S., Gitlin, A. D., Wang, Q., Gazumyan, A., and Nussenzweig, M. C. (2016). Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nature protocols 11, 1908-1923. [0283] Wahala, W. M., and Silva, A. M. (2011). The human antibody response to dengue virus infection. Viruses 3, 2374-2395. [0284] Wang, Q., Yang, H., Liu, X., Dai, L., Ma, T., Qi, J., Wong, G., Peng, R., Liu, S., Li, J., et al. (2016). Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science translational medicine 8, 369ra179. [0285] Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., and Nussenzweig, M. C. (2003). Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377. [0286] Weaver, S. C., Costa, F., Garcia-Blanco, M. A., Ko, A. I., Ribeiro, G. S., Saade, G., Shi, P. Y., and Vasilakis, N. (2016). Zika virus: History, emergence, biology, and prospects for control. Antiviral research 130, 69-80. [0287] Weaver, S. C., and Reisen, W. K. (2010). Present and future arboviral threats. Antiviral research 85, 328-345. [0288] West, A. P., Jr., Diskin, R., Nussenzweig, M. C., and Bjorkman, P. J. (2012). Structural basis for germline gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America 109, E2083-2090. [0289] West, A. P., Jr., Scharf, L., Horwitz, J., Klein, F., Nussenzweig, M. C., and Bjorkman, P. J. (2013). Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proceedings of the National Academy of Sciences of the United States of America 110, 10598-10603. [0290] Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., et al. (2011). Overview of the CCP4 suite and current developments. Acta crystallographica Section D, Biological crystallography 67, 235-242. [0291] Wrammert, J., Koutsonanos, D., Li, G. M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W. I., et al. (2011). Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. The Journal of experimental medicine 208, 181-193. [0292] Ye, J., Ma, N., Madden, T. L., and Ostell, J. M. (2013). IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic acids research 41, W34-40. [0293] Yurasov, S., Wardemann, H., Hammersen, J., Tsuiji, M., Meffre, E., Pascual, V., and Nussenzweig, M. C. (2005). Defective B cell tolerance checkpoints in systemic lupus erythematosus. The Journal of experimental medicine 201, 703-711. [0294] Zhang, Y., Zhang, W., Ogata, S., Clements, D., Strauss, J. H., Baker, T. S., Kuhn, R. J., and Rossmann, M. G. (2004). Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618. [0295] Zhou, T., Georgiev, I., Wu, X., Yang, Z. Y., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., et al. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-81.

TABLE-US-00015 [0295] TABLE 1 Antibody SEQ ID SEQ ID SEQ ID SEQ ID Clone ID amino acids NO: VH DH JH CDR3 NO: amino acids NO: VK/L JK/L CDR3 NO: MEX 84 - refers to an individual donor. Sequences were analyzed with IgBlast VH3- MEX84_p2-02 GGGLIQPGGT 131 IGHV3- IGHD3- IGHJ5*01 AKDRP 171 SASVGDRVT 211 IGKV1- IGKJ1*01 QKFNSV 251 23/VK1-5 LRLSCAASGF 23*01 10*01 RQGVG ITCRASQSIG 5*03 PWT SFTNYAMSW ELYDS SWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSAITGD IYTASILESG GESTYYSDSV VPSRFSGSGS KGRFTISRDN GTEFTLTINS SKNTLYLQM LQPDDFATY NSLTADDTAL YCQKFNSVP YYCAKDRPR WTFGPGTK QGVGELYDS VEVK WGQGTLVTV SS MEX84_p2-49 GGGLVQPGGS 132 IGHV3- IGHD3- IGHJ5*01 AKDRL 172 SASLGDRVTI 212 IGKV1- IGKJ1*01 QHYHSY 252 LRLSCAASGF 23*01 10*01 EKGIGE TCRASQSISP 5*03 PWT TFSAYAMSW LFHS WLAWYQQK VRQAPGKGL PGKAPKFLIY EWVSSISVQS QTSILESGVP DSTYFADSVK SRFSGSGSGT GRFTISRDNS EFTLTISSLQ KNTLYLQMN PDDFATYYC SLRAEDTALY QHYHSYPW YCAKDRLEK TFGQGTKVE GIGELFHSWG IK QGTLVTVSS MEX84_p4-18 GGGLVQPGGS 133 IGHV3- IGHD3- IGHJ5*02 AKDRL 173 SASIGDRVTI 213 IGKV1- IGKJ1*01 QHYHSY 253 LRLSCAASGF 23*01 10*01 RQGVG TCRASQSISP 5*03 PWT TFSAYAMSW ELFHS WLAWYQQK VRQAPGKGL PGKAPKFLIY EWVSGISVQS QTSILESGVP DSTYLADSVK SRFSGSGSGT GRFTTSRDNS EFTLTISSLQ KNTLYLQMN PDDLATYYC SLRVEDTALY QHYHSYPW YCAKDRLRQ TFGQGTKVE GVGELFHSW IK GQGTLVTVSS MEX84_p4-19 GGGLVQPGGS 134 IGHV3- IGHD3- IGHJ4*01 AKDRL 174 SASVGDRVT 214 IGKV1- IGKJ1*01 QHYHSY 254 LRLSCAASGF 23*01 10*01 REGVG ITCRASQNIS 5*03 PWT TFGAYAMSW ELYQY PWLAWYQQ VRQAPGKGL KPGKAPKFL EWVSSISVHS IYQTSILESG DSTYYADSVR VPSRFSGSGS GRFTISRDNS GTDFTLTISS KNTLYLQMN LQPDDFATY SLRAEDTALY YCQHYHSYP YCAKDRLRE WTFGQGTK GVGELYQYW VEIK GHGTLVTVSS MEX84_p4-53 GGGLVQPGGS 135 IGHV3- IGHD3- IGHJ5*02 AKDRL 175 SASIGDRVTI 215 IGKV1- IGKJ1*01 QHYHSY 255 LRLSCAASGF 23*01 10*01 REGIGE TCRASQSITP 5*03 PWT TFSAYAMSW LFHS WLAWYQQK VRQAPGKGL PGKAPKFLIY EWVSSINGHS QTSILESGVP DSTYFADSVK SRFSGSGSGT GRFTISRDNS EFTLTISSLQ KNTLYLQMN PDDFATYYC SLRAEDTALY QHYHSYPW YCAKDRLRE TFGQGTKVE GIGELFHSWG IK QGTLVTVSS MEX84_p4-89 GGGLVQPGGS 136 IGHV3- IGHD1- IGHJ3*01 AKDRD 176 SASVGGRVTI 216 IGKV1- IGKJ3*01 QRYDSY 256 LRLSCAGSGF 23*01 14*01 HFDGH TCRASQSISS 5*03 PFT TFSSFAMSW DV WLAWYQQK VRQAPGKGL PGKAPKLLIS EWVSTITGIG KASNLESGV GDTYYTDSVK PSRFSGGGS GRFTVSRDNS ETEFTLTISS KKTVFLHMN LQPDDFATY SLRAEDTAVY YCQRYDSYP YCAKDRDHF FTFGPGTKV DGHDVWGQ TIK GTMVTVSS VH1- MEX84_p2-13 GAGVKKPGAS 137 IGHV1- IGHD3- IGHJ5*02 ARGGP 177 SLSPGERAT 217 IGKV3- IGKJ4*01 QQYVSS 257 2/VK3-20 VKVSCKASGY 2*02 22*01 VNAPR LSCRASQEIG 20*01 PLT IFSDYYMQW GFDP SFSLGWYQQ VRQAPGQGL KFGQPPRLLI QWMGWINP YGASSRATGI KSGFTNYAQ PDRFSGSGS KFQGRVTMT GTDFTLTISR RDTSISTAYM LEPEDVAVY ELTGLTSDDT YCQQYVSSP AIYYCARGGP LTFGGGTKV VNAPRGFDP EIK WGQGTLVTV SS MEX84_p2-15 GAGVKIPGAS 138 IGHV1- IGHD1- IGHJ5*02 ARGGP 178 SLSPGDRAT 218 IGKV3- IGKJ4*01 QQYVSS 258 VKVSCKASGY 2*02 26*01 VNSPL LSCRASQSIG 20*01 PLT IFSDYYMQW GFDP SFSLAWYQQ VRQAPGQGL KFGHAPRLL EWMGWINP IYGASSRATG KSGFSDYAQK IPDRFSGSGS FQGRVSMTR DTDYTLTIS DTAISTAYME RLEPEDFAV LTRLTSDDTA YYCQQYVSS VYYCARGGPV PLTFGGGTK NSPLGFDPW VEIK GQGTLVTVSS MEX84_p2-45 GPGVKKPGAS 139 IGHV1- IGHD1- IGHJ5*02 ARGGR 179 SLSPGERAT 219 IGKV3- IGKJ4*01 QQYVSS 259 VKVSCKASGY 2*02 26*01 INSPLG LSCRASQSIS 20*01 PLT IFSDYYILWV FDP TFSLAWYQQ RQAPGQGLE KFGQAPRLL YMGWMNPIS IYGASSRATG GFTHYAQNF IPDRFSGSGS QGRVTMTRD GTDFTLTISR TSISTAYMEL LEPEDFAVY TRLASDDTA YCQQYVSSP VYYCARGGRI LTFGGGTKV NSPLGFDPW EIR GQGTLVTVSS MEX84_p2-51 GAEVKKPGAS 140 IGHV1- IGHD5- IGHJ5*02 ARGGQ 180 SLSPGERAT 220 IGKV3- IGKJ4*01 QQYGSS 260 VKVSCKVSGY 2*02 24*01 ISAPHG LSCRASQSVS 20*01 PLT TFTGYYMQW FDP SIHLGWYQQ VRQAPGQGL KPGQAPRLL EWMGWINP IYGASSRATG KTGHTNFAQ IPDRFSGSGS RDTSISTAYM GTDFTLTISR ELARLTSDDT LEPEDFAVY AVYFCARGG YCQQYGSSP KFQGRVTMT LTFGGGTKV QISAPHGFDP EIK WGQGTLVTV SS MEX84_p2-58 GAGMRKPGA 141 IGHV1- IGHD2- IGHJ5*02 ARGGR 181 SLSPGETAT 221 IGKV3- IGKJ4*01 QQYVSS 261 SVKVSCKASG 2*02 8*01 INAPLG LSCRASQSIG 20*01 PLR YSFNDYYIH FDP SISLGWYQQ WVRQAPGQG KFGQAPRLL LEWMGWINP IYGASTRAT KSGFTNYAQ GTPDRFSGS RFQGRVTMT GSETDFTLTI GDTSNSVAY SRLEPEDSA MELTRLTSD VYYCQQYVS DTAVYYCAR SPLRFGGGT GGRINAPLGF KVEIK DPWGQGTLV TVSS MEX84_p4-65 GAEVKKPGAS 142 IGHV1- IGHD6- IGHJ5*02 ARGGPI 182 SLSPGERAT 222 IGKV3- IGKJ4*01 QQYGSS 262 VKVSCKVSGY 2*02 6*01 SAPLGF LSCRASQSVS 20*01 PLT TFSDYYMQW DP SIHLAWYQQ VRQAPGQGL RPGQAPRLL EWMGWINP INGASSRAT KTGHTNFAQ GIPDRFSGSG KFQGRVTVT SGTDFTLTIS RDTSITTAYM RLEPEDFAV ELRTLTSDDT YYCQQYGSS AVYFCARGGP PLTFGGGTK ISAPLGFDPW VEIK GQGTLVTVSS MEX84_p4-91 GAEVKKPGAS 143 IGHV1- IGHD1- IGHJ3*01 ARAAM 183 SLSPGERAT 223 IGKV3- IGKJ1*01 QQYGSS 263 VKVSCKASAY 2*02 14*01 NRISGV LSCRASQSLS 20*01 RGT SFTDYYIHWV VPPGD SNYLAWYQ RQAPGQGLQ AFDL QKPGQAPRL WMGWINPDS LIYGASSRAT GEVNYVQKF GIPDRFSGSG QDRVTMTRG SGTDFTLTIS TSISTAYMEL RLEPEDFAV RRLRSDDTA YYCQQYGSS VYYCARAAM RGTFGQGTK NRISGVVPPG VEIK DAFDLWGQG TLVTVSS VH1- MEX84_p2-44 GAEVKKPGAS 144 IGHV1- IGHD2- IGHJ4*02 TRSLV 184 SLSPGERAT 224 IGKV3- IGKJ3*01 QQYGSS 264 46/VK3-20 VKLSCKSSGY 46*01 2*01 TPAAQ LSCRASQSVS 20*01 PLT SFTSYYMHW SVQYF LSFLAWYQQ VRQAPGQGL DS KPGQAPRLL EWMGIINPSG IYGASNRAT VFTSYAQRFQ GIPDRFSGSG GRVTMTSDT SGTDFTLTIS ATSTVYMELS RLEPGDFAV SLRSGDTAVY YYCQQYGSS YCTRSLVTPA PLTFGPGTK AQSVQYFDS VDIK WGQGTLITVS S MEX84_p2-55 GAEVKKPGAS 145 IGHV1- IGHD2- IGHJ4*02 ARTLV 185 SLSPGERGT 225 IGKV3- IGKJ3*01 QQYGSS 265 VKLSCKASGY 46*01 8*02 APSAQ LSCRASQYIT 20*01 PVT TFTSYYVHW SMYYF TGHFAWYQ VRQAPGQGL DF QKPGRAPRL EWMGIINPG LIYGASVRAT NNFVSFAQN GVPDRFSGS FYDRATMTR GAETDFTLT DTSTNTVYM ISRLDPEDV ELTNLQSEDT GVYYCQQYG AVYYCARTLV SSPVTFGPG APSAQSMYYF TKVEIK DFWGQGTLV TVSS MEX84_p4-33 GSEVKKPGAS 146 IGHV1- IGHD2 - IGHJ4*02 TRTQV 186 SLSPGERAT 226 IGKV3- IGKJ3*01 QQYGSS 266 VKLSCKASGY 46*01 15*01 VPSAQ LSCRASQNIG 20*01 PVT TFTSYYIHWV SVYYF LDYFAWYQ RQAPGQGLE DF QKPGQAPRL WVGVINPGN LIYGASIRAT VFTSYAQRFH GIPDRFSGSG DRVTMTRDT SGTDFTLTIS STSTVYMEM RLVPEDIAV SSLRSEDTAV YYCQQYGSS YYCTRTQVVP PVTFGPGTK SAQSVYYFDF VEVK WGQGTLVTV SS MEX84_p4-68 GAEVKKPGTS 147 IGHV1- IGHD3- IGHJ4*02 TRTRV 187 SLSPGERAT 227 IGKV3- IGKJ3*01 QQYGSS 267 VKVSCKASGY 46*01 3*01 VPSAQ LSCRASQSV 20*01 PVT TFTSYYIHWV SVYYF TSGYFAWYQ REAPGQGLE DF HKPGQAPRL WVGIINPGNT LIYGASIRAT FTSYAPRFHG GIPDRFSGSE RVSMTRDTS SGTDFTLTIS TSTVYMELSS RLEPEDVAV LRSEDTAVYY YYCQQYGSS CTRTRVVPSA PVTFGPGTK QSVYYFDFW VDIK GQGTLVTVSS MEX84_p4-85 GAEVKKPGAS 148 IGHV1- IGHD2- IGHJ4*02 TRTQII 188 SLSPGERAT 228 IGKV3- IGKJ3*01 QQYGSS 268 VKVSCKTSGF 46*01 2*01 PAAQS LSCRASQFVI 20*01 PPT TFTSYYIHWV VYFFD SGHFAWYQ RQAPGQGLE Y QKPGQAPRL WMGFINPTS LIYGTSNRA GFTSYTQNLH TGIPDRFSGS GRVTMTRDT ESGADFTLTI STRTVFMELR SRLEPEDFA SLASGDTAVY VYFCQQYGS

YCTRTQIIPA SPPTFGPGT AQSVYFFDY KVDIK WGPGTLVTV SS MEX84_p4-92 GAEVAKPGTS 149 IGHV1- IGHD6- IGHJ5*02 TRTRII 189 SLSPGDRAT 229 IGKV3- IGKJ3*01 QQYGSS 269 VKVSCKASGY 46*01 6*01 AAAQS LSCRASQHIT 20*01 PVT TFTSYYIHWV VYHYD TGHFAWYQ RQAPGQGLE L QKPGQAPRL WVGIINPGGA LIYGASIRAS FTSYAQRFHG GIPDRFSGSG RVRMTRDTS SGTDFSLTIS ASTVYVELSS RLEPEDCAV LRSDDTAVYY YYCQQYGSS CTRTRIIAAA PVTFGPGTK QSVYHYDLW VDIK GQGTLVTVSS VH1- MEX84_p2-21 GAEVKKPGAS 150 IGHV1- IGHD2- IGHJ4*02 ARAQD 190 SASVGDRVT 230 IGKV1- IGKJ4*01 QQSYITP 270 46/VK1-39 VKVSCKASGY 46*01 21*02 PATAIR ITCRASQSID 39*01 LT TFSSYYIHWV GLRWE TYLNWYQQ RQAPGQGLE Y KPGKVPAILI WMGIIKPSSG YAASSLQSG STNYAHKFQ VPSRFSGSGS DRVTMTTDT GTDFTLTIN STSTVYMELS SLQPEDFAT SLRYQDTAVY YYCQQSYITP YCARAQDPA LTFGGGTKV TAIRGLRWEY EIK WGQGSLVTV SS MEX84_p4-16 GAEVKKPGAS 151 IGHV1- IGHD2- IGHJ3*02 ARGGS 191 SASVGDRVT 231 IGKV1- IGKJ4*01 QQSFST 271 VKVSCKASGY 46*01 2*02 YPVAIR ITCRASQSIS 39*01 PLT TFTTYFIHWV GVTFGI NYLNWYQQ RQAPGQGLE KPGKAPNLL WMGIINPNS IFATSSLQSG GSTNYAQKIQ VPSRFSGSGS GRVTMTTDT GTDFTLTISS SASTVYMELS LQPEDFATY GLRSEDTAVY YCQQSFSTP YCARGGSYPV LTFGGGTKV AIRGVTFGIW EIR GQGTMVTVS S MEX84_p4-41 GAEVKKPGAS 152 IGHV1- IGHD2- IGHJ3*01 ARGAA 192 SASVGDRVT 232 IGKV1- IGKJ4*01 QQSYISP 272 VRVSCKASGY 46*01 2*02 YPTAIR ITCRASQSIS 39*01 LT TFTSYYMHW GVIYGF TYLNWYQQ VRQAPGQGL KPGKAPKLL EWMGIINPSS IFAASTLQSG GSTSYAQKLH VPSRFSGSGS DRVTMTRDT GTEFTLTITS STSTVYMEM LQPADFAIY SSLRSEDTAV YCQQSYISPL YYCARGAAYP TFGGGTKVE TAIRGVIYGF IN WGQGTMVTV SS MEX84_p4-80 GAEVKKPGAS 153 IGHV1- IGHD6- IGHJ5*02 ATSPA 193 SASVGDRVT 233 IGKVI- IGKJS*01 HQSFSA 273 VKISCKASAD 46*01 13*01 AAGSG ITCRASQSII 39*01 PYT TFTKNYVHW HPSGW NYLNWYQQ VRQAPGQGL FDP KPGKAPKLL EWMGIINPSS IYTASSLQSG GWTSNPQKF VPSRFSGSGS QGRVTMTRD GTSFTLTISS TSTSTVYMEL LQPEDFAIY SSLRSDDTAL YCHQSFSAP YYCATSPAAA YTFGQGTKL GSGHPSGWF EIK DPWGPGTLV TVSS MEX84_p4-82 GAEMKKPGA 154 IGHV1- IGHD2- IGHJ6*02 ARPPG 194 SASVGHRVT 234 IGKV1- IGKJ1*01 QQSYST 274 SVKVSCQASG 46*01 21*01 RSFLD ITCRASQSIS 39*01 PLS YSFTNHFIH GMDV SYLNWYQQ WVRQAPGQG KPGKAPKLL LEWMGTINP IFAASSLQSG SGGSTTFAQK VPSRFSGSGS FQGRVTMTR GTDFTLTIN DTSTSTVYME SLQPGDFAT LSSLRSEDTA YYCQQSYST VYYCARPPGR PLSFGQGTR SFLDGMDVW VEIK GQGTTVTVSS VH4- MEX84_p2-68 GAGLLKTSET 155 IGHV4- IGHD3- IGHJ4*02 TRVRW 195 PASVSGSPG 235 IGLV2- IGLJ1*01 CSYANS 275 34/VL2-32 LYLTCTVYGD 34*01 3*01 DGIEFT QSITIYCSGS 23*02 GTFV SFNHYYWGW MFFDS SSDVGSYNL IRQPPGKGLE VSWYQQHP WLGEINHRG GKAPKLIIYG TTNYNPSLKS VTRRPSGVS RVSILVDTSQ SRFSGSKSG KQFSLRVTSV NTASLTFSG TAADTSVYYC LQVEDDADY TRVRWDGIE YCCSYANSG FTMFFDSWG TFVFGTGTK QGSLVTVSP VTV MEX84_p2-76 GAGLLKTSET 156 IGHV4- IGHD5- IGHJ4*02 ARVRW 196 PASVSGSPG 236 IGLV2- IGLJ1*01 CSYANS 276 LYLTCTVYGD 34*01 12*01 DGIEST QSITIYCSGS 23*02 GTFV SFNHYYWGW MFFDS SSDVGSYNL IRQPPGKGLE VSWYQQHP WLGEINHRG GKAPKLIIYG TTNYNPSLKS VTRRPSGVS RVSILVDTSH SRFSGSKSG KQFSLRVTSV NTASLTFSG TAADTSVYYC LQVEDDADY TRVRWDGIE YCCSYANSG STMFFDSWG TFVFGTGTK QGSLVTVSP VTV MEX84_p2-83 GAGLLKTSET 157 IGHV4- IGHD5- IGHJ4*02 TRVRW 197 PASVSGSPG 237 IGLV2- IGLJ1*01 CSYANS 277 LYLTCTVYGD 34*01 12*01 DGIEST QSITIYCSGS 23*02 GTFV SFNHYYWGW MFFDS SSDVGSYNL IRQPPGKGLE VSWYQQHP WLGEINHRG GKAPKLIIYG TTNYNPSLKS VTRRPSGVS RVSILVDTSQ SRFSGSKSG KQFSLRVTSV NTASLTFSG TAADTSVYYC LQVEDDADY TRVRWDGIE YCCSYANSG STMFFDSWG TFVFGTGTK QGSLVTVSP VTV VH4- MEX84_p4-30 GARPLKPSET 158 IGHV4- IGHD3- IGHJ6*02 ARDVV 198 SLSPGDRAT 238 IGKV3- IGKJ1*01 QIYDSSV 278 34/VK- LSLTCGVNGG 34*01 10*01 TMVEG LSCGASQSVS 20*01 RT 3-20 SFSGYHWSW LRFHY SNYLAWYQ IRQPPGKGLE YYNYY QKLGQAPRL WIGEIDHNG GMDV LIYAASTRAT RINYNPSLKS GIPDRFSGG RVTISIDTFKS GSGTDFTLTI QFSLRLTSIIA NKLEAEDFA ADTAVYYCA MYYCQIYDS RDVVTMVEG SVRTFGQGT LRFHYYYNYY KVEIK GMDVWGQG TPVTVSS MEX84_p4-37 GARPLKPSET 159 IGHV4- IGHD3- IGHJ6*02 ARDVV 199 SLSPGDRAT 239 IGKV3- IGKJ1*01 QIYDSSV 279 LSLTCGVNGG 34*01 10*01 TMVEG LSCRASQSVS 20*01 RT SFSGYHWTW LRFHY SNYLAWYQ IRQPPGKGLE YYNYY QKLGQAPRL WIGEIDHNG GMDV LIYGASTRAT RINYNPSLKS GIPDRFSGG RVTISIDTFKS GSGTDFTLTI QFSLRLTSIT NKLEAEDFA AADTAIYYCA VYYCQIYDSS RDVVTMVEG VRTFGQGTK LRFHYYYNYY VEIK GMDVWGQG TPVTVSS MEX84_p4-57 GARPLKPSET 160 IGHV4- IGHD3- IGHJ6*02 ARDVV 200 SLSPGDRAT 240 IGKV3- IGKJ1*01 QIYDSSL 280 LSLTCGVNGG 34*01 10*01 TMVEG LSCGASQSVS 20*01 RT SFSGYHWSW LRFHY SNYLAWYQ IRQPPGKGLE YYNYY QKLGQAPRL WIGEIDHNG GMDV LIYGASTRAT RINYNPSLKS GIPDRFSGG RVTMSIDTFK GSGTDFTLTI SQFSLRLTSIT NKLEAEDFA AADTAVYYC MYYCQIYDS ARDVVTMVE SLRTFGQGT GLRFHYYYNY KVEIK YGMDVWGQ GTPVTVSS VH4- MEX84_p4-10 GPGLVKPSET 161 IGHV4- IGHD3- IGHJ4*02 ARNQP 201 SLSPGQRAT 241 IGKV3- IGKJ1*01 QERNN 281 59/VK3-11 LSLTCTVSGG 59*01 16*01 GGRAF LSCRASQSVS 11*01 WPLTW SISTYYWSWI DY NYFAWYQQ T RQTPGKGLE KPGQAPRLL WIGCIYYSVD IYDTSKRAT THFNPSLESR GTPARFSGS VTISVDTSKN GSGTDFTLTI QFSLKMTSM SSLEPEDFA TAADTAVYY VYYCQERNN CARNQPGGR WPLTWTFG AFDYWGPGT LGTKVEIK LVTVSS MEX84_p4-23 GPGLVKPSET 162 IGHV4- IGHD3- IGHJ4*02 ARNQP 202 SLSPGQRAT 242 IGKV3- IGKJ1*01 QERNN 282 LSLTCTVSGG 59*01 16*01 GGRAF LSCRASQSVS 11*01 WPLTW SIDTYYWSWI DY NYFAWYQQ T RQTPGKGLE KPGQAPRLL WIGCFYYSVD IYDTSKRAT NHFNPSLESR GTPARFSGS VTISVDTSKN GSGTDFTLTI QFSLKMTSM SSLEPEDFA TASDTAVYYC VYYCQERNN ARNQPGGRA WPLTWTFG FDYWGPGTL LGTKVEIK VTVSS VH5- MEX84_p2-11 GAEVKKPGES 163 IGHV5- IGHD2- IGHJ6*02 ARHDG 203 SASVGDRVT 243 IGKV1- IGKJ1*01 QQTDRT 283 51/VK1-39 LRISCKTSGY 51*03 15*01 RGYCS ITCRASQSIS 39*01 PLT TFTSHWLAW PTRCF NYLNWYQQ VRQMPGKGL FSGMD KPGKAPNLL EWMGIIYPGD V IYAASSLQSG SDTRYSPSFQ VPSRFSGSGS GQISISADKSI GTDFTLTISS NTAYLQWSS LQPEDYAIY LKASDTAIYY YCQQTDRTP CARHDGRGY LTFGQGTKV CSPTRCFFSG EIK MDVWGQGT TVIVSP MEX84_p4-12 GAEVRKPGES 164 IGHV5- IGHD2- IGHJ6*02 ARHDG 204 SASVGDRVT 244 IGKV1- IGKJ1*01 QQTDRT 284 LRISCKTSGY 51*03 15*01 RGYCS ITCRASQSIS 39*01 PLT TFTSHWVAW PTRCF NYLNWYQQ VRQMPGKGL FSGMD KPGKAPNLL EWMGIIYPGD V IYAASSLQSG SDTRYSPSFQ VPSRFSGSGS GQISISADKSI GTDFTLTISS NTAYLQWSS LQPEDYAIY LKASDTGIYY YCQQTDRTP CARHDGRGY LTFGQGTKV CSPTRCFFSG EIK MDVWGQGT TVIVSP VH1- MEX84_p2-38 GAEVKKPGAS 165 IGHV1- IGHD3- IGHJ2*01 ARRTY 205 SASVGDRVT 245 IGKV1- IGKJ2*01 QQSISAP 285 2/VK1-39 VRVSCKASGY 2*02 16*01 YDNRF ITCRASQSIG 39*01 YT TFSDYYVHW PYWYF KYLNWYQQ LRQAPGQRLE DL KPGLAPEVLI WMGWINAN SGATTLQSG TGGSDSGPKF VPSRFSGSGS YGRVTLTRDT ETDFTLTINS SVNTAYMELS LQPEDLATY RLRSDDTAVY VCQQSISAPY FCARRTYYD TFGPGTKLEI NRFPYWYFD K LWGRGTLVT VSS MEX84_p4-61 GAEVKKPGAS 165 IGHV1- IGHD3- IGHJ2*01 ARRTY 206 SASVGDRVT 246 IGKV1- IGKJ2*01 QQSLSA 286 VKVSCKASGY 2*02 22*01 YDTRF ITCRASQDIG 39*01 PYT TFSGYYIHWL PYWYF SYLNWYQQ RQAPGQGLE DL KPGKAPNVL WMGWINSNS ISAASTLQSG GGADSGPRF VPSRISGIGS HGRVTMTRD GTDFTLTISS TSINTAYLEL LQPEDFATY TNLRSDDTA YCQQSLSAP

VYYCARRTYY YTFGQGTKL DTRFPYWYF EIK DLWGRGTLV TVSS VH1- MEX84_p2-53 GAEVKKPGSS 167 IGHV1- IGHD2- IGHJ4*02 ARSWG 207 SVSPGERAT 247 IGKV3- IGKJ2*01 QYYTN 287 69/VK3-15 VKVSCKASGG 69*05 8*02 TAATG LSCRASHSV 15*01 WPPHV TFSSYAIIWV GSFVQ TSNLAWYQ A RQAPGQGLE QKPGQAPRL WMGGIIPIFG LIYGASTRAT TTNYAQKFR GIPARFSGSG GRVTIATDAS SGTEFTLTIS KSAAYMDLSS SLQSEDSAV LKSEDTAIYY YYCQYYTN CARSWGTAA WPPHVAFG TGGSFVQWG QGTKLEIK QGTLVTVSS MEX84_p4-34 GAEVKTPGSS 168 IGHV1- IGHD2- IGHJ5*02 ARGRD 208 SVSPGERAT 248 IGKV3- IGKJ4*01 QQYNN 288 VKVSCKTSGG 69*13 21*02 SSGRLL LSCRASQTV 15*01 WPPLT TFSNFAITWV DH NRNLAWYQ RQAPGQGLE QKPGQAPRL WMGGIIPLFG LIYAASARA ITNYTQKFQG TGVPARFSG RVTITTDESK SGSGTEFTL TTAYMDLSG TISSLQSEDF LRSEDTAVYF AVYYCQQYN CARGRDSSGR NWPPLTFG LLDHWGQGT GGTKVEIK LVTVSS VH1- MEX84_p2-94 GAEVKKPGAS 169 IGHV1- IGHD6- IGHJ4*02 ARGGM 209 SASVGDRVT 249 IGKV1- IGKJ2*01 QQYQSS 289 2/VK1-5 VKVSCKASGN 2*02 13*01 LGQLW ITCRASQSIS 5*03 PYT TFMGYYFHW ALDN HWLAWYQQ VRQAPGQGL RPGEAPKLLI EWMGWINP YQASTLESG NSGHANIAQT VPSRFSGSGS FQGRVTMTR GTEFTLSISS DPSITTAYME LQPDDFATY LSRLRSDDTA YCQQYQSSP VFYCARGGM YTFGQGTKL LGQLWALDN EIK WGQGTLVTV SS MEX84_p4-54 GAEVKRPGAS 170 IGHV1- IGHD2- IGHJ4*02 ARGGR 210 STFVGDRVT 250 IGKV1- IGKJ1*01 QQYMSY 290 VKVSCKASGY 2*02 21*01 INVAE ITCRASQTIG 5*03 PWT TFADYYIHW ALRY DWLAWYQQ VRQAPGLGLE KPGKAPKLL WMGWINPK ISKATRLESG TGFSHYEQTF VPSRFSGSGS QGRVTMARD ETEFSLTINS TSIPAAYMEL LQPDDVAAY SSLKSDDTAI YCQQYMSYP YYCARGGRIN WTFGQGTK VAEALRYWG VEIK QGSLVIVSS MEX 18 - refers to an individual donor. Sequences were analyzed with IgBlast VH3- MEX18_07 GGGLVQPGGS 291 IGHV3- none IGHJ3*01 AKDRVA 315 SASVGDRVT 339 IGKV1- IGKJ1*01 QQYNSYP 363 23/VK1-5 LRLSCAASGF 23*01 FDGFHV ITCRASQSIS 5*03 WT TFSSYAMNW SWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSGIGGRG IYKASSLESG AIAGDGSIYY VPSRFSGSGS ADSVKGRFTI GTEFSLTISS SRDNSKNTLY LQPDDFATY LQMNGLRVE YCQQYNSYP DTAVYYCAK WTFGQGTK DRVAFDGFH VEIK VWGQGTTVT VSS MEX18_15 GGGLIQPGGS 292 IGHV3- IGHD3- IGHJ1*01 AKDRLT 316 SASVGDRVT 340 IGKV1- IGKJ1*01 QHYYSYP 364 LRLSCSASGF 23*01 10*01 MGVGEL ITCRASQNIN 5*03 WT TFSSYAMSW FVD SWLAWYQQ VRQAPGKGL KPGKAPKFL EWVSGISPLD IYQASTLQN GSTYYAASVK GVPSRFSGS GRFTISRDNS GSGTEFTLTI KNTLFLQMN SSLQPDDFA SLRVEDTAIY TYYCQHYYS YCAKDRLTM YPWTFGQG GVGELFVDW TKVEIK GPGTLVSVSS MEX18_21 GGGLVQPGGS 293 IGHV3- IGHD3- IGHJ4*02 AKDRGP 317 SASVGDRVT 341 IGKV1- IGKJ1*01 QHFHSVP 365 RRLSCATSGF 23*01 10*01 RGIGELF ITCRASQSIS 5*03 WT SFDTYAMSW DF RWLAWYQQ LRQAPGKGLE KPGKAPKLL WVSSFSGLD IYKTSTLKSE DSTYYADSVK VPSRFSGSGS GRFTISRDNS GTEFTLTISS KNTLYLQMN LQPDDFATY SLRAEDTAIY YCQHFHSVP YCAKDRGPR WTFGQGTK GIGELFDFWG VEIK QGTLVSVSS MEX18_24 GGGLVQPGGS 294 IGHV3- IGHD5- IGHJ4*02 SKDRGP 318 SASVGDRVT 342 IGKV1- IGKJ1*01 QHFYSVP 366 LRLSCVTSGF 23*01 24*01 RGVGEL ITCRASQSIS 5*03 WT SFDTYALSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSFSGID IYTTSTLKSG DSTYYTESVK VPSRFSGSGS GRFTMSRDN GTEFTLTISS SKSTLFLQMN LQPDDFATY GLRAEDTAM YCQHFYSVP YYCSKDRGPR WTFGQGTK GVGELFDSW VEIK GQGTLVIFSS MEX18_27 GGGLVQPGGS 295 IGHV3- IGHD3- IGHJ4*02 AKDRGP 319 SASVGDRVT 343 IGKV1- IGKJ1*01 QHFHSVP 367 LRLSCATSGF 23*01 10*01 RGVGEL MTCRASQSI 5*03 WT TFSTYAMSW FDS NRWLAWYQ VRQAPGKGL QKPGKAPKL EWVSSFSGVD LIYTTSTLKS DSTYYAESVK GVPSRFSGS GRFTISRDNS GSGTEFTLTI KNTVYLQMT SSLQPDDFA RLRAEDTAV TYYCQHFHS YYCAKDRGP VPWTFGQG RGVGELFDS TKVEIK WGQGTLVTV SS MEX18_36 GGGLVRPGGS 296 IGHV3- IGHD3- IGHJ4*02 AKDRGP 320 SASVGDRVT 344 IGKV1- IGKJ1*01 QHFYSVP 368 LTLTCATSGF 23*01 10*01 RGVGEL ITCRASQSIS 5*03 WT TFSDYAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSYSGID IYTTSTLKSG DSTYYADSVK VPSRFSGSGS GRFTISRDNS GTEFTLTISS KRTLSLHMN LQPDDFATY SLRAGDSALY YCQHFYSVP YCAKDRGPR WTFGQGTK GVGELFDSW VEIK GPGTLVTVSS MEX18_38 GGGLVQPGGS 297 IGHV3- IGHD3- IGHJ4*02 AKDRLP 321 SAAIGDRVT 345 IGKV1- IGKJ1*01 QHYYSYP 369 LRLSCAASGF 23*01 10*01 EGFGKL FTCRASQSIN 5*03 WT TFSDYAMGW FDY TWLAWYQQ VRQAPGKGL KPGKAPKLL EWLSSMTRT MHKASTLHS GDNLYYADS GVPSRFSGS VKGRFTISRD GSGTEFTLTI NSKNTLYLQ SSLQPDDFA MSSLRVEDT TYYCQHYYS AIYFCAKDRL YPWTFGQG PEGFGKLFDY TKVEIK WGQGTLVTV ST MEX18_41 GGGLVQPGGS 298 IGHV3- IGHD1- IGHJ5*02 ARDQEV 322 SVSVGDRVTI 346 IGKV1- IGKJ4*01 QQYSSFFT 370 LRLSCAASGF 23*01 26*01 IGHYPS TCRASQNIN 5*03 SFSDFAMSW DH SWLAWYQQ VRQAPNQGL KPGKAPKLL DWVSCVSGG IYKASRLERG GDTTYYADSV VPSRFSGRG KGRFTISRDN SGTEFALTIS SKNTVFLEM GLQPDDFAT NNLRPEDTA YYCQQYSSF VYYCARDQE FTFGGGTKV VIGHYPSDH EIK WGQGTLVIVS S MEX18_50 GGGLVQPGGS 299 IGHV3- IGHD3- IGHJ3*01 TKDRIL 323 SASVGDRVT 347 IGKV1- IGKJ1*01 QQYNNYP 371 LRLSCVASGF 23*01 9*01 FDAFHV ITCRASQSIS 5*03 WT TFSNYGMNW SWLAWYQQ VRQAPGKGL KPGKAPNLL EWVSGITGSG IYKASTLESG DDTYYADSV VPSRFSGSGS KGRFTISRDN GTEFTLTISS SRNTLYVQM LQPDDFATY NNLRAEDTAI YCQQYNNYP YYCTKDRILF WTFGQGTK DAFHVWGQG VEIK TMVTVSS MEX18_54 GGDLVQPGGS 300 IGHV3- IGHD3- IGHJ4*02 AKDRVS 324 SASVGDRVT 348 IGKV1- IGKJ1*01 QHYYSYP 372 LRLSCVASGF 23*01 10*01 GGFGEL ITCRASQNIN 5*03 WT TFSAYGMSW QDY SWLAWFQQ VRQAPGKGL KPGKAPELLI EWVSAMTGS YKTSTLHTG GDSTYYADSV VPSRFRGRG KGRFTISRDN SGTEFTLTIS SKNTLYLQM SLQPDDFAT NSLRVEDTAI YYCQHYYSY YYCAKDRVSG PWTFGQGT GFGELQDYW KVEIK GQGTLVTVSS MEX18_58 GGGLVQPGGS 301 IGHV3- IGHD3- IGHJ5*02 AKDRGP 325 SASVGDRVT 349 IGKV1- IGKJ1*01 QHFFSVP 373 LRLSCATSGF 23*01 10*01 RGVGEL ITCRASQSIS 5*03 WT TFTTFAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPRLL EWVSSISGAD IYTTSTLKSG DSTYYAASVK VPSRFSGSGS GRFTISRDNS GTEFTLTISS RSTLFLQMNS LQPDDFATY LRAEDTAVYY YCQHFFSVP CAKDRGPRG WTFGQGTK VGELFDSWG VEIK QGTVVSVSS MEX18_65 GGGLVQPGGS 302 IGHV3- IGHD3- IGHJ4*02 AKDRVT 326 SASIGDRVTI 350 IGKV1- IGKJ1*01 QHYYSYP 374 LTLSCAGSGF 23*01 10*01 MGFGEL TCRASQSVS 5*03 WT PFNTYALIWV FAH GWLAWYQQ RQAPGKGLE KPGKAPKLL WVSSISYDSA IHKASTLQS STYYAESVKG GVPSRFSGS RFTISRDNSQ GSGTEFTLTI NTLYLEMNF TSLQPDDFA LRADDTAVY TYYCQHYYS FCAKDRVTM YPWTFGQG GFGELFAHW TKVEVK GQGTLVAVSS MEX18_79 GGGLKQPGGS 303 IGHV3- IGHD3- IGHJ4*02 AKDRVE 327 PASVGDRVT 351 IGKV1- IGKJ1*01 QHYHSYP 375 LRLSCAASGF 23*01 10*01 KGFGEL ITCRASQNIN 5*03 WT TFRNYGMSW WAS SWLAWYQQ VRQAPGKGL TPGRPPKLLI EWVSSISSLD YKASASLDG DSTYYADSVK VPSRFSGSGS GRSAISRDDS GTEFTLTITS KNTLYLQIHS LQPHDFATY LRAEDTALYF YCQHYHSYP CAKDRVEKG WTFGQGTK FGELWASWG VEIK QGTLVTVSS MEX18_80 GGGLVQPGGS 304 IGHV3- IGHD3- IGHJ4*02 AKDRGP 328 SASVGDRVT 352 IGKV1- IGKJ1*01 QHFHSVP 376 LRLTCATSGF 23*01 10*01 RGVGEL ITCRASQSIS 5*03 WT TFSDYAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSYSGID IYTTSTLKSG DSTYYADSVK VPSRFSGSGS GRFIISRDNSK GTEFTLTISS NTLSLHMNS LQPDDFATY LRAEDSALYF YCQHFHSVP CAKDRGPRG WTFGQGTK VGELFDSWG VEIK QGTLVTVSS MEX18_83 GGGLVQPGGS 305 IGHV3- IGHD3- IGHJ4*02 AKDRGP 329 SASVGDRVT 353 IGKV1- IGKJ1*01 QHFHSVP 377 LRLTCATSGF 23*01 10*01 RGVGEL ITCRASQSVS 5*03 WA

TFSDYAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSYSGID IYTTSTLKSG DSTYYADSVK VPSRFSGSGS GRFTISRDNS GTEFTLTISS RSTLSLHMNS LQPDDFATY LRAEDSALYF YCQHFHSVP CAKDRGPRG WAFGQGTK VGELFDSWG VEIK QGTLVTVSS MEX18_84 GGGLVQPGGS 306 IGHV3- none IGHJ3*01 AKDRVA 330 SASVGDRVT 354 IGKV1- IGKJ1*01 QQYNSYP 378 LRLSCAASGF 23*01 FDGFHV ITCRASQSIS 5*03 WT TFTSYAMNW SWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSGIGGRG IYKASSLESG AIAGDGSIYY VPSRFSGSGS ADSVKGRFTI GTEFSLTISS SRDNSKNIVY LQPEDFATY LQMNGLRVE YCQQYNSYP DTAVYYCAK WTFGQGTK DRVAFDGFH VEIK VWGQGTITT VSS MEX18_86 GGGLVQPGGS 307 IGHV3- IGHD1- IGHJ4*02 AKDRGP 331 SASVGDRVT 355 IGKV1- IGKJ1*01 QHFYSVP 379 LRLTCATSGF 23*01 26*01 RGVGEL ITCRASQSIS 5*03 WT TFSDYAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSYSGID IYTTSTLKSG DSTYYADSVK VPSRFSGSGS GRFIISRDNSK GTEFTLTISS STLSLHMNSL LQPDDFATY RAEDSALYFC YCQHFYSVP AKDRGPRGV WTFGQGTK GELFDSWGQ VEIK GTLVTVSS MEX18_89 GGGLVQPGGS 308 IGHV3- IGHD3- IGHJ4*02 AKDRGP 332 SASVGDRVT 356 IGKV1- IGKJ1*01 QHFYSVP 380 LRLTCATSGF 23*01 10*01 RGVGEL ITCRASQSIS 5*03 WT TFRDYAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSYSGID IYTTSTLKSG DSTYYADSVK VPSRFSGSGS GRFTISRDNS GTEFTLTISS KSTLSLHMNS LQPDDFATY LRAEDSALYF YCQHFYSVP CAKDRGPRG WTFGQGTK VGELFDSWG VEIK QGTLVTVSS MEX18_93 GGGLVQPGGS 309 IGHV3- IGHD3- IGHJ4*02 AKDRGP 333 SASVGDRVT 357 IGKV1- IGKJ1*01 QHFFSVP 381 LRLTCATSGF 23*01 10*01 RGVGEL ITCRASQSIS 5*03 WT TFSDYAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSYSGID IYTTSTLKSG DSTYYADSVK VPSRFSGSGS GRFTISRDNS GTEFTLTISG KSTLSLYMKS LQPDDFATY LRAEDSALYY YCQHFFSVP CAKDRGPRG WTFGQGTK VGELFDSWG VESK QGTLVTVSS MEX18_94 GGGLVQPGGS 310 IGHV3- IGHD3- IGHJ4*02 AKDRGP 334 SASVGDRVT 358 IGKV1- IGKJ1*01 QHFYSVP 382 LRLTCATSGF 23*01 10*01 RGVGEL ITCRASQSIS 5*03 WT TFSDYAMSW FDS KWLAWYQQ VRQAPGKGL KPGKAPKLL EWVSSYSGID IYTTSTLKTG DSTYYADSVK VPSRFSGSGS GRFTISRDNS GTEFTLTISS KSTLSLHMNS LQPDDFATY LRAEDSALYF YCQHFYSVP CAKDRGPRG WTFGQGTK VGELFDSWG VEIK QGTLVTVSS VH3- MEX18_09 GGDLVQPGGS 311 IGHV3- IGHD3- IGHJ5*02 AKDRLV 335 SASVGDRVT 359 IGKV1- IGKJ1*01 QKYNSVP 383 23/VK1-27 LRLSCAASGF 23*01 10*01 RGFGEV ITCRASQGIS 27*01 WT TFSSYGMSW LAS NYLAWYQQ VRQAPGKGL KPREVPKLLI EWVSSISGFD YAASTLHSG PSTYYADSVR VPSRFSGSGS GRFTIARDNS GTDFTLTISG KNTLYLQMK LQPEDVATY SLRVEDTAIY YCQKYNSVP YCAKDRLVR WTFGQGTK GFGEVLASW VEMK GQGTLVTVSS MEX18_13 GGGLVQPGGS 312 IGHV3- IGHD6- IGHJ4*02 AKDRLV 336 SASVGDRVT 360 IGKV1- IGKJ1*01 QKYNSVP 384 LRLSCAASGF 23*01 6*01 RGFAEV ITCRASQDIS 27*01 WT TFSSYAMSW LDY KYLAWYQQ VRQAPGKGL RPGKVPNLL EWVSSFSGID IYTASTLQSG DSTWYADSV VPSRFSGSGS KGRFTISRDN GTHFTLTISS SKSTLYLQMN LQPEDVATY SLRAEDTAVY YCQKYNSVP YCAKDRLVR WTFGQGTK GFAEVLDYW VEIK GRGTLVTVSS MEX18_52 GGGLVQPGGS 313 IGHV3- IGHD6- IGHJ4*02 AKDRLV 337 SASVGDRVT 361 IGKV1- IGKJ1*01 QKYNSVP 385 LRLSCAASGF 23*01 6*01 RGFAEV ITCRASQDIS 27*01 WT TFSSYAMSW LEH KYLAWYQQ VRQAPGKGL RPGKVPNLL EWVSSFSGID IYTASTLQSG DSTWYADSV VPSRFSGSGS KGRFTISRDN GTHFTLTISS SKSTLFLQMN LQPEDVATY SLRAEDTAVY YCQKYNSVP YCAKDRLVR WTFGQGTK GFAEVLEHW VEIK GRGTLVTVSS MEX18_91 GGDLVQPGGS 314 IGHV3- IGHD3- IGHJ4*02 AKDRLV 338 SASVGDRVT 362 IGKV1- IGKJ1*01 QKYNSVP 386 LRLSCAASGF 23*01 10*01 RGFGEV ITCRASQGIS 27*01 WT TFSSYGMSW LDS NYLAWYQQ VRQAPGKGL KPREVPKLLI EWVSSISGFD YAASTLHSG PSTYYADSVR VPSRFSGSGS GRFTIARDNS GTDFTLTISG KNTLYLQMK LQPEDVATY SLRVEDTAIY YCQKYNSVP YCAKDRLVR WTFGQGTK GFGEVLDSW VEMK GQGTLVTVSS MEX 105 - refers to an individual donor. Sequences were analyzed with IgBlast VH3- MEX105_01 GGGLVRPGG 387 IGHV3- IGHD6- IGHJ4*02 VKDRD 416 SASVGDRVT 445 IGKV1- IGKJ1*01 QQYSTYW 474 23/VK1-5 SLRLSCKASG 23*03 19*01 TGWSS ITCRTSQTIA 5*03 T FTFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY IYQASILESG NGDDSTYYA VPSRFSGSGS KSVKGRFTIS GTEFTLTIRS RDDSQSTLS LQPEDFATY LQMNSLRAE FCQQYSTYW DTAVYYCVK TFGQGTKVG DRDTGWSSI IK VDWGQGTL VTVSS MEX105_02 GGGLVRPGG 388 IGHV3- IGHD6- IGHJ4*02 VKDRD 417 SASVGDTVTI 446 IGKV1- IGKJ1*01 QQYSTFW 475 SLRLSCTASG 23*03 19*01 NGWSS TCRASQTLG 5*03 T FTFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY IYQASILESG NGDDSTYYS VPSRFSGSGS KSVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNSLRVE FCQQYSTFW DTAVYYCVK TFGQGTKVG DRDNGWSSI IK VDWGQGTL VTVSS MEX105_04 GGGLVRPGG 389 IGHV3- IGHD6- IGHJ4*02 VKDRD 418 SASVGDRVT 447 IGKV1- IGKJ1*01 HQYSTYW 476 SLRLSCTASG 23*03 19*01 NGWSS ITCRASQTIG 5*03 T FTFRRYAMA IVD SWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIF IYQASILESG NGDDSTYYA VPSRFSGSGS ASVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNSLRAE FCHQYSTYW DTAVYYCVK TFGQGTKVG DRDNGWSSI MK VDWGQGTL VTVSS MEX105_05 GGGLVRPGG 390 IGHV3- IGHD6- IGHJ4*02 VKDRD 419 SASVGDRVT 448 IGKV1- IGKJ1*01 QQYSTYW 477 SLRLSCTASG 23*03 19*01 NGWSS ITCRASHNIG 5*03 T FTFRRYALA IVD GLLAWYQQ WVRQVPGK KPGKAPKLL GLEWVSLIY IYQASRLESG NGDDSTYYA VPSRFSGSGS ESVKGRFTIS GTEFTLTIRG RDNSQNTLS LQPEDFATY LQMNSLRAE FCQQYSTYW DTAVYYCVK TFGQGTKVA DRDNGWSSI IK VDWGQGTL VTVSS MEX105_09 GGGLVRPGG 391 IGHV3- IGHD6- IGHJ4*02 VKDRD 420 SASVGDRVT 449 IGKV1- IGKJ1*01 QQYSTFW 478 SLRLSCTASG 23*03 19*01 TGWSS ITCRTSHTIG 5*03 T FTFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGRAPKLL GLEWVSLIY IYQASILESG NGDDSTYYA VPSRFSGSGS ESVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNSLRAE FCQQYSTFW DTAIYYCVK TFGQGTKVG DRDTGWSSI IK VDWGQGTL VTVSS MEX105_11 GGGLVRPGG 392 IGHV3- IGHD6- IGHJ4*02 VKDRD 421 SASVGDRVT 450 IGKV1- IGKJ1*01 HQYSTYW 479 SLRLSCTASG 23*03 19*01 NGWSS ITCRASQTIG 5*03 T FTFRRYAMA IVD SWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY IYQASILESG DGEDSTYYA VPSRFSGSGS ASVKGRFTIS GTEFTLTIKS RDNSQNTLS LQPEDFATY LQMNSLRAE FCHQYSTYW DTAIYYCVK TFGQGTKVG DRDNGWSSI IK VDWGQGTL VTVSS MEX105_14 GGDLAQPGG 393 IGHV3- IGHD2- IGHJ3*02 AKDRL 422 SASVGDSVTI 451 IGKV1- IGKJ1*01 QQYNNYP 480 SLRLSCAVSG 23*01 8*01 MFDGF SCRASRSISS 5*03 WT LSIGRYGMN HM WLAWYQQK WIRQAPGKG PGKAPKLLIY LEWVSGISD TASTLETGV DGGSTYYAA PSRFSGSGSG SVKGRFTISR AEFTLTISSL DNSKNSVYL QPDDFATYY QMSSLRAED CQQYNNYP TARYYCAKD WTFGQGTT RLMFDGFH VEIK MWGQGTMV TVSS MEX105_15 GGGLVQPGG 394 IGHV3- IGHD3- IGHJ5 AKDRL 423 SASVGDRVT 452 IGKV1- IGKJ1*01 QHYHSYP 481 SLRLSCAASG 23*01 16*01 *02 QLGVG ITCRASQNIN 5*03 WT FTFRTYAMS ELYES SWLAWYQQ WVRQPPGK KPGKAPKLL GLEWVSSIS IYMASSLQS AREDSTYFA GVPSRFSGS ASVRGRFTIS GSGTEFTLT RDNSKNTLY VSSLQPDDF LQMNNLRA ATYYCQHYH EDTALYYCA SYPWTFGQG KDRLQLGVG TKLEIK ELYESWGQG TLVTVSS MEX105_23 GGGLVRPGG 395 IGHV3- IGHD6- IGHJ4*02 VKDRD 424 SASVGDRVT 453 IGKV1- IGKJ1*01 QQYSTFW 482 SLRLSCTASG 23*03 19*01 TGWSS ITCRASQNV 5*03 T FTFRRYAMA IVD DNWLAWYQ WVRQAPGK QKPGKAPKL GLEWVSLIY LIYQASILEN NADDSTYYA GVPSRFSGS

ESVKGRFTIS GSGTEFTLTI RDNSQNTLS RSLQPEDVA LQMNSLRAE TYFCQQYST DTAVYYCVK FWTFGQGT DRDTGWSSI KVGIK VDWGQGTL VTVSS MEX105_25 GGGLVRPGG 396 IGHV3- IGHD6- IGHJ4*02 VKDRD 425 SASVGDRVT 454 IGKV1- IGKJ1*01 QQYSTFW 483 SLRLSCSASG 23*03 19*01 TGWSS ITCRASQTIS 5*03 T FTFRRYAMA IVD HWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLLY IYQASVLETG NGDDSTYYA VPSRFSGSGS ESVKGRFIIS GTEFTLTIRS RDNSLNTLS LQPEDFGTY LQMNSLRAE FCQQYSTFW DTAVYYCVK TFGQGTKVE DRDTGWSSI IK VDWGRGTL VTVSS MEX105_27 GGGLVRPGG 397 IGHV3- IGHD6- IGHJ4*02 VKDRD 426 SASVGDTVTI 455 IGKV1- IGKJ1*01 QQYSTYW 484 SLRLSCTASG 23*03 19*01 NGWSS TCRASRTIGS 5*03 T FTFRRYAMA IVD WLAWYQQK WVRQAPGK PGKAPKLLIY GLEWVSLIY QASILESGVP DGHDTTYYA SRFSGSGSGT DSVKGRFTIS EFTLTIRSLQ RDNSQNTLS PEDFATYFC LQMNSLRAE QQYSTYWTF DTAVYYCVK GQGTTVGVK DRDNGWSSI VDWGQGTL VAVSS MEX105_28 GGGLVRPGG 398 IGHV3- IGHD6- IGHJ4*02 VKDRD 427 SAFVGDRVT 456 IGKV1- IGKJ1*01 QQYSTFW 485 SLRLSCTASG 23*03 19*01 NGWSS ITCRASQTIG 5*03 T FNFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLLY IYQASILESG NGDDSTYYA VPSRFSGSGS KSVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNSLRAE FCQQYSTFW DTAVYYCVK TFGQGTKVE DRDNGWSSI IK VDWGQGTL VTVSS MEX105_33 GGGLVRPGG 399 IGHV3- IGHD6- IGHJ4*02 VKDRD 428 SASVGDRVT 457 IGKV1- IGKJ1*01 QQYSTYW 486 SLRLSCTASG 23*03 19*01 NGWSS ITCRASQTIG 5*03 T FTFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIW IYQASILESG NGDDSTYYA VPSRFSGSGS SSVKGRFTIS GTEFTLTIRG RDNSQNTLS LQPEDFATY LQMNSLRAE FCQQYSTYW DTAVYYCVK TFGQGTKVG DRDNGWSSI IK VDWGQGTL VTVSA MEX105_37 GGGLVRPGG 400 IGHV3- IGHD2- IGHJ4*02 VKDRD 429 SASVGDRVT 458 IGKV1- IGKJ1*01 QQYSTYW 487 SLRLSCTASG 23*03 15*01 TGRSSI ITCRASQTIG 5*03 T FTFRRYAMA VE NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLLY IYQASILESG NGDDSTYYA VPSRFSGSGS ESVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNSLRAE FCQQYSTYW DTAVYYCVK TFGQGTKVE DRDTGRSSI IK VEWGQGTW VTVSS MEX105_39 GGGLVQPGG 401 IGHV3- IGHD3- IGHJ4*02 AKDRL 430 SASVGDRVT 459 IGKV1- IGKJ1*01 QHYYSYP 488 SLRLSCAASG 23*01 10*01 ELGVG ITCRASQNIN 5*03 WT FTFRTYAMS ELYEF SWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSSIS IYKASSLQSG ASDDSTYFA VPSRFSGSGS ASVRGRFTIS GTEFTLTVS RDNSKNTLY SLQPDDFAT LQMNNLRA YYCQHYYSY EDTALYYCA PWTFGQGT KDRLELGVG KVEIK ELYEFWGQG TLVTVSS MEX105_42 GGGLVQPGG 402 IGHV3- IGHD2- IGHJ4*02 VRDRS 431 SASVGDRVT 460 IGKV1- IGKJ1*01 QQYSTFW 489 SLRLSCAASG 23*03 15*01 NGWSS MTCRASQTI 5*03 T FTFKNYAMA INL SGWLAWYQ WVRQAPGK QKPGKAPKL GLEWVSLLY LIYQASRLES NSEESTYYA GIPSRFSGSG DSVKGRFTIS SGTEFTLTIS RDNSKNTLF SLQPDDVAT LQMNRLRVE YYCQQYSTF DTAVYFCVR WTFGLGTR DRSNGWSSI VEIK NLWGRGTL VTVSS MEX105_45 GGGLVRPGG 403 IGHV3- IGHD6- IGHJ4*02 VKDRD 432 SASVGDRVT 461 IGKV1- IGKJ1*01 QQYSTYW 490 SLRLSCTASG 23*03 19*01 NGWSS ITCRASQTIG 5*03 T FNFRRYAMA IVD SWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSQIY IYQASILESG NGEDSTYYA VPSRFSGSGS ESVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNGLRAE FCQQYSTYW DTAIYYCVK TFGQGTKVG DRDNGWSSI IK VDWGQGTL VTVSS MEX105_48 GGGLVRPGG 404 IGHV3- IGHD6- IGHJ4*02 VKDRD 433 SASVGDRVT 462 IGKV1- IGKJ1*01 QHYHSYP 491 SLRLSCTASG 23*03 19*01 NGWSS ITCRASQTL 5*03 WT FTFRRYAMA IVD NVWLAWYQ WVRQAPGK QQPGKAPKL GLEWVSLIY LIYKASTLQS DGDDSTYYA GVPSRFSGS ESVKGRFTIS GSGTEFTLTI RDNSQNTVS NSLQPEDFA LQMTSLRAE TYYCQHYHS DTALYYCVK YPWTFGQG DRDNGWSSI TKVEIK VDWGQGTL VTVSS MEX105_50 GGGLVRPGG 405 IGHV3- IGHD6- IGHJ4*02 VKDRD 434 SASVGDRVT 463 IGKV1- IGKJ1*01 QQYSTFW 492 SLRLSCTASG 23*03 19*01 NGWSS ITCRASHSIS 5*03 T FTFRRYAMA IVD GWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY IYQASILESG DGDDSTYYA VPSRFSGSGS KSVKGRFAIS GTEFTLTIGS RDNSKNTLS LQPEDFATY LQMNSLRAE FCQQYSTFW DTAVYYCVK TFGQGTKVE DRDNGWSSI IK VDWGQGTL VTVSS MEX105_51 GGGLVRPGG 406 IGHV3- IGHD6- IGHJ4*02 VRDRD 435 SASVGDRVT 464 IGKV1- IGKJ1*01 QQYSTFW 493 SLRLSCTASG 23*03 19*01 NGWSS ITCRASQTIG 5*03 T FTFRRYAMA IVD SWLAWYQQ WVRQAPGK KPGKAPRLL GLEWVSLLY IYQASILESG NGDDSTYYA VPSRFSGSGS KSVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNSLRAE FCQQYSTFW DTAVYYCVR TFGQGTKVG DRDNGWSSI IK VDWGQGTL VTVSS MEX105_54 GGGLVRPGG 407 IGHV3- IGHD6- IGHJ4*02 VKDRD 436 SASVGDRVT 465 IGKV1- IGKJ1*01 QQYSTYW 494 SLRLSCTASG 23*03 19*01 TGWSS ITCRASRTIG 5*03 T FTFRRFAMA IVD NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY IYQASILESGI NGDDSTYYA PSRFSGSGSG QSVKGRFTIS TEFTLTIRGL RDNSQNTLS QPEDFGTYF LQMNSLRVE CQQYSTYWT DTAVYYCVK FGQGTKVGI DRDTGWSSI K VDWGQGTL VTVSS MEX105_60 GGGLVRPGG 408 IGHV3- IGHD6- IGHJ4*02 VKDRD 437 SVGDRVTIT 466 IGKV1- IGKJ1*01 QQYSTFW 495 SLRLSCTASG 23*03 19*01 NGWSS CRASQTIGN 5*03 T FTFRRFAMA IVD WLAWYQQK WVRQAPGK PGKAPKLLIY GLEWVSLIW QASVLESGV NGDDSTYYA PSRFSGSGSG ESVRGRFTIS TEFTLTISSL RDNSHNTLS QPEDFATYF LQMRSLRAE CQQYSTFWT DTAIYYCVK FGQGTKVGI DRDNGWSSI K VDWGQGTL VTVSS MEX105_64 GGGLVRPGG 409 IGHV3- IGHD6- IGHJ4*02 VRDRD 438 SASVGDRVT 467 IGKV1- IGKJ1*01 QQYSTFW 496 SLRLSCTASG 23*03 19*01 NGWSS ITCRASRTIG 5*03 T FTFRRYAMA IVD SWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY IYQASILEGG NGDDSTYYA VPSRFSGSVS ESVKGRFTV GTEFTLTIRS SRDNSQNTL LQPEDFATY SLQMNSLRA FCQQYSTFW EDTAIYYCV TFGQGTKVE RDRDNGWS IK SIVDWGQGT LVTVSS MEX105_66 GGGLARPGG 410 IGHV3- IGHD6- IGHJ4*02 VKDRD 439 SASVGDRVT 468 IGKV1- IGKJ1*01 QQYSTFW 497 SLRLSCTASG 23*03 19*01 TGWSS ITCRASQTIA 5*03 T FTFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGQPPKLL GLEWVSLIW IYQASILESG NGDDSTYYA VPSRFSGSGS ESVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMNSLRAE FCQQYSTFW DTAVYYCVK TFGQGTKVG DRDTGWSSI IK VDWGQGTL VTVSS MEX105_78 GGGLVRPGG 411 IGHV3- IGHD6- IGHJ4*02 VKDRD 440 SASVGDRVT 469 IGKV1- IGKJ1*01 QQYSTYW 498 SLRLSCTASG 23*03 19*01 TGWSS ITCRASHTIG 5*03 T FTFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY IYQASILESG NAYDSTYYA VPSRFSGSGS ESVKGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFATY LQMSSLRAE FCQQYSTYW DTAVYYCVK TFGQGTKVG DRDTGWSSI IK VDWGQGTL VTVSP MEX105_87 GGGLVRPGG 412 IGHV3- IGHD6- IGHJ4*02 VKDRD 441 SASVGDRVT 470 IGKV1- IGKJ1*01 QQYSTFW 499 SLRLSCTASG 23*03 19*01 TGWSS ITCRASHTIS 5*03 T FTFRRYAMA IVD NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIY VYQASILETG NGDDSTYYA VPSRFSGSGS ESVRGRFTIS GTEFTLTIRS RDNSQNTLS LQPEDFGTY LQMNSLRAE FCQQYSTFW DTAVYYCVK TFGQGTKVE DRDTGWSSI IK VDWGQGTL VTVSS MEX105_88 GGGLVQPGG 413 IGHV3- IGHD2- IGHJ4*02 VKDRG 442 SASVGDRVT 471 IGKV1- IGKJ1*01 QQYSTYW 500 SLRLSCAASG 23*03 15*01 TGWSS ITCRASQTIS 5*03 T FTFSNYAMA IVH NWLAWYQQ WVRQAPGK KPGKAPKLL GLEWVSLIYS IYQASSLESG

GDDSTYYAD VPSRFSGSGS FVKGRFTISR GTEFTLTISS HNSKNTLSL LQPDDFATY QMNSLRAED YCQQYSTYW TAIYYCVKD TFGQGTKVE RGTGWSSIV IK HWGQGTLV TVSS VH1- MEX105_40 GAEVKRPGA 414 IGHV1- IGHD4- IGHJ6*02 ARGKA 443 SASVGDRVT 472 IGKV1- IGKJ2 QQANSFP 501 46/VK1-12 SVKVSCKAS 46*01 23*01 HQTTV ITCRASQGIS 12*01 *01 YT GYTFTSYYM VILSW SWLAWYQQ HWVRQAPG YYGMD KPGKAPKLL QGLEWMGII V ISAASSLQSG NPRGGSTTY VPSRFSGSGS AQKFQGRVA GTDFTLTISS LTGDTSTST LQPEDFATY VYMELTSLR YCQQANSFP SDDTAVYYC YTFGQGTKL ARGKAHQTT EIK VVILSWYYG MDVWGQGT TVTVSS MEX105_57 GAEVKKSGA 415 IGHV1- IGHD4- IGHJ6*02 ARGKN 444 SASVGDRVT 473 IGKV1- IGKJ2*01 QQANSFP 502 SVKVSCKAS 46*01 23*01 HQTTV ITCRASQGIS 12*01 YT GYSFTTNYIH AVLSW SWLAWYQQ WVRQAPGQ YYGMD KPGKAPKLL GPEWMGIIN V ISAASSLQSG PRGGSTTYA VPSRFSGSGS QKFQGRVLM GTDFTLTIS TSDTSTSTV NLQPEDFAT YMELSSLRS YFCQQANSF EDRAVYYCA PYTFGQGTK RGKNHQTTV LEIK AVLSWYYG MDVWGQGT TVTVSS BRA112 - refers to an individual donor. Sequences were analyzed with IgBlast VH3- BRA112_08 GGGLVQPGG 503 IGHV3- IGHD3- IGHJ4*02 ARDRGI 527 SASVGDRVTI 551 IGKV1- IGKJ1*01 QHYYSYP 575 23/VK1-5 SLKLSCSAAG 23*03 10*01 EGLGEL TCRASQSINS 5*03 WT FNFRSYAMS YSH WVAWYQQK WIRQAPGKG PGKAPKFLIY LEWVSSLGT KASTLESGVP RGTETTYYA SRFSGSGSGT ASVKGRFTIS EFTLTITSLQP RDNSKNILY DDFATYYCQ LQMNILGAE HYYSYPWTF DTAVYYCAR GQGTKVEIK DRGIEGLGEL YSHWGQGT LVTVSS BRA112_09 GGGLAQPGG 504 IGHV3- IGHD5- IGHJ4*02 VRDRIQ 528 SASVGDRVT 552 IGKV1- IGKJ1*01 QHYHGYP 576 SLRLSCETSG 23*05 18*01 GGFGEL MTCRASQSV 5*03 WT FTFRSYGMG YRY NKWLAWYQ WVRQAPGK QKPGKAPKLL GLEWVSSIYI IYETSILESGV SGDSTYYAA SSRFSGSGSGT SVKGRFTISR EFTLTISSLQP DNSKSTLYL DDFATYYCQ QMDRLTAE HYHGYPWTF DTAVYYCVR GQGTKVEIR DRIQGGFGE LYRYWGQG TLVTVSS BRA112_21 GGGLAQPGG 505 IGHV3- IGHD3- IGHJ4*02 AKDRD 529 SAAVGDSVTI 553 IGKV1- IGKJ3*01 QKYNSYP 577 SLRLSCAASG 23*01 3*01 HFDGHD TCRASQSISS 5*03 FT FTFSSYAMT F WLAWYQQK WVRQAPGK PGRAPKLLIS GLEWVSTIT KASNVESGVP GRDGSTYYA SRFSGSGSGT DSVKGRFTIS EFTLTISSLQP RANSKNTLY DDFATYYCQK LQMNGLRAE YNSYPFTFGP DTAVYFCAK GTKLDIK DRDHFDGH DFWGQGAL VTVSS BRA112_24 GGRLVQPGG 506 IGHV3- IGHD3- IGHJ4*02 AKDRLH 530 SASVGDRVNI 554 IGKV1- IGKJ1*01 QHYFSYP 578 SLTLSCAASG 23*01 10*01 SGLGEL TCRASQSINQ 5*03 WT FPFSTYAMS FSY WLAWYQQK WLRQAPGK PGKAPKFLM GLEWVSGIT YKASTLETGV GDSGSTYYA PSRFSGSGSG ASVKGRFTIS TEFTLTISSLQ RDNSKNTLY PDDFATYYCQ LQMNSLTAD HYFSYPWTF DTAVYYCAK GQGTKVEIK DRLHSGLGE LFSYWGQGT LVTVSS BRA112_33 GGGLVQPGG 507 IGHV3- IGHD3- IGHJ5*02 AKDRLA 531 SASVGDRVTI 555 IGKV1- IGKJ1*01 QHYHSYP 579 SLRLSCAASG 23*01 10*01 SGIGELF TCRASQNIDM 5*03 WT FSFRTYGMS SS WLAWYQQK WVRQAPGK PGRAPKFLIH GLEWVSSISS KASTLESGVP VDDSTYYAD SRFSGSGSGT SVKGRFTISR EFTLTISSLQP DNSKNTLYL DDFATYYCQ QMHNLSAK HYHSYPWTF DTALYYCAK GQGTKVDIK DRLASGIGEL FSSWGQGTL VTVAS BRA112_37 GGGLVQPGG 508 IGHV3- IGHD3- IGHJ5*02 AKDRMS 532 SASVGDRVTI 556 IGKV1- IGKJ1*01 QHYFSYP 580 SLRLSCAASG 23*01 10*01 GGFGEL TCRASQSISG 5*03 WT FTFRTYGMN NES WLAWYQQK WVRQAPGK PGRAPNLLIY GLEWVAGIS QASALHSGVP SVDPSTYYA SRFSGSGSGT GSVKGRFTIS EFSLTISSLQP RDNSKNML DDFATYYCQ YLQMNSLTA HYFSYPWTF DDSAVYYCA GQGTKVEIK KDRMSGGFG ELNESWGQG TRVTVSS BRA112_46 GGGLVQPGG 509 IGHV3- IGHD3- IGHJ4*02 AKDRLN 533 SASVGDSVTI 557 IGKV1- IGKJ1*01 QHYHSYP 581 SLRLSCVASG 23*01 10*01 GGFGEL TCRASQSISS 5*03 WT FTFGSYGMA FAS WLAWYQQK WVRQAPGK PGKAPKFLIH GLEWISSISSI KASSLESGIPS DPSTYYADS RFSGSGSGTE VKGRFTVSR FTLTINNLQP DNSENTLYL DDFATYYCQ HMSSLKVED HYHSYPWTF TAVYFCAKD GQGTKVEIK RLNGGFGEL FASWGQGTL VTVSS BRA112_48 GGGLGQPGG 510 IGHV3- IGHD3- IGHJ4*02 ARDRIK 534 SASVGDRVTII 558 IGKV1- IGKJ2*03 QHYFSSPY 582 SLRLSCAASG 23*01 10*01 GGLGEL CRASRSIDSW 5*03 S FPFSDFGMS FHL LAWYQQKPG WVRQAPGK KAPRLLIHKA GLEWVSSISG STLHSGVPSR PGFDTYYAD FSGSGSGTEF SVKGRFTISR TLTISSLQPD DNSKDTLFL DFATYFCQHY QMSRLRVED FSSPYSFGQG TAVYYCARD TKLEIK RIKGGLGELF HLWGQGAL VTVSS BRA112_51 GGGLVQPGG 511 IGHV3- IGHD3- IGHJ4*02 AKDRLA 535 SASVGDRVTI 559 IGKV1- IGKJ1*01 QHYHSYP 583 SLRLSCAASG 23*01 16*01 AGLGEL TCRAGQNINS 5*03 WT FTFNTHAM FSH WLAWYQQK AWLRQAPG PGKAPKFLIH KGLEWVSSV KASTLESGVS TANGGDSW SRFSGSGSGT YADSVKGRF EFTLTINNLQ TISRDNSRNI PDDFATYYCQ LYLQMSSLR HYHSYPWTF VEDTAVYYC GQGTKVEIK AKDRLAAGL GELFSHWGQ GTLVSVSS BRA112_56 GGGLVQPGG 512 IGHV3- IGHD3- IGHJ4*02 TRDRLP 536 SASVGDRVSI 560 IGKV1- IGKJ1*01 QHYHSYP 584 SLRLSCAASG 23*01 10*01 NGIGEL TCRASQNIDM 5*03 WT FTFSTYAMS HDH WLAWYQQK WVRQAPGK PGKAPKFLIY GLKWVSGIT KASNLKSGVP GDSGSTYYA SRFSGSGSGT RSVKGRFTIS EFTLTISSLQP RDNSKNTLY DDFATYYCQ LEISSLRAED HYHSYPWTF TAFYFCTRD GQGTKVEIK RLPNGIGEL HDHWGQGT LVTVSS BRA112_65 GGGLVQPGG 513 IGHV3- IGHD3- IGHJ5*02 TKDRLS 537 SASIGARVTIT 561 IGKV1- IGKJ1*01 QHYHSYP 585 SLRLSCAASG 23*01 10*01 GAFGEL CRASQDISGW 5*03 WT FTFRTYGMN NES LAWYQQKPG WVRQAPGK RAPKLLIYQA GLEWVSGIS STLYNGVPPR GIDPSTYYA FSGSGSGTEF DSVKGRFTIS TLTISGLQPD RDNSKNILF DFATYYCQHY LQMNSLTAD HSYPWTFGQ DTAVYYCTK GTKVEIK DRLSGAFGE LNESWGQG TMVIVSS BRA112_69 GGALVQPGG 514 IGHV3- IGHD3- IGHJ5*02 TKDRVQ 538 SASVGDRVTI 562 IGKV1- IGKJ1*01 QQYHSYP 586 SLRLSCAASG 23*01 10*01 GGFGEL TCRASQNINS 5*03 WT FTFRNYGVS FHS WLAWYQQK WVRQAPGK PGQAPKFLM GLEWVSSIN HKASILESGV TDGGSTYYA PSRFSGSGSG ASVKGRFTIS TEFTLTISSLQ RDNSRNTLY PDDFASYFCQ LQMDGLTVA QYHSYPWTF DTAMYFCTK GPGTKVEIK DRVQGGFGE LFHSWGQGT LVTVSP BRA112_71 GGGLIQPGGS 515 IGHV3- IGHD3- IGHJ4*02 AKDRLS 539 AASVGDRVTI 563 IGKV1- IGKJ2*01 QHYYSYP 587 LRLSCAASGF 23*01 10*01 GGFGEL TCRASQNINS 5*03 YT TFSSYAMSW FQK WLAWYQQK VRQAPGKGL PGKAPKFLIY EWVSGISGS KASTLESGAP GGASDNGAS SRFSGSGSGT RYYADSVKG EFTLTISSLQP RFSISRDNSK DDFATYYCQ NTVYLQMNS HYYSYPYTFG LRAEDTAVY QGTKLEIK YCAKDRLSG GFGELFQKW GQGTLVTVS S BRA112_91 GGDLVQPGG 516 IGHV3- IGHD3- IGHJ4*02 AKDRIP 540 SASVGDRVTI 564 IGKV1- IGKJ2 QHYHSYP 588 SLRLSCAASG 23*01 16*01 HGLGEL TCRASQSISG 5*03 *01 YT FTFSTYGMA YAN WLAWYQQK WVRQAPGK PGKAPRLLM GLEWLSSISS HKASILYRGV VDDSKYYAA PSRFSGSGSG SVKGRFTISR TEFTLTISSLQ DNSRNTLYL PDDFATYYCQ HMNSLRVD HYHSYPYTFG DTAVYYCAK QGTKLEIK DRIPHGLGE LYANWGQG TLVAVSS BRA112_94 GGDLVQPGG 517 IGHV3- IGHD3- IGHJ4*02 AKDRSP 541 SASVGDRVTI 565 IGKV1- IGKJ2*01 QHYFSYP 589 SLRLSCAASG 23*01 16*01 HGLGEL TCRASQSISS 5*03 YT FTFRTYGMT YGD WLAWYQQK WVRQAPGK PGKAPKLLM GLEWVSSISS HKASNLHVG VDDSTYYAK VPSRFSGSGS SVKGRFTISR GTEFTLTITSL DNSKNTLYL QPDDFATYYC HITNLRVDD QHYFSYPYTF TAMYYCAKD GQGTKVEIK RSPHGLGEL

YGDWGQGT LVTVSS VH3- BRA112_23 GGGLVKPGG 518 IGHV3- IGHD3- IGHJ4*02 VNGGFS 542 SLSPGERATL 566 IGKV3- IGKJ4*01 QQRSNWL 590 23/VK3-11 SLRLSCAASG 23*01 22*01 GYYSDY SCRASQSVSN 11*01 T LTFSTYAMS YLAWYQQKP WVRQAPGK GQAPRLLIYD GLEWVSAIS ASNMAPGIPA PGSGDNIYY RFSGSGSGTD GDSVKGRFT FTLTISSLEPE ISRDNSKNT DFAVYYCQQR LYLQMNSLR SNWLTFGGG AEDTAVYYC TKIEIK VNGGFSGYY SDYWGQGTL VAVSS BRA112_52 GGGLGQPGG 519 IGHV3- IGHD3- IGHJ6*03 AKVKDS 543 SLSPGERTTL 567 IGVK3- IGKJ4*01 QQRGKW 591 SLRLSCGASG 23*01 22*01 SGYMYY SCRASQSISNY 11*01 PPS FTFSTYAMT YYMDV LAWYQQKPG WVRQAPGK QAPRLLIYDA GLEWVSDIS SNRAAGIPAR ADSDTTSYA FSGSGSGIDFT DSVKGRFTIS LTISSLEPEDF RDNSKNTLY GVYYCQQRG LQMNSLRAE KWPPSFGGG DSAVYYCAK TKVEIK VKDSSGYMY YYYMDVWG KGTTVTVSS BRA112_63 GGGLVLPGG 520 IGHV3- IGHD1- IGHJ4*02 AKDLYN 544 SLSPGERATL 568 IGKV3- IGKJ4*01 QQRGNW 592 SLRLSCAASG 23*01 14*01 GYFDY SCRASQSVRN 11*01 PPAT FTFSTHAMT FLAWYQQKP WVRQAPGK GQAPRLLIYD GLEWVSVIS ASNRATGIPA HSGTTTYYA FTLTISSLEPE DSFRGRFTIS RFSGSGSGTD RDNSKNTVY DFAVYYCQQR LQMNRLRVE GNWPPATFG DTAVYYCAK GGTKVEIK DLYNGYFDY WGQGTLVT VSS VH3- BRA112_36 GGGVVQPGR 521 IGHV3- IGHD1- IGHJ2*01 ARGEVG 545 SLSPGERATL 569 IGKV3- IGKJ5*01 QQRSNW 593 30/VK3-11 SLRLSCAASG 30*04 26*01 YFDL SCRASQSVSS 11*01 PPIT FTFSISTIHW FLAWYQQKP VRQAPGKGL GQPPRLLIYD EYVVVISHD ASTRATGIPA GNTKYYADS RFSGSGSGTD VKGRFIISRD FTLTISSLEPE NSKNTVFLQ DFAVYYCQQR MNSLRPVDT SNWPPITFGQ AVYYCARGE GTRLEIK VGYFDLWGR GTLVTVSS BRA112_70 GGGVVQPGR 522 IGHV3- IGHD5- IGHJ1*01 AREVDG 546 SLSPGERATL 570 IGKV3- IGKJ5*01 QQRSYSIT 594 SLRLSCAASG 30*07 24*01 IYGYLHY SCRARQNVR 11*01 FSFSSHAMY NFLAWYQQK WVRQAPGK PGQAPRLLIY GLEWVAIVS DASNRATDIP YDGSTKNYA ARFSGSGSGT DSVKGRFTIS DFTLTISSLEP RDNSKNTIY EDFAVYYCQQ LHLNSLRAE RSYSITFGQG DTAVYFCAR TRLEMK EVDGIYGYL HYWGQGTL VTVSS BRA112_75 GGGVVQPGR 523 IGHV3- IGHD4- IGHJ6*03 ARDGTT 547 SLSPGERATL 571 IGKV3- IGKJ4*01 QQRSNGP 595 SLRLSCAASG 30*03 17*01 VTNFYL SCRASQSVSN 11*01 LT FTFSNYGMH DV YLAWYQQKP WVRQAPGK GQAPRLLIYD GLEWVAIISY ASSRATGIPA DGNTKYYAD RFSGSGSGTD SVKGRFTISR FSLTISSLEPE DNSKNTLYL DFAVYYCQQR QLNSLRAED SNGPLTFGGG TAIYYCARD TKVEIK GTTVTNFYL DVWGKGST VTVSS BRA112_76 GGGVVQPGR 524 IGHV3- IGHD5- IGHJ4*02 ARDFHG 548 SLSPGERATL 572 IGKV3- IGKJ4*01 QQRSNW 596 SLRLSCAASG 30*10 18*01 YLDS SCRASQSVSN 11*01 PPLT FTFNTYAVH FFAWYQQKP WVRQAPGK GQAPRLLIYD GLDWVTVLS ASKRATGIPA HDGNSKYYT RFSGSGSGTD DSVRGRFTIS FTLTISSLEPE RDSSKKTVF DFAVYYCQQR LQMDNLRTE SNWPPLTFG DTAVYYCAR GGTKVEIK DFHGYLDS WGQGTLVT VSS VH4- BRA112_20 GPGLVKPSE 525 IGHV4- IGHD3- IGHJ3*02 ARTETI 549 SLSPGERATL 573 IGKV3- IGKJ4*01 QQYGTSP 597 38-2/VK3-20 TLSLTCGVSG 38-2*01 10*01 TIRGAV SCRASQSVSSS 20*01 PEFT YSLTSGYYW SFDI YLAWYQQKP SWIRQPPGK GQAPRLLIYG GLEWIGSIYH AYNRATGIPD TGNTYYNPS RFSGSGSGTD LKSRVTILVD FTLTINRLEP TSKNHFSLK EDFAVYYCQQ LTSVTAADT YGTSPPEFTF AMYYCARTE GRGTKVEIK TITIRGAVSF DIWGQGRM VTVSS BRA112_57 GPGLVKPSE 526 IGHV4- IGHD6- IGHJ5*02 ARDARS 550 SLSPGERATL 574 IGKV3- IGKJ2*02 QQYGSSW 598 TLSLTCSVSG 38-2*02 13*01 RSWDR SCRASQSLSSS 20*01 GT YFISSGHYW TGFFGP FLAWYQQKP GWIRQSPGK GQSPRLLIYG GLEWIASIYQ TSSRDTGIPD SGSKFQTGN RFSGSGSGTD TYYNPSLES FTLTISRLEPE RVTISMDTS DSAVYYCQQY KNQFSLKLS GSSWGTFGQ SVTAADTAV GTKLEIK YFCARDARS RSWDRTGFF GPWGQGILV TISS BRA 12 - refers to an individual donor. Sequences were analyzed with IgBlast VH3- BRA12_08 GGALVQPGG 599 IGHV3- IGHD6- IGHJ4*02 VKHLRG 603 SLSPGERAT 607 IGKV3 IGKJ2*01 QQFGSSP 611 23/VK3-20 SLRLSCAASG 23*01 19*01 WYTFEI LSCRASQSVS 20*01 RYT FTFNYYAMT GSYLAWYQ WVRQAPGR QKPGQAPRL GLEWVSTIT LIYGASRRA DNGGTTYLA TGIPDRFSGS DSVKGRFTIS GSGTDFTLTI RDNSQNTQS SRLEPEDFA LQMNNLRA VYYCQQFGS DDTAVYFCV SPRYTFGQG KHLRGWYT TKLEIK FEIWGQGTL VTVSS BRA12 21 GGGLVQPGG 600 IGHV3- IGHD3- IGHJ4 AKSPYV 604 SLSPGERAT 608 IGKV3- IGKJ4*01 QQYGDS 612 SLRLSCAASG 23*01 16*01 *02 GGYGLP LSCRASQTIF 20*01 PPT YIFDNYAMS GDS FNYLAWYQ WVRQAPGK KKPGQAPRL GLEWVSYIN LVHGASTRA GGGYGTDYA TGIPDRFSGS DSVKGRFTIS GSGTDFTLTI RDNSKRILY NSLDPEDFA LQMNSLRVG VYYCQQYGD DTAVYYCAK SPPTFGGGT SPYVGGYGL KVDIK PGDSWGQG TLVTVSS VH4- BRA12_06 GPGLVKPSE 601 IGHV4- IGHD3- IGHJ6*02 ARGPHY 605 SLSPGERAT 609 IGKV3- IGKJ5*01 QQYGSSP 613 59/VK3-20 TLSLTCTVX 59*01 22*01 YDSSAY LSCRVSQSVS 20*01 PVT GGSISRYFXS FTYNGM SNSLAWYQ WIRQPPGKG DV QKPGQAPRL LEWIGYIYYT LIYGASSRAT GSTNYNPSL GIPDRFSGSG KSRVIILVDT SGTDFTLTIS SKNQFSXKL RLEPEDFAV SSVTXADTA YYCQQYGSS VYYCARGPH PPVTFGQGT YYDSSAYFT RLEIK YNGMDVWG QGTTVTVSS BRA12_58 GPGLVKPSE 602 IGHV4- IGHD3- IGHJ4*02 ARGDYY 606 SLSPGERAT 610 IGKV3- IGKJ4*01 QQYGTS 614 TLSLTCTVSG 59*01 22*01 YDSSGY LSCRASQSVS 20*01 VT GSISSYYWS LYYFDY SSSLAWYQQ WIRQPPGKG KPGQAPRLL LEWIGFIYYS IYGASNRAT GSTNYNPSL GIPDRFSGSG KSRVTISVDT SGTDFTLTIS SKNQFSLKL RLEPEDFAV SSVTAADTA YYCQQYGTS VYYCARGDY VTFGGGTKV YYDSSGYLYY EIK FDYWGQGT LVTVSS BRA 138 - refers to an individual donor. Sequences were analyzed with IgBlast VH1- BRA138_23 GAEVKKPGSS 615 IGHV1- IGHD2- IGHJ5*02 ARQKCT 627 SGRAIESVSGX 639 IGKV3- IGKJ4*01 HQSIKWP 651 69/VK3-11 VRVSCKASGD 69*06 8*02 GGSCYS LAWYQQKPG 11*01 PT TFSNYAISWV GNFDP QAPRLLIYDA RQAPGQGLE SNRATGIPPR WMGGIIPIFG FSGSGXGTEF TASYAQRFQD TLTISSAEPED RVTITADKST FAVYYCHQSI GTVYMELSSL KWPPTFGGG RSEDTAVFYC SKVEIK ARQKCTGGSC YSGNFDPWG QGTLVTVSS BRA138_28 GAEVKKPGSS 616 IGHV1- IGHD3- IGHJ4*02 ARFRYY 628 ERVTLSCRAS 640 IGKV3- IGKJ4*01 QQRSNW 652 VKVSCKAPGG 69*01 22*01 YESGGY QSVSSYLAWY 11*01 PLT TFSRYSIAWV SDASPY QQKPGQAPR RQAPGQGLE YLDY LLIYDASNRA WMGGINPTF TGIPARFTGS TTPNYAQKFQ GSGTDFTLTIS GRVTITADES SLEPEDFAVY TNTAYLDLSS YCQQRSNWP LRSEDTAVYY LTFGGGTKVE CARFRYYYES IK GGYSDASPYY LDYWGQGTL VTVSS VH4- BRA138_59 GPGLVKPSQT 617 IGHV4- IGHD1- IGHJ5*02 ARAWC 629 SLSPGERATL 641 IGKV3- IGKJ2*01 QQYGRSP 653 31/VK3-20 LSLTCTVSGV 31*03 EYAAYC SCRASQSVTS 20*01 FT SISSGGYYYS 26*01 WFDP SYLAWYQHK WFRQLPGKG PGQAPRLLIY LEWIGHIYYT GASSRAPGIP GNTHYNPSLR DRFSGSGSGT SRLTISVDTSK DFTLTISRLEP NQFSLKLSSV EDFAVYWCQ TAADTARYYC QYGRSPFTFG ARAWCEYAA QGTNLEIK YCWFDPWGR GTLVTVSS BRA138_62 GPGLVKPSQT 618 IGHV4- IGHD4- IGHJ3*02 ARAGFD 630 SLSPGERATL 642 IGKV3- IGKJ2*01 QQYAHSP 654 LSLTCTVSGG 31*03 17*01 YGSPVS SCRASQSVSS 20*01 RGYT SITGGVYYWN AFDI TYLVWYQQK WIRHHPGKG PGQAPRLLIY LEWIGYMFYS GASSRATGIP GDTDYNPSLR DRFSGSGSGT SRVTISGDTS DFTLTISRLEP KNKFSLNLNS EDFAVYFCQQ VTAADTAVYY YAHSPRGYTF CARAGFDYGS GQGTKLEIK PVSAFDIWGQ GTMVTVSS VH4- BRA138_65 GPGLVKPSET 619 IGHV4- IGHD3- IGHJ2*01 ARHGPG 631 SLSPGERATL 643 IGKV3- IGKJ4*01 QQRSTWL 655

39/VK3-11 LSLTCTVSGG 39*01 16*01 MGHNW SCRASQSISSY 11*01 T SISSYNYYWG YFDL LAWYQQKPG WIRQPPGKGL QAPRLLIYDA EFIGSIYYTGS SNRAPGIPAR TYYNPSLRSR FSGSGSGTDF VTISVDTSKN TLTISSLEPED QFSLKLTSVT FAVYYCQQRS AADTAVYYCA TWLTFGGGT RHGPGMGHN KVEIK WYFDLWGRG TLVTVSS BRA138_94 GPRLVKPSET 620 IGHV4- IGHD6- IGHJ4*02 AKHLYS 632 SLSPGERATL 644 IGKV3- IGKJ2*01 QQGSKWP 656 LFLTCTVSGD 39*01 13*01 SSWNIG SCRASQSVSX 11*01 VYT SISSSSYFWG SSFDS YLAWYQQKP WIRQPPGKGL GQAPRLLXYD EWIGSISYSGS ASSRATGIPA TYYNPSLKSR RFSGSGSGTD VTISVDTSKN FTLTISSLEPE QFSLKLSSVT DFAVYYCQQG AADTVVYYCA SKWPVYTFG KHLYSSSWNI QGTKLEIK GSSFDSWGPG TLVTVSS VH4- BRA138_17 GPGLVKPSET 621 IGHV4- IGHD3- IGHJ4*02 ARGPDN 633 SVSPGERVTL 645 IGKV3- IGKJ3*01 QQYNNW 657 59/VK3-15 LSLSCTVSSGS 59*1 16*02 RY SCRASQSVSY 15*01 PPVFT ISNYYWNWIR NLAWHQQKP QPPGKGLEWI GQAPRLLIYG GYIYYSGSISY ASTRATGIPA NPSLKSRVTIS RFSGSGSGTE VDTSKNQLSL FTLTISNMQS KLNSVTAADT EDFAVYYCQQ AVYYCARGPD YNNWPPVFT NRYWGQGTL FGPGTKVDIK VTVSS BRA138_79 GPGLVKPSET 622 IGHV4- IGHD3- IGHJ4*02 ARGPDN 634 SVSPGERVTL 646 IGKV3- IGKJ3*01 QQYNNW 658 LSLTCTVSGG 59*1 16*02 RY SCRASQSVSY 15*01 PPVFT SISNYYWNWI NLAWHQQKP RQPPGKGLE GQAPRLLIYS WIGYIYYSGSI ASTRATGIPA SYNPSLKSRV RFSGSGSGTE TISVDTSKNQ FTLTISNMQS LSLKLNSVTA EDFAVYYCQQ ADTAVYYCAR YNNWPPVFT GPDNRYWGQ FGPGTKVDIK GTLVTVSS VH1- BRA138_49 GAEVKKPGSS 623 IGHV1- IGHD6- IGHJ4*02 ATPDW 635 PVTPGEPASIS 647 IGKV2- IGKJ3*01 MQALQTP 659 69/VK2-28 VRLSCKASGG 69*11 25*01 QYSSAY CRSSQSLLHS 28*01 FT SYSTYAISWV SLDH TGYNYLDWY RQAPGQGLE LQKPGQSPQL WMGRIIPSLG LIYLGSNRAS KTHLAQKFQ GVPDRFSGSG GRVTFTADES SGTDFTLKIS TTTVYMVLSS RVEAEDVGVY LKSDDTALYY YCMQALQTP CATPDWQYS FTFGPGTKVD SAYSLDHWG IK QGTLVTVSS BRA138_57 GAEVKKPGSS 624 IGHV1- IGHD6- IGHJ4*02 ATPDW 636 PVTPGEPASIS 648 IGKV2- IGKJ3*01 MQALQTP 660 VRLSCKASGG 69*11 25*01 QYSSAY CRSSQSLLHS 28*01 FT SYSTYAISWV SLDH TGYNYLDWY RQAPGQGLE LQKPGQSPQL WMGRIIPSLG LIYLGSNRAS KTHLAQKFQ GVPDRFSGSG GRVTFTADES SGTDFTLKIS TTTVYMILSS RVEAEDVGVY LKSEDTALYY YCMQALQTP CATPDWQYS FTFGPGTKVD SAYSLDHWG IK QGTLVTVSS VH1- BRA138_15 GAEVKKPGAS 625 IGHV1- IGHD5- IGHJ4*02 GRDSKG 637 PASVSGSPGQ 649 IGLV2- IGLJ1*01 CSYAGSST 661 46/VL2-23 VKVSCKTSGY 46*01 24*01 WLQLR SITISCAGTSS 23*02 YV TFTSYYMNW GDIDY DVGNYNLVS VRQAPGQGLE WYQQHPGKA WMGIIKPSDG PKLLIYEVSK STNYAQKFQG RPSGVSNRFS RVTMTRDTS GSKSGNTASL TSTVYMELRS TISGLQAEDE LRSEDTAVYY ADYYCCSYAG CGRDSKGWL SSTYVFGTGT QLRGDIDYW EVTV GQGTLVTVSS BRA138_46 GAEVKKPGAS 626 IGHV1- IGHD6- IGHJ3*02 ARDFGG 638 PASVSGSPGQ 650 IGLV2- IGLJ1*01 CSYAGSSR 662 VKVSCKASGY 46*01 6*01 YSSSSVS SITISCTGTSS 23*02 FV TFTSTYIHWV DAFDI DVGSFNLVS RQAPGQGLE WYQQHPGKA WMGIINPSSS PKLIIYEVSKR NTNYAQKFQ PSGVSNRFSG GRVTMTRDT SKSGNTASLT STSTVYMELS ISGLQAEDEV SLRSEDTAVY HYYCCSYAGS YCARDFGGYS SRFVFGTGTK SSSVSDAFDI VTV WGQGTMVTV SS

TABLE-US-00016 TABLE 2 IgH IgL Antibody SEQ ID SEQ ID ID VH DH JH CDR3 NO: VK/L JK/L CDR3 NO: MEX 84-refers to an individual donor. Sequences were analyzed with IgBlast MEX84_ IGHV4- IGHD6- IGHJ6 ARTAGDYGMDV 663 IGLV3-1*01 IGLJ2*01 QAWDSSTAVV 707 p2_03 39*01 13*01 *02 MEX84_ IGHV3- IGHD2- IGHJ3 YRVVAFDDPVNI 664 IGLV3-25*02 IGLJ2*01 QSADTNGSSWI 708 p2_04 30*03 15*01 *02 MEX84_ IGHV5- IGHD3- IGHJ4 ARLPAYYDILTG 665 IGKV4-1*01 IGKJ1*01 QQYYTTPQT 709 p2_07 51*03 9*01 *02 HIKGGYFDY MEX84_ IGHV4- IGHD3- IGHJ6 ARLGGFSRTLYS 666 IGKV3-20*01 IGKJ1*01 QQSGSLPWT 710 p2_09 30-4*01 10*01 *02 YYSMNV MEX84_ IGHV3- IGHD5- IGHJ6 ARGDYRSSYGYR 667 IGLV3-25*03 IGLJ2*01 QSADTNGSSWI 711 p2_12 11*01 18*01 *02 YYGFDV MEX84_ IGHV3- IGHD6- IGHJ4 AKDLYSSGWYMG 668 IGLV1-40*01 IGLJ1*01 QSYDSSLSGYV 712 p2_19 30*02 19*01 *02 PDY MEX84_ IGHV3- IGHD6- IGHJ3 ARDLWDKYSSSL 669 IGKV3D-15*01 IGKJ4*01 QQYNNWPLH 713 p2_20 30-3*01 13*01 *02 GAFHI MEX84_ IGHV4- IGHD1- IGHJ4 ARNQPGGRAFDF 670 IGKV3-11*01 IGKJ1*01 QERDNWPLTWP 714 p2_27 4*07 14*01 *02 MEX84_ IGHV4- IGHD5- IGHJ6 ARKKGGYGSHYY 671 IGKV3/ IGKJ1*01 QQDYSLPTT 715 p2_30 34*01 12*01 *01 YGMDV OR2-268*02 MEX84_ IGHV4- IGHD3- IGHJ4 GRTFTSAPFVDQ 672 IGKV4-1*01 IGKJ2*01 QQYYSTPYT 716 p2_32 30-4*01 10*01 *02 MEX84_ IGHV4- None IGHJ6 ARHLPYYYGMDV 673 IGKV3-15*01 IGKJ2*01 QQYNNWPPT 717 p2_34 59*08 *02 MEX84_ IGHV3- IGHD2/OR1 IGHJ6 ARGRRRIQGVGE 674 IGKV2-28*01 IGKJ4*01 MQSLQTPRALT 718 p2_36 13*01 5-2a*01 *02 YSGMDV MEX84_ IGHV3- IGHD4- IGHJ4 ASHDYGGNFRV 675 IGKV3-20*01 IGKJ1*01 QQYGSSPRT 719 p2_46 7*01 23*01 *02 MEX84_ IGHV4- IGHD2- IGHJ5 ARVGGRVWWFDP 676 IGKV1-39*01 IGKJ1*01 QQTYSTPWT 720 p2_48 59*01 21*01 *02 MEX84_ IGHV3- IGHD3- IGHJ3 AKYRDLWSGYDA 677 IGKV3-20*01 IGKJ4*01 QQYGSSLT 721 p2_56 23*01 10*01 *02 FDI MEX84_ IGHV4- IGHD3- IGHJ4 ATVIRHFDN 678 IGKV1-33*01 IGKJ3*01 QQYDNLPGFT 722 p2_59 39*01 22*01 *02 MEX84_ IGHV3- IGHD3- IGHJ3 AKVQTFVGAFDL 679 IGKV1-33*01 IGKJ3*01 QHYDSLPLLIS 723 p2_61 9*01 16*01 *01 MEX84_ IGHV3- IGHD3- IGHJ6 ARDYGNMRYGMDG 680 IGKV1-39*01 IGKJ1*01 QQNDDARALT 724 p2_64 30*04 16*01 *02 MEX84_ IGHV4- IGHD3- IGHJ6 ARGLRFLYGMDV 681 IGKV3-20*01 IGKJ5*01 QHYDSSIT 725 p2_66 61*02 3*01 *02 MEX84_ IGHV4- IGHD2- IGHJ6 ASENLISQGHCTG 682 IGKV1-39*01 IGKJ1*01 QQSYTVPRT 726 p2_71 4*02 8*02 *02 AICYSTYGMDV MEX84_ IGHV4- IGHD3- IGHJ4 ARDSPYYYDATGS 683 IGKV1-5*03 IGKJ1*01 QQYNSYPRT 727 p2_73 31*03 22*01 *02 PLLGPGTLVTVSS MEX84_ IGHV3- IGHD5- IGHJ4 ANHWGSAVMVTGY 684 IGKV1-8*01 IGKJ1*01 QQYYSYPRT 728 p2_88 23*01 18*01 *02 FDY MEX84_ IGHV4- IGHD5- IGHJ4 TRVRWDGIESTMF 685 IGLV2-8*01 IGLJ2*01 SSYAGSNNFEVV 729 p2_89 34*01 12*01 *02 FDS MEX84_ IGHV1- IGHD5- IGHJ4 ARVKMANGAIPPY 686 IGKV1-9*01 IGKJ3*01 QQLISYPPT 730 p2_92 2*02 24*01 *02 FDH MEX84_ IGHV3- IGHD1- IGHJ4 VRVNRLHSGSYFS 687 IGLV2-23*02 IGLJ2*01 CSYAAGSTFV 731 p4_01 64D*06 26*01 *02 FDY MEX84_ IGHV4- IGHD5- IGHJ6 ARLGLIQSLRNYY 688 IGLV3-1*01 IGLJ2*01 QAWDSRSVV 732 p4_02 59*08 18*01 *02 YGLDV MEX84_ IGHV3- IGHD3- IGHJ6 TTAIRVTGMDV 689 IGLV1-40*01 IGLJ1*01 QSYDSSHYV 733 p4_04 15*07 10*01 *02 MEX84_ IGHV3- IGHD2- IGHJ6 ARGWSDNSMDV 690 IGKV3-20*01 IGKJ5*01 QQYGSSPIT 734 p4_07 20*01 2*01 *02 MEX84_ IGHV4- IGHD4- IGHJ4 VTLLHDYGDYSFDY 691 IGKV1-39*01 IGKJ2*01 QQSSSIPYT 735 p4_26 31*06 17*01 *02 MEX84_ IGHV4- IGHD5- IGHJ4 ARGNITHYDLLPCDS 692 IGKV4-1*01 IGKJ2*01 QQYYSTPHT 736 p4_27 31*03 12*01 *02 MEX84_ IGHV3- IGHD3- IGHJ4 SLGRINYFFDY 693 IGKV1-9*01 IGKJ4*01 QQLNSYPLT 737 p4_28 23*01 10*01 *02 MEX84_ IGHV4- IGHD6- IGHJ4 ARASQLVPDY 694 IGKV3-11*01 IGKJ4*01 QQRSNWLT 738 p4_32 30-4*01 6*01 *02 MEX84_ IGHV1- IGHD3- IGHJ5 ARGGPINVPLGFDP 695 IGKV3-20*01 IGKJ4*01 HQYVSSPLT 739 p4_35 2*02 10*02 *02 MEX84_ IGHV1- IGHD2- IGHJ6 ARDEGGPNCSGGNC 696 IGKV1-33*01 IGKJ4*01 NNMILSLQL 740 p4_43 69*06 15*01 *02 YYYYGMDV MEX84_ IGHV3- IGHD2- IGHJ5 ANGGWQVPHWFDP 697 IGKV1-39*01 IGKJ4*01 QQSYSIPLT 741 p4_44 23*01 15*01 *02 MEX84_ IGHV4- IGHD5- IGHJ4 ARARSGYSLGYYFD 698 IGKV1-33*01 IGKJ4*01 QQYDDLLT 742 p4_46 61*02 18*01 *02 Y MEX84_ IGHV3- IGHD3- IGHJ5 AKVSRPKGAQASFDP 699 IGKV1-6*01 IGKJ1*01 LQDYDYPLS 743 p4_47 30*18 16*01 *02 MEX84_ IGHV3- IGHD5- IGHJ4 ATPKGGYSGYDQLDY 700 IGKV1-39*01 IGKJ4*01 QQSYNFPRT 744 p4_52 15*07 12*01 *02 MEX84_ IGHV1- IGHD3- IGHJ6 ARPGYTFGYHSYYY 701 IGKV3-11*01 IGKJ5*01 QQRAGT 745 p4_59 69*01 22*01 *02 AMDV MEX84_ IGHV3- IGHD6- IGHJ4 ARGIDY 702 IGKV2-24*01 IGKJ1*01 TQATQFPWT 746 p4_66 23*01 13*01 *01 MEX84_ IGHV1- IGHD6- IGHJ6 ARGSLRGTNGWHS 703 IGKV1-39*01 IGKJ2*01 HQSFSSPDT 747 p4_69 2*02 19*01 *02 HLGYYGMDV MEX84_ IGHV3- IGHD6- IGHJ4 ARSRLRYSSSWYFDY 704 IGKV4-1*01 IGKJ5*01 QQYYSTPRIT 748 p4_72 48*03 6*01 *02 MEX84_ IGHV3- IGHD1- IGHJ2 ARDILPHGTHGWYF 705 IGKV3-11*01 IGKJ2*01 QHRRDWPRYT 749 p4_73 48*01 7*01 *01 DV MEX84_ IGHV3- IGHD2- IGHJ4 ARAKGMIAELDY 706 IGKV4-1*01 IGKJ2*01 QQYRDTPSYT 750 p4_75 53*01 21*01 *02 MEX 18-refers to an individual donor. Sequences were analyzed with IgBlast MEX18_01 IGHV3- IGHD5- IGHJ6*02 TTEIGLGGPNTPSAQ 751 IGLV1-47*01 IGLJ3*02 VAWDDSLSGRV 773 15*01 24*01 LYYYGIDV MEX18_06 IGHV3- IGHD1- IGHJ3*02 ASFRSGAFEI 752 IGKV3-20*01 IGKJ3*01 QQYGSSAVS 774 11*06 26*01 MEX18_08 IGHV4- IGHD3- IGHJ4*02 ARVRYEYDSGGYYY 753 IGLV2-11*01 IGLJ1*01 CSYAGSYV 775 59*01 22*01 VYDFEY MEX18_12 IGHV4- IGHD6- IGHJ6*02 ARVALSSSSFGEHY 754 IGKV3-20*01 IGKJ3*01 QQYGGSPLFT 776 31*03 6*01 YGVDV MEX18_14 IGHV3- IGHD4- IGHJ6*02 ARAGTVFAGHYGMDV 755 IGKV1-16*02 IGKJ4*01 QQYKSYPLT 777 72*01 17*01 MEX18_17 IGHV3- IGHD3- IGHJ4*02 AKDPRRDYYDSSGYY 756 IGLV2-8*01 IGLJ3*02 SSYAGSRTWV 778 23*01 22*01 YPSRGHFDY MEX18_18 IGHV4- IGHD1-14*01 IGHJ3*02 ARIITRNGDAFDI 757 IGLV2-11*01 IGLJ2*0 CSYAGSYT 779 61*01 MEX18_25 IGHV3- IGHD1-20*01 IGHJ4*02 AKFQSSNWSPFDS 758 IGKV3-20*01 IGKJ1*01 QQYGNLPRT 780 23*01 MEX18_26 IGHV4- IGHD3- IGHJ4*02 ARGVWFGEFAVGY 759 IGKV3-15*01 IGKJ3*01 QQYNNWPPRGAT 781 30-4*01 10*01 MEX18_31 IGHV3- IGHD1-1*01 IGHJ4*02 ITGIFKSTWKTDY 760 IGKV3-11*01 IGKJ1*01 QQRSNGWT 782 15*01 MEX18_32 IGHV4- IGHD4/OR15- IGHJ4*02 ARESDFNYGAVDH 761 IGKV3-15*01 IGKJ2*01 QQYNNWPYT 783 31*03 4a*01 MEX18_35 IGHV5- IGHD1-1*01 IGHJ4*02 AKTQGYNPNWPHDF 762 IGKV1-9*01 IGKJ2*01 QQLNGHPRT 784 51*01 MEX18_37 IGHV3- IGHD3-10*01 IGHJ4*02 AKDGRGSIDY 763 IGKV2D-29*02 IGKJ5*01 MQSIQLPPIT 785 30*18 MEX18_43 IGHV3- IGHD2-15*01 IGHJ4*02 ERDIVWGVAGTDY 764 IGKV3-20*01 IGKJ1*01 QYYGDSPRP 786 7*03 MEX18_44 IGHV4- IGHD6-19*01 IGHJ3*02 ARENIAVFFDI 765 IGKV1-33*01 IGKJ4*01 QQHDNLQVI 787 61*03 MEX18_51 IGHV4- IGHD6-19*01 IGHJ4*02 ARDKRYSSGWYYFES 766 IGKV3-11*01 IGKJ1*01 QHRANWPT 788 30-4*01 MEX18_59 IGHV3- IGHD4-17*01 IGHJ4*02 VKPSVTTHYFDY 767 IGKV3-11*01 IGKJ2*01 QQRSNWPPFT 789

64D*06 MEX18_61 IGHV4- IGHD1-1*01 IGHJ6*02 ARDHSPGTTWGNYN 768 IGKV1-39*01 IGKJ2*01 QQSYSTPQT 790 31*03 YGMDV MEX18_74 IGHV1- IGHD3-22*01 IGHJ6*02 ARDSRYYDSRSSYYY 769 IGKV2-28*01 IGKJ1*01 MQALQTPKT 791 18*04 YGMDV MEX18_75 IGHV3- IGHD5-12*01 IGHJ4*02 ARVARPGGYGRTFDE 770 IGKV1-39*01 IGKJ4*01 QQSYSDFS 792 11*01 MEX18_88 IGHV3- None IGHJ6*02 ARVRERYYYFYGLDV 771 IGKV2-28*01 IGKJ5*01 MQALQTFT 793 33*05 MEX18_92 IGHV3- IGHD6-19*01 IGHJ4*02 AKGVAAPGYFEY 772 IGKV3-11*01 IGKJ5*01 QQRSNWPPIT 794 30*18 MEX 105-refers to an individual donor. Sequences were analyzed with IgBlast MEX105_10 IGHV1- IGHD3-10*01 IGHJ4*02 ARGNSYGSGNLGY 795 IGLV1-44*01 IGLJ3*02 STWDDSLNGPV 809 46*01 YLDF MEX105_21 IGHV1- IGHD3-22*01 IGHJ4*02 ARGPDYNDTPGYY 796 IGKV3-20*01 IGKJ3*01 HHYGRT 810 69*01 GNY MEX105_29 IGHV1- IGHD3-22*01 IGHJ6*02 ARGAHYYDSSGYRQ 797 IGKV3-11*01 IGKJ4*01 QQRANWPALT 811 18*01 LYGLDV MEX105_35 IGHV3- IGHD2-21*01 IGHJ4*02 ARANVATRYFDY 798 IGKV1-9*01 IGKJ5*01 QHLSTYPIT 812 72*01 MEX105_44 IGHV4- IGHD3-10*01 IGHJ3*01 ARLRVRGAGWAFDL 799 IGKV3-11*01 IGKJ5*01 QQRSNWPPAIT 813 39*01 MEX105_47 IGHV3- IGHD3-10*01 IGHJ4*02 AKSDYYGSGHYTTI 800 IGKV3D-15*01 IGKJ3*01 QQYNNWPLT 814 23*03 PSSFED MEX105_55 IGHV5- IGHD3-22*01 IGHJ5*02 ARHPTQNYASGDYYT 801 IGKV1-9*01 IGKJ4*01 QQLTTYPGT 815 51*03 MEX105_61 IGHV1- IGHD3-3*01 IGHJ6*02 AKGARITVFGGLDV 802 IGKV1-5*03 IGKJ2*03 QQYMSLPYS 816 2*02 MEX105_69 IGHV1- IGHD4-11*01 IGHJ4*02 ARPYFDGRSNSNLI 803 IGKV3-15*01 IGKJ1*01 QQYNTWPPALT 817 46*01 FFDY MEX105_72 IGHV1- IGHD2-15*01 IGHJ5*02 ARVIVVVVAATSDLP 804 IGKV1-5*03 IGKJ1*01 QHYHSYPWT 818 18*01 VGFDP MEX105_79 IGHV3- IGHD5-18*01 IGHJ4*02 ARWLDNGIQGKY 805 IGKV3-11*01 IGKJ2*01 QQRHEWPV 819 21*01 DY MEX105_84 IGHV4- IGHD3-10*01 IGHJ5*02 ARGPVWFGEYGG 806 IGKV3-20*01 IGKJ5*01 SNMLGHRSP 820 59*01 AFDP MEX105_93 IGHV5- IGHD3-10*02 IGHJ5*02 ARAKGRGLQNWFDP 807 IGKV3D-20*01 IGKJ5*01 QQYGSSPPIT 821 51*01 MEX105_94 IGHV4- IGHD3-10*01 IGHJ6*02 ARVSPLWDYYDSG 808 IGKV3-15*01 IGKJ2*01 QQHMYT 822 31*03 PYYNDFYYGMDV BRA 112-refers to an individual donor. Sequences were analyzed with IgBlast BRA112_01 IGHV4- IGHD5-24*01 IGHJ4*02 ARGGDGYTTRW 823 IGKV1-NL1*01 IGKJ4*01 QQYYSAPLT 842 31*01 FYFNH BRA112_04 IGHV4- IGHD3-22*01 IGHJ4*02 ARLGAEYYVDSS 824 IGKV2-28*01 IGKJ4*01 MQALQTLSLT 843 31*03 GYRGIDH BRA112_11 IGHV1- IGHD3-10*01 IGHJ6*02 ARVERGHTYGLNY 825 IGLV1-47*01 IGLJ3*02 AAWDDSLRGHWV 844 8*01 YYYYGMDV BRA112_12 IGHV4- IGHD3-22*01 IGHJ4*02 ARDSSNTFHHDS 826 IGLV4-69*01 IGLJ3*02 QTWGTGIRV 845 31*03 SGYFDN BRA112_15 IGHV4- IGHD6-19*01 IGHJ4*02 ARLIPGSGWRKGG 827 IGKV3-15*01 IGKJ1*01 QHYKNWPGT 846 31*03 FDY BRA112_22 IGHV1- IGHD3-10*01 IGHJ4*02 ARDSGWSGITTVR 828 IGKV3-15*01 IGKJ2*01 LHYNNWPPRYT 847 46*01 GVPPDF BRA112_29 IGHV1- IGHD3-10*01 IGHJ4*02 ARGYFYTSSNYYN 829 IGKV1-16*02 IGKJ3*01 QQYKSYPFT 848 8*01 TDH BRA112_31 IGHV1- IGHD3-10*01 IGHJ6*02 ARDRFSRHYGSGS 830 IGLV2-14*01 IGLJ1*01 GSYTSTSTCV 849 2*04 LHYAMDV BRA112_32 IGHV3- IGHD4-23*01 IGHJ3*02 ATGYGGNFAFDM 831 IGKV2-28*01 IGKJ1*01 MQALQTPPT 850 7*01 BRA112_34 IGHV3- IGHD4-17*01 IGHJ4*02 ASGGYGVYGFDY 832 IGKV1-5*03 IGKJ1*01 HQYNAYPWT 851 7*01 BRA112_39 IGHV4- IGHD3-10*02 IGHJ6*03 ARAHSYYVYYYMDV 833 IGKV3-15*01 IGKJ5*01 QQYNNWLPIT 852 39*07 BRA112_42 IGHV4- IGHD3-10*01 IGHJ4*02 VRHGPHPGVLVWFG 834 IGKV4-1*01 IGKJ5*01 QQYYTTPLT 853 39*01 EQSKIDY BRA112_53 IGHV3- IGHD6-13*01 IGHJ6*02 AKDIGNIAGVAQGI 835 IGKV1-9*01 IGKJ4*01 QRLNSYPRVT 854 9*01 YFYFGMDV BRA112_54 IGHV3- IGHD4-17*01 IGHJ4*02 ARKSYGDPFFDY 836 IGLV2-14*01 IGLJ3*02 SSYTSRSTWV 855 21*01 BRA112_58 IGHV4- IGHD2-15*01 IGHJ4*02 ASSVMVVAQFDS 837 IGKV3-20*01 IGKJ1*01 QQYGNSPWT 856 31*03 BRA112_59 IGHV1- IGHD5-18*01 IGHJ6*02 ATGAGYSYPVAMDV 838 IGKV2-28*01 IGKJ2*01 MQALQTPYT 857 3*01 BRA112_68 IGHV4- IGHD3-10*01 IGHJ4*02 ARIIINRGQSFDY 839 IGLV2-11*01 IGLJ1*01 CSYAGKYV 858 59*01 BRA112_87 IGHV3- IGHD3-10*01 IGHJ5*02 ARNAPKVFGSGSYY 840 IGKV3-11*01 IGKJ5*01 QQRLYWPVT 859 20*01 SNWFDP BRA112_89 IGHV4- IGHD3-22*01 IGHJ4*01 ARSYSEVLVGYD 841 IGKV3-11*01 IGKJ4*01 QQRSNWLT 860 31*03 BRA 12-refers to an individual donor. Sequences were analyzed with IgBlast BRA12_02 IGHV3- IGHD6-19*01 IGHJ4*02 AKDRTGNIGAGTG 861 IGKV1-5*03 IGKJ1*01 QQYNNYPWT 895 23*01 YFDK BRA12_03 IGHV1- IGHD5-24*01 IGHJ1*01 ARTPREYIAEYFQH 862 IGKV3-15*01 IGKJ5*01 QQYNNWLIT 896 18*01 BRA12_05 IGHV3- IGHD6-13*01 IGHJ3*02 ARVKLRDGSSWYHA 863 IGKV4-1*01 IGKJ1*01 QQYYTTPPWT 897 53*01 FDI BRA12_11 IGHV1- IGHD6-19*01 IGHJ4*02 ARWGLSSAWVAPLG 864 IGKV4-1*01 IGKJ3*01 QQYYTTPFT 898 3*01 FDY BRA12_13 IGHV1- IGHD1-26*01 IGHJ6*02 ARELLYSGRQTYYY 865 IGLV2-14*01 IGLJ3*02 SSYTSDNTRV 899 2*04 SYYGMDV BRA12_14 IGHV5- IGHD1-26*01 IGHJ6*02 ARRQGAHGRDLGFH 866 IGLV2-11*01 IGLJ3*02 CSYAGSYSWV 900 51*03 YAMDV BRA12_16 IGHV1- IGHD6-13*01 IGHJ4*02 ARDGAAAGDY 867 IGKV1-8*01 IGKJ3*01 QQYYDYPLT 901 18*01 BRA12_19 IGHV4- IGHD1-26*01 IGHJ6*02 GNLATVGATAPYY 868 IGLV1-47*01 IGLJ1*01 AAWDDSLNGRV 902 34*01 NYYGMYV BRA12_31 IGHV1- IGHD5-24*01 IGHJ4*02 ARGMATPALLN 869 IGKV3-15*01 IGKJ4*01 HQYNNWPLT 903 3*01 BRA12_36 IGHV4- IGHD5-24*01 IGHJ6*02 ARGHNKWLQLN 870 IGKV3-11*01 IGKJ5*01 QQRINWPIT 904 34*01 FYAMDV BRA12_37 IGHV4- IGHD6-19*01 IGHJ4*03 LVQLQQWGAGLL 871 IGKV1-39*01 IGKJ2*03 QQSYSRPYS 905 34*01 KPSETL BRA12_38 IGHV3- IGHD6-19*01 IGHJ6*02 VKGGYNSVWSNS 872 IGKV1-33*01 IGKJ2*01 QQYDNVPYT 906 9*01 YGMDV BRA12_40 IGHV1- IGHD3-10*01 IGHJ6*02 ARALYVRGYNYG 873 IGKV3-20*01 IGKJ3*01 QQYDNSRFT 907 69*01 FLYGMDV BRA12_42 IGHV1- IGHD1-1*01 IGHJ4*02 AKGGPTARVLSGQ 874 IGKV2-29*03 IGKJ1*01 MQGIHLWT 908 2*02 LYYFDY BRA12_46 IGHV4- IGHD6-19*01 IGHJ6*02 ARGPSGLAVAGTVG 875 IGLV2-8*01 IGLJ1*01 SSYAGTSYV 909 34*01 ERDRNYHYYYGMDV BRA12_51 IGHV1- IGHD3-9*01 IGHJ6*02 ARLGDILTGYVDY 876 IGLV1-44*01 IGLJ1*01 AAWDDSLNGLYV 910 8*02 GMDV BRA12_54 IGHV1- IGHD4-17*01 IGHJ5*02 ARSPIYGDYGFDP 877 IGKV2-28*01 IGKJ1*01 MQALQIPPT 911 3*01 BRA12_55 IGHV1- IGHD2-15*01 IGHJ4*01 ARTHCTGGSCFSS 878 IGKV1-16*02 IGKJ4*01 QQYNSYPPT 912 69*01 SFDY BRA12_56 IGHV3- IGHD3-10*01 IGHJ6*02 ARDRDYGSGSQPL 879 IGKV1-39*01 IGKJ2*03 QQSYSTPYS 913 21*01 YYYYAMDV BRA12_60 IGHV1- IGHD7-27*01 IGHJ4*02 ARVLGNWGFDY 880 IGKV1-9*01 IGKJ3*01 QQLNSYPFT 914 69*06 BRA12_63 IGHV3- IGHD3-16*02 IGHJ6*02 ARGGKRLGELSLF 881 IGKV2-28*01 IGKJ1*01 MQALHTPWT 915 48*03 HYYGMDV BRA12_67 IGHV5- IGHD3-22*01 IGHJ4*02 ARHRRGYYDSSG 882 IGLV2-14*01 IGLJ2*01 SSYTRSSTVV 916 51*01 YYYDY BRA12_70 IGHV4- IGHD5-18*01 IGHJ4*02 TRYSYGFSYFDY 883 IGKV3-11*01 IGKJ4*01 QQRSNWPLT 917

39*01 BRA12_71 IGHV3- IGHD6-6*01 IGHJ6*02 ARAPTRSIGHGMDL 884 IGLV8-61*01 IGLJ3*02 VLYVGAAISL 918 30*04 BRA12_75 IGHV3- IGHD2/OR15- IGHJ6*02 ARENNNIALPYYYY 885 IGKV3-11*01 IGKJ4*01 QQSSNWPIT 919 48*03 2a*01 GMDV BRA12_77 IGHV4- IGHD1-1*01 IGHJ6*01 ARDIRYTYGPMWGG 886 IGKV3-20*01 IGKJ2*01 QQYGGSPYT 920 39*07 DYGMDV BRA12_79 IGHV4- IGHD1-1*01 IGHJ6*02 ARRPPLLRSHNYNY 887 IGKV3-20*01 IGKJ5*01 QQYGSSPLIT 921 34*01 LGMDV BRA12_81 IGHV3- IGHD1-20*01 IGHJ6*02 AKSSGGHNWNYVDY 888 IGKV1-9*01 IGKJ3*01 QQLNSYPVT 922 23*01 YYGMDV BRA12_82 IGHV1- None IGHJ6*02 ASTHLGGLDV 889 IGKV2-30*01 IGKJ4*01 MQGTHWPLT 923 46*01 BRA12_84 IGHV3- IGHD3-10*01 IGHJ4*02 SRATNYYALGY 890 IGLV2-14*01 IGLJ3*02 SSYTSSATWV 924 49*04 BRA12_86 IGHV4- None IGHJ6*02 ARDWPVMDV 891 IGKV2-30*01 IGKJ1*01 MQGTHWPPWT 925 39*07 BRA12_88 IGHV1- IGHD2-15*01 IGHJ4*02 ARVVGTTLYSMGY 892 IGKV4-1*01 IGKJ1*01 QQYYNTWT 926 3*01 BRA12_93 IGHV3- IGHD6-13*01 IGHJ4*02 ARVAAWYAGSFDS 893 IGLV2-18*02 IGLJ1*01 SSYTSTSAF 927 21*01 BRA12_94 IGHV3- IGHD2-21*02 IGHJ4*02 AKAGAYCGGDCYS 894 IGKV1-5*03 IGKJ3*01 QQYQSDLFT 928 33*06 YLQY BRA138_02 IGHV4- IGHD4-11*01 IGHJ3*02 ARLLIDYTNYKSV 929 IGKV3-15*01 IGKJ4*01 QQYHNWPPRLT 953 38-2*02 ASAFDI BRA 138-refers to an individual donor. Sequences were analyzed with IgBlast BRA138_05 IGHV4- IGHD3-22*01 IGHJ4*02 ASSPGYDTRGYYI 930 IGKV1-5*03 IGKJ4*01 QQYNRYVS 954 30-4*01 AGQYYFVN BRA138_06 IGHV3- IGHD4-17*01 IGHJ4*02 ARDGTIPGYGDY 931 IGKV3-11*01 IGKJ1*01 QQRSNWPPWT 955 30-3*01 BRA138_09 IGHV4- IGHD6-19*01 IGHJ6*02 ARMPVAAHYFYD 932 IGKV3-20*01 IGKJ5*01 QQYGSSPIT 956 61*01 GMDV BRA138_12 IGHV3- IGHD6-13*01 IGHJ4*02 AKFPHRSTSWYY 933 IGLV1-40*01 IGLJ1*01 QSYDSSLSGSFYV 957 9*01 FDS BRA138_22 IGHV5- IGHD1-1*01 IGHJ4*01 ARGLRVEIPIFAY 934 IGKV3-20*01 IGKJ3*01 QQYGGSPPRFT 958 51*01 BRA138_26 IGHV1- IGHD3-9*01 IGHJ3*02 TRDTIVGATYAFDI 935 IGKV4-1*01 IGKJ3*01 QQHYSTPFT 959 69*01 BRA138_27 IGHV3- IGHD6-13*01 IGHJ6*02 AREPDSSSWYQDYY 936 IGLV2-23*02 IGLJ1*01 CSYAGSRTRV 960 21*01 CAMDV BRA138_34 IGHV4- IGHD3-16*02 IGHJ6*03 TRDLGNFIAYMDV 937 IGLV1-44*01 IGLJ2*01 ASWDDNLNSRV 961 61*02 BRA138_35 IGHV3- IGHD3-22*01 IGHJ4*02 SRGSYYYDSRGYY 938 IGKV2-29*02 IGKJ5*01 MQGIIFPPIT 962 49*05 FRPPSAGPFDY BRA138_51 IGHV3- IGHD1-26*01 IGHJ4*02 VKIAVGGSWSS 939 IGLV2-14*01 IGLJ2*0 SSYTSSSTLV 963 64D*06 EALDY BRA138_54 IGHV3- IGHD1-26*01 IGHJ6*02 ARGHLVGATSY 940 IGKV1-9*01 IGKJ1*01 QQLNSYPET 964 7*02 YYGMDV BRA138_63 IGHV4- IGHD3-10*01 IGHJ4*02 ARVSLLWFGELG 941 IGKV1-9*01 IGKJ3*01 LQVNSYPLT 965 34*01 AVPYYFDY BRA138_66 IGHV1- IGHD6-19*01 IGHJ6*02 ARDRHRAGAL 942 IGLV2-14*01 IGLJ2*01 SSYTTSTTVI 966 69*01 RYGMDV BRA138_68 IGHV3- IGHD6-19*01 IGHJ5*02 AKGGTSVAIGWN 943 IGLV2-11*01 IGLJ1*01 CSYGGTYSPYV 967 9*01 WFDP BRA138_70 IGHV4- IGHD3-9*01 IGHJ4*02 ARGYRGNILTG 944 IGKV1-33*01 IGKJ1*01 QQYAKYPLT 968 30-2*01 RLGYFDY BRA138_71 IGHV3- IGHD3-22*01 IGHJ4*02 TTAGNYYDSRGY 945 IGKV3-20*01 IGKJ4*01 QQYATSSLT 969 49*04 YFSRPRHSFDY BRA138_77 IGHV3- IGHD3-10*01 IGHJ4*02 ARAPQNYYGSGR 946 IGLV1-51*01 IGLJ1*01 GTWDSSLSAYV 970 33*01 YYSGCDY BRA138_78 IGHV4- IGHD6-19*01 IGHJ6*03 ARTAVDRYSSGW 947 IGLV1-51*01 IGLJ2*01 GTWDSSLSAGV 971 59*01 YGEYYYYSMDV BRA138_84 IGHV1- IGHD3-22*01 IGHJ4*02 ARRPLTSYYDSGA 948 IGLV6-57*01 IGLJ1*01 QSFDSSNQEV 972 18*01 YYPYYFDY BRA138_87 IGHV3- IGHD3-22*01 IGHJ4*02 TRDTTYFYDNSGY 949 IGLV1-40*01 IGLJ2*01 QSYDRSLSGSRV 973 49*04 YGWASKGGYFDY BRA138_89 IGHV4- IGHD6-25*01 IGHJ6*02 ARQPVRGRHSSS 950 IGKV1-13*02 IGKJ1*01 QQFNSYPQT 974 39*01 GYRHYYYGMDV BRA138_90 IGHV4- IGHD3-16*01 IGHJ4*02 ARVETYDHVWGA 951 IGKV3-15*01 IGKJ1*01 HHYNNWT 975 31*03 FRFGEGGYFDH BRA138_91 IGHV4- IGHD3-22*01 IGHJ4*01 ARGGHYYDSRG 952 IGKV3-15*01 IGKJ1*01 QQYHDWPLWT 976 30-2*01 YFTLAGPIDY

TABLE-US-00017 TABLE 3 List of primers for cloning recombinant antibodies by the SLIC method. Related to Methods of this example. Best V or J gene SEQ Primer ID Primer sequence segment match ID NO: Human antibody heavy chain (forward) p1355DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG VH 1 977 p1356DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG VH 1/5 978 p1357DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG VH 1-18 979 p1358DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG VH 1-24 980 p1359DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG VH 3 981 p1360DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG VH 3-11 982 p1361DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG VH 3-23 983 p1362DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG VH 3-33 984 p1363DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG VH 3-9 985 p1364DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG VH 4 986 p1365DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG VH 4-34 987 p1366DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG VH 4-39 988 p1367DFR 5'CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG VH 6-1 989 Human antibody heavy chain (reverse) p1370DFR 5'CCGATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCAG JH 1/2 990 p1371DFR 5'CCGATGGGCCCTTGGTCGACGCTGAAGAGACGGTGACCATTG JH 3 991 p1372DFR 5 'CCGATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCAG JH 4/5 992 p1373DFR 5'CCGATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCGTG JH 6 993 Human antibody light chain kappa (forward) p1379DFR 5'GTAGCAACTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC VK 1-5 994 p1380DFR 5'GTAGCAACTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT VK 1-9 995 p1381DFR 5'GTAGCAACTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC VK 1D-43 996 p1382DFR 5'GTAGCAACTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC VK 2-2 997 p1383DFR 5'GTAGCAACTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC VK 2-28 998 p1384DFR 5'GTAGCAACTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC VK 2-30 999 p1385DFR 5'GTAGCAACTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC VK 3-11 1000 p1386DFR 5'GTAGCAACTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC VK 3-15 1001 p1387DFR 5'GTAGCAACTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT VK 3-20 1002 p1388DFR 5'GTAGCAACTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC VK 4-1 1003 Human antibody light chain kappa (reverse) p1390DFR GAAGACAGATGGTGCAGCCACCGTACGTTTGATYTCCACCTTGGTC JK 1/4 1004 p1391DFR GAAGACAGATGGTGCAGCCACCGTACGTTTGATCTCCAGCTTGGTC JK 2 1005 p1392DFR GAAGACAGATGGTGCAGCCACCGTACGTTTGATATCCACTTTGGTC JK 3 1006 p1393DFR GAAGACAGATGGTGCAGCCACCGTACGTTTAATCTCCAGTCGTGTC JK 5 1007 Human antibody light chain lambda (forward) p1402DFR CTAGTAGCAACTGCAACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG VL 1 1008 p1403DFR CTAGTAGCAACTGCAACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG VL 2 1009 p1404DFR CTAGTAGCAACTGCAACCGGTTCTGTGACCTCCTATGAGCTGACWCAG VL 3 1010 p1405DFR CTAGTAGCAACTGCAACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA VL 4/5 1011 p1406DFR CTAGTAGCAACTGCAACCGGTTCTTGGGCCAATTTTATGCTGACTCAG VL 6 1012 p1407DFR CTAGTAGCAACTGCAACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG VL 7/8 1013 Human antibody light chain lambda (reverse) p1409DFR GGCTTGAAGCTCCTCACTCGAGGGYGGGAACAGAGTG Constant L 1014

TABLE-US-00018 TABLE 4 List of primers for the generation of RVP expression constructs. Related to Methods of this example. Primer ID Primer sequence Comments SEQ ID NO: Mutation of BspHI sites in pZIKV/HPF/CprME to generate pZIKV/HPF/CprM*E* RU-O-24303 GTTAAGGGATTTTGGACATGAGATTATC BspHI at nt 6419 forward 1015 RU-O-24304 GATAATCTCATGTCCAAAATCCCTTAAC BspHI at nt 6419 reverse 1016 RU-O-24309 CTTGGTTGAGTACTCACCAGTCA Reverse outer (for 6419) 1017 RU-O-24310 GAAGACTACAGCGTCGCCAG Forward outer (for 6419) 1018 RU-O-24305 GTTATTGTCTCATGCGCGGATAC BspHI at nt 7427 forward 1019 RU-O-24306 GTATCCGCGCATGAGACAATAAC BspHI at nt 7427 reverse 1020 RU-O-24307 CTTCATGCAATTGTCGGTCAAGCC Reverse outer (for 7427) 1021 RU-O-24308 TGACTGGTGAGTACTCAACCAAG Forward outer (for 7427) 1015 Generation of E mutations in pZIKV/HPF/CprM*E* RU-O-24998 AGGAGTCGGGGCGAAGAAGATCAC E393A forward 1022 RU-O-24999 GTGATCTTCTTCGCCCCGACTCCT E393A reverse 1023 RU-O-25000 AGGAGTCGGGGAGGCGAAGATCAC K394A forward 1024 RU-O-25001 GTGATCTTCGCCTCCCCGACTCCT K394A reverse 1025 RU-O-24379 ACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGTGCATAGGAGT Forward outer 1026 RU-O-24380 TTCGAACCGCGGCTGGGTCCTATTAAGCAGAGACAGCTGTGGATAAGAAGATC Reverse outer 1027 Generation of pDENV1/PUO-359/CprME RU-O-24611 CTTGACCGACAATTGCATGAAG Upstream of SnaBI site 1029 forward RU-O-24610 GTCTTTTTCCGTTGGTTGTTCATAGCCTGCTTTTTTGTACAAAC CMV promoter-Capsid 1030 fusion reverse RU-O-24608 GTTTGTACAAAAAAGCAGGCTATGAACAACCAACGGAAAAAGAC CMV promoter-Capsid 1031 fusion forward RU-O-24609 TTCGAACCGCGGCTGGGTCCTATTACGCCTGAACCATGACTCCTAGGTAC E C-terminus-SacII 1032 site reverse Generation of pZIKV/HPF-CprM/MR766-E RU-O-24994 CAAAGAGTGGTTCCATGACATCCCATTG BspHI site mutation 1033 forward RU-O-24995 CAATGGGATGTCATGGAACCACTCTTTG BspHI site mutation 1034 reverse RU-O-24379 ACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGTGCATAGGAGT Forward outer 1035 RU-O-24380 TTCGAACCGCGGCTGGGTCCTATTAAGCAGAGACAGCTGTGGATAAGAAGATC Reverse outer 1036

TABLE-US-00019 TABLE 5 Data collection and refinement statistics. Related to Figure 5. Z006-ZIKV EDIII Z004-DENV1 EDIII Data Collection Resolution Range (.ANG.) 29.75-3.0 (3.107-3.0) 37.11-3.0 (3.107-3.0) Space group R32:H P4.sub.32.sub.12 Cell dimensions .alpha., .beta., .chi. (.sym.) 385.08, 385.08, 56.64 74.23, 74.23, 190.76 .alpha., .beta., .gamma. (.ident.) 90, 90, 120 90, 90, 90 Total reflections 170795 (25781) 121867 (20556) Unique reflections 31520 (3151) 11154 (1101) Multiplicity 5.4 (5.6) 10.9 (11.6) Completeness (%) 98.71 (99.78) 98.30 (99.73) Mean I/.sigma.(I) 8.2 (2.3) 11.1 (3.3) Wilson B-factor (.ANG..sup.2) 77.8 58.7 R.sub.merge 0.120 (0.598) 0.179 (0.829) R.sub.pim 0.083 (0.410) 0.079 (0.358) CC1/2 0.992 (0.779) 0.994 (0.869) Refinement R.sub.work/R.sub.free 0.210/0.256 0.258/0.315 Number of atoms 7878 3759 Protein residues 1050 492 RMS (bonds) (.ANG.) 0.013 0.005 RMS (angles) (.degree.) 1.42 0.97 Clashscore 15.93 13.28 Average B-factor (.ANG..sup.2) 103.02 56.59 Number of TLS groups 6 17 Statistics for the highest-resolution shell are shown in parentheses.

TABLE-US-00020 TABLE 6 Antibody-antigen contacts. Related to FIG. 5. Z006 ZIKV Closest Z004 DENV1 Closest Chain Fab EDIII distance Fab EDIII distance Description Origin Count in clones HC N31 Q350, T351 Y52 T351 I53 P336, A382 D54 M301 E55 K340, S306, L307, Y305 S56 L307 S56 M301, V300 T57 S306 Y58 L307, S306, 3.07 Y58 M301, V300, 2.54 Tyr-OH w/ antigen V Germline 62 Y, 1 W T309 T303 backbone oxygen R96 E393 3.44 R96 E384 2.55 electrostatic/salt N addition 62 R, 1 H bridge S97 K395, G392, E393 N98 L352, G392, V391, K395 G99 G392 R99 G383, S338, A382 W100 T309, K394 G100 G383 S100A G392 V100A T303 S100B E393 E100C E384, G383, K385, A382 L100D E384 LC Q27 T335 3.28 Q27 T329 3.96 V Germline 58 Q, 6 H, 5 R S30 E327 W32 K394, A311 3.08 W32 K385, S305, 3.37 hydrophobic (plus V Germline 68 W, 1 L E327 cation-pi) Y49 E393 Q50 E393 Y91 K394, E393 2.45 F91 K385 2.28 hydrophobic (plus V Germline/ 57 Y, 12 F Tyr-OH/Glu H-bond SHM for ZIKV) S92 A310, K394, 3.03 Y92 G328, K385, T309 327, G304, T303 T93 T335, G334, 3.22 S93 T329, T303, 2.68 H-bond to antigen V 42 S, 23 T, 3 N D336, A310, G328 backbone nitrogen Germline/SHM T309 antigen sidechain F94 T309, D336 3.42 V94 T303, T329 3.1 H-bond to LC 43 Y, 13 F, 12 V D330 backbone plus vDW for antibody sidechain W96 T303

[0296] Contacts are defined as residues in which any atom is within 4 .ANG. of an atom from a residue on the interacting partner using AntibodyDatabase (West et al., 2013). Table 6 is organized by antibody residue, listing all antigen residues contacted by each antibody residue (ordered by contact distance). Antibody residues are highlighted when corresponding interactions occur in both complexes. For the highlighted interactions additional information is listed including the antibody residue's origin in V(D)J recombination and the residue distribution at that antibody position in the sequenced antibody clones.

Example 3

[0297] This Example extends the disclosure of Examples 1 and 2 above. Zika virus (ZIKV) infection causes severe neurologic complications and fetal aberrations.sup.1. As discussed in Examples 1 and 2, human monoclonal antibody Z004 is a VH3-23/VK1-5 antibody that recognizes the lateral ridge of the Envelope Domain III (EDIII) of ZIKV, is a potent neutralizer in vitro, and prevents disease in mice. In this Example we demonstrate that when Z004 is administered to macaques for prophylaxis, it leads to emergence of resistant ZIKV variants bearing mutations in the antibody target site. As discussed above, Z021 has a structure in complex with the antigen that reveals a distinct although overlapping epitope on EDIII. Z021 potently neutralizes ZIKV in vitro and prevents disease in mice. This Example shows that in a clinically relevant macaque model, prophylactic co-administration of Z004 with Z021 is protective and suppresses emergence of resistant variants. Thus, a combination of two potent human monoclonal antibodies to EDIII is sufficient to suppress infection and thwart viral escape in macaques, a natural host for ZIKV.

[0298] In more detail, to determine whether human monoclonal antibodies are efficacious against ZIKV in primates, who are natural hosts for infection, we administered Z004 to rhesus macaques 24 hours before intravenous challenge with high dose (10.sup.5 PFU) of a Brazilian strain of ZIKV. Infection was monitored by PCR to detect viral RNA in the plasma (FIG. 11A). All four control animals developed viremia, which peaked on day 3 with plasma viral loads ranging between 10.sup.5-10.sup.7 RNA copies/ml (FIG. 11A, in black). Similar to previous reports, viremia cleared spontaneously beginning on day 7 (FIGS. 11A, and .sup.19). In contrast, viremia was either undetectable or below 10.sup.4 RNA copies/ml in the Z004-treated macaques on day 3. However, the Z004-treated macaques showed delayed viremia peaking on day 7-10 at 3.times.10.sup.2-5.times.10.sup.5 RNA copies/ml (FIG. 11A, in grey). Thus, Z004 alone alters the course of ZIKV infection and leads to prolonged but lower levels of viremia.

[0299] To determine whether the viremia in Z004-treated animals was associated with viral escape mutations, we sequenced the EDIII from the virus found in the plasma of the treated macaques on day 7 and 10. In both animals the circulating viruses carried mutations in the Z004 target site; K394R in one animal and E393D or K394R in the other (FIGS. 11B and 11C). We were unable to find these mutant viruses at earlier time points in the same animals, in untreated controls, or in the inoculum (data not shown). While D393 is present in ZIKV strains of African origin, no ZIKV sequences with R394 were found out of 704 ZIKV sequences that were analyzed (ViPR database, Oct. 9, 2017). ELISA assays using ZIKV EDIII.sub.E393D and EDIII.sub.K394R mutant proteins confirmed that these mutations interfere with Z004 binding (FIG. 11D). In contrast to the macaque, antibody resistance mutations were rare in Ifnar1.sup.-/- mice treated with Z004; nevertheless, the only mouse that developed mutations had the same K394R as observed in macaque (n=8; FIG. 17). Therefore, when administered prophylactically to macaques prior to a high-dose intravenous ZIKV inoculation, Z004 selects for resistant viral mutants.

[0300] We tested whether a second antibody could help prevent the development of resistance. Z021 is a human monoclonal antibody that, like Z004, was isolated from an individual with exceptional serum neutralizing activity against ZIKV.sup.5. Z021 binds to the EDIII of both ZIKV and DENV1, it neutralizes ZIKV reporter viral particles (RVPs) bearing Asian/American or African lineage E proteins with an IC.sub.50 of 1 ng/ml and 0.7 ng/ml, respectively (FIG. 12 and FIG. 18), and has strong activity in plaque reduction neutralization assays using an infectious Puerto Rican strain of ZIKV (PRNT; IC.sub.50 of 4 ng/ml, FIG. 12A). Z021 is also a potent neutralizer of DENV1 (IC50 of 10.1 ng/ml; FIG. 12B).

[0301] To determine whether Z021 neutralizes ZIKV in vivo, we administered Z021 to Ifnar1.sup.-/- mice either 24 hours before or 24 hours after ZIKV challenge (FIG. 12C). Whereas 100% of control mice developed symptoms and died (n=11, FIG. 12D), only 15% did so when Z021 was administered before infection (n=13; p=0.0002 for disease and p<0.0001 for survival; FIG. 12D). Moreover, only 42% developed symptoms and 33% succumbed to disease when the antibody was administered 1 day after infection (n=12; p=0.0006 for disease and p=0.0002 for survival; FIG. 12E). Thus, Z021 is efficacious against ZIKV in vitro and in Ifnar1.sup.-/- mice. Z004 binding and neutralization of ZIKV and DENV1 is dependent on ZIKV EDIII residue K394 and also partially dependent on E393 (DENV1 residues K385 and E384, respectively; FIGS. 11D and .sup.5). To determine whether Z004 and Z021 recognize distinct neutralizing epitopes on EDIII, we performed ELISA assays (FIG. 13A and see Methods of this Example). Each monoclonal antibody was incubated with saturating amounts of either wild type ZIKV EDIII, or an EDIII bearing mutations in the Z004 target site that interfere with its binding and neutralizing activity (EDIII.sub.E393A/K394A). Residual binding to wild type EDIII was measured by ELISA. Whereas, Z004 binding to ZIKV EDIII was only blocked by wild type ZIKV EDIII, binding of Z021 was blocked by both wild type and ZIKV EDIII.sub.E393A/K394A, indicating that residues E393 and K394 are critical for Z004 but dispensable for Z021 binding (FIG. 13A). In agreement with this finding, Z004 failed to neutralize ZIKV RVPs that were altered to bear the E393A/K394A mutations but Z021 remained active against the mutant RVPs in vitro (FIG. 13B). To determine whether the Z004 and Z021 epitopes overlap, we performed competition ELISA assays, which showed that Z004 prevented binding by Z021, and vice-versa (FIG. 13C and see Methods of this Example). Thus, Z021 binds to a neutralizing epitope on the EDIII that does not require E393/K394 but is close to or overlapping with the epitope recognized by Z004.

[0302] Structural analysis of Z004 and of the related VH3-23/VK1-5 antibody Z006 with the EDIII of DENV1 and ZIKV, respectively, revealed that VH3-23/VK1-5 antibodies bind to these two different flaviviruses in a very similar manner, with E393/K394.sub.ZIKV and E384/K385.sub.DENV1 being central to the epitope.sup.5. To gain structural insights into how Z021 recognizes its epitope, we crystallized Z021 in complex with the EDIII of ZIKV and of DENV1 (FIG. 14). Z021 recognizes the EDIII of both flaviviruses in a similar fashion, and makes no contacts with the E393/K394.sub.ZIKV and E384/K385.sub.DENV1 residues (FIG. 14A). Similar to Z004, Z021 recognizes the lateral ridge region of DENV1 EDIII, but its epitope is distinct. Compared to the Z004 Fab, the Z021 Fab is rotated .about.48.degree. around an axis near the complementarity determining region 2 (CDRH2), positioning the heavy chains in similar regions, while the light chains exhibit divergent footprints (FIG. 14B). Z021 uses both its heavy and light chains to contact the N-terminal region and the BC loop of DENV EDIII, makes light chain contacts to the DE loop, and heavy chain contacts to the FG loop. Notably, when compared to Z004 Fab, Z021 Fab makes unique contacts to the N-terminal region of DENV1 EDIII and shows no ordered contacts with K385.sub.DENV1 (FIG. 14C). Thus, consistent with the ELISA and neutralization results (FIG. 13), Z021 recognizes a distinct but overlapping epitope on EDIII from that of Z004.

[0303] Since Z021 binding and neutralizing activity is resistant to mutations in EDIII E393 and K394, and its epitope is distinct from Z004 (FIGS. 13 and 14), we co-administered the two antibodies to macaques 24 hours before challenge with ZIKV. Two out of three macaques developed low viremia, with approximately 10.sup.2 or lower RNA copies/ml at around day 5 or 13 after infection. The third macaque developed viremia below 10.sup.3 RNA copies/ml starting on day 13 (FIG. 15). Viremia was not a consequence of rapid clearance of Z004 and Z021, as high levels of human antibodies were detectable in the macaque plasma (FIG. 19). In contrast to macaques treated with Z004 alone (FIG. 11), no mutations in the EDIII region of the circulating virus were detected in animals treated with the combination of Z004 with Z021 (data not shown). We conclude that treatment of non-human primates with the combination of Z004 and Z021, two antibodies that target distinct but overlapping epitopes, suppresses and delays viremia and prevents the emergence of ZIKV escape mutants upon high-dose intravenous ZIKV challenge.

[0304] Viremia in the absence of viral escape could result from antibody Z004 and Z021 promoting ZIKV infection through antibody-dependent enhancement (ADE). ADE depends on the ability of antibodies to engage Fc-gamma receptors. We modified the fragment crystallizable (Fc) region of both antibodies to preclude Fc-gamma receptor binding (GRLR or GRLR/LS mutations. These modifications prevented Fc binding and ADE in vitro, while maintaining neutralization potentcy against ZIKV in vitro and in mice (FIGS. 20 and 21). To determine whether the late-onset low-level plasma viremia of macaques treated with the combination of Z004 and Z021 was dependent on Fc-gamma receptors, we administered to macaques Z004-GRLR and Z021-GRLR antibodies and challenged them with ZIKV. Human antibody levels were comparable in macaques treated with the wild type or GRLR version of Z004 and Z021 (FIG. 19). Low plasma viremia was detected in all three animals (FIG. 15): one macaque had a single viral blip less than 10.sup.2 RNA copies/ml on day 3, one had viremia below 10.sup.3 RNA copies/ml between days 2-4, and one was viremic between days 6-13 (peak viremia of 10.sup.4 RNA copies/ml). No mutations were identified in the EDIII region of the emerging viruses. We conclude that the low-level viremia that develops in the presence of Z004 and Z021 is not dependent on Fc-gamma receptor engagement.

[0305] The most common mean of ZIKV transmission is through the bite of an infected mosquito. To determine whether the combination of Z004-GRLR and Z021-GRLR was protective against subcutaneous challenge, we infected macaques with 10.sup.3 PFU of a Puerto Rican strain of ZIKV by this route. As the size of the inoculum during mosquito feeding is uncertain, we chose this dose of virus because it is similar to recent vaccination experiments in non-human primates.sup.18,20,21. None of the challenged macaques developed viremia during the observation period (FIG. 16). Without intending to be bound by any particular viewpoint, we conclude that combining Z004-GRLR with Z021-GRLR prevents viremia altogether after subcutaneous infection with ZIKV.

[0306] Those skilled in the art will recognize that although the error rate of the ZIKV polymerase has not been determined, flaviviruses are RNA viruses that are generally assumed to undergo high rates of error prone replication thereby producing mutant forms that can be selected for antibody resistance.sup.29-31. Antibody evasion by flaviviruses such as DENV.sup.32-34, WNV.sup.35-36, YFV.sup.37, Japanese encephalitis virus.sup.38, tick-borne encephalitis virus.sup.39, and recently ZIKV.sup.40, has been amply documented using cell culture experiments. Resistant virus also emerged upon administration of a single monoclonal antibody to mice challenged with WNV.sup.41 or to Rhesus monkeys challenged with DENV.sup.42,43. In macaques, a combination of 3 antibodies (including 2 VH3-23/VK1-5 antibodies) is effective against subcutaneous challenge with 10.sup.3 PFU of ZIKV.sup.18, but whether escape occurs with single antibodies, or whether fewer than 3 antibodies might be sufficient to protect was not determined. The present disclosure demonstrates that in contrast to in Ifnar1.sup.-/- mice escape is a significant problem upon challenge with 10.sup.5 PFU of ZIKV in single-antibody treated primates, which are a natural host for the virus. Moreover, it is demonstrated herein that prophylaxis with 2 antibodies to the EDIII is sufficient to prevent escape.

[0307] The Z004 and Z021 antibodies share a number of important features including potent neutralizing activity against both ZIKV and DENV1 but no binding to any of the other flaviviruses tested.sup.5. The overlapping activity can be attributed to distinct but overlapping target sites. Although the epitopes are similar, Z021 makes unique contacts to the N-terminal region of DENV1 EDIII with both its heavy and light chains, while Z004 makes more extensive contacts to the FG loop, including the E384/K385.sub.DENV1 motif. Because the E384/K385.sub.DENV1 motif is peripheral to the Z021 epitope, viruses with mutations at these positions will likely remain sensitive to Z021. These differences account for the efficacy of the combination of the two antibodies despite the similarities in their target sites.

[0308] Method for this Example.

[0309] Reagents.

[0310] Antibodies. Z021, Z004, Z015 and 10-1074 were prepared by transient transfection of mammalian HEK-293-6E cells and purified as previously described.sup.5. LPS was removed with TritonX-114 and the antibodies concentrated to 4.6 to 19 mg/ml in PBS. The GRLR, LS and combined (GRLR/LS) modifications in the Fc portion of Z004 and Z021 human IgG1 expression plasmids were generated with Q5 site-directed mutagenesis kit (New England Biolabs) according to the company's instructions and primers: DFRp1455 5' TGAACTCCTGaGGGGACCGTCAGTC (SEQ ID NO: 1037) and DFRp1456 5' GGTGCTGGGCACGGTGGG (SEQ ID NO: 1038); DFRp1457 5'AACAAAGCCCgCCCAGCCCCC (SEQ ID NO: 1039) and DFRp1458 5'GGAGACCTTGCACTTGTACTCCTTG (SEQ ID NO: 1040); DFRp1459 5'ATGCTCCGTGcTGCATGAGGC (SEQ ID NO: 1041) and DFRp1460 5'GAGAAGACGTTCCCCTGC (SEQ ID NO: 1042); DFRp1461 5'GCTCTGCACAgCCACTACACG (SEQ ID NO: 1043) and DFRp1462 5'CTCATGCAGCACGGAGCATG (SEQ ID NO: 1044).

[0311] Virus. For in vitro experiments, ZIKV 2015 Puerto Rican PRVABC59.sup.44 was obtained from the CDC and passaged twice in human Huh-7.5 cells, and the Thai isolate of DENV1 PUO-359 (TVP-1140) was obtained from Robert Tesh and amplified by three passages in C6/36 insect cells. For mouse experiments, ZIKV 2015 Puerto Rican PRVABC59 was passaged once in STAT1.sup.-/- human fibroblasts. For macaque experiments, a 2015 isolate of ZIKV from Brazil (strain Zika virus/H.sapiens-tc/BRA/2015/Brazil_SPH2015; genbank accession number KU321639.1) was used. The strain was isolated from the plasma of a transfusion recipient and was passaged twice in mycoplasma free Vero cells. The Puerto Rican ZIKV strain (PRVABC59; KU501215) was used for subcutansous challenge. Virus titration was as previously described.sup.5,19.

[0312] Reporter viral particles (RVPs). Wild type ZIKV RVPs with E proteins corresponding to Asian/American or African lineage were previously reported.sup.5. A plasmid for expression of ZIKV CprME with E393A/K394A mutations was generated from plasmid pZIKV/HPF/CprM*E*.sup.5, a derivative of pZIKV/HPF/CprME, a ZIKV C-prM-E expression construct provided by Ted Pierson (NIH), engineered to contain unique BspHI and SacII restriction sites flanking the envelope region, allowing facile manipulation. Assembly PCR-based site-directed mutagenesis was used to introduce the E393A/K394A double mutation into the envelope of ZIKV H/PF/2013 in pZIKV/HPF/CprM*E*, resulting in plasmid pZIKV/HPF/CprME(E393A/K394A). All PCR-derived plasmid regions were verified by sequencing. Primers used for assembly PCR and mutagenesis were: Forward outer (RU-O-24379) 5'ACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGTGCATAGGA GT (SEQ ID NO: 1045); Reverse outer (RU-O-24380) 5' TTCGAACCGCGGCTGGGTCCTATTAAGCAGAGACAGCTGTGGATAAGAAGATC (SEQ ID NO: 1046); E393A/K394A forward (RU-O-25002) 5'AGGAGTCGGGGCGGCGAAGATCACCCAC (SEQ ID NO: 1047); and E393A/K394A reverse (RU-O-25003) 5' GTGGGTGATCTTCGCCGCCCCGACTCCT (SEQ ID NO: 1048). RVPs bearing the ZIKV E protein with E393A/K394A mutations were generated by cotransfection of Lenti-X-293T cells with plasmids pZIKV/HPF/CprME(E393A/K394A) and pWNVII-Rep-REN-IB.sup.45 as previously described.sup.5.

[0313] EDIII proteins. Expression plasmids encoding the ZIKV mutant proteins EDIII.sub.E393A/K394A, EDIII.sub.E393D and EDIII.sub.K394R were generated by QuikChange site-directed mutagenesis (Agilent Technologies) and confirmed by DNA sequencing. Primers used for mutagenesis are the following: E393A/K394A 5' TTGTCATAGGAGTCGGGGCGGCGAAGATCACCCACCACTG (SEQ ID NO: 1049); E393D 5' CATAGGAGTCGGGGACAAGAAGATCACCCAC (SEQ ID NO: 1050); and K394R: 5'GTCATAGGAGTCGGGGAGCGTAAGATCACCCACCACTGG (SEQ ID NO: 1051).

[0314] Mutant ZIKV EDIII proteins were expressed in E. coli, refolded from inclusion bodies, and purified as described previously.sup.5,13.

[0315] Animal Care and Experiments.

[0316] Mice. Interferon-.alpha..beta. receptor knock-out mice were obtained from The Jackson Laboratory (Ifnar1.sup.-/-; B6.129 S2-Ifnar 1.sup.tm1Agt/Mmjax) and were bred and maintained in the animal facility at the Rockefeller University. Mice were specific pathogen free and on a standard chow diet. Both male and female mice (3-4 week old) were used for experiments and were equally distributed within experimental and control groups. 125 .mu.g of monoclonal antibodies in 200 .mu.l of PBS were administered intraperitoneally to Ifnar1.sup.-/- mice one day before or one day after footpad infection with 1.25.times.10.sup.5 plaque forming units (PFU) of ZIKV Puerto Rican strain in 50 .mu.l. Mice were monitored for symptoms and survival over time. Animal protocols were in agreement with NIH guidelines and approved by the Rockefeller University Institutional Animal Care and Use Committee.

[0317] Macaques. Macaques were from the conventional colony at the California National Primate Research Center (CNPRC), and were type D retrovirus-free, SIV-free and simian lymphocyte tropic virus type 1 antibody negative. Animals were housed in accordance with Association for Assessment and Accreditation of Laboratory Animal Care Standards. We strictly adhered to Guide for the Care and Use of Laboratory Animals prepared by the Institute for Laboratory Animal Research. The study was approved by the Institutional Animal Care and Use Committee of the University of California Davis. Z004 and Z021 antibodies were administered to macaques at doses of 15 mg/kg body weight each by slow intravenous (i.v.) infusion (2 ml/minute) 24 hours before saphenous vein i.v. inoculation with ZIKV Brazilian strain (10.sup.5 PFU in 1 ml of RPMI-1640 medium). Macaques were evaluated twice daily for clinical signs of disease including poor appetence, stool quality, dehydration, diarrhea, and inactivity. When necessary, macaques were immobilized with 10 mg/kg ketamine hydrochloride (Parke-Davis) injected intramuscularly after overnight fasting. Animals were sedated at time zero (time of virus inoculation), daily for 7 to 8 days, and then every few days for sample collection. EDTA-anti-coagulated blood samples were collected using venipuncture. Complete blood counts and separation of plasma for cryopreservation of aliquots were performed as described earlier.sup.19.

[0318] Neutralization and ADE Assays In Vitro.

[0319] Plaque reduction neutralization test with ZIKV PRVABC59, and flow cytometry-based neutralization assay with DENV1 PUO-359 were used to measure antibody neutralization activity in Vero cells, as described.sup.5. Neutralization of luciferase-encoding RVPs by antibodies using the ZIKV wild type, E393A/K394A, and African mutant RVPs was performed as previously described.sup.5. Antibody dependent enhancement (ADE) assays using antibodies or macaque plasma were similar to neutralization assays with RVPs, except that Fc-receptor bearing K562 cells were used, and that the cells were in 96-well plates coated with 0.01% poly-L-lysine (Sigma).

[0320] ELISA Assays.

[0321] ELISA after antibody blocking, Serial dilutions of Z004 or Z021 antibody were incubated overnight with nutation at 4.degree. C. in V-bottom 96-well plates in the presence of saturating concentrations of either wild type EDIII, EDIII.sub.E393A/K394A, or no protein control. In preliminary experiments, the saturating concentration of EDIII protein was determined as being approximately 1 .mu.g/ml, and was increased to 10 .mu.g/ml for the actual experiment. After overnight incubation the samples were added to ELISA plates that had been pre-coated with wild type EDIII and the residual antibody binding to EDIII was detected as previously described.sup.5, with the exception that the signal was enhanced by two amplification steps. First, after incubating with goat anti-human IgG-HRP (Jackson ImmunoResearch Cat #109-035-098; 1 hour, room temperature) and washing with PBS containing Tween-20 0.05%, anti-goat IgG-biotin was added (Jackson ImmunoResearch Cat #705-065-147; 1 hour, room temperature). Second, after washing, streptavidin-HRP was added (Jackson ImmunoResearch Cat #016-030-084; 1 hour, room temperature). After the final washes, the reaction was developed with ABTS substrate (Life Technologies).

[0322] Competition ELISA. Z004 or Z021 IgG (5 .mu.g/mL) was adsorbed overnight at 4.degree. C. in a Nunc MaxiSorp 384-well ELISA plate. The ELISA plate was blocked with 3% bovine serum albumin (BSA) in TRIS buffered saline with 0.05% Tween-20 (TBS-T), and then 5 .mu.g/mL EDIII (ZIKV EDIII or DENV1 EDIII) was added and incubated for 3 hours at room temperature. The plate was washed with TB S-T to remove excess antigen, and serial dilutions of Fab were then added and incubated for 3 hours at room temperature. Bound His-tagged Fab was detected using THE His Tag Antibody (Genscript Cat #A00186; 1 hour, room temperature), followed by goat-anti mouse IgG-HRP (Jackson ImmunoResearch Cat #115-035-003; 1 hour, room temperature), and developed with SuperSignal ELISA Femto Substrate (Thermo Fisher). Relative light units (RLU) were plotted as a function of Fab concentration for each IgG-antigen pair.

[0323] Fab ELISA. 5 .mu.g/mL EDIII antigen (WT ZIKV EDIII, E393A/K394A ZIKV EDIII, E393D ZIKV EDIII, or K394R ZIKV EDIII) was adsorbed to a Nunc MaxiSorp 384-well ELISA plate overnight at 4.degree. C. The ELISA plate was blocked with 3% BSA in TBS-T, washed with TBS-T, and then serial dilutions of Fab were added and incubated for 3 hours at room temperature. After washing the plate with TBS-T, bound Fab was detected using goat-anti-human IgG-HRP (GenScript Cat #A00166; 1 hour, room temperature) and developed with SuperSignal ELISA Femto Substrate (Thermo Fisher).

[0324] ELISA for human IgG detection in macaque plasma. Neutravidin (ThermoScientific 31000; 2 .mu.g/ml in PBS) was absorbed to high binding 96-well plates for overnight at 4.degree. C. After washing the plate using PBS with 0.05% Tween-20 (PBS-T), the biotinylated anti-human IgG capture antibody was added (ThermoScientific 7103322100; 2 .mu.g/ml in PBS-T, 1 hour at room temperature). Upon washes, the plates were blocked with 2% BSA in PBS-T (2 hours at room temperature), blotted, and then serial dilutions of the macaque plasma were added to the wells (5 steps of 1:4 dilutions in PBS-T, starting with 1:10). Each plate included two dilution series of the standard (Z004 IgG, 11 steps of 1:3 dilutions in PBS-T, starting with 10 .mu.g/ml). Plates were incubated for 1 hour at room temperature and washed prior to adding the detection reagent anti-human IgG-HRP (Jackson Immunoresearch 109-036-088; 1 hour at room temperature). After the final washes, the reaction was developed with ABTS substrate (Life Technologies).

[0325] Surface Plasmon Resonance.

[0326] Fc.gamma.R and FcRn binding affinity of the Z004 Fc domain variants was determined by surface plasmon resonance (SPR), using previously described protocols.sup.46,47. All experiments were performed on a Biacore T200 SPR system (GE Healthcare) at 25.degree. C. in EMS-EP.sup.+ buffer (GE Healthcare; pH 7.4 for Fc.gamma.Rs, pH 6.0 for FcRn). Recombinant protein G (Thermo Fisher) was immobilized to the surface of a CMS sensor chip (GE Healthcare) using amine coupling chemistry at a density of 500 resonance units (RU). Fc variants of the Z004 antibody were captured on the Protein G-coupled surface (250 nM injected for 60s at 20 .mu.l/min) and recombinant human Fc.gamma.R ectodomains (7.8125-2000 nM; Sinobiological) or FcRn/.beta.2 microglobulin (1.95-500 nM; Sinobiological) were injected through flow cells at a flow rate of 20 .mu.l/min. Association time was 60 s followed by a 600-s dissociation step. At the end of each cycle, the sensor surface was regenerated with 10 mM glycine, pH 2.0 (50 .mu.l/min; 40 s). Background binding to blank immobilized flow cells was subtracted and affinity constants were calculated using BIAcore T200 evaluation software (GE Healthcare) using the 1:1 Langmuir binding model.

[0327] Crystallization and Structure Determination.

[0328] Crystallization and structure determination. The complex for crystallization was produced by mixing Z021 Fab and DENV1 EDIII at a 1:1 molar ratio, incubating at room temperature for 1-2 hours, and concentrating to 12.25 mg/mL. Crystals of Z021 Fab-DENV1 EDIII complex (space group C2221; a=60.54 .ANG., b=91.60 .ANG., c=187.14 .ANG.; one molecule per asymmetric unit) were obtained by combining 0.2 .mu.L of crystallization sample with 0.2 .mu.L of 0.1M sodium citrate pH 4.8, 28% Jeffamine.RTM. ED-2001 pH 7.0 in sitting drops at 22.degree. C. Crystals were cryoprotected with Fomblin Y oil.

[0329] X-ray diffraction data were collected at Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12-2 using a Dectris Pilatus 6M detector. The data were integrated using Mosflm.sup.48 and scaled using CCP4.sup.49. The Z021-DENV1 DIII complex structure was solved by molecular replacement using the V.sub.HV.sub.L and C.sub.HC.sub.L domains from PDB 4YK4 and DENV1 DIII from PDB 4L5F as search models in Phenix.sup.50. The model was refined to 2.07 .ANG. resolution using an iterative approach involving refinement in Phenix and manual rebuilding into a simulated annealing composite omit map using Coot.sup.51. The final model (R.sub.work=18.8%; R.sub.free=23.0%) contains 532 protein residues and 120 water molecules. 95%, 4%, and 1% of the protein residues were in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot. Residues that were disordered and not included in the model were: HC residues 215-219 and the 6.times. His tag; LC residues 1 and 213-214.

[0330] Isolation and Quantitation of Viral RNA.

[0331] Zika virus RNA was isolated from plasma and measured by qRT-PCR according to methods described previously.sup.52 and modified to increase the initial volume of sample tested from 140 to 300 .mu.l (when available) to increase sensitivity. The limit of detection for plasma viral RNA copies was typically 1.1 log.sub.10.

[0332] Virus Sequencing

[0333] For detection of virus escape mutations in macaques, ZIKV RNA was extracted from plasma using the Qiaamp viral RNA mini kit following the manufacturer's recommendations with elution of RNA in water. Qiagen One-Step RT-PCR was performed using either of 2 primer sets targeting sequences surrounding the ZIKV EDIII region: 1618p 5'ACAAGGAGTGGTTCCATGACA (SEQ ID NO: 1052) and 2204n 5'TTTTCCGATGGTGCTGCCAC (SEQ ID NO: 1053) or 1970p 5'GTATGCAGGGACAGATGGACC (SEQ ID NO: 1054) and 2537n 5'ACCGCATCTCGTTTCCTTCTT (SEQ ID NO: 1055) with 50.degree. C. for 30 m, 95.degree. C. for 15 m. Next, 40 cycles of each of the 3 steps were performed: 94.degree. C. for 1 m, 58.degree. C. for 1 m, 72.degree. C. for 1m15.degree. s, followed by final extension of 72.degree. C. for 10 m. RT-PCR amplicons were visualized on 1% agarose gels stained with ethidium bromide and sequenced after purification using the Qiaquick PCR purification kit. Sequences were called based on clean chromatograms sequenced with the primers used for amplification. Viral sequences in mice were from blood. RNA was extracted from TRIzol-LS (Life Technologies) and reverse transcribed with Superscript III RT (Thermo Fisher Scientific) and random primers according to the company's protocol prior to PCR amplification of the ZIKV EDIII region with primers DFRp1284 5'GGATGATCGTTAATGACACAG (SEQ ID NO: 1056) and DFRp1469 5'ACCATCTTCCCAGGCTTG (SEQ ID NO: 1057) followed by PCR clean-up with Nucleospin (Macherey-Nagel) and direct sequencing with primer DFRp1283 5'GGATCCTGATTTGAAAGCTGC (SEQ ID NO: 1058). Where necessary, a second round of nested PCR was performed with primers DFRp1472 5' TTCCACGACATTCCATTACC (SEQ ID NO: 1059) and DFRp1470 5'ATCTACGGGGGGAGTCAGGATG (SEQ ID NO: 1060).

[0334] References cited for this Example. This reference listing is not an indication that any of the references are material to patentability of any invention encompassed by this disclosure [0335] 1 Miner, J. J. & Diamond, M. S. Zika Virus Pathogenesis and Tissue Tropism. Cell host & microbe 21, 134-142, doi:10.1016/j.chom.2017.01.004 (2017). [0336] 2 Harrison, S. C. Immunogenic cross-talk between dengue and Zika viruses. Nature immunology 17, 1010-1012, doi:10.1038/ni.3539 (2016). [0337] 3 Screaton, G. & Mongkolsapaya, J. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine. Cold Spring Harbor perspectives in biology, doi:10.1101/cshperspect.a029520 (2017). [0338] 4 Heinz, F. X. & Stiasny, K. The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiology and molecular biology reviews: MMBR 81, doi:10.1128/MMBR.00055-16 (2017). [0339] 5 Examples 1 and 2 of this disclosure. [0340] 6 Weaver, S. C. & Reisen, W. K. Present and future arboviral threats. Antiviral research 85, 328-345, doi:10.1016/j.antiviral.2009.10.008 (2010). [0341] 7 Munoz, L. S., Barreras, P. & Pardo, C. A. Zika Virus-Associated Neurological Disease in the Adult: Guillain-Barre Syndrome, Encephalitis, and Myelitis. Seminars in reproductive medicine 34, 273-279, doi:10.1055/s-0036-1592066 (2016). [0342] 8 Brasil, P. et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. The New England journal of medicine 375, 2321-2334, doi:10.1056/NEJMoa1602412 (2016). [0343] 9 Del Campo, M. et al. The phenotypic spectrum of congenital Zika syndrome. American journal of medical genetics. Part A 173, 841-857, doi:10.1002/ajmg.a.38170 (2017). [0344] 10 George, J. et al. Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques. Scientfic reports 7, 10498, doi:10.1038/s41598-017-10901-1 (2017). [0345] 11 Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929-932, doi:10.1 126/science.aan6836 (2017). [0346] 12 Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823-826, doi:10.1 126/science.aaf8505 (2016). [0347] 13 Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443-447, doi:10.1038/nature20564 (2016). [0348] 14 Fernandez, E. et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nature immunology, doi:10.1038/ni.3849 (2017). [0349] 15 Swanstrom, J. A. et al. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. mBio 7, doi:10.1128/mBio.01123-16 (2016). [0350] 16 Yu, L. et al. Delineating antibody recognition against Zika virus during natural infection. JCI insight 2, doi:10.1172/jci.insight.93042 (2017). [0351] 17 Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell host & microbe 8, 271-283, doi:10.1016/j.chom.2010.08.007 (2010). [0352] 18 Magnani, D. M. et al. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. Science translational medicine 9, doi:10.1126/scitranslmed.aan8184 (2017). [0353] 19 Coffey, L. L. et al. Zika Virus Tissue and Blood Compartmentalization in Acute Infection of Rhesus Macaques. PloS one 12, e0171148, doi:10.1371/journal.pone.0171148 (2017). [0354] 20 Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474-478, doi:10.1038/nature18952 (2016). [0355] 21 Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237-240, doi:10.1126/science.aai9137 (2016). [0356] 22 Whitehead, S. S. & Subbarao, K. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination. Cold Spring Harbor perspectives in biology, doi:10.1101/cshperspect.a028811 (2017). [0357] 23 Halstead, S. B. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner. Cold Spring Harbor perspectives in biology, doi:10.1101/cshperspect.a030700 (2017). [0358] 24 de Silva, A. M. & Harris, E. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harbor perspectives in biology, doi:10.1101/cshperspect.a029371 (2017). [0359] 25 Horton, H. M. et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer research 68, 8049-8057, doi:10.1 158/0008-5472.CAN-08-2268 (2008). [0360] 26 Lu, C. L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001-1004, doi:10.1 126/science.aafl279 (2016). [0361] 27 Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nature biotechnology 28, 157-159, doi:10.1038/nbt.1601 (2010). [0362] 28 Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642-645, doi:10.1038/nature13612 (2014). [0363] 29 Elena, S. F., Miralles, R., Cuevas, J. M., Turner, P. E. & Moya, A. The two faces of mutation: extinction and adaptation in RNA viruses. IUBMB life 49, 5-9, doi:10.1080/713803585 (2000). [0364] 30 Drake, J. W., Charlesworth, B., Charlesworth, D. & Crow, J. F. Rates of spontaneous mutation. Genetics 148, 1667-1686 (1998). [0365] 31 Diamond, M. S. Evasion of innate and adaptive immunity by flaviviruses. Immunology and cell biology 81, 196-206, doi:10.1046/j.1440-1711.2003.01157.x (2003). [0366] 32 Lin, B., Parrish, C. R., Murray, J. M. & Wright, P. J. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202, 885-890, doi:10.1006/viro.1994.1410 (1994). [0367] 33 Lok, S. M., Ng, M. L. & Aaskov, J. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. Journal of medical virology 65, 315-323 (2001). [0368] 34 Zou, G. et al. Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1. Antiviral research 95, 216-223, doi:10.1016/j.antiviral.2012.06.010 (2012). [0369] 35 Beasley, D. W. & Barrett, A. D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. Journal of virology 76, 13097-13100 (2002). [0370] 36 Chambers, T. J., Halevy, M., Nestorowicz, A., Rice, C. M. & Lustig, S. West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. The Journal of general virology 79 (Pt 10), 2375-2380, doi:10.1099/0022-1317-79-10-2375 (1998). [0371] 37 Daffis, S. et al. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology 337, 262-272, doi:10.1016/j.virol.2005.04.031 (2005). [0372] 38 Shimoda, H. et al. Production and characterization of monoclonal antibodies to Japanese encephalitis virus. The Journal of veterinary medical science 75, 1077-1080 (2013). [0373] 39 Holzmann, H., Mandl, C. W., Guirakhoo, F., Heinz, F. X. & Kunz, C. Characterization of antigenic variants of tick-borne encephalitis virus selected with neutralizing monoclonal antibodies. The Journal of general virology 70 (Pt 1), 219-222, doi:10.1099/0022-1317-70-1-219 (1989). [0374] 40 Wang, J. et al. A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. Cell 171, 229-241 e215, doi:10.1016/j.cell.2017.09.002 (2017). [0375] 41 Sapkal, G. N. et al. Neutralization escape variant of West Nile virus associated with altered peripheral pathogenicity and differential cytokine profile. Virus research 158, 130-139, doi:10.1016/j.virusres.2011.03.023 (2011). [0376] 42 Lai, C. J. et al. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. Journal of virology 81, 12766-12774, doi:10.1 128/JVI.01420-07 (2007). [0377] 43 Magnani, D. M. et al. Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys. Molecular therapy: the journal of the American Society of Gene Therapy 25, 2323-2331, doi:10.1016/j.ymthe.2017.06.020 (2017). [0378] 44 Lanciotti, R. S., Lambert, A. J., Holodniy, M., Saavedra, S. & Signor Ldel, C. Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerging infectious diseases 22, 933-935, doi:10.3201/eid2205.160065 (2016). [0379] 45 Pierson, T. C. et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346, 53-65, doi:10.1016/j.virol.2005.10.030 (2006). [0380] 46 Li, T. et al. Modulating IgG effector function by Fc glycan engineering. Proceedings of the National Academy of Sciences of the United States of America 114, 3485-3490, doi:10.1073/pnas.1702173114 (2017). [0381] 47 Wang, T. T. et al. IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science 355, 395-398, doi:10.1126/science.aai8128 (2017). [0382] 48 Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta crystallographica. Section D, Biological crystallography 67, 271-281, doi:10.1107/S0907444910048675 (2011). [0383] 49 Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta crystallographica. Section D, Biological crystallography 67, 235-242, doi:10.1107/S0907444910045749 (2011). [0384] 50 Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica. Section D, Biological crystallography 66, 213-221, doi:10.1107/S0907444909052925 (2010). [0385] 51 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta crystallographica. Section D, Biological crystallography 60, 2126-2132, doi:10.1107/S0907444904019158 (2004). [0386] 52 Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerging infectious diseases 14, 1232-1239, doi:10.3201/eid1408.080287 (2008).

[0387] While the invention has been described through specific embodiments, routine modifications will be apparent to those skilled in the art and such modifications are intended to be within the scope of the present invention.

Sequence CWU 1

1

107018PRTHomo sapiens 1Gly Phe Thr Phe Arg Asp Tyr Ala1 528PRTHomo sapiens 2Tyr Ser Gly Ile Asp Asp Ser Thr1 5315PRTHomo sapiens 3Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1546PRTHomo sapiens 4Gln Ser Ile Ser Lys Trp1 559PRTHomo sapiens 5Gln His Phe Tyr Ser Val Pro Trp Thr1 568PRTHomo sapiens 6Gly Gly Ser Ile Asp Thr Tyr Tyr1 577PRTHomo sapiens 7Phe Tyr Tyr Ser Val Asp Asn1 5812PRTHomo sapiens 8Ala Arg Asn Gln Pro Gly Gly Arg Ala Phe Asp Tyr1 5 1096PRTHomo sapiens 9Gln Ser Val Ser Asn Tyr1 51011PRTHomo sapiens 10Gln Glu Arg Asn Asn Trp Pro Leu Thr Trp Thr1 5 1011122PRTHomo sapiens 11Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Arg Asp Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Tyr Ser Gly Ile Asp Asp Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Ser65 70 75 80Leu His Met Asn Ser Leu Arg Ala Glu Asp Ser Ala Leu Tyr Phe Cys 85 90 95Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12012107PRTHomo sapiens 12Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Lys Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Tyr Ser Val Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10513118PRTHomo sapiens 13Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asp Thr Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Cys Phe Tyr Tyr Ser Val Asp Asn His Phe Asn Pro Ser Leu Glu 50 55 60Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Met Thr Ser Met Thr Ala Ser Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Asn Gln Pro Gly Gly Arg Ala Phe Asp Tyr Trp Gly Pro Gly Thr 100 105 110Leu Val Thr Val Ser Ser 11514109PRTHomo sapiens 14Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Gln Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Thr Ser Lys Arg Ala Thr Gly Thr Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Arg Asn Asn Trp Pro Leu 85 90 95Thr Trp Thr Phe Gly Leu Gly Thr Lys Val Glu Ile Lys 100 10515451PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 15Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Arg Asp Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Tyr Ser Gly Ile Asp Asp Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Ser65 70 75 80Leu His Met Asn Ser Leu Arg Ala Glu Asp Ser Ala Leu Tyr Phe Cys 85 90 95Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr145 150 155 160Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 210 215 220Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu225 230 235 240Arg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn305 310 315 320Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Arg Pro Ala Pro 325 330 335Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro385 390 395 400Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445Ser Pro Gly 45016214PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 16Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Lys Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Tyr Ser Val Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys 21017447PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 17Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asp Thr Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Cys Phe Tyr Tyr Ser Val Asp Asn His Phe Asn Pro Ser Leu Glu 50 55 60Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Met Thr Ser Met Thr Ala Ser Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Asn Gln Pro Gly Gly Arg Ala Phe Asp Tyr Trp Gly Pro Gly Thr 100 105 110Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn145 150 155 160Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Arg Gly Pro Ser225 230 235 240Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr305 310 315 320Lys Cys Lys Val Ser Asn Lys Ala Arg Pro Ala Pro Ile Glu Lys Thr 325 330 335Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp385 390 395 400Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala 420 425 430Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 44518216PRTHomo sapiens 18Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Gln Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Thr Ser Lys Arg Ala Thr Gly Thr Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Arg Asn Asn Trp Pro Leu 85 90 95Thr Trp Thr Phe Gly Leu Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn145 150 155 160Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205Lys Ser Phe Asn Arg Gly Glu Cys 210 21519122PRTHomo sapiens 19Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Arg Arg Leu Ser Cys Ala Thr Ser Gly Phe Ser Phe Asp Thr Tyr 20 25 30Ala Met Ser Trp Leu Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Phe Ser Gly Leu Asp Asp Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Gly Pro Arg Gly Ile Gly Glu Leu Phe Asp Phe Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12020107PRTHomo sapiens 20Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Lys Thr Ser Thr Leu Lys Ser Glu Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe His Ser Val Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10521120PRTHomo sapiens 21Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Tyr 20 25 30Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Leu Leu Tyr Asn Ser Glu Glu Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe65 70 75 80Leu Gln Met Asn Arg Leu Arg Val Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95Val Arg Asp Arg Ser Asn Gly Trp Ser Ser Ile Asn Leu Trp Gly Arg 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 12022106PRTHomo sapiens 22Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln Thr Ile Ser Gly Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gln Ala Ser Arg Leu Glu Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Phe Trp Thr 85 90 95Phe Gly Leu Gly Thr Lys Val Glu Ile Lys 100 10523120PRTHomo sapiens 23Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Leu Ile Tyr Ser Gly Asp Asp Ser Thr Tyr Tyr Ala Asp Phe Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Ser65

70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Val Lys Asp Arg Gly Thr Gly Trp Ser Ser Ile Val His Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 12024106PRTHomo sapiens 24Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Asn Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gln Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Tyr Trp Thr 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10525128PRTHomo sapiens 25Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Ser Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Thr Asn 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met 35 40 45Gly Ile Ile Asn Pro Arg Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Leu Met Thr Ser Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Arg Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Lys Asn His Gln Thr Thr Val Ala Val Leu Ser Trp Tyr 100 105 110Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 12526107PRTHomo sapiens 26Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ala Asn Ser Phe Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 10527122PRTHomo sapiens 27Glu Val Gln Leu Leu Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Phe Asp Pro Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Arg Gly Arg Phe Thr Ile Ala Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Lys Ser Leu Arg Val Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Leu Val Arg Gly Phe Gly Glu Val Leu Asp Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12028107PRTHomo sapiens 28Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Arg Glu Val Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Gln Pro65 70 75 80Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Val Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10529124PRTHomo sapiens 29Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Leu Ser Cys Lys Ser Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Asn Pro Ser Gly Val Phe Thr Ser Tyr Ala Gln Arg Phe 50 55 60Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ala Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Gly Asp Thr Ala Val Tyr Tyr Cys 85 90 95Thr Arg Ser Leu Val Thr Pro Ala Ala Gln Ser Val Gln Tyr Phe Asp 100 105 110Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12030108PRTHomo sapiens 30Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu Ser 20 25 30Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Gly Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95Leu Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 10531121PRTHomo sapiens 31Gln Val Gln Leu Val Gln Ser Gly Pro Gly Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ser Asp Tyr 20 25 30Tyr Ile Leu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Tyr Met 35 40 45Gly Trp Met Asn Pro Ile Ser Gly Phe Thr His Tyr Ala Gln Asn Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr65 70 75 80Met Glu Leu Thr Arg Leu Ala Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Arg Ile Asn Ser Pro Leu Gly Phe Asp Pro Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115 12032108PRTHomo sapiens 32Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Thr Phe 20 25 30Ser Leu Ala Trp Tyr Gln Gln Lys Phe Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Ser Ser Pro 85 90 95Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10533128PRTHomo sapiens 33Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Arg Lys Pro Gly Glu1 5 10 15Ser Leu Arg Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser His 20 25 30Trp Val Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln Gly Gln Ile Ser Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Gly Ile Tyr Tyr Cys 85 90 95Ala Arg His Asp Gly Arg Gly Tyr Cys Ser Pro Thr Arg Cys Phe Phe 100 105 110Ser Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 12534107PRTHomo sapiens 34Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Tyr Ala Ile Tyr Tyr Cys Gln Gln Thr Asp Arg Thr Pro Leu 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10535122PRTHomo sapiens 35Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Asn Gly His Ser Asp Ser Thr Tyr Phe Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Leu Arg Glu Gly Ile Gly Glu Leu Phe His Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12036107PRTHomo sapiens 36Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Ile Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Thr Pro Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45Tyr Gln Thr Ser Ile Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr His Ser Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10537122PRTHomo sapiens 37Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Gly Ser Tyr 20 25 30Gly Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Ser Ser Ile Ser Ser Ile Asp Pro Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr65 70 75 80Leu His Met Ser Ser Leu Lys Val Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95Ala Lys Asp Arg Leu Asn Gly Gly Phe Gly Glu Leu Phe Ala Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12038107PRTHomo sapiens 38Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45His Lys Ala Ser Ser Leu Glu Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Asn Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr His Ser Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10539128PRTHomo sapiens 39Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile Ser Gly Ser Gly Gly Ala Ser Asp Asn Gly Ala Ser Arg 50 55 60Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn65 70 75 80Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 85 90 95Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Leu Ser Gly Gly Phe Gly 100 105 110Glu Leu Phe Gln Lys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12540107PRTHomo sapiens 40Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ala Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Asn Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45Tyr Lys Ala Ser Thr Leu Glu Ser Gly Ala Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr Tyr Ser Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10541130PRTHomo sapiens 41Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Tyr Phe Ile Ser Ser Gly 20 25 30His Tyr Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp 35 40 45Ile Ala Ser Ile Tyr Gln Ser Gly Ser Lys Phe Gln Thr Gly Asn Thr 50 55 60Tyr Tyr Asn Pro Ser Leu Glu Ser Arg Val Thr Ile Ser Met Asp Thr65 70 75 80Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp 85 90 95Thr Ala Val Tyr Phe Cys Ala Arg Asp Ala Arg Ser Arg Ser Trp Asp 100 105 110Arg Thr Gly Phe Phe Gly Pro Trp Gly Gln Gly Ile Leu Val Thr Val 115 120 125Ser Ser 13042108PRTHomo sapiens 42Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Ser Ser Ser 20 25 30Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45Ile Tyr Gly Thr Ser Ser Arg Asp Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Trp 85 90 95Gly Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 10543127PRTHomo sapiens 43Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Thr Leu Gly Ala Thr Asp Asn Ser Gly Asp Ser Thr Tyr Tyr Val 50 55 60Glu Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn65 70 75 80Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val 85 90 95Tyr Phe Cys Ala Lys Asp Arg Thr Gly Asn Ile Gly Ala Gly Thr Gly 100 105 110Tyr Phe Asp Lys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12544107PRTHomo sapiens 44Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser His Arg Ile Ser Gly Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gln Ala Ser Gly Leu Glu Ser Gly Val Pro

Ser Arg Phe Ser Gly 50 55 60Ser Gly Tyr Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Asn Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10545122PRTHomo sapiens 45Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ile Phe Asp Asn Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Tyr Ile Asn Gly Gly Gly Tyr Gly Thr Asp Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Arg Ile Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Ser Pro Tyr Val Gly Gly Tyr Gly Leu Pro Gly Asp Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12046108PRTHomo sapiens 46Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Ile Phe Phe Asn 20 25 30Tyr Leu Ala Trp Tyr Gln Lys Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Val His Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Asp65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Asp Ser Pro 85 90 95Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10547122PRTHomo sapiens 47Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Ser Tyr Ser Thr Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Arg Ile Ile Pro Ser Leu Gly Lys Thr His Leu Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Phe Thr Ala Asp Glu Ser Thr Thr Thr Val Tyr65 70 75 80Met Ile Leu Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Thr Pro Asp Trp Gln Tyr Ser Ser Ala Tyr Ser Leu Asp His Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12048112PRTHomo sapiens 48Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly1 5 10 15Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30Thr Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 11049114PRTHomo sapiens 49Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Ser Cys Thr Val Ser Ser Gly Ser Ile Ser Asn Tyr 20 25 30Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Tyr Ile Tyr Tyr Ser Gly Ser Ile Ser Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu65 70 75 80Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Gly Pro Asp Asn Arg Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser50109PRTHomo sapiens 50Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Tyr Asn 20 25 30Leu Ala Trp His Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asn Met Gln Ser65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 85 90 95Val Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 10551123PRTHomo sapiens 51Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Lys Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Gly Arg Asp Ser Lys Gly Trp Leu Gln Leu Arg Gly Asp Ile Asp Tyr 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12052110PRTHomo sapiens 52Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1 5 10 15Ser Ile Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Asn Tyr 20 25 30Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45Leu Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu65 70 75 80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser 85 90 95Ser Thr Tyr Val Phe Gly Thr Gly Thr Glu Val Thr Val Leu 100 105 11053122PRTHomo sapiens 53Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Phe Ser Gly Val Asp Asp Ser Thr Tyr Tyr Ala Glu Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Thr Arg Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12054107PRTHomo sapiens 54Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln Ser Ile Asn Arg Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe His Ser Val Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10555122PRTHomo sapiens 55Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Thr Thr Phe 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ala Asp Asp Ser Thr Tyr Tyr Ala Ala Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Ser Thr Leu Phe65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12056107PRTHomo sapiens 56Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Lys Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 35 40 45Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Phe Ser Val Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10557122PRTHomo sapiens 57Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Phe Ser Gly Ile Asp Asp Ser Thr Trp Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Leu Val Arg Gly Phe Ala Glu Val Leu Asp Tyr Trp 100 105 110Gly Arg Gly Thr Leu Val Thr Val Ser Ser 115 12058107PRTHomo sapiens 58Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Val Pro Asn Leu Leu Ile 35 40 45Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr His Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Val Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10559120PRTHomo sapiens 59Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Arg Arg Tyr 20 25 30Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Leu Ile Tyr Asp Gly Asp Asp Ser Thr Tyr Tyr Ala Lys Ser Val 50 55 60Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Ser65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 12060106PRTHomo sapiens 60Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser His Ser Ile Ser Gly Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Gly Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Ser Thr Phe Trp Thr 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10561120PRTHomo sapiens 61Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Arg Arg Phe 20 25 30Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Leu Ile Trp Asn Gly Asp Asp Ser Thr Tyr Tyr Ala Glu Ser Val 50 55 60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser His Asn Thr Leu Ser65 70 75 80Leu Gln Met Arg Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 12062106PRTHomo sapiens 62Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Gly Asn Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gln Ala Ser Val Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Ser Thr Phe Trp Thr 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10563120PRTHomo sapiens 63Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Arg Arg Tyr 20 25 30Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Leu Ile Tyr Asn Gly Asp Asp Ser Thr Tyr Tyr Ala Glu Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Gln Asn Thr Leu Ser65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Val Arg Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 12064106PRTHomo sapiens 64Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Thr Ile Gly Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gln Ala Ser Ile Leu Glu Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Val Ser Gly Thr Glu Phe Thr Leu Thr Ile Arg Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Ser Thr Phe Trp Thr 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10565122PRTHomo sapiens 65Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Thr Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Ala Arg Glu Asp Ser Thr Tyr Phe Ala Ala Ser Val 50 55 60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr

Ala Leu Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Leu Gln Leu Gly Val Gly Glu Leu Tyr Glu Ser Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12066107PRTHomo sapiens 66Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Asn Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Met Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Val Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr His Ser Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10567124PRTHomo sapiens 67Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Ser Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile Gly Gly Arg Gly Ala Ile Ala Gly Asp Gly Ser Ile Tyr 50 55 60Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser65 70 75 80Lys Asn Ile Val Tyr Leu Gln Met Asn Gly Leu Arg Val Glu Asp Thr 85 90 95Ala Val Tyr Tyr Cys Ala Lys Asp Arg Val Ala Phe Asp Gly Phe His 100 105 110Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12068107PRTHomo sapiens 68Asp Ile Gln Met Thr Gln Ser Pro Pro Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10569124PRTHomo sapiens 69Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Tyr Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Asn Pro Gly Asn Asn Phe Val Ser Phe Ala Gln Asn Phe 50 55 60Tyr Asp Arg Ala Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr65 70 75 80Met Glu Leu Thr Asn Leu Gln Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Thr Leu Val Ala Pro Ser Ala Gln Ser Met Tyr Tyr Phe Asp 100 105 110Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12070108PRTHomo sapiens 70Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Gly Thr Leu Ser Cys Arg Ala Ser Gln Tyr Ile Thr Thr Gly 20 25 30His Phe Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Val Arg Ala Thr Gly Val Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ala Glu Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Asp65 70 75 80Pro Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 10571121PRTHomo sapiens 71Gln Val Gln Leu Val Gln Ser Gly Ala Gly Met Arg Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Asn Asp Tyr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Asn Pro Lys Ser Gly Phe Thr Asn Tyr Ala Gln Arg Phe 50 55 60Gln Gly Arg Val Thr Met Thr Gly Asp Thr Ser Asn Ser Val Ala Tyr65 70 75 80Met Glu Leu Thr Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Arg Ile Asn Ala Pro Leu Gly Phe Asp Pro Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115 12072108PRTHomo sapiens 72Glu Ile Val Leu Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Thr Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Ser Ile 20 25 30Ser Leu Gly Trp Tyr Gln Gln Lys Phe Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Thr Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Val Ser Ser Pro 85 90 95Leu Arg Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10573124PRTHomo sapiens 73Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30Phe Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Asn Pro Asn Ser Gly Ser Thr Asn Tyr Ala Gln Lys Ile 50 55 60Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Ala Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Gly Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Ser Tyr Pro Val Ala Ile Arg Gly Val Thr Phe Gly 100 105 110Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 12074107PRTHomo sapiens 74Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45Phe Ala Thr Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Phe Ser Thr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10575130PRTHomo sapiens 75Gln Val Gln Leu Gln Gln Trp Gly Ala Arg Pro Leu Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Gly Val Asn Gly Gly Ser Phe Ser Gly Tyr 20 25 30His Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Glu Ile Asp His Asn Gly Arg Ile Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Ile Ser Ile Asp Thr Phe Lys Ser Gln Phe Ser Leu65 70 75 80Arg Leu Thr Ser Ile Ile Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Asp Val Val Thr Met Val Glu Gly Leu Arg Phe His Tyr Tyr Tyr 100 105 110Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val 115 120 125Ser Ser 13076108PRTHomo sapiens 76Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Asp Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Asn 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Leu Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Ala Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Lys Leu Glu65 70 75 80Ala Glu Asp Phe Ala Met Tyr Tyr Cys Gln Ile Tyr Asp Ser Ser Val 85 90 95Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10577122PRTHomo sapiens 77Glu Val Gln Leu Leu Glu Ser Gly Gly Arg Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Thr Tyr 20 25 30Ala Met Ser Trp Leu Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile Thr Gly Asp Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Thr Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Leu His Ser Gly Leu Gly Glu Leu Phe Ser Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12078107PRTHomo sapiens 78Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Asn Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Gln Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Met 35 40 45Tyr Lys Ala Ser Thr Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr Phe Ser Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10579122PRTHomo sapiens 79Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Ala Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Thr Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Tyr Ile Ser Gly Asp Ser Thr Tyr Tyr Ala Ala Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr65 70 75 80Leu Gln Met Asp Arg Leu Thr Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Val Arg Asp Arg Ile Gln Gly Gly Phe Gly Glu Leu Tyr Arg Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12080107PRTHomo sapiens 80Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln Ser Val Asn Lys Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Glu Thr Ser Ile Leu Glu Ser Gly Val Ser Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr His Gly Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10581122PRTHomo sapiens 81Glu Val Gln Leu Leu Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30Gly Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45Ser Ser Ile Ser Ser Val Asp Asp Ser Lys Tyr Tyr Ala Ala Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr65 70 75 80Leu His Met Asn Ser Leu Arg Val Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Ile Pro His Gly Leu Gly Glu Leu Tyr Ala Asn Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12082107PRTHomo sapiens 82Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Gly Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Met 35 40 45His Lys Ala Ser Asn Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr His Ser Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10583127PRTHomo sapiens 83Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Ser Gly Ser Gly Arg Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Ser Ser Gly Gly His Asn Trp Asn Tyr Val Asp Tyr Tyr Tyr 100 105 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 12584107PRTHomo sapiens 84Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Val 85 90 95Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 10585125PRTHomo sapiens 85Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Asn Pro Ser Ser Ser Asn Thr Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Phe Gly Gly Tyr Ser Ser Ser Ser Val Ser Asp Ala Phe 100 105 110Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 12586110PRTHomo sapiens 86Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1 5 10 15Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Phe 20 25 30Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45Ile Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu65 70 75 80Gln Ala Glu Asp Glu

Val His Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser 85 90 95Ser Arg Phe Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 11087119PRTHomo sapiens 87Glu Val Gln Leu Leu Glu Ser Gly Gly Ala Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Tyr Tyr 20 25 30Ala Met Thr Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val 35 40 45Ser Thr Ile Thr Asp Asn Gly Gly Thr Thr Tyr Leu Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Asn Thr Gln Ser65 70 75 80Leu Gln Met Asn Asn Leu Arg Ala Asp Asp Thr Ala Val Tyr Phe Cys 85 90 95Val Lys His Leu Arg Gly Trp Tyr Thr Phe Glu Ile Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser 11588109PRTHomo sapiens 88Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Gly Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Ser Ser Pro 85 90 95Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 10589120PRTHomo sapiens 89Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Thr Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Ser Pro Gly Ser Gly Asp Asn Ile Tyr Tyr Gly Asp Ser 50 55 60Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu65 70 75 80Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys Val Asn Gly Gly Phe Ser Gly Tyr Tyr Ser Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 12090106PRTHomo sapiens 90Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Met Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Leu Thr 85 90 95Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 10591129PRTHomo sapiens 91Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Pro Gly Gly Thr Phe Ser Arg Tyr 20 25 30Ser Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Asn Pro Thr Phe Thr Thr Pro Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr65 70 75 80Leu Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Phe Arg Tyr Tyr Tyr Glu Ser Gly Gly Tyr Ser Asp Ala Ser 100 105 110Pro Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser92107PRTHomo sapiens 92Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Thr Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10593123PRTHomo sapiens 93Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Ser Ser Gly 20 25 30Gly Tyr Tyr Tyr Ser Trp Phe Arg Gln Leu Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly His Ile Tyr Tyr Thr Gly Asn Thr His Tyr Asn Pro Ser 50 55 60Leu Arg Ser Arg Leu Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Arg Tyr Tyr 85 90 95Cys Ala Arg Ala Trp Cys Glu Tyr Ala Ala Tyr Cys Trp Phe Asp Pro 100 105 110Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser 115 12094108PRTHomo sapiens 94Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala Pro Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Trp Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 10595124PRTHomo sapiens 95Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Gly Gly 20 25 30Val Tyr Tyr Trp Asn Trp Ile Arg His His Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly Tyr Met Phe Tyr Ser Gly Asp Thr Asp Tyr Asn Pro Ser 50 55 60Leu Arg Ser Arg Val Thr Ile Ser Gly Asp Thr Ser Lys Asn Lys Phe65 70 75 80Ser Leu Asn Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg Ala Gly Phe Asp Tyr Gly Ser Pro Val Ser Ala Phe Asp 100 105 110Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12096110PRTHomo sapiens 96Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Thr 20 25 30Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Ala His Ser Pro 85 90 95Arg Gly Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 11097123PRTHomo sapiens 97Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45Phe Ile Gly Ser Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg His Gly Pro Gly Met Gly His Asn Trp Tyr Phe Asp Leu 100 105 110Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser 115 12098106PRTHomo sapiens 98Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Thr Trp Leu Thr 85 90 95Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10599125PRTHomo sapiens 99Gln Leu Gln Leu Gln Glu Ser Gly Pro Arg Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Phe Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30Ser Tyr Phe Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Val Val Tyr Tyr 85 90 95Cys Ala Lys His Leu Tyr Ser Ser Ser Trp Asn Ile Gly Ser Ser Phe 100 105 110Asp Ser Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser 115 120 125100108PRTHomo sapiens 100Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Val 85 90 95Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105101124PRTHomo sapiens 101Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Gly Tyr 20 25 30Tyr Ile His Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Asn Ser Asn Ser Gly Gly Ala Asp Ser Gly Pro Arg Phe 50 55 60His Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr65 70 75 80Leu Glu Leu Thr Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg Thr Tyr Tyr Asp Thr Arg Phe Pro Tyr Trp Tyr Phe Asp 100 105 110Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser 115 120102107PRTHomo sapiens 102Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Gly Ser Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Val Leu Ile 35 40 45Ser Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Ile Ser Gly 50 55 60Ile Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Leu Ser Ala Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105103121PRTHomo sapiens 103Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Met Gly Tyr 20 25 30Tyr Phe His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Asn Pro Asn Ser Gly His Ala Asn Ile Ala Gln Thr Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Pro Ser Ile Thr Thr Ala Tyr65 70 75 80Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Phe Tyr Cys 85 90 95Ala Arg Gly Gly Met Leu Gly Gln Leu Trp Ala Leu Asp Asn Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115 120104107PRTHomo sapiens 104Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser His Trp 20 25 30Leu Ala Trp Tyr Gln Gln Arg Pro Gly Glu Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gln Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Ser Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Ser Ser Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105105121PRTHomo sapiens 105Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Asp Tyr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Asn Pro Lys Thr Gly Phe Ser His Tyr Glu Gln Thr Phe 50 55 60Gln Gly Arg Val Thr Met Ala Arg Asp Thr Ser Ile Pro Ala Ala Tyr65 70 75 80Met Glu Leu Ser Ser Leu Lys Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Arg Ile Asn Val Ala Glu Ala Leu Arg Tyr Trp Gly 100 105 110Gln Gly Ser Leu Val Thr Val Ser Ser 115 120106107PRTHomo sapiens 106Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Thr Phe Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Gly Asp Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Ser Lys Ala Thr Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Glu Thr Glu Phe Ser Leu Thr Ile Asn Ser Leu Gln Pro65 70 75 80Asp Asp Val Ala Ala Tyr Tyr Cys Gln Gln Tyr Met Ser Tyr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105107122PRTHomo sapiens 107Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe 50 55 60Arg Gly Arg Val Thr Ile Ala Thr Asp Ala Ser Lys Ser Ala Ala Tyr65 70 75 80Met Asp Leu Ser Ser Leu Lys Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85

90 95Ala Arg Ser Trp Gly Thr Ala Ala Thr Gly Gly Ser Phe Val Gln Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120108109PRTHomo sapiens 108Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser His Ser Val Thr Ser Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asp Ser Ala Val Tyr Tyr Cys Gln Tyr Tyr Thr Asn Trp Pro Pro 85 90 95His Val Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105109120PRTHomo sapiens 109Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Thr Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Asn Phe 20 25 30Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Leu Phe Gly Ile Thr Asn Tyr Thr Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr Thr Asp Glu Ser Lys Thr Thr Ala Tyr65 70 75 80Met Asp Leu Ser Gly Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95Ala Arg Gly Arg Asp Ser Ser Gly Arg Leu Leu Asp His Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 120110108PRTHomo sapiens 110Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Asn Arg Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Ala Ala Ser Ala Arg Ala Thr Gly Val Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asp Phe Val Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 85 90 95Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105111124PRTHomo sapiens 111Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Phe Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Gly Asp Tyr Tyr Tyr Asp Ser Ser Gly Tyr Leu Tyr Tyr Phe Asp 100 105 110Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120112107PRTHomo sapiens 112Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Val 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105113117PRTHomo sapiens 113Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Ser 20 25 30Thr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45Val Val Ile Ser His Asp Gly Asn Thr Lys Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Val Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Glu Val Gly Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115114108PRTHomo sapiens 114Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 85 90 95Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105115120PRTHomo sapiens 115Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser His 20 25 30Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Ile Val Ser Tyr Asp Gly Ser Thr Lys Asn Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Ile Tyr65 70 75 80Leu His Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95Ala Arg Glu Val Asp Gly Ile Tyr Gly Tyr Leu His Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 120116106PRTHomo sapiens 116Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Arg Gln Asn Val Arg Asn Phe 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Arg Ala Thr Asp Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Tyr Ser Ile Thr 85 90 95Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105117101PRTZika virus 117Val Ser Tyr Ser Leu Cys Thr Ala Ala Phe Thr Phe Thr Lys Ile Pro1 5 10 15Ala Glu Thr Leu His Gly Thr Val Thr Val Glu Val Gln Tyr Ala Gly 20 25 30Thr Asp Gly Pro Cys Lys Val Pro Ala Gln Met Ala Val Asp Met Gln 35 40 45Thr Leu Thr Pro Val Gly Arg Leu Ile Thr Ala Asn Pro Val Ile Thr 50 55 60Glu Ser Thr Glu Asn Ser Lys Met Met Leu Glu Leu Asp Pro Pro Phe65 70 75 80Gly Asp Ser Tyr Ile Val Ile Gly Val Gly Glu Lys Lys Ile Thr His 85 90 95His Trp His Arg Ser 10011898PRTDengue virus 1 118Met Ser Tyr Val Met Cys Thr Gly Ser Phe Lys Leu Glu Lys Glu Val1 5 10 15Ala Glu Thr Gln His Gly Thr Val Leu Val Gln Val Lys Tyr Glu Gly 20 25 30Thr Asp Ala Pro Cys Lys Ile Pro Phe Ser Ser Gln Asp Glu Lys Gly 35 40 45Val Thr Gln Asn Gly Arg Leu Ile Thr Ala Asn Pro Ile Val Thr Asp 50 55 60Lys Glu Lys Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Glu Ser65 70 75 80Tyr Ile Val Val Gly Ala Gly Glu Lys Ala Leu Lys Leu Ser Trp Phe 85 90 95Lys Lys11924PRTHomo sapiens 119Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu Leu Gly1 5 10 15Met Leu Val Ala Ser Cys Leu Gly 2012021PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 120His His His His His His Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys1 5 10 15Ile Glu Trp His Glu 20121303DNAZika virus 121gtgtcatact ccttgtgtac cgcagcgttc acattcacca agatcccggc tgaaacactg 60cacgggacag tcacagtgga ggtacagtac gcagggacag atggaccttg caaggttcca 120gctcagatgg cggtggacat gcaaactctg accccagttg ggaggttgat aaccgctaac 180cccgtaatca ctgaaagcac tgagaactct aagatgatgc tggaacttga tccaccattt 240ggggactctt acattgtcat aggagtcggg gagaagaaga tcacccacca ctggcacagg 300agt 303122294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 122atgtcatatg tgatgtgtac ggggtccttt aaacttgaaa aggaggtggc agaaacacag 60cacggaacag tacttgtgca ggttaaatat gagggaaccg atgctccttg taaaataccg 120ttttcaagcc aggacgaaaa gggtgtaaca caaaatggtc gcctgattac agccaaccca 180atagtcactg ataaggagaa acctgtgaat atcgaggcag agccaccatt cggcgaaagt 240tatatcgtag ttggtgctgg agaaaaggcc ctgaaactct cttggtttaa gaag 294123294DNADengue virus 2 123atgtcatact ctatgtgcac aggaaagttt aaagttgtga aggaaatagc agaaacacaa 60catggaacaa tagttatcag agtgcaatat gaaggggacg gctctccatg caagatccct 120tttgagataa tggatttgga aaaaagacat gtcttaggtc gcctgattac agtcaaccca 180attgtgacag aaaaagatag cccagtcaac atagaagcag aacctccatt cggagacagc 240tacatcatca taggagtaga gccgggacaa ctgaagctca actggtttaa gaaa 294124294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 124atgtcatacg caatgtgtac gaacacattc gttcttaaaa aagaggtaag tgaaacccaa 60catggtacta tccttataaa agttgagtac aagggcgagg acgctccctg caaaataccg 120ttttccacag aggacgggca aggtaaggca cacaatggga gacttataac cgccaatcca 180gtagtgacca agaaagagga accagtcaac attgaagcgg agcccccttt cggagaatcc 240aacatagtga taggcattgg ggacaacgct ctgaagatca actggtataa gaag 294125294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 125atgtcatata caatgtgtag cggtaaattc agcattgata aagaaatggc cgagacacag 60cacggcacca ccgtggtaaa agtgaaatac gaaggagcgg gagccccgtg caaggtcccc 120atcgaaatca gggatgtaaa caaagagaag gtcgttggta gaataatttc ttctacacca 180ctggccgaga acactaattc agttacgaat atagaacttg agcccccctt tggtgacagc 240tatatagtta ttggcgtggg aaattctgca ctgactctgc attggttccg aaaa 294126294DNAYellow fever virus 126acatcctaca aaatgtgcac tgacaaaatg tcttttgtca agaacccaac tgacactggc 60catggcactg ttgtgatgca ggtgaaagtg ccaaaaggag ccccctgcaa gattccagtg 120atagtagctg atgatcttac agcggcaatc aataaaggca ttttggttac agttaacccc 180atcgcctcaa ccaatgatga tgaagtgctg attgaggtga acccaccttt tggagacagc 240tacattatcg ttgggacagg agattcacgt ctcacttacc agtggcacaa agag 294127294DNAYellow fever virus 127acatcctaca aaatatgcac tgacaaaatg ttttttgtca agaacccaac tgacactggc 60catggcactg ttgtgatgca ggtgaaagtg tcaaaaggag ccccctgcag gattccagtg 120atagtagctg atgatcttac agcggcaatc aataaaggca ttttggttac agttaacccc 180atcgcctcaa ccaatgatga tgaagtgctg attgaggtga acccaccttt tggagacagc 240tacattatcg ttgggagagg agattcacgt ctcacttacc agtggcacaa agag 294128303DNAWest Nile virus 128acaacctatg gcgtctgttc aaaggctttc aagtttcttg ggactcccgc agacacaggt 60cacggcactg tggtgttgga attgcagtac actggcacgg atggaccttg caaagttcct 120atctcgtcag tggcttcatt gaacgaccta acgccagtgg gcagattggt cactgtcaac 180ccttttgttt cagtggccac ggccaacgct aaggtcctga ttgaattgga accacccttt 240ggagactcat acatagtggt gggcagagga gaacaacaga tcaatcacca ctggcacaag 300tct 303129367DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 129gaggtgcagc tgttggagtc tgggggaggt cttgttcagc cgggtggatc attgagactt 60tcttgtgctg caagtggatt tactttctct tcctacgcca tgtcttgggt tcgacaagct 120ccagggaaag gactcgaatg ggttagtgcg atatctgggt ctggaggatc tacttactac 180gcagattcag taaaagggcg cttcacaata tcacgcgata attccaagaa tacgctctac 240cttcagatga acagtcttcg ggcagaggac acagcggttt attattgtgc gaaagatcgc 300ggtcccagag gcgtgggcga actgttcgac tattggggac aaggcaccct ggtcaccgtc 360tcctcag 367130322DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 130gacatccaga tgacccagtc accgtctacc ttgtcagcgt cagttggtga ccgggtaacc 60attacttgcc gcgctagtca gagtatttcc tcctggctcg cctggtatca acaaaaacca 120ggtaaagccc ccaaattgct gatctataag gcaagtagct tggaatcagg agttcccagc 180cgcttctctg gctcagggtc cggtactgaa tttacattga ccatctcttc tctccagcca 240gatgacttcg ccacgtacta ttgtcaacag tataactcat atccctggac ttttggacag 300gggaccaagg tggaaatcaa ac 322131115PRTHomo sapiens 131Gly Gly Gly Leu Ile Gln Pro Gly Gly Thr Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Ser Phe Thr Asn Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Gly Asp Gly 35 40 45Glu Ser Thr Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Thr65 70 75 80Ala Asp Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Pro Arg Gln 85 90 95Gly Val Gly Glu Leu Tyr Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115132115PRTHomo sapiens 132Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ala Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Val Gln Ser 35 40 45Asp Ser Thr Tyr Phe Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Leu Glu Lys 85 90 95Gly Ile Gly Glu Leu Phe His Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115133115PRTHomo sapiens 133Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ala Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Val Gln Ser 35 40 45Asp Ser Thr Tyr Leu Ala Asp Ser Val Lys Gly Arg Phe Thr Thr Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Leu Arg Gln 85 90 95Gly Val Gly Glu Leu Phe His Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115134115PRTHomo sapiens 134Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Gly Ala Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Val His Ser 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Leu Arg Glu 85 90 95Gly Val Gly Glu Leu Tyr Gln Tyr Trp Gly His Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115135115PRTHomo sapiens 135Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ala Tyr Ala Met Ser Trp Val Arg Gln

20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asn Gly His Ser 35 40 45Asp Ser Thr Tyr Phe Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Leu Arg Glu 85 90 95Gly Ile Gly Glu Leu Phe His Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115136112PRTHomo sapiens 136Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Gly Ser Gly Phe Thr Phe Ser Ser Phe Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Thr Gly Ile Gly 35 40 45Gly Asp Thr Tyr Tyr Thr Asp Ser Val Lys Gly Arg Phe Thr Val Ser 50 55 60Arg Asp Asn Ser Lys Lys Thr Val Phe Leu His Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Asp His Phe 85 90 95Asp Gly His Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 100 105 110137114PRTHomo sapiens 137Gly Ala Gly Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Ile Phe Ser Asp Tyr Tyr Met Gln Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Gln Trp Met Gly Trp Ile Asn Pro Lys Ser 35 40 45Gly Phe Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Thr Gly Leu Thr65 70 75 80Ser Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Gly Pro Val Asn 85 90 95Ala Pro Arg Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser138114PRTHomo sapiens 138Gly Ala Gly Val Lys Ile Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Ile Phe Ser Asp Tyr Tyr Met Gln Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Lys Ser 35 40 45Gly Phe Ser Asp Tyr Ala Gln Lys Phe Gln Gly Arg Val Ser Met Thr 50 55 60Arg Asp Thr Ala Ile Ser Thr Ala Tyr Met Glu Leu Thr Arg Leu Thr65 70 75 80Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Pro Val Asn 85 90 95Ser Pro Leu Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser139114PRTHomo sapiens 139Gly Pro Gly Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Ile Phe Ser Asp Tyr Tyr Ile Leu Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Tyr Met Gly Trp Met Asn Pro Ile Ser 35 40 45Gly Phe Thr His Tyr Ala Gln Asn Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Thr Arg Leu Ala65 70 75 80Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg Ile Asn 85 90 95Ser Pro Leu Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser140114PRTHomo sapiens 140Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Val Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met Gln Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Lys Thr 35 40 45Gly His Thr Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ala Arg Leu Thr65 70 75 80Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Arg Gly Gly Gln Ile Ser 85 90 95Ala Pro His Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser141114PRTHomo sapiens 141Gly Ala Gly Met Arg Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Ser Phe Asn Asp Tyr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Lys Ser 35 40 45Gly Phe Thr Asn Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Met Thr 50 55 60Gly Asp Thr Ser Asn Ser Val Ala Tyr Met Glu Leu Thr Arg Leu Thr65 70 75 80Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg Ile Asn 85 90 95Ala Pro Leu Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser142114PRTHomo sapiens 142Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Val Ser Gly Tyr Thr Phe Ser Asp Tyr Tyr Met Gln Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Lys Thr 35 40 45Gly His Thr Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr 50 55 60Arg Asp Thr Ser Ile Thr Thr Ala Tyr Met Glu Leu Arg Thr Leu Thr65 70 75 80Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Arg Gly Gly Pro Ile Ser 85 90 95Ala Pro Leu Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser143120PRTHomo sapiens 143Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Ala Tyr Ser Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Gln Trp Met Gly Trp Ile Asn Pro Asp Ser 35 40 45Gly Glu Val Asn Tyr Val Gln Lys Phe Gln Asp Arg Val Thr Met Thr 50 55 60Arg Gly Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Arg Arg Leu Arg65 70 75 80Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ala Met Asn Arg 85 90 95Ile Ser Gly Val Val Pro Pro Gly Asp Ala Phe Asp Leu Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 120144117PRTHomo sapiens 144Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys1 5 10 15Ser Ser Gly Tyr Ser Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly 35 40 45Val Phe Thr Ser Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Met Thr 50 55 60Ser Asp Thr Ala Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Ser Gly Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ser Leu Val Thr Pro 85 90 95Ala Ala Gln Ser Val Gln Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu 100 105 110Ile Thr Val Ser Ser 115145117PRTHomo sapiens 145Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Val His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Gly Asn 35 40 45Asn Phe Val Ser Phe Ala Gln Asn Phe Tyr Asp Arg Ala Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Asn Thr Val Tyr Met Glu Leu Thr Asn Leu Gln65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Leu Val Ala Pro 85 90 95Ser Ala Gln Ser Met Tyr Tyr Phe Asp Phe Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115146117PRTHomo sapiens 146Gly Ser Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Val Ile Asn Pro Gly Asn 35 40 45Val Phe Thr Ser Tyr Ala Gln Arg Phe His Asp Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Thr Gln Val Val Pro 85 90 95Ser Ala Gln Ser Val Tyr Tyr Phe Asp Phe Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115147117PRTHomo sapiens 147Gly Ala Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Glu 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Ile Ile Asn Pro Gly Asn 35 40 45Thr Phe Thr Ser Tyr Ala Pro Arg Phe His Gly Arg Val Ser Met Thr 50 55 60Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Thr Arg Val Val Pro 85 90 95Ser Ala Gln Ser Val Tyr Tyr Phe Asp Phe Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115148117PRTHomo sapiens 148Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Thr Ser Gly Phe Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Asn Pro Thr Ser 35 40 45Gly Phe Thr Ser Tyr Thr Gln Asn Leu His Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Arg Thr Val Phe Met Glu Leu Arg Ser Leu Ala65 70 75 80Ser Gly Asp Thr Ala Val Tyr Tyr Cys Thr Arg Thr Gln Ile Ile Pro 85 90 95Ala Ala Gln Ser Val Tyr Phe Phe Asp Tyr Trp Gly Pro Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115149117PRTHomo sapiens 149Gly Ala Glu Val Ala Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Ile Ile Asn Pro Gly Gly 35 40 45Ala Phe Thr Ser Tyr Ala Gln Arg Phe His Gly Arg Val Arg Met Thr 50 55 60Arg Asp Thr Ser Ala Ser Thr Val Tyr Val Glu Leu Ser Ser Leu Arg65 70 75 80Ser Asp Asp Thr Ala Val Tyr Tyr Cys Thr Arg Thr Arg Ile Ile Ala 85 90 95Ala Ala Gln Ser Val Tyr His Tyr Asp Leu Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115150117PRTHomo sapiens 150Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Lys Pro Ser Ser 35 40 45Gly Ser Thr Asn Tyr Ala His Lys Phe Gln Asp Arg Val Thr Met Thr 50 55 60Thr Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Tyr Gln Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gln Asp Pro Ala 85 90 95Thr Ala Ile Arg Gly Leu Arg Trp Glu Tyr Trp Gly Gln Gly Ser Leu 100 105 110Val Thr Val Ser Ser 115151117PRTHomo sapiens 151Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Phe Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Asn Ser 35 40 45Gly Ser Thr Asn Tyr Ala Gln Lys Ile Gln Gly Arg Val Thr Met Thr 50 55 60Thr Asp Thr Ser Ala Ser Thr Val Tyr Met Glu Leu Ser Gly Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Pro 85 90 95Val Ala Ile Arg Gly Val Thr Phe Gly Ile Trp Gly Gln Gly Thr Met 100 105 110Val Thr Val Ser Ser 115152117PRTHomo sapiens 152Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Ser 35 40 45Gly Ser Thr Ser Tyr Ala Gln Lys Leu His Asp Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala Ala Tyr Pro 85 90 95Thr Ala Ile Arg Gly Val Ile Tyr Gly Phe Trp Gly Gln Gly Thr Met 100 105 110Val Thr Val Ser Ser 115153118PRTHomo sapiens 153Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys1 5 10 15Ala Ser Ala Asp Thr Phe Thr Lys Asn Tyr Val His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Ser 35 40 45Gly Trp Thr Ser Asn Pro Gln Lys Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Ser Asp Asp Thr Ala Leu Tyr Tyr Cys Ala Thr Ser Pro Ala Ala Ala 85 90 95Gly Ser Gly His Pro Ser Gly Trp Phe Asp Pro Trp Gly Pro Gly Thr 100 105 110Leu Val Thr Val Ser Ser 115154114PRTHomo sapiens 154Gly Ala Glu Met Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Gln1 5 10 15Ala Ser Gly Tyr Ser Phe Thr Asn His Phe Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Thr Ile Asn Pro Ser Gly 35 40 45Gly Ser Thr Thr Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Pro Gly Arg Ser 85 90 95Phe Leu Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val 100 105 110Ser Ser155115PRTHomo sapiens 155Gly Ala Gly Leu Leu Lys Thr Ser Glu Thr Leu Tyr Leu Thr Cys Thr1 5 10 15Val Tyr Gly Asp Ser Phe Asn His Tyr Tyr Trp Gly Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Glu Ile Asn His Arg Gly 35 40 45Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Leu Val 50 55 60Asp Thr Ser Gln Lys Gln Phe Ser Leu Arg Val Thr Ser Val Thr Ala65 70 75 80Ala Asp Thr Ser Val Tyr Tyr Cys Thr Arg Val Arg Trp Asp Gly Ile 85 90 95Glu Phe Thr Met Phe Phe Asp Ser Trp Gly Gln Gly Ser Leu Val Thr 100 105 110Val Ser Pro 115156115PRTHomo sapiens 156Gly Ala Gly Leu Leu Lys Thr Ser Glu Thr Leu Tyr Leu Thr Cys Thr1 5 10 15Val Tyr Gly Asp Ser Phe Asn His Tyr Tyr Trp Gly Trp Ile Arg Gln 20

25 30Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Glu Ile Asn His Arg Gly 35 40 45Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Leu Val 50 55 60Asp Thr Ser His Lys Gln Phe Ser Leu Arg Val Thr Ser Val Thr Ala65 70 75 80Ala Asp Thr Ser Val Tyr Tyr Cys Ala Arg Val Arg Trp Asp Gly Ile 85 90 95Glu Ser Thr Met Phe Phe Asp Ser Trp Gly Gln Gly Ser Leu Val Thr 100 105 110Val Ser Pro 115157115PRTHomo sapiens 157Gly Ala Gly Leu Leu Lys Thr Ser Glu Thr Leu Tyr Leu Thr Cys Thr1 5 10 15Val Tyr Gly Asp Ser Phe Asn His Tyr Tyr Trp Gly Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Glu Ile Asn His Arg Gly 35 40 45Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Leu Val 50 55 60Asp Thr Ser Gln Lys Gln Phe Ser Leu Arg Val Thr Ser Val Thr Ala65 70 75 80Ala Asp Thr Ser Val Tyr Tyr Cys Thr Arg Val Arg Trp Asp Gly Ile 85 90 95Glu Ser Thr Met Phe Phe Asp Ser Trp Gly Gln Gly Ser Leu Val Thr 100 105 110Val Ser Pro 115158123PRTHomo sapiens 158Gly Ala Arg Pro Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Gly1 5 10 15Val Asn Gly Gly Ser Phe Ser Gly Tyr His Trp Ser Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asp His Asn Gly 35 40 45Arg Ile Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile 50 55 60Asp Thr Phe Lys Ser Gln Phe Ser Leu Arg Leu Thr Ser Ile Ile Ala65 70 75 80Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Val Val Thr Met Val 85 90 95Glu Gly Leu Arg Phe His Tyr Tyr Tyr Asn Tyr Tyr Gly Met Asp Val 100 105 110Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser 115 120159123PRTHomo sapiens 159Gly Ala Arg Pro Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Gly1 5 10 15Val Asn Gly Gly Ser Phe Ser Gly Tyr His Trp Thr Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asp His Asn Gly 35 40 45Arg Ile Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile 50 55 60Asp Thr Phe Lys Ser Gln Phe Ser Leu Arg Leu Thr Ser Ile Thr Ala65 70 75 80Ala Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asp Val Val Thr Met Val 85 90 95Glu Gly Leu Arg Phe His Tyr Tyr Tyr Asn Tyr Tyr Gly Met Asp Val 100 105 110Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser 115 120160123PRTHomo sapiens 160Gly Ala Arg Pro Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Gly1 5 10 15Val Asn Gly Gly Ser Phe Ser Gly Tyr His Trp Ser Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asp His Asn Gly 35 40 45Arg Ile Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Met Ser Ile 50 55 60Asp Thr Phe Lys Ser Gln Phe Ser Leu Arg Leu Thr Ser Ile Thr Ala65 70 75 80Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Val Val Thr Met Val 85 90 95Glu Gly Leu Arg Phe His Tyr Tyr Tyr Asn Tyr Tyr Gly Met Asp Val 100 105 110Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser 115 120161111PRTHomo sapiens 161Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr1 5 10 15Val Ser Gly Gly Ser Ile Ser Thr Tyr Tyr Trp Ser Trp Ile Arg Gln 20 25 30Thr Pro Gly Lys Gly Leu Glu Trp Ile Gly Cys Ile Tyr Tyr Ser Val 35 40 45Asp Thr His Phe Asn Pro Ser Leu Glu Ser Arg Val Thr Ile Ser Val 50 55 60Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Met Thr Ser Met Thr Ala65 70 75 80Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Gln Pro Gly Gly Arg 85 90 95Ala Phe Asp Tyr Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser 100 105 110162111PRTHomo sapiens 162Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr1 5 10 15Val Ser Gly Gly Ser Ile Asp Thr Tyr Tyr Trp Ser Trp Ile Arg Gln 20 25 30Thr Pro Gly Lys Gly Leu Glu Trp Ile Gly Cys Phe Tyr Tyr Ser Val 35 40 45Asp Asn His Phe Asn Pro Ser Leu Glu Ser Arg Val Thr Ile Ser Val 50 55 60Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Met Thr Ser Met Thr Ala65 70 75 80Ser Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Gln Pro Gly Gly Arg 85 90 95Ala Phe Asp Tyr Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser 100 105 110163121PRTHomo sapiens 163Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys1 5 10 15Thr Ser Gly Tyr Thr Phe Thr Ser His Trp Leu Ala Trp Val Arg Gln 20 25 30Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp 35 40 45Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Ile Ser Ile Ser 50 55 60Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys65 70 75 80Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg His Asp Gly Arg Gly 85 90 95Tyr Cys Ser Pro Thr Arg Cys Phe Phe Ser Gly Met Asp Val Trp Gly 100 105 110Gln Gly Thr Thr Val Ile Val Ser Pro 115 120164121PRTHomo sapiens 164Gly Ala Glu Val Arg Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys1 5 10 15Thr Ser Gly Tyr Thr Phe Thr Ser His Trp Val Ala Trp Val Arg Gln 20 25 30Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp 35 40 45Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Ile Ser Ile Ser 50 55 60Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys65 70 75 80Ala Ser Asp Thr Gly Ile Tyr Tyr Cys Ala Arg His Asp Gly Arg Gly 85 90 95Tyr Cys Ser Pro Thr Arg Cys Phe Phe Ser Gly Met Asp Val Trp Gly 100 105 110Gln Gly Thr Thr Val Ile Val Ser Pro 115 120165117PRTHomo sapiens 165Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Ser Asp Tyr Tyr Val His Trp Leu Arg Gln 20 25 30Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Trp Ile Asn Ala Asn Thr 35 40 45Gly Gly Ser Asp Ser Gly Pro Lys Phe Tyr Gly Arg Val Thr Leu Thr 50 55 60Arg Asp Thr Ser Val Asn Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg65 70 75 80Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Arg Arg Thr Tyr Tyr Asp 85 90 95Asn Arg Phe Pro Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115166117PRTHomo sapiens 166Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Ser Gly Tyr Tyr Ile His Trp Leu Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Ser Asn Ser 35 40 45Gly Gly Ala Asp Ser Gly Pro Arg Phe His Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Ile Asn Thr Ala Tyr Leu Glu Leu Thr Asn Leu Arg65 70 75 80Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Thr Tyr Tyr Asp 85 90 95Thr Arg Phe Pro Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115167115PRTHomo sapiens 167Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ile Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe 35 40 45Gly Thr Thr Asn Tyr Ala Gln Lys Phe Arg Gly Arg Val Thr Ile Ala 50 55 60Thr Asp Ala Ser Lys Ser Ala Ala Tyr Met Asp Leu Ser Ser Leu Lys65 70 75 80Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ser Trp Gly Thr Ala 85 90 95Ala Thr Gly Gly Ser Phe Val Gln Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115168113PRTHomo sapiens 168Gly Ala Glu Val Lys Thr Pro Gly Ser Ser Val Lys Val Ser Cys Lys1 5 10 15Thr Ser Gly Gly Thr Phe Ser Asn Phe Ala Ile Thr Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe 35 40 45Gly Ile Thr Asn Tyr Thr Gln Lys Phe Gln Gly Arg Val Thr Ile Thr 50 55 60Thr Asp Glu Ser Lys Thr Thr Ala Tyr Met Asp Leu Ser Gly Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Gly Arg Asp Ser Ser 85 90 95Gly Arg Leu Leu Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser169114PRTHomo sapiens 169Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Asn Thr Phe Met Gly Tyr Tyr Phe His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser 35 40 45Gly His Ala Asn Ile Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Pro Ser Ile Thr Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg65 70 75 80Ser Asp Asp Thr Ala Val Phe Tyr Cys Ala Arg Gly Gly Met Leu Gly 85 90 95Gln Leu Trp Ala Leu Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ser170114PRTHomo sapiens 170Gly Ala Glu Val Lys Arg Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Ala Asp Tyr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Leu Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Lys Thr 35 40 45Gly Phe Ser His Tyr Glu Gln Thr Phe Gln Gly Arg Val Thr Met Ala 50 55 60Arg Asp Thr Ser Ile Pro Ala Ala Tyr Met Glu Leu Ser Ser Leu Lys65 70 75 80Ser Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Gly Arg Ile Asn 85 90 95Val Ala Glu Ala Leu Arg Tyr Trp Gly Gln Gly Ser Leu Val Ile Val 100 105 110Ser Ser17115PRTHomo sapiens 171Ala Lys Asp Arg Pro Arg Gln Gly Val Gly Glu Leu Tyr Asp Ser1 5 10 1517215PRTHomo sapiens 172Ala Lys Asp Arg Leu Glu Lys Gly Ile Gly Glu Leu Phe His Ser1 5 10 1517315PRTHomo sapiens 173Ala Lys Asp Arg Leu Arg Gln Gly Val Gly Glu Leu Phe His Ser1 5 10 1517415PRTHomo sapiens 174Ala Lys Asp Arg Leu Arg Glu Gly Val Gly Glu Leu Tyr Gln Tyr1 5 10 1517515PRTHomo sapiens 175Ala Lys Asp Arg Leu Arg Glu Gly Ile Gly Glu Leu Phe His Ser1 5 10 1517612PRTHomo sapiens 176Ala Lys Asp Arg Asp His Phe Asp Gly His Asp Val1 5 1017714PRTHomo sapiens 177Ala Arg Gly Gly Pro Val Asn Ala Pro Arg Gly Phe Asp Pro1 5 1017814PRTHomo sapiens 178Ala Arg Gly Gly Pro Val Asn Ser Pro Leu Gly Phe Asp Pro1 5 1017914PRTHomo sapiens 179Ala Arg Gly Gly Arg Ile Asn Ser Pro Leu Gly Phe Asp Pro1 5 1018014PRTHomo sapiens 180Ala Arg Gly Gly Gln Ile Ser Ala Pro His Gly Phe Asp Pro1 5 1018114PRTHomo sapiens 181Ala Arg Gly Gly Arg Ile Asn Ala Pro Leu Gly Phe Asp Pro1 5 1018214PRTHomo sapiens 182Ala Arg Gly Gly Pro Ile Ser Ala Pro Leu Gly Phe Asp Pro1 5 1018320PRTHomo sapiens 183Ala Arg Ala Ala Met Asn Arg Ile Ser Gly Val Val Pro Pro Gly Asp1 5 10 15Ala Phe Asp Leu 2018417PRTHomo sapiens 184Thr Arg Ser Leu Val Thr Pro Ala Ala Gln Ser Val Gln Tyr Phe Asp1 5 10 15Ser18517PRTHomo sapiens 185Ala Arg Thr Leu Val Ala Pro Ser Ala Gln Ser Met Tyr Tyr Phe Asp1 5 10 15Phe18617PRTHomo sapiens 186Thr Arg Thr Gln Val Val Pro Ser Ala Gln Ser Val Tyr Tyr Phe Asp1 5 10 15Phe18717PRTHomo sapiens 187Thr Arg Thr Arg Val Val Pro Ser Ala Gln Ser Val Tyr Tyr Phe Asp1 5 10 15Phe18817PRTHomo sapiens 188Thr Arg Thr Gln Ile Ile Pro Ala Ala Gln Ser Val Tyr Phe Phe Asp1 5 10 15Tyr18917PRTHomo sapiens 189Thr Arg Thr Arg Ile Ile Ala Ala Ala Gln Ser Val Tyr His Tyr Asp1 5 10 15Leu19017PRTHomo sapiens 190Ala Arg Ala Gln Asp Pro Ala Thr Ala Ile Arg Gly Leu Arg Trp Glu1 5 10 15Tyr19117PRTHomo sapiens 191Ala Arg Gly Gly Ser Tyr Pro Val Ala Ile Arg Gly Val Thr Phe Gly1 5 10 15Ile19217PRTHomo sapiens 192Ala Arg Gly Ala Ala Tyr Pro Thr Ala Ile Arg Gly Val Ile Tyr Gly1 5 10 15Phe19318PRTHomo sapiens 193Ala Thr Ser Pro Ala Ala Ala Gly Ser Gly His Pro Ser Gly Trp Phe1 5 10 15Asp Pro19414PRTHomo sapiens 194Ala Arg Pro Pro Gly Arg Ser Phe Leu Asp Gly Met Asp Val1 5 1019516PRTHomo sapiens 195Thr Arg Val Arg Trp Asp Gly Ile Glu Phe Thr Met Phe Phe Asp Ser1 5 10 1519616PRTHomo sapiens 196Ala Arg Val Arg Trp Asp Gly Ile Glu Ser Thr Met Phe Phe Asp Ser1 5 10 1519716PRTHomo sapiens 197Thr Arg Val Arg Trp Asp Gly Ile Glu Ser Thr Met Phe Phe Asp Ser1 5 10 1519824PRTHomo sapiens 198Ala Arg Asp Val Val Thr Met Val Glu Gly Leu Arg Phe His Tyr Tyr1 5 10 15Tyr Asn Tyr Tyr Gly Met Asp Val 2019924PRTHomo sapiens 199Ala Arg Asp Val Val Thr Met Val Glu Gly Leu Arg Phe His Tyr Tyr1 5 10 15Tyr Asn Tyr Tyr Gly Met Asp Val 2020024PRTHomo sapiens 200Ala Arg Asp Val Val Thr Met Val Glu Gly Leu Arg Phe His Tyr Tyr1 5 10 15Tyr Asn Tyr Tyr Gly Met Asp Val 2020112PRTHomo sapiens 201Ala Arg Asn Gln Pro Gly Gly Arg Ala Phe Asp Tyr1 5 1020212PRTHomo sapiens 202Ala Arg Asn Gln Pro Gly Gly Arg Ala Phe Asp Tyr1 5 1020321PRTHomo sapiens 203Ala Arg His Asp Gly Arg Gly Tyr Cys Ser Pro Thr Arg Cys Phe Phe1 5 10 15Ser Gly Met Asp Val 2020421PRTHomo sapiens 204Ala Arg His Asp Gly Arg Gly Tyr Cys Ser Pro Thr Arg Cys Phe Phe1 5 10 15Ser Gly Met Asp Val 2020517PRTHomo sapiens 205Ala Arg Arg Thr Tyr Tyr Asp Asn Arg Phe Pro Tyr Trp Tyr Phe Asp1 5 10 15Leu20617PRTHomo sapiens 206Ala Arg Arg Thr Tyr Tyr Asp Thr Arg Phe Pro Tyr Trp Tyr Phe Asp1 5 10 15Leu20715PRTHomo sapiens 207Ala Arg Ser Trp Gly Thr Ala Ala Thr Gly Gly Ser Phe Val Gln1 5

10 1520813PRTHomo sapiens 208Ala Arg Gly Arg Asp Ser Ser Gly Arg Leu Leu Asp His1 5 1020914PRTHomo sapiens 209Ala Arg Gly Gly Met Leu Gly Gln Leu Trp Ala Leu Asp Asn1 5 1021014PRTHomo sapiens 210Ala Arg Gly Gly Arg Ile Asn Val Ala Glu Ala Leu Arg Tyr1 5 1021196PRTHomo sapiens 211Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Gly Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Asn Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Lys Phe65 70 75 80Asn Ser Val Pro Trp Thr Phe Gly Pro Gly Thr Lys Val Glu Val Lys 85 90 9521296PRTHomo sapiens 212Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Pro Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Gln Thr Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9521396PRTHomo sapiens 213Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Pro Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Gln Thr Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Leu Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9521496PRTHomo sapiens 214Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Ser Pro Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Gln Thr Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9521596PRTHomo sapiens 215Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Thr Pro Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Gln Thr Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9521696PRTHomo sapiens 216Ser Ala Ser Val Gly Gly Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Ser Lys Ala Ser Asn Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Gly Gly Ser Glu Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Arg Tyr65 70 75 80Asp Ser Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Thr Ile Lys 85 90 9521797PRTHomo sapiens 217Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Glu Ile Gly Ser Phe Ser Leu Gly Trp Tyr Gln Gln Lys Phe Gly Gln 20 25 30Pro Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Val Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys21897PRTHomo sapiens 218Ser Leu Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Ile Gly Ser Phe Ser Leu Ala Trp Tyr Gln Gln Lys Phe Gly His 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Asp Thr Asp Tyr Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Val Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys21997PRTHomo sapiens 219Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Thr Phe Ser Leu Ala Trp Tyr Gln Gln Lys Phe Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Val Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Arg22097PRTHomo sapiens 220Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Ser Ile His Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys22197PRTHomo sapiens 221Ser Leu Ser Pro Gly Glu Thr Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Ile Gly Ser Ile Ser Leu Gly Trp Tyr Gln Gln Lys Phe Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Thr 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Val Ser Ser Pro Leu Arg Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys22297PRTHomo sapiens 222Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Ser Ile His Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Asn Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys22397PRTHomo sapiens 223Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Leu Ser Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Arg Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 85 90 95Lys22497PRTHomo sapiens 224Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Leu Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Gly Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Leu Thr Phe Gly Pro Gly Thr Lys Val Asp Ile 85 90 95Lys22597PRTHomo sapiens 225Ser Leu Ser Pro Gly Glu Arg Gly Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Tyr Ile Thr Thr Gly His Phe Ala Trp Tyr Gln Gln Lys Pro Gly Arg 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Val Arg Ala Thr Gly Val 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ala Glu Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Asp Pro Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Val Thr Phe Gly Pro Gly Thr Lys Val Glu Ile 85 90 95Lys22697PRTHomo sapiens 226Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Asn Ile Gly Leu Asp Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ile Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Val Pro Glu Asp Ile Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Val Thr Phe Gly Pro Gly Thr Lys Val Glu Val 85 90 95Lys22797PRTHomo sapiens 227Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Thr Ser Gly Tyr Phe Ala Trp Tyr Gln His Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ile Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile 85 90 95Lys22897PRTHomo sapiens 228Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Phe Val Ile Ser Gly His Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Thr Ser Asn Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Glu Ser Gly Ala Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Pro Thr Phe Gly Pro Gly Thr Lys Val Asp Ile 85 90 95Lys22997PRTHomo sapiens 229Ser Leu Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15His Ile Thr Thr Gly His Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ile Arg Ala Ser Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Cys Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile 85 90 95Lys23096PRTHomo sapiens 230Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Asp Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Val 20 25 30Pro Ala Ile Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser65 70 75 80Tyr Ile Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 85 90 9523196PRTHomo sapiens 231Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Asn Leu Leu Ile Phe Ala Thr Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser65 70 75 80Phe Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg 85 90 9523296PRTHomo sapiens 232Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Phe Ala Ala Ser Thr Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Thr Ser Leu Gln Pro Ala Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ser65 70 75 80Tyr Ile Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Asn 85 90 9523396PRTHomo sapiens 233Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ile Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile 50 55 60Ile Ser Leu Gln Pro Glu Asp Phe Ala Ile Tyr Tyr Cys His Gln Ser65 70 75 80Phe Ser Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9523496PRTHomo sapiens 234Ser Ala Ser Val Gly His Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Phe Ala Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Asn Ser Leu Gln Pro Gly Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser65 70 75 80Tyr Ser Thr Pro Leu Ser Phe Gly Gln Gly Thr Arg Val Glu Ile Lys 85 90 95235103PRTHomo sapiens 235Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Tyr Cys1 5 10 15Ser Gly Ser Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr 20 25 30Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Gly Val Thr 35 40 45Arg Arg Pro Ser Gly Val Ser Ser

Arg Phe Ser Gly Ser Lys Ser Gly 50 55 60Asn Thr Ala Ser Leu Thr Phe Ser Gly Leu Gln Val Glu Asp Asp Ala65 70 75 80Asp Tyr Tyr Cys Cys Ser Tyr Ala Asn Ser Gly Thr Phe Val Phe Gly 85 90 95Thr Gly Thr Lys Val Thr Val 100236103PRTHomo sapiens 236Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Tyr Cys1 5 10 15Ser Gly Ser Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr 20 25 30Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Gly Val Thr 35 40 45Arg Arg Pro Ser Gly Val Ser Ser Arg Phe Ser Gly Ser Lys Ser Gly 50 55 60Asn Thr Ala Ser Leu Thr Phe Ser Gly Leu Gln Val Glu Asp Asp Ala65 70 75 80Asp Tyr Tyr Cys Cys Ser Tyr Ala Asn Ser Gly Thr Phe Val Phe Gly 85 90 95Thr Gly Thr Lys Val Thr Val 100237103PRTHomo sapiens 237Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Tyr Cys1 5 10 15Ser Gly Ser Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr 20 25 30Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Gly Val Thr 35 40 45Arg Arg Pro Ser Gly Val Ser Ser Arg Phe Ser Gly Ser Lys Ser Gly 50 55 60Asn Thr Ala Ser Leu Thr Phe Ser Gly Leu Gln Val Glu Asp Asp Ala65 70 75 80Asp Tyr Tyr Cys Cys Ser Tyr Ala Asn Ser Gly Thr Phe Val Phe Gly 85 90 95Thr Gly Thr Lys Val Thr Val 10023897PRTHomo sapiens 238Ser Leu Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln1 5 10 15Ser Val Ser Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Leu Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Asn Lys Leu Glu Ala Glu Asp Phe Ala Met Tyr Tyr Cys Gln Ile65 70 75 80Tyr Asp Ser Ser Val Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 85 90 95Lys23997PRTHomo sapiens 239Ser Leu Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Leu Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Asn Lys Leu Glu Ala Glu Asp Phe Ala Val Tyr Tyr Cys Gln Ile65 70 75 80Tyr Asp Ser Ser Val Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 85 90 95Lys24097PRTHomo sapiens 240Ser Leu Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln1 5 10 15Ser Val Ser Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Leu Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Asn Lys Leu Glu Ala Glu Asp Phe Ala Met Tyr Tyr Cys Gln Ile65 70 75 80Tyr Asp Ser Ser Leu Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 85 90 95Lys24198PRTHomo sapiens 241Ser Leu Ser Pro Gly Gln Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Thr Ser Lys Arg Ala Thr Gly Thr Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Arg65 70 75 80Asn Asn Trp Pro Leu Thr Trp Thr Phe Gly Leu Gly Thr Lys Val Glu 85 90 95Ile Lys24298PRTHomo sapiens 242Ser Leu Ser Pro Gly Gln Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Thr Ser Lys Arg Ala Thr Gly Thr Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Arg65 70 75 80Asn Asn Trp Pro Leu Thr Trp Thr Phe Gly Leu Gly Thr Lys Val Glu 85 90 95Ile Lys24396PRTHomo sapiens 243Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Asn Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Tyr Ala Ile Tyr Tyr Cys Gln Gln Thr65 70 75 80Asp Arg Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9524496PRTHomo sapiens 244Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Asn Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Tyr Ala Ile Tyr Tyr Cys Gln Gln Thr65 70 75 80Asp Arg Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9524596PRTHomo sapiens 245Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Gly Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Leu Ala 20 25 30Pro Glu Val Leu Ile Ser Gly Ala Thr Thr Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr Ile 50 55 60Asn Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Val Cys Gln Gln Ser65 70 75 80Ile Ser Ala Pro Tyr Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys 85 90 9524696PRTHomo sapiens 246Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asp Ile Gly Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Asn Val Leu Ile Ser Ala Ala Ser Thr Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Ile Ser Gly Ile Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser65 70 75 80Leu Ser Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9524798PRTHomo sapiens 247Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser His1 5 10 15Ser Val Thr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gln Tyr Tyr65 70 75 80Thr Asn Trp Pro Pro His Val Ala Phe Gly Gln Gly Thr Lys Leu Glu 85 90 95Ile Lys24897PRTHomo sapiens 248Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Thr Val Asn Arg Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Ala Ala Ser Ala Arg Ala Thr Gly Val Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr65 70 75 80Asn Asn Trp Pro Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys24996PRTHomo sapiens 249Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser His Trp Leu Ala Trp Tyr Gln Gln Arg Pro Gly Glu Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Thr Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Ser Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Gln Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9525096PRTHomo sapiens 250Ser Thr Phe Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Asp Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Ser Lys Ala Thr Arg Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Glu Phe Ser Leu Thr Ile 50 55 60Asn Ser Leu Gln Pro Asp Asp Val Ala Ala Tyr Tyr Cys Gln Gln Tyr65 70 75 80Met Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 952519PRTHomo sapiens 251Gln Lys Phe Asn Ser Val Pro Trp Thr1 52529PRTHomo sapiens 252Gln His Tyr His Ser Tyr Pro Trp Thr1 52539PRTHomo sapiens 253Gln His Tyr His Ser Tyr Pro Trp Thr1 52549PRTHomo sapiens 254Gln His Tyr His Ser Tyr Pro Trp Thr1 52559PRTHomo sapiens 255Gln His Tyr His Ser Tyr Pro Trp Thr1 52569PRTHomo sapiens 256Gln Arg Tyr Asp Ser Tyr Pro Phe Thr1 52579PRTHomo sapiens 257Gln Gln Tyr Val Ser Ser Pro Leu Thr1 52589PRTHomo sapiens 258Gln Gln Tyr Val Ser Ser Pro Leu Thr1 52599PRTHomo sapiens 259Gln Gln Tyr Val Ser Ser Pro Leu Thr1 52609PRTHomo sapiens 260Gln Gln Tyr Gly Ser Ser Pro Leu Thr1 52619PRTHomo sapiens 261Gln Gln Tyr Val Ser Ser Pro Leu Arg1 52629PRTHomo sapiens 262Gln Gln Tyr Gly Ser Ser Pro Leu Thr1 52639PRTHomo sapiens 263Gln Gln Tyr Gly Ser Ser Arg Gly Thr1 52649PRTHomo sapiens 264Gln Gln Tyr Gly Ser Ser Pro Leu Thr1 52659PRTHomo sapiens 265Gln Gln Tyr Gly Ser Ser Pro Val Thr1 52669PRTHomo sapiens 266Gln Gln Tyr Gly Ser Ser Pro Val Thr1 52679PRTHomo sapiens 267Gln Gln Tyr Gly Ser Ser Pro Val Thr1 52689PRTHomo sapiens 268Gln Gln Tyr Gly Ser Ser Pro Pro Thr1 52699PRTHomo sapiens 269Gln Gln Tyr Gly Ser Ser Pro Val Thr1 52709PRTHomo sapiens 270Gln Gln Ser Tyr Ile Thr Pro Leu Thr1 52719PRTHomo sapiens 271Gln Gln Ser Phe Ser Thr Pro Leu Thr1 52729PRTHomo sapiens 272Gln Gln Ser Tyr Ile Ser Pro Leu Thr1 52739PRTHomo sapiens 273His Gln Ser Phe Ser Ala Pro Tyr Thr1 52749PRTHomo sapiens 274Gln Gln Ser Tyr Ser Thr Pro Leu Ser1 527510PRTHomo sapiens 275Cys Ser Tyr Ala Asn Ser Gly Thr Phe Val1 5 1027610PRTHomo sapiens 276Cys Ser Tyr Ala Asn Ser Gly Thr Phe Val1 5 1027710PRTHomo sapiens 277Cys Ser Tyr Ala Asn Ser Gly Thr Phe Val1 5 102789PRTHomo sapiens 278Gln Ile Tyr Asp Ser Ser Val Arg Thr1 52799PRTHomo sapiens 279Gln Ile Tyr Asp Ser Ser Val Arg Thr1 52809PRTHomo sapiens 280Gln Ile Tyr Asp Ser Ser Leu Arg Thr1 528111PRTHomo sapiens 281Gln Glu Arg Asn Asn Trp Pro Leu Thr Trp Thr1 5 1028211PRTHomo sapiens 282Gln Glu Arg Asn Asn Trp Pro Leu Thr Trp Thr1 5 102839PRTHomo sapiens 283Gln Gln Thr Asp Arg Thr Pro Leu Thr1 52849PRTHomo sapiens 284Gln Gln Thr Asp Arg Thr Pro Leu Thr1 52859PRTHomo sapiens 285Gln Gln Ser Ile Ser Ala Pro Tyr Thr1 52869PRTHomo sapiens 286Gln Gln Ser Leu Ser Ala Pro Tyr Thr1 528711PRTHomo sapiens 287Gln Tyr Tyr Thr Asn Trp Pro Pro His Val Ala1 5 1028810PRTHomo sapiens 288Gln Gln Tyr Asn Asn Trp Pro Pro Leu Thr1 5 102899PRTHomo sapiens 289Gln Gln Tyr Gln Ser Ser Pro Tyr Thr1 52909PRTHomo sapiens 290Gln Gln Tyr Met Ser Tyr Pro Trp Thr1 5291117PRTHomo sapiens 291Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Gly Gly Arg Gly 35 40 45Ala Ile Ala Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val Lys Gly 50 55 60Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln65 70 75 80Met Asn Gly Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys 85 90 95Asp Arg Val Ala Phe Asp Gly Phe His Val Trp Gly Gln Gly Thr Thr 100 105 110Val Thr Val Ser Ser 115292115PRTHomo sapiens 292Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Pro Leu Asp 35 40 45Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asp Arg Leu Thr Met 85 90 95Gly Val Gly Glu Leu Phe Val Asp Trp Gly Pro Gly Thr Leu Val Ser 100 105 110Val Ser Ser 115293115PRTHomo sapiens 293Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Arg Arg Leu Ser Cys Ala1 5 10 15Thr Ser Gly Phe Ser Phe Asp Thr Tyr Ala Met Ser Trp Leu Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Phe Ser Gly Leu Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Ile Gly Glu Leu Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Ser 100 105 110Val Ser Ser 115294115PRTHomo sapiens 294Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val1 5 10 15Thr Ser Gly Phe Ser Phe Asp Thr Tyr Ala Leu Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Phe Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Thr Glu Ser Val Lys Gly Arg Phe Thr Met Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Phe Leu Gln Met Asn Gly Leu Arg65 70 75 80Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ser Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Ile 100 105 110Phe Ser Ser 115295115PRTHomo sapiens 295Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Thr Ser Gly

Phe Thr Phe Ser Thr Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Phe Ser Gly Val Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Thr Arg Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115296115PRTHomo sapiens 296Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Thr Leu Thr Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Tyr Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Arg Thr Leu Ser Leu His Met Asn Ser Leu Arg65 70 75 80Ala Gly Asp Ser Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Pro Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115297115PRTHomo sapiens 297Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Gly Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Leu Ser Ser Met Thr Arg Thr Gly 35 40 45Asp Asn Leu Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Ile Tyr Phe Cys Ala Lys Asp Arg Leu Pro Glu 85 90 95Gly Phe Gly Lys Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Thr 115298114PRTHomo sapiens 298Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Ser Phe Ser Asp Phe Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Asn Gln Gly Leu Asp Trp Val Ser Cys Val Ser Gly Gly Gly 35 40 45Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Val Phe Leu Glu Met Asn Asn Leu Arg65 70 75 80Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gln Glu Val Ile 85 90 95Gly His Tyr Pro Ser Asp His Trp Gly Gln Gly Thr Leu Val Ile Val 100 105 110Ser Ser299112PRTHomo sapiens 299Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val1 5 10 15Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met Asn Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Thr Gly Ser Gly 35 40 45Asp Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Arg Asn Thr Leu Tyr Val Gln Met Asn Asn Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Lys Asp Arg Ile Leu Phe 85 90 95Asp Ala Phe His Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 100 105 110300115PRTHomo sapiens 300Gly Gly Asp Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ala Tyr Gly Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Met Thr Gly Ser Gly 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asp Arg Val Ser Gly 85 90 95Gly Phe Gly Glu Leu Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115301115PRTHomo sapiens 301Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Thr Thr Phe Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ala Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Arg Ser Thr Leu Phe Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Val Val Ser 100 105 110Val Ser Ser 115302115PRTHomo sapiens 302Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ala1 5 10 15Gly Ser Gly Phe Pro Phe Asn Thr Tyr Ala Leu Ile Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Tyr Asp Ser 35 40 45Ala Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Tyr Leu Glu Met Asn Phe Leu Arg65 70 75 80Ala Asp Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp Arg Val Thr Met 85 90 95Gly Phe Gly Glu Leu Phe Ala His Trp Gly Gln Gly Thr Leu Val Ala 100 105 110Val Ser Ser 115303115PRTHomo sapiens 303Gly Gly Gly Leu Lys Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Arg Asn Tyr Gly Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Leu Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Ser Ala Ile Ser 50 55 60Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Ile His Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Leu Tyr Phe Cys Ala Lys Asp Arg Val Glu Lys 85 90 95Gly Phe Gly Glu Leu Trp Ala Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115304115PRTHomo sapiens 304Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Thr Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Tyr Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Ser Leu His Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Ser Ala Leu Tyr Phe Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115305115PRTHomo sapiens 305Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Thr Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Tyr Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Arg Ser Thr Leu Ser Leu His Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Ser Ala Leu Tyr Phe Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115306117PRTHomo sapiens 306Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Thr Ser Tyr Ala Met Asn Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Gly Gly Arg Gly 35 40 45Ala Ile Ala Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val Lys Gly 50 55 60Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Val Tyr Leu Gln65 70 75 80Met Asn Gly Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys 85 90 95Asp Arg Val Ala Phe Asp Gly Phe His Val Trp Gly Gln Gly Thr Thr 100 105 110Val Thr Val Ser Ser 115307115PRTHomo sapiens 307Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Thr Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Tyr Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Ser Leu His Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Ser Ala Leu Tyr Phe Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115308115PRTHomo sapiens 308Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Thr Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Arg Asp Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Tyr Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Ser Leu His Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Ser Ala Leu Tyr Phe Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115309115PRTHomo sapiens 309Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Thr Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Tyr Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Ser Leu Tyr Met Lys Ser Leu Arg65 70 75 80Ala Glu Asp Ser Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115310115PRTHomo sapiens 310Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Thr Cys Ala1 5 10 15Thr Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Tyr Ser Gly Ile Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Ser Leu His Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Ser Ala Leu Tyr Phe Cys Ala Lys Asp Arg Gly Pro Arg 85 90 95Gly Val Gly Glu Leu Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115311115PRTHomo sapiens 311Gly Gly Asp Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Phe Asp 35 40 45Pro Ser Thr Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ala 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Lys Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asp Arg Leu Val Arg 85 90 95Gly Phe Gly Glu Val Leu Ala Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115312115PRTHomo sapiens 312Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Phe Ser Gly Ile Asp 35 40 45Asp Ser Thr Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Leu Val Arg 85 90 95Gly Phe Ala Glu Val Leu Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115313115PRTHomo sapiens 313Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Phe Ser Gly Ile Asp 35 40 45Asp Ser Thr Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Phe Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Leu Val Arg 85 90 95Gly Phe Ala Glu Val Leu Glu His Trp Gly Arg Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115314115PRTHomo sapiens 314Gly Gly Asp Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Phe Asp 35 40 45Pro Ser Thr Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ala 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Lys Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asp Arg Leu Val Arg 85 90 95Gly Phe Gly Glu Val Leu Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 11531512PRTHomo sapiens 315Ala Lys Asp Arg Val Ala Phe Asp Gly Phe His Val1 5 1031615PRTHomo sapiens 316Ala Lys Asp Arg Leu Thr Met Gly Val Gly Glu Leu Phe Val Asp1 5 10 1531715PRTHomo sapiens 317Ala Lys Asp Arg Gly Pro Arg Gly Ile Gly Glu Leu Phe Asp Phe1 5 10 1531815PRTHomo sapiens 318Ser Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1531915PRTHomo sapiens 319Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1532015PRTHomo sapiens 320Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1532115PRTHomo sapiens 321Ala Lys Asp Arg Leu Pro Glu Gly Phe Gly Lys Leu Phe Asp Tyr1 5 10 1532214PRTHomo

sapiens 322Ala Arg Asp Gln Glu Val Ile Gly His Tyr Pro Ser Asp His1 5 1032312PRTHomo sapiens 323Thr Lys Asp Arg Ile Leu Phe Asp Ala Phe His Val1 5 1032415PRTHomo sapiens 324Ala Lys Asp Arg Val Ser Gly Gly Phe Gly Glu Leu Gln Asp Tyr1 5 10 1532515PRTHomo sapiens 325Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1532615PRTHomo sapiens 326Ala Lys Asp Arg Val Thr Met Gly Phe Gly Glu Leu Phe Ala His1 5 10 1532715PRTHomo sapiens 327Ala Lys Asp Arg Val Glu Lys Gly Phe Gly Glu Leu Trp Ala Ser1 5 10 1532815PRTHomo sapiens 328Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1532915PRTHomo sapiens 329Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1533012PRTHomo sapiens 330Ala Lys Asp Arg Val Ala Phe Asp Gly Phe His Val1 5 1033115PRTHomo sapiens 331Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1533215PRTHomo sapiens 332Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1533315PRTHomo sapiens 333Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1533415PRTHomo sapiens 334Ala Lys Asp Arg Gly Pro Arg Gly Val Gly Glu Leu Phe Asp Ser1 5 10 1533515PRTHomo sapiens 335Ala Lys Asp Arg Leu Val Arg Gly Phe Gly Glu Val Leu Ala Ser1 5 10 1533615PRTHomo sapiens 336Ala Lys Asp Arg Leu Val Arg Gly Phe Ala Glu Val Leu Asp Tyr1 5 10 1533715PRTHomo sapiens 337Ala Lys Asp Arg Leu Val Arg Gly Phe Ala Glu Val Leu Glu His1 5 10 1533815PRTHomo sapiens 338Ala Lys Asp Arg Leu Val Arg Gly Phe Gly Glu Val Leu Asp Ser1 5 10 1533996PRTHomo sapiens 339Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Asn Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534096PRTHomo sapiens 340Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Gln Ala Ser Thr Leu Gln Asn Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Tyr Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534196PRTHomo sapiens 341Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Arg Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Lys Thr Ser Thr Leu Lys Ser Glu Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80His Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534296PRTHomo sapiens 342Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80Tyr Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534396PRTHomo sapiens 343Ser Ala Ser Val Gly Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Asn Arg Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80His Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534496PRTHomo sapiens 344Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80Tyr Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534596PRTHomo sapiens 345Ser Ala Ala Ile Gly Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Asn Thr Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Met His Lys Ala Ser Thr Leu His Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Tyr Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534695PRTHomo sapiens 346Ser Val Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Lys Ala Ser Arg Leu Glu Arg Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Arg Gly Ser Gly Thr Glu Phe Ala Leu Thr Ile 50 55 60Ser Gly Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Ser Ser Phe Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 85 90 9534796PRTHomo sapiens 347Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Asn Leu Leu Ile Tyr Lys Ala Ser Thr Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Asn Asn Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534896PRTHomo sapiens 348Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Glu Leu Leu Ile Tyr Lys Thr Ser Thr Leu His Thr Gly Val Pro 35 40 45Ser Arg Phe Arg Gly Arg Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Tyr Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9534996PRTHomo sapiens 349Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Arg Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80Phe Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535096PRTHomo sapiens 350Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile His Lys Ala Ser Thr Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Thr Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Tyr Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Val Lys 85 90 9535196PRTHomo sapiens 351Pro Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Thr Pro Gly Arg Pro 20 25 30Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ala Ser Leu Asp Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Thr Ser Leu Gln Pro His Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535296PRTHomo sapiens 352Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80His Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535396PRTHomo sapiens 353Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80His Ser Val Pro Trp Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535496PRTHomo sapiens 354Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Asn Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535596PRTHomo sapiens 355Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80Tyr Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535696PRTHomo sapiens 356Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80Tyr Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535796PRTHomo sapiens 357Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Gly Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80Phe Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ser Lys 85 90 9535896PRTHomo sapiens 358Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Thr Ser Thr Leu Lys Thr Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe65 70 75 80Tyr Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9535996PRTHomo sapiens 359Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Arg Glu Val 20 25 30Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu His Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Gly Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr65 70 75 80Asn Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Met Lys 85 90 9536096PRTHomo sapiens 360Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asp Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Val 20 25 30Pro Asn Leu Leu Ile Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr His Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr65 70 75 80Asn Ser Val Pro Trp Thr Phe Gly Gln Gly Thr

Lys Val Glu Ile Lys 85 90 9536196PRTHomo sapiens 361Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asp Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Val 20 25 30Pro Asn Leu Leu Ile Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr His Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr65 70 75 80Asn Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9536296PRTHomo sapiens 362Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Arg Glu Val 20 25 30Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu His Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Gly Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr65 70 75 80Asn Ser Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Met Lys 85 90 953639PRTHomo sapiens 363Gln Gln Tyr Asn Ser Tyr Pro Trp Thr1 53649PRTHomo sapiens 364Gln His Tyr Tyr Ser Tyr Pro Trp Thr1 53659PRTHomo sapiens 365Gln His Phe His Ser Val Pro Trp Thr1 53669PRTHomo sapiens 366Gln His Phe Tyr Ser Val Pro Trp Thr1 53679PRTHomo sapiens 367Gln His Phe His Ser Val Pro Trp Thr1 53689PRTHomo sapiens 368Gln His Phe Tyr Ser Val Pro Trp Thr1 53699PRTHomo sapiens 369Gln His Tyr Tyr Ser Tyr Pro Trp Thr1 53708PRTHomo sapiens 370Gln Gln Tyr Ser Ser Phe Phe Thr1 53719PRTHomo sapiens 371Gln Gln Tyr Asn Asn Tyr Pro Trp Thr1 53729PRTHomo sapiens 372Gln His Tyr Tyr Ser Tyr Pro Trp Thr1 53739PRTHomo sapiens 373Gln His Phe Phe Ser Val Pro Trp Thr1 53749PRTHomo sapiens 374Gln His Tyr Tyr Ser Tyr Pro Trp Thr1 53759PRTHomo sapiens 375Gln His Tyr His Ser Tyr Pro Trp Thr1 53769PRTHomo sapiens 376Gln His Phe His Ser Val Pro Trp Thr1 53779PRTHomo sapiens 377Gln His Phe His Ser Val Pro Trp Ala1 53789PRTHomo sapiens 378Gln Gln Tyr Asn Ser Tyr Pro Trp Thr1 53799PRTHomo sapiens 379Gln His Phe Tyr Ser Val Pro Trp Thr1 53809PRTHomo sapiens 380Gln His Phe Tyr Ser Val Pro Trp Thr1 53819PRTHomo sapiens 381Gln His Phe Phe Ser Val Pro Trp Thr1 53829PRTHomo sapiens 382Gln His Phe Tyr Ser Val Pro Trp Thr1 53839PRTHomo sapiens 383Gln Lys Tyr Asn Ser Val Pro Trp Thr1 53849PRTHomo sapiens 384Gln Lys Tyr Asn Ser Val Pro Trp Thr1 53859PRTHomo sapiens 385Gln Lys Tyr Asn Ser Val Pro Trp Thr1 53869PRTHomo sapiens 386Gln Lys Tyr Asn Ser Val Pro Trp Thr1 5387113PRTHomo sapiens 387Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Lys1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Lys Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asp Ser Gln Ser Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser388113PRTHomo sapiens 388Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ser Lys Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser389113PRTHomo sapiens 389Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Phe Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser390113PRTHomo sapiens 390Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Leu Ala Trp Val Arg Gln 20 25 30Val Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser391113PRTHomo sapiens 391Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser392113PRTHomo sapiens 392Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asp Gly Glu 35 40 45Asp Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser393112PRTHomo sapiens 393Gly Gly Asp Leu Ala Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Val Ser Gly Leu Ser Ile Gly Arg Tyr Gly Met Asn Trp Ile Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Asp Asp Gly 35 40 45Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Ser Val Tyr Leu Gln Met Ser Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Arg Tyr Tyr Cys Ala Lys Asp Arg Leu Met Phe 85 90 95Asp Gly Phe His Met Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 100 105 110394115PRTHomo sapiens 394Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Arg Thr Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ala Arg Glu 35 40 45Asp Ser Thr Tyr Phe Ala Ala Ser Val Arg Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Arg65 70 75 80Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Leu Gln Leu 85 90 95Gly Val Gly Glu Leu Tyr Glu Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115395113PRTHomo sapiens 395Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Ala Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser396113PRTHomo sapiens 396Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Leu Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Ile Ile Ser 50 55 60Arg Asp Asn Ser Leu Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Arg Gly Thr Leu Val Thr Val Ser 100 105 110Ser397113PRTHomo sapiens 397Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asp Gly His 35 40 45Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Ala Val Ser 100 105 110Ser398113PRTHomo sapiens 398Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Asn Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Leu Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Lys Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser399113PRTHomo sapiens 399Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Trp Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ala400113PRTHomo sapiens 400Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Leu Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Arg Ser Ser Ile Val Glu Trp Gly Gln Gly Thr Trp Val Thr Val Ser 100 105 110Ser401115PRTHomo sapiens 401Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Arg Thr Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ala Ser Asp 35 40 45Asp Ser Thr Tyr Phe Ala Ala Ser Val Arg Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Arg65 70 75 80Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Leu Glu Leu 85 90 95Gly Val Gly Glu Leu Tyr Glu Phe Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115402113PRTHomo sapiens 402Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Lys Asn Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Leu Tyr Asn Ser Glu 35 40 45Glu Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Arg Leu Arg65 70 75 80Val Glu Asp Thr Ala Val Tyr Phe Cys Val Arg Asp Arg Ser Asn Gly 85 90 95Trp Ser Ser Ile Asn Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser 100 105 110Ser403113PRTHomo sapiens 403Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Asn Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gln Ile Tyr Asn Gly Glu 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Gly Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser404113PRTHomo sapiens 404Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asp Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser

Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Val Ser Leu Gln Met Thr Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser405113PRTHomo sapiens 405Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asp Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Lys Ser Val Lys Gly Arg Phe Ala Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser406113PRTHomo sapiens 406Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Leu Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Lys Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser407113PRTHomo sapiens 407Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Phe Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Gln Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser408113PRTHomo sapiens 408Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Phe Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Trp Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Arg Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser His Asn Thr Leu Ser Leu Gln Met Arg Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser409113PRTHomo sapiens 409Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Val Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Arg Asp Arg Asp Asn Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser410113PRTHomo sapiens 410Gly Gly Gly Leu Ala Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Trp Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser411113PRTHomo sapiens 411Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Ala Tyr 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Ser Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Pro412113PRTHomo sapiens 412Gly Gly Gly Leu Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr1 5 10 15Ala Ser Gly Phe Thr Phe Arg Arg Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Asn Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Glu Ser Val Arg Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Arg Asp Thr Gly 85 90 95Trp Ser Ser Ile Val Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser413113PRTHomo sapiens 413Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Phe Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg His Asn Ser Lys Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Arg Gly Thr Gly 85 90 95Trp Ser Ser Ile Val His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser414121PRTHomo sapiens 414Gly Ala Glu Val Lys Arg Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Arg Gly 35 40 45Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Ala Leu Thr 50 55 60Gly Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Thr Ser Leu Arg65 70 75 80Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Lys Ala His Gln 85 90 95Thr Thr Val Val Ile Leu Ser Trp Tyr Tyr Gly Met Asp Val Trp Gly 100 105 110Gln Gly Thr Thr Val Thr Val Ser Ser 115 120415121PRTHomo sapiens 415Gly Ala Glu Val Lys Lys Ser Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Ser Phe Thr Thr Asn Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Pro Glu Trp Met Gly Ile Ile Asn Pro Arg Gly 35 40 45Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Leu Met Thr 50 55 60Ser Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Ser Glu Asp Arg Ala Val Tyr Tyr Cys Ala Arg Gly Lys Asn His Gln 85 90 95Thr Thr Val Ala Val Leu Ser Trp Tyr Tyr Gly Met Asp Val Trp Gly 100 105 110Gln Gly Thr Thr Val Thr Val Ser Ser 115 12041613PRTHomo sapiens 416Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1041713PRTHomo sapiens 417Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1041813PRTHomo sapiens 418Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1041913PRTHomo sapiens 419Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1042013PRTHomo sapiens 420Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1042113PRTHomo sapiens 421Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1042212PRTHomo sapiens 422Ala Lys Asp Arg Leu Met Phe Asp Gly Phe His Met1 5 1042315PRTHomo sapiens 423Ala Lys Asp Arg Leu Gln Leu Gly Val Gly Glu Leu Tyr Glu Ser1 5 10 1542413PRTHomo sapiens 424Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1042513PRTHomo sapiens 425Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1042613PRTHomo sapiens 426Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1042713PRTHomo sapiens 427Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1042813PRTHomo sapiens 428Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1042913PRTHomo sapiens 429Val Lys Asp Arg Asp Thr Gly Arg Ser Ser Ile Val Glu1 5 1043015PRTHomo sapiens 430Ala Lys Asp Arg Leu Glu Leu Gly Val Gly Glu Leu Tyr Glu Phe1 5 10 1543113PRTHomo sapiens 431Val Arg Asp Arg Ser Asn Gly Trp Ser Ser Ile Asn Leu1 5 1043213PRTHomo sapiens 432Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1043313PRTHomo sapiens 433Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1043413PRTHomo sapiens 434Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1043513PRTHomo sapiens 435Val Arg Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1043613PRTHomo sapiens 436Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1043713PRTHomo sapiens 437Val Lys Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1043813PRTHomo sapiens 438Val Arg Asp Arg Asp Asn Gly Trp Ser Ser Ile Val Asp1 5 1043913PRTHomo sapiens 439Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1044013PRTHomo sapiens 440Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1044113PRTHomo sapiens 441Val Lys Asp Arg Asp Thr Gly Trp Ser Ser Ile Val Asp1 5 1044213PRTHomo sapiens 442Val Lys Asp Arg Gly Thr Gly Trp Ser Ser Ile Val His1 5 1044321PRTHomo sapiens 443Ala Arg Gly Lys Ala His Gln Thr Thr Val Val Ile Leu Ser Trp Tyr1 5 10 15Tyr Gly Met Asp Val 2044421PRTHomo sapiens 444Ala Arg Gly Lys Asn His Gln Thr Thr Val Ala Val Leu Ser Trp Tyr1 5 10 15Tyr Gly Met Asp Val 2044595PRTHomo sapiens 445Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln1 5 10 15Thr Ile Ala Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9544695PRTHomo sapiens 446Ser Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Leu Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9544795PRTHomo sapiens 447Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys His Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Met Lys 85 90 9544895PRTHomo sapiens 448Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser His1 5 10 15Asn Ile Gly Gly Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Arg Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Gly Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Ala Ile Lys 85 90 9544995PRTHomo sapiens 449Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser His1 5 10 15Thr Ile Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9545095PRTHomo sapiens 450Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Lys Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys His Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9545196PRTHomo sapiens 451Ser Ala Ser Val Gly Asp Ser Val Thr Ile Ser Cys Arg Ala Ser Arg1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Thr Ala Ser Thr Leu Glu Thr Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr

Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Asn Asn Tyr Pro Trp Thr Phe Gly Gln Gly Thr Thr Val Glu Ile Lys 85 90 9545296PRTHomo sapiens 452Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Met Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Val 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9545395PRTHomo sapiens 453Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Val Asp Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Asn Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9545495PRTHomo sapiens 454Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Ser His Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Val Leu Glu Thr Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9545595PRTHomo sapiens 455Ser Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Arg Ala Ser Arg1 5 10 15Thr Ile Gly Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Thr Val Gly Val Lys 85 90 9545695PRTHomo sapiens 456Ser Ala Phe Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9545795PRTHomo sapiens 457Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Gly Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9545895PRTHomo sapiens 458Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9545996PRTHomo sapiens 459Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Val 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Tyr Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9546095PRTHomo sapiens 460Ser Ala Ser Val Gly Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Arg Leu Glu Ser Gly Ile Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Leu Gly Thr Arg Val Glu Ile Lys 85 90 9546195PRTHomo sapiens 461Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9546296PRTHomo sapiens 462Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Leu Asn Val Trp Leu Ala Trp Tyr Gln Gln Gln Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9546395PRTHomo sapiens 463Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser His1 5 10 15Ser Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Gly Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9546495PRTHomo sapiens 464Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Gly Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Arg Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9546595PRTHomo sapiens 465Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg1 5 10 15Thr Ile Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Ile Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Gly Leu Gln Pro Glu Asp Phe Gly Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9546693PRTHomo sapiens 466Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile1 5 10 15Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys 20 25 30Leu Leu Ile Tyr Gln Ala Ser Val Leu Glu Ser Gly Val Pro Ser Arg 35 40 45Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser 50 55 60Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Ser Thr65 70 75 80Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 9046795PRTHomo sapiens 467Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg1 5 10 15Thr Ile Gly Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Gly Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Val Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9546895PRTHomo sapiens 468Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Ala Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9546995PRTHomo sapiens 469Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser His1 5 10 15Thr Ile Gly Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Gly Ile Lys 85 90 9547095PRTHomo sapiens 470Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser His1 5 10 15Thr Ile Ser Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Val Tyr Gln Ala Ser Ile Leu Glu Thr Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Arg Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Phe Cys Gln Gln Tyr65 70 75 80Ser Thr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9547195PRTHomo sapiens 471Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Thr Ile Ser Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Ser Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr65 70 75 80Ser Thr Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9547296PRTHomo sapiens 472Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala65 70 75 80Asn Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9547396PRTHomo sapiens 473Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ala65 70 75 80Asn Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 954748PRTHomo sapiens 474Gln Gln Tyr Ser Thr Tyr Trp Thr1 54758PRTHomo sapiens 475Gln Gln Tyr Ser Thr Phe Trp Thr1 54768PRTHomo sapiens 476His Gln Tyr Ser Thr Tyr Trp Thr1 54778PRTHomo sapiens 477Gln Gln Tyr Ser Thr Tyr Trp Thr1 54788PRTHomo sapiens 478Gln Gln Tyr Ser Thr Phe Trp Thr1 54798PRTHomo sapiens 479His Gln Tyr Ser Thr Tyr Trp Thr1 54809PRTHomo sapiens 480Gln Gln Tyr Asn Asn Tyr Pro Trp Thr1 54819PRTHomo sapiens 481Gln His Tyr His Ser Tyr Pro Trp Thr1 54828PRTHomo sapiens 482Gln Gln Tyr Ser Thr Phe Trp Thr1 54838PRTHomo sapiens 483Gln Gln Tyr Ser Thr Phe Trp Thr1 54848PRTHomo sapiens 484Gln Gln Tyr Ser Thr Tyr Trp Thr1 54858PRTHomo sapiens 485Gln Gln Tyr Ser Thr Phe Trp Thr1 54868PRTHomo sapiens 486Gln Gln Tyr Ser Thr Tyr Trp Thr1 54878PRTHomo sapiens 487Gln Gln Tyr Ser Thr Tyr Trp Thr1 54889PRTHomo sapiens 488Gln His Tyr Tyr Ser Tyr Pro Trp Thr1 54898PRTHomo sapiens 489Gln Gln Tyr Ser Thr Phe Trp Thr1 54908PRTHomo sapiens 490Gln Gln Tyr Ser Thr Tyr Trp Thr1 54919PRTHomo sapiens 491Gln His Tyr His Ser Tyr Pro Trp Thr1 54928PRTHomo sapiens 492Gln Gln Tyr Ser Thr Phe Trp Thr1 54938PRTHomo sapiens 493Gln Gln Tyr Ser Thr Phe Trp Thr1 54948PRTHomo sapiens 494Gln Gln Tyr Ser Thr Tyr Trp Thr1 54958PRTHomo sapiens 495Gln Gln Tyr Ser Thr Phe Trp Thr1 54968PRTHomo sapiens 496Gln Gln Tyr Ser Thr Phe Trp Thr1 54978PRTHomo sapiens 497Gln Gln Tyr Ser Thr Phe Trp Thr1 54988PRTHomo sapiens 498Gln Gln Tyr Ser Thr Tyr Trp Thr1 54998PRTHomo sapiens 499Gln Gln Tyr Ser Thr Phe Trp Thr1 55008PRTHomo sapiens 500Gln Gln Tyr Ser Thr Tyr Trp Thr1

55019PRTHomo sapiens 501Gln Gln Ala Asn Ser Phe Pro Tyr Thr1 55029PRTHomo sapiens 502Gln Gln Ala Asn Ser Phe Pro Tyr Thr1 5503116PRTHomo sapiens 503Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ser1 5 10 15Ala Ala Gly Phe Asn Phe Arg Ser Tyr Ala Met Ser Trp Ile Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Leu Gly Thr Arg Gly 35 40 45Thr Glu Thr Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile 50 55 60Ser Arg Asp Asn Ser Lys Asn Ile Leu Tyr Leu Gln Met Asn Ile Leu65 70 75 80Gly Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Ile 85 90 95Glu Gly Leu Gly Glu Leu Tyr Ser His Trp Gly Gln Gly Thr Leu Val 100 105 110Thr Val Ser Ser 115504115PRTHomo sapiens 504Gly Gly Gly Leu Ala Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu1 5 10 15Thr Ser Gly Phe Thr Phe Arg Ser Tyr Gly Met Gly Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Tyr Ile Ser Gly 35 40 45Asp Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asp Arg Leu Thr65 70 75 80Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Arg Ile Gln Gly 85 90 95Gly Phe Gly Glu Leu Tyr Arg Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115505112PRTHomo sapiens 505Gly Gly Gly Leu Ala Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Thr Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Thr Gly Arg Asp 35 40 45Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Ala Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Gly Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp Arg Asp His Phe 85 90 95Asp Gly His Asp Phe Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser 100 105 110506115PRTHomo sapiens 506Gly Gly Arg Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Pro Phe Ser Thr Tyr Ala Met Ser Trp Leu Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Thr Gly Asp Ser 35 40 45Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Thr65 70 75 80Ala Asp Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Leu His Ser 85 90 95Gly Leu Gly Glu Leu Phe Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115507115PRTHomo sapiens 507Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Ser Phe Arg Thr Tyr Gly Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Val Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met His Asn Leu Ser65 70 75 80Ala Lys Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Leu Ala Ser 85 90 95Gly Ile Gly Glu Leu Phe Ser Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ala Ser 115508115PRTHomo sapiens 508Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Arg Thr Tyr Gly Met Asn Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly Ile Ser Ser Val Asp 35 40 45Pro Ser Thr Tyr Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Thr65 70 75 80Ala Asp Asp Ser Ala Val Tyr Tyr Cys Ala Lys Asp Arg Met Ser Gly 85 90 95Gly Phe Gly Glu Leu Asn Glu Ser Trp Gly Gln Gly Thr Arg Val Thr 100 105 110Val Ser Ser 115509115PRTHomo sapiens 509Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val1 5 10 15Ala Ser Gly Phe Thr Phe Gly Ser Tyr Gly Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Ile Ser Ser Ile Ser Ser Ile Asp 35 40 45Pro Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser 50 55 60Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu His Met Ser Ser Leu Lys65 70 75 80Val Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp Arg Leu Asn Gly 85 90 95Gly Phe Gly Glu Leu Phe Ala Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115510115PRTHomo sapiens 510Gly Gly Gly Leu Gly Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Pro Phe Ser Asp Phe Gly Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Pro Gly 35 40 45Phe Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asp Thr Leu Phe Leu Gln Met Ser Arg Leu Arg65 70 75 80Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ile Lys Gly 85 90 95Gly Leu Gly Glu Leu Phe His Leu Trp Gly Gln Gly Ala Leu Val Thr 100 105 110Val Ser Ser 115511115PRTHomo sapiens 511Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Asn Thr His Ala Met Ala Trp Leu Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Val Thr Ala Asn Gly 35 40 45Gly Asp Ser Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Arg Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg65 70 75 80Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Leu Ala Ala 85 90 95Gly Leu Gly Glu Leu Phe Ser His Trp Gly Gln Gly Thr Leu Val Ser 100 105 110Val Ser Ser 115512115PRTHomo sapiens 512Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Lys Trp Val Ser Gly Ile Thr Gly Asp Ser 35 40 45Gly Ser Thr Tyr Tyr Ala Arg Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Ile Ser Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Phe Tyr Phe Cys Thr Arg Asp Arg Leu Pro Asn 85 90 95Gly Ile Gly Glu Leu His Asp His Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115513115PRTHomo sapiens 513Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Arg Thr Tyr Gly Met Asn Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ile Asp 35 40 45Pro Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Ile Leu Phe Leu Gln Met Asn Ser Leu Thr65 70 75 80Ala Asp Asp Thr Ala Val Tyr Tyr Cys Thr Lys Asp Arg Leu Ser Gly 85 90 95Ala Phe Gly Glu Leu Asn Glu Ser Trp Gly Gln Gly Thr Met Val Ile 100 105 110Val Ser Ser 115514115PRTHomo sapiens 514Gly Gly Ala Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Arg Asn Tyr Gly Val Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asn Thr Asp Gly 35 40 45Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asp Gly Leu Thr65 70 75 80Val Ala Asp Thr Ala Met Tyr Phe Cys Thr Lys Asp Arg Val Gln Gly 85 90 95Gly Phe Gly Glu Leu Phe His Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Pro 115515121PRTHomo sapiens 515Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ser Gly 35 40 45Gly Ala Ser Asp Asn Gly Ala Ser Arg Tyr Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg Phe Ser Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Lys Asp Arg Leu Ser Gly Gly Phe Gly Glu Leu Phe Gln Lys Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115 120516115PRTHomo sapiens 516Gly Gly Asp Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Thr Tyr Gly Met Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Leu Ser Ser Ile Ser Ser Val Asp 35 40 45Asp Ser Lys Tyr Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg65 70 75 80Val Asp Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Ile Pro His 85 90 95Gly Leu Gly Glu Leu Tyr Ala Asn Trp Gly Gln Gly Thr Leu Val Ala 100 105 110Val Ser Ser 115517115PRTHomo sapiens 517Gly Gly Asp Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Arg Thr Tyr Gly Met Thr Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Val Asp 35 40 45Asp Ser Thr Tyr Tyr Ala Lys Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Ile Thr Asn Leu Arg65 70 75 80Val Asp Asp Thr Ala Met Tyr Tyr Cys Ala Lys Asp Arg Ser Pro His 85 90 95Gly Leu Gly Glu Leu Tyr Gly Asp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115518113PRTHomo sapiens 518Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Leu Thr Phe Ser Thr Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Pro Gly Ser 35 40 45Gly Asp Asn Ile Tyr Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile 50 55 60Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu65 70 75 80Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Asn Gly Gly Phe Ser 85 90 95Gly Tyr Tyr Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser 100 105 110Ser519117PRTHomo sapiens 519Gly Gly Gly Leu Gly Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Gly1 5 10 15Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met Thr Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Asp Ile Ser Ala Asp Ser 35 40 45Asp Thr Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Ala Glu Asp Ser Ala Val Tyr Tyr Cys Ala Lys Val Lys Asp Ser Ser 85 90 95Gly Tyr Met Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr 100 105 110Val Thr Val Ser Ser 115520111PRTHomo sapiens 520Gly Gly Gly Leu Val Leu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Thr His Ala Met Thr Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser His Ser Gly 35 40 45Thr Thr Thr Tyr Tyr Ala Asp Ser Phe Arg Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Arg Leu Arg65 70 75 80Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Leu Tyr Asn Gly 85 90 95Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105 110521110PRTHomo sapiens 521Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Ile Ser Thr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Tyr Val Val Val Ile Ser His Asp Gly 35 40 45Asn Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Val Phe Leu Gln Met Asn Ser Leu Arg65 70 75 80Pro Val Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu Val Gly Tyr 85 90 95Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser 100 105 110522113PRTHomo sapiens 522Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Ser Phe Ser Ser His Ala Met Tyr Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ile Val Ser Tyr Asp Gly 35 40 45Ser Thr Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Ile Tyr Leu His Leu Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Glu Val Asp Gly Ile 85 90 95Tyr Gly Tyr Leu His Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser523114PRTHomo sapiens 523Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ile Ile Ser Tyr Asp Gly 35 40 45Asn Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Leu Asn Ser Leu Arg65 70 75 80Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asp Gly Thr Thr Val 85 90

95Thr Asn Phe Tyr Leu Asp Val Trp Gly Lys Gly Ser Thr Val Thr Val 100 105 110Ser Ser524110PRTHomo sapiens 524Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Val His Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Asp Trp Val Thr Val Leu Ser His Asp Gly 35 40 45Asn Ser Lys Tyr Tyr Thr Asp Ser Val Arg Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Ser Ser Lys Lys Thr Val Phe Leu Gln Met Asp Asn Leu Arg65 70 75 80Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe His Gly Tyr 85 90 95Leu Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105 110525116PRTHomo sapiens 525Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Gly1 5 10 15Val Ser Gly Tyr Ser Leu Thr Ser Gly Tyr Tyr Trp Ser Trp Ile Arg 20 25 30Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr His Thr 35 40 45Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Leu 50 55 60Val Asp Thr Ser Lys Asn His Phe Ser Leu Lys Leu Thr Ser Val Thr65 70 75 80Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Thr Glu Thr Ile Thr 85 90 95Ile Arg Gly Ala Val Ser Phe Asp Ile Trp Gly Gln Gly Arg Met Val 100 105 110Thr Val Ser Ser 115526123PRTHomo sapiens 526Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser1 5 10 15Val Ser Gly Tyr Phe Ile Ser Ser Gly His Tyr Trp Gly Trp Ile Arg 20 25 30Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile Ala Ser Ile Tyr Gln Ser 35 40 45Gly Ser Lys Phe Gln Thr Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Glu 50 55 60Ser Arg Val Thr Ile Ser Met Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95Arg Asp Ala Arg Ser Arg Ser Trp Asp Arg Thr Gly Phe Phe Gly Pro 100 105 110Trp Gly Gln Gly Ile Leu Val Thr Ile Ser Ser 115 12052715PRTHomo sapiens 527Ala Arg Asp Arg Gly Ile Glu Gly Leu Gly Glu Leu Tyr Ser His1 5 10 1552815PRTHomo sapiens 528Val Arg Asp Arg Ile Gln Gly Gly Phe Gly Glu Leu Tyr Arg Tyr1 5 10 1552912PRTHomo sapiens 529Ala Lys Asp Arg Asp His Phe Asp Gly His Asp Phe1 5 1053015PRTHomo sapiens 530Ala Lys Asp Arg Leu His Ser Gly Leu Gly Glu Leu Phe Ser Tyr1 5 10 1553115PRTHomo sapiens 531Ala Lys Asp Arg Leu Ala Ser Gly Ile Gly Glu Leu Phe Ser Ser1 5 10 1553215PRTHomo sapiens 532Ala Lys Asp Arg Met Ser Gly Gly Phe Gly Glu Leu Asn Glu Ser1 5 10 1553315PRTHomo sapiens 533Ala Lys Asp Arg Leu Asn Gly Gly Phe Gly Glu Leu Phe Ala Ser1 5 10 1553415PRTHomo sapiens 534Ala Arg Asp Arg Ile Lys Gly Gly Leu Gly Glu Leu Phe His Leu1 5 10 1553515PRTHomo sapiens 535Ala Lys Asp Arg Leu Ala Ala Gly Leu Gly Glu Leu Phe Ser His1 5 10 1553615PRTHomo sapiens 536Thr Arg Asp Arg Leu Pro Asn Gly Ile Gly Glu Leu His Asp His1 5 10 1553715PRTHomo sapiens 537Thr Lys Asp Arg Leu Ser Gly Ala Phe Gly Glu Leu Asn Glu Ser1 5 10 1553815PRTHomo sapiens 538Thr Lys Asp Arg Val Gln Gly Gly Phe Gly Glu Leu Phe His Ser1 5 10 1553915PRTHomo sapiens 539Ala Lys Asp Arg Leu Ser Gly Gly Phe Gly Glu Leu Phe Gln Lys1 5 10 1554015PRTHomo sapiens 540Ala Lys Asp Arg Ile Pro His Gly Leu Gly Glu Leu Tyr Ala Asn1 5 10 1554115PRTHomo sapiens 541Ala Lys Asp Arg Ser Pro His Gly Leu Gly Glu Leu Tyr Gly Asp1 5 10 1554212PRTHomo sapiens 542Val Asn Gly Gly Phe Ser Gly Tyr Tyr Ser Asp Tyr1 5 1054317PRTHomo sapiens 543Ala Lys Val Lys Asp Ser Ser Gly Tyr Met Tyr Tyr Tyr Tyr Met Asp1 5 10 15Val54411PRTHomo sapiens 544Ala Lys Asp Leu Tyr Asn Gly Tyr Phe Asp Tyr1 5 1054510PRTHomo sapiens 545Ala Arg Gly Glu Val Gly Tyr Phe Asp Leu1 5 1054613PRTHomo sapiens 546Ala Arg Glu Val Asp Gly Ile Tyr Gly Tyr Leu His Tyr1 5 1054714PRTHomo sapiens 547Ala Arg Asp Gly Thr Thr Val Thr Asn Phe Tyr Leu Asp Val1 5 1054810PRTHomo sapiens 548Ala Arg Asp Phe His Gly Tyr Leu Asp Ser1 5 1054916PRTHomo sapiens 549Ala Arg Thr Glu Thr Ile Thr Ile Arg Gly Ala Val Ser Phe Asp Ile1 5 10 1555017PRTHomo sapiens 550Ala Arg Asp Ala Arg Ser Arg Ser Trp Asp Arg Thr Gly Phe Phe Gly1 5 10 15Pro55196PRTHomo sapiens 551Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Asn Ser Trp Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Lys Ala Ser Thr Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Thr Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Tyr Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9555296PRTHomo sapiens 552Ser Ala Ser Val Gly Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln1 5 10 15Ser Val Asn Lys Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Ile Tyr Glu Thr Ser Ile Leu Glu Ser Gly Val Ser 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Gly Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Arg 85 90 9555396PRTHomo sapiens 553Ser Ala Ala Val Gly Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala 20 25 30Pro Lys Leu Leu Ile Ser Lys Ala Ser Asn Val Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Lys Tyr65 70 75 80Asn Ser Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Asp Ile Lys 85 90 9555496PRTHomo sapiens 554Ser Ala Ser Val Gly Asp Arg Val Asn Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Asn Gln Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Met Tyr Lys Ala Ser Thr Leu Glu Thr Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Phe Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9555596PRTHomo sapiens 555Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asp Met Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala 20 25 30Pro Lys Phe Leu Ile His Lys Ala Ser Thr Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 85 90 9555696PRTHomo sapiens 556Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala 20 25 30Pro Asn Leu Leu Ile Tyr Gln Ala Ser Ala Leu His Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Phe Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9555796PRTHomo sapiens 557Ser Ala Ser Val Gly Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile His Lys Ala Ser Ser Leu Glu Ser Gly Ile Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Asn Asn Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9555896PRTHomo sapiens 558Ser Ala Ser Val Gly Asp Arg Val Thr Ile Ile Cys Arg Ala Ser Arg1 5 10 15Ser Ile Asp Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Arg Leu Leu Ile His Lys Ala Ser Thr Leu His Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Phe Cys Gln His Tyr65 70 75 80Phe Ser Ser Pro Tyr Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9555996PRTHomo sapiens 559Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Gly Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile His Lys Ala Ser Thr Leu Glu Ser Gly Val Ser 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Asn Asn Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9556096PRTHomo sapiens 560Ser Ala Ser Val Gly Asp Arg Val Ser Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asp Met Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Lys Ala Ser Asn Leu Lys Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9556196PRTHomo sapiens 561Ser Ala Ser Ile Gly Ala Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asp Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala 20 25 30Pro Lys Leu Leu Ile Tyr Gln Ala Ser Thr Leu Tyr Asn Gly Val Pro 35 40 45Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Gly Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9556296PRTHomo sapiens 562Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Lys Phe Leu Met His Lys Ala Ser Ile Leu Glu Ser Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Ser Tyr Phe Cys Gln Gln Tyr65 70 75 80His Ser Tyr Pro Trp Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys 85 90 9556396PRTHomo sapiens 563Ala Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Asn Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Phe Leu Ile Tyr Lys Ala Ser Thr Leu Glu Ser Gly Ala Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9556496PRTHomo sapiens 564Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Arg Leu Leu Met His Lys Ala Ser Ile Leu Tyr Arg Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80His Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 85 90 9556596PRTHomo sapiens 565Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 20 25 30Pro Lys Leu Leu Met His Lys Ala Ser Asn Leu His Val Gly Val Pro 35 40 45Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Thr Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr65 70 75 80Phe Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 85 90 9556695PRTHomo sapiens 566Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Met Ala Pro Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Ser Asn Trp Leu Thr Phe Gly Gly Gly Thr Lys Ile Glu Ile Lys 85 90 9556796PRTHomo sapiens 567Ser Leu Ser Pro Gly Glu Arg Thr Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Ala Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Ile Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Gly Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Gly Lys Trp Pro Pro Ser Phe Gly Gly Gly Thr

Lys Val Glu Ile Lys 85 90 9556897PRTHomo sapiens 568Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Arg Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Gly Asn Trp Pro Pro Ala Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys56997PRTHomo sapiens 569Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Ser Asn Trp Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile 85 90 95Lys57095PRTHomo sapiens 570Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Arg Gln1 5 10 15Asn Val Arg Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Asp Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Ser Tyr Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Met Lys 85 90 9557196PRTHomo sapiens 571Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Ser Asn Gly Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 85 90 9557297PRTHomo sapiens 572Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Asn Phe Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Lys Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Ser Asn Trp Pro Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 85 90 95Lys57399PRTHomo sapiens 573Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Tyr Asn Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Asn Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Thr Ser Pro Pro Glu Phe Thr Phe Gly Arg Gly Thr Lys Val 85 90 95Glu Ile Lys57497PRTHomo sapiens 574Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Leu Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ser Pro Arg Leu Leu Ile Tyr Gly Thr Ser Ser Arg Asp Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Trp Gly Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 85 90 95Lys5759PRTHomo sapiens 575Gln His Tyr Tyr Ser Tyr Pro Trp Thr1 55769PRTHomo sapiens 576Gln His Tyr His Gly Tyr Pro Trp Thr1 55779PRTHomo sapiens 577Gln Lys Tyr Asn Ser Tyr Pro Phe Thr1 55789PRTHomo sapiens 578Gln His Tyr Phe Ser Tyr Pro Trp Thr1 55799PRTHomo sapiens 579Gln His Tyr His Ser Tyr Pro Trp Thr1 55809PRTHomo sapiens 580Gln His Tyr Phe Ser Tyr Pro Trp Thr1 55819PRTHomo sapiens 581Gln His Tyr His Ser Tyr Pro Trp Thr1 55829PRTHomo sapiens 582Gln His Tyr Phe Ser Ser Pro Tyr Ser1 55839PRTHomo sapiens 583Gln His Tyr His Ser Tyr Pro Trp Thr1 55849PRTHomo sapiens 584Gln His Tyr His Ser Tyr Pro Trp Thr1 55859PRTHomo sapiens 585Gln His Tyr His Ser Tyr Pro Trp Thr1 55869PRTHomo sapiens 586Gln Gln Tyr His Ser Tyr Pro Trp Thr1 55879PRTHomo sapiens 587Gln His Tyr Tyr Ser Tyr Pro Tyr Thr1 55889PRTHomo sapiens 588Gln His Tyr His Ser Tyr Pro Tyr Thr1 55899PRTHomo sapiens 589Gln His Tyr Phe Ser Tyr Pro Tyr Thr1 55908PRTHomo sapiens 590Gln Gln Arg Ser Asn Trp Leu Thr1 55919PRTHomo sapiens 591Gln Gln Arg Gly Lys Trp Pro Pro Ser1 559210PRTHomo sapiens 592Gln Gln Arg Gly Asn Trp Pro Pro Ala Thr1 5 1059310PRTHomo sapiens 593Gln Gln Arg Ser Asn Trp Pro Pro Ile Thr1 5 105948PRTHomo sapiens 594Gln Gln Arg Ser Tyr Ser Ile Thr1 55959PRTHomo sapiens 595Gln Gln Arg Ser Asn Gly Pro Leu Thr1 559610PRTHomo sapiens 596Gln Gln Arg Ser Asn Trp Pro Pro Leu Thr1 5 1059711PRTHomo sapiens 597Gln Gln Tyr Gly Thr Ser Pro Pro Glu Phe Thr1 5 105989PRTHomo sapiens 598Gln Gln Tyr Gly Ser Ser Trp Gly Thr1 5599112PRTHomo sapiens 599Gly Gly Ala Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Phe Thr Phe Asn Tyr Tyr Ala Met Thr Trp Val Arg Gln 20 25 30Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Thr Ile Thr Asp Asn Gly 35 40 45Gly Thr Thr Tyr Leu Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Gln Asn Thr Gln Ser Leu Gln Met Asn Asn Leu Arg65 70 75 80Ala Asp Asp Thr Ala Val Tyr Phe Cys Val Lys His Leu Arg Gly Trp 85 90 95Tyr Thr Phe Glu Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105 110600115PRTHomo sapiens 600Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala1 5 10 15Ala Ser Gly Tyr Ile Phe Asp Asn Tyr Ala Met Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Asn Gly Gly Gly 35 40 45Tyr Gly Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 50 55 60Arg Asp Asn Ser Lys Arg Ile Leu Tyr Leu Gln Met Asn Ser Leu Arg65 70 75 80Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Pro Tyr Val Gly 85 90 95Gly Tyr Gly Leu Pro Gly Asp Ser Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115601119PRTHomo sapiensMOD_RES(18)..(18)Any amino acidMOD_RES(27)..(27)Any amino acidMOD_RES(73)..(73)Any amino acidMOD_RES(80)..(80)Any amino acid 601Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr1 5 10 15Val Xaa Gly Gly Ser Ile Ser Arg Tyr Phe Xaa Ser Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Thr Gly 35 40 45Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ile Ile Leu Val 50 55 60Asp Thr Ser Lys Asn Gln Phe Ser Xaa Lys Leu Ser Ser Val Thr Xaa65 70 75 80Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro His Tyr Tyr Asp 85 90 95Ser Ser Ala Tyr Phe Thr Tyr Asn Gly Met Asp Val Trp Gly Gln Gly 100 105 110Thr Thr Val Thr Val Ser Ser 115602117PRTHomo sapiens 602Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr1 5 10 15Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Phe Ile Tyr Tyr Ser Gly 35 40 45Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val 50 55 60Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala65 70 75 80Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Tyr Asp 85 90 95Ser Ser Gly Tyr Leu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser 11560312PRTHomo sapiens 603Val Lys His Leu Arg Gly Trp Tyr Thr Phe Glu Ile1 5 1060415PRTHomo sapiens 604Ala Lys Ser Pro Tyr Val Gly Gly Tyr Gly Leu Pro Gly Asp Ser1 5 10 1560520PRTHomo sapiens 605Ala Arg Gly Pro His Tyr Tyr Asp Ser Ser Ala Tyr Phe Thr Tyr Asn1 5 10 15Gly Met Asp Val 2060618PRTHomo sapiens 606Ala Arg Gly Asp Tyr Tyr Tyr Asp Ser Ser Gly Tyr Leu Tyr Tyr Phe1 5 10 15Asp Tyr60798PRTHomo sapiens 607Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Gly Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Arg Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Phe Gly Ser Ser Pro Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu 85 90 95Ile Lys60897PRTHomo sapiens 608Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Thr Ile Phe Phe Asn Tyr Leu Ala Trp Tyr Gln Lys Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Val His Gly Ala Ser Thr Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Asn Ser Leu Asp Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Asp Ser Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Asp Ile 85 90 95Lys60998PRTHomo sapiens 609Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Val Ser Gln1 5 10 15Ser Val Ser Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Ser Ser Pro Pro Val Thr Phe Gly Gln Gly Thr Arg Leu Glu 85 90 95Ile Lys61096PRTHomo sapiens 610Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln65 70 75 80Tyr Gly Thr Ser Val Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 85 90 9561110PRTHomo sapiens 611Gln Gln Phe Gly Ser Ser Pro Arg Tyr Thr1 5 106129PRTHomo sapiens 612Gln Gln Tyr Gly Asp Ser Pro Pro Thr1 561310PRTHomo sapiens 613Gln Gln Tyr Gly Ser Ser Pro Pro Val Thr1 5 106148PRTHomo sapiens 614Gln Gln Tyr Gly Thr Ser Val Thr1 5615117PRTHomo sapiens 615Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Val Ser Cys Lys1 5 10 15Ala Ser Gly Asp Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe 35 40 45Gly Thr Ala Ser Tyr Ala Gln Arg Phe Gln Asp Arg Val Thr Ile Thr 50 55 60Ala Asp Lys Ser Thr Gly Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Phe Tyr Cys Ala Arg Gln Lys Cys Thr Gly 85 90 95Gly Ser Cys Tyr Ser Gly Asn Phe Asp Pro Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115616122PRTHomo sapiens 616Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Pro Gly Gly Thr Phe Ser Arg Tyr Ser Ile Ala Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Asn Pro Thr Phe 35 40 45Thr Thr Pro Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr 50 55 60Ala Asp Glu Ser Thr Asn Thr Ala Tyr Leu Asp Leu Ser Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Phe Arg Tyr Tyr Tyr 85 90 95Glu Ser Gly Gly Tyr Ser Asp Ala Ser Pro Tyr Tyr Leu Asp Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120617116PRTHomo sapiens 617Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr1 5 10 15Val Ser Gly Val Ser Ile Ser Ser Gly Gly Tyr Tyr Tyr Ser Trp Phe 20 25 30Arg Gln Leu Pro Gly Lys Gly Leu Glu Trp Ile Gly His Ile Tyr Tyr 35 40 45Thr Gly Asn Thr His Tyr Asn Pro Ser Leu Arg Ser Arg Leu Thr Ile 50 55 60Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val65 70 75 80Thr Ala Ala Asp Thr Ala Arg Tyr Tyr Cys Ala Arg Ala Trp Cys Glu 85 90 95Tyr Ala Ala Tyr Cys Trp Phe Asp Pro Trp Gly Arg Gly Thr Leu Val 100 105 110Thr Val Ser Ser 115618117PRTHomo sapiens 618Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr1 5 10 15Val Ser Gly Gly Ser Ile Thr Gly Gly Val Tyr Tyr Trp Asn Trp Ile 20 25 30Arg His His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Met Phe Tyr 35 40 45Ser Gly Asp Thr Asp Tyr Asn Pro Ser Leu Arg Ser Arg Val Thr Ile 50 55 60Ser Gly Asp Thr Ser Lys Asn Lys Phe Ser Leu Asn Leu Asn Ser Val65 70 75 80Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Phe Asp 85 90 95Tyr Gly Ser Pro Val Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr Met 100 105 110Val Thr Val Ser Ser 115619116PRTHomo sapiens 619Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu

Ser Leu Thr Cys Thr1 5 10 15Val Ser Gly Gly Ser Ile Ser Ser Tyr Asn Tyr Tyr Trp Gly Trp Ile 20 25 30Arg Gln Pro Pro Gly Lys Gly Leu Glu Phe Ile Gly Ser Ile Tyr Tyr 35 40 45Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Arg Ser Arg Val Thr Ile 50 55 60Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Thr Ser Val65 70 75 80Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Pro Gly 85 90 95Met Gly His Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val 100 105 110Thr Val Ser Ser 115620118PRTHomo sapiens 620Gly Pro Arg Leu Val Lys Pro Ser Glu Thr Leu Phe Leu Thr Cys Thr1 5 10 15Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Phe Trp Gly Trp Ile 20 25 30Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Ser Tyr 35 40 45Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile 50 55 60Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val65 70 75 80Thr Ala Ala Asp Thr Val Val Tyr Tyr Cys Ala Lys His Leu Tyr Ser 85 90 95Ser Ser Trp Asn Ile Gly Ser Ser Phe Asp Ser Trp Gly Pro Gly Thr 100 105 110Leu Val Thr Val Ser Ser 115621107PRTHomo sapiens 621Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Ser Cys Thr1 5 10 15Val Ser Ser Gly Ser Ile Ser Asn Tyr Tyr Trp Asn Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly 35 40 45Ser Ile Ser Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val 50 55 60Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Asn Ser Val Thr Ala65 70 75 80Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Asn Arg Tyr 85 90 95Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105622107PRTHomo sapiens 622Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr1 5 10 15Val Ser Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Asn Trp Ile Arg Gln 20 25 30Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly 35 40 45Ser Ile Ser Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val 50 55 60Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Asn Ser Val Thr Ala65 70 75 80Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Asn Arg Tyr 85 90 95Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105623115PRTHomo sapiens 623Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys1 5 10 15Ala Ser Gly Gly Ser Tyr Ser Thr Tyr Ala Ile Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ser Leu 35 40 45Gly Lys Thr His Leu Ala Gln Lys Phe Gln Gly Arg Val Thr Phe Thr 50 55 60Ala Asp Glu Ser Thr Thr Thr Val Tyr Met Val Leu Ser Ser Leu Lys65 70 75 80Ser Asp Asp Thr Ala Leu Tyr Tyr Cys Ala Thr Pro Asp Trp Gln Tyr 85 90 95Ser Ser Ala Tyr Ser Leu Asp His Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115624115PRTHomo sapiens 624Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys1 5 10 15Ala Ser Gly Gly Ser Tyr Ser Thr Tyr Ala Ile Ser Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ser Leu 35 40 45Gly Lys Thr His Leu Ala Gln Lys Phe Gln Gly Arg Val Thr Phe Thr 50 55 60Ala Asp Glu Ser Thr Thr Thr Val Tyr Met Ile Leu Ser Ser Leu Lys65 70 75 80Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Thr Pro Asp Trp Gln Tyr 85 90 95Ser Ser Ala Tyr Ser Leu Asp His Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115625116PRTHomo sapiens 625Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Thr Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met Asn Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Lys Pro Ser Asp 35 40 45Gly Ser Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Arg Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Gly Arg Asp Ser Lys Gly Trp 85 90 95Leu Gln Leu Arg Gly Asp Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110Thr Val Ser Ser 115626118PRTHomo sapiens 626Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys1 5 10 15Ala Ser Gly Tyr Thr Phe Thr Ser Thr Tyr Ile His Trp Val Arg Gln 20 25 30Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Ser 35 40 45Ser Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr 50 55 60Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg65 70 75 80Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Gly Gly Tyr 85 90 95Ser Ser Ser Ser Val Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110Met Val Thr Val Ser Ser 11562717PRTHomo sapiens 627Ala Arg Gln Lys Cys Thr Gly Gly Ser Cys Tyr Ser Gly Asn Phe Asp1 5 10 15Pro62822PRTHomo sapiens 628Ala Arg Phe Arg Tyr Tyr Tyr Glu Ser Gly Gly Tyr Ser Asp Ala Ser1 5 10 15Pro Tyr Tyr Leu Asp Tyr 2062915PRTHomo sapiens 629Ala Arg Ala Trp Cys Glu Tyr Ala Ala Tyr Cys Trp Phe Asp Pro1 5 10 1563016PRTHomo sapiens 630Ala Arg Ala Gly Phe Asp Tyr Gly Ser Pro Val Ser Ala Phe Asp Ile1 5 10 1563115PRTHomo sapiens 631Ala Arg His Gly Pro Gly Met Gly His Asn Trp Tyr Phe Asp Leu1 5 10 1563217PRTHomo sapiens 632Ala Lys His Leu Tyr Ser Ser Ser Trp Asn Ile Gly Ser Ser Phe Asp1 5 10 15Ser6338PRTHomo sapiens 633Ala Arg Gly Pro Asp Asn Arg Tyr1 56348PRTHomo sapiens 634Ala Arg Gly Pro Asp Asn Arg Tyr1 563515PRTHomo sapiens 635Ala Thr Pro Asp Trp Gln Tyr Ser Ser Ala Tyr Ser Leu Asp His1 5 10 1563615PRTHomo sapiens 636Ala Thr Pro Asp Trp Gln Tyr Ser Ser Ala Tyr Ser Leu Asp His1 5 10 1563716PRTHomo sapiens 637Gly Arg Asp Ser Lys Gly Trp Leu Gln Leu Arg Gly Asp Ile Asp Tyr1 5 10 1563818PRTHomo sapiens 638Ala Arg Asp Phe Gly Gly Tyr Ser Ser Ser Ser Val Ser Asp Ala Phe1 5 10 15Asp Ile63986PRTHomo sapiensMOD_RES(11)..(11)Any amino acidMOD_RES(46)..(46)Any amino acid 639Ser Gly Arg Ala Ile Glu Ser Val Ser Gly Xaa Leu Ala Trp Tyr Gln1 5 10 15Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn 20 25 30Arg Ala Thr Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Xaa Gly Thr 35 40 45Glu Phe Thr Leu Thr Ile Ser Ser Ala Glu Pro Glu Asp Phe Ala Val 50 55 60Tyr Tyr Cys His Gln Ser Ile Lys Trp Pro Pro Thr Phe Gly Gly Gly65 70 75 80Ser Lys Val Glu Ile Lys 8564091PRTHomo sapiens 640Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr1 5 10 15Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 20 25 30Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Thr Gly 35 40 45Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 50 55 60Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu65 70 75 80Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 85 9064197PRTHomo sapiens 641Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Thr Ser Ser Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Pro Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Trp Cys Gln Gln65 70 75 80Tyr Gly Arg Ser Pro Phe Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile 85 90 95Lys64299PRTHomo sapiens 642Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Ser Thr Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln 20 25 30Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 35 40 45Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 50 55 60Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln65 70 75 80Tyr Ala His Ser Pro Arg Gly Tyr Thr Phe Gly Gln Gly Thr Lys Leu 85 90 95Glu Ile Lys64395PRTHomo sapiens 643Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg65 70 75 80Ser Thr Trp Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 85 90 9564497PRTHomo sapiensMOD_RES(20)..(20)Any amino acidMOD_RES(37)..(37)Any amino acid 644Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Xaa Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Xaa Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 50 55 60Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly65 70 75 80Ser Lys Trp Pro Val Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 85 90 95Lys64598PRTHomo sapiens 645Ser Val Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Tyr Asn Leu Ala Trp His Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Asn Met Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr65 70 75 80Asn Asn Trp Pro Pro Val Phe Thr Phe Gly Pro Gly Thr Lys Val Asp 85 90 95Ile Lys64698PRTHomo sapiens 646Ser Val Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln1 5 10 15Ser Val Ser Tyr Asn Leu Ala Trp His Gln Gln Lys Pro Gly Gln Ala 20 25 30Pro Arg Leu Leu Ile Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro 35 40 45Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile 50 55 60Ser Asn Met Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr65 70 75 80Asn Asn Trp Pro Pro Val Phe Thr Phe Gly Pro Gly Thr Lys Val Asp 85 90 95Ile Lys647101PRTHomo sapiens 647Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln1 5 10 15Ser Leu Leu His Ser Thr Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln 20 25 30Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg 35 40 45Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 50 55 60Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr65 70 75 80Tyr Cys Met Gln Ala Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr 85 90 95Lys Val Asp Ile Lys 100648101PRTHomo sapiens 648Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln1 5 10 15Ser Leu Leu His Ser Thr Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln 20 25 30Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg 35 40 45Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 50 55 60Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr65 70 75 80Tyr Cys Met Gln Ala Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr 85 90 95Lys Val Asp Ile Lys 100649103PRTHomo sapiens 649Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys1 5 10 15Ala Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Leu Val Ser Trp Tyr 20 25 30Gln Gln His Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Glu Val Ser 35 40 45Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly 50 55 60Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala65 70 75 80Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Tyr Val Phe Gly 85 90 95Thr Gly Thr Glu Val Thr Val 100650103PRTHomo sapiens 650Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys1 5 10 15Thr Gly Thr Ser Ser Asp Val Gly Ser Phe Asn Leu Val Ser Trp Tyr 20 25 30Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Glu Val Ser 35 40 45Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly 50 55 60Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Val65 70 75 80His Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Arg Phe Val Phe Gly 85 90 95Thr Gly Thr Lys Val Thr Val 1006519PRTHomo sapiens 651His Gln Ser Ile Lys Trp Pro Pro Thr1 56529PRTHomo sapiens 652Gln Gln Arg Ser Asn Trp Pro Leu Thr1 56539PRTHomo sapiens 653Gln Gln Tyr Gly Arg Ser Pro Phe Thr1 565411PRTHomo sapiens 654Gln Gln Tyr Ala His Ser Pro Arg Gly Tyr Thr1 5 106558PRTHomo sapiens 655Gln Gln Arg Ser Thr Trp Leu Thr1 565610PRTHomo sapiens 656Gln Gln Gly Ser Lys Trp Pro Val Tyr Thr1 5 1065711PRTHomo sapiens 657Gln Gln Tyr Asn Asn Trp Pro Pro Val Phe Thr1 5 1065811PRTHomo sapiens 658Gln Gln Tyr Asn Asn Trp Pro Pro Val Phe Thr1 5 106599PRTHomo sapiens 659Met Gln Ala Leu Gln Thr Pro Phe Thr1 56609PRTHomo sapiens 660Met Gln Ala Leu Gln Thr Pro Phe Thr1

566110PRTHomo sapiens 661Cys Ser Tyr Ala Gly Ser Ser Thr Tyr Val1 5 1066210PRTHomo sapiens 662Cys Ser Tyr Ala Gly Ser Ser Arg Phe Val1 5 1066311PRTHomo sapiens 663Ala Arg Thr Ala Gly Asp Tyr Gly Met Asp Val1 5 1066412PRTHomo sapiens 664Tyr Arg Val Val Ala Phe Asp Asp Pro Val Asn Ile1 5 1066521PRTHomo sapiens 665Ala Arg Leu Pro Ala Tyr Tyr Asp Ile Leu Thr Gly His Ile Lys Gly1 5 10 15Gly Tyr Phe Asp Tyr 2066618PRTHomo sapiens 666Ala Arg Leu Gly Gly Phe Ser Arg Thr Leu Tyr Ser Tyr Tyr Ser Met1 5 10 15Asn Val66718PRTHomo sapiens 667Ala Arg Gly Asp Tyr Arg Ser Ser Tyr Gly Tyr Arg Tyr Tyr Gly Phe1 5 10 15Asp Val66815PRTHomo sapiens 668Ala Lys Asp Leu Tyr Ser Ser Gly Trp Tyr Met Gly Pro Asp Tyr1 5 10 1566917PRTHomo sapiens 669Ala Arg Asp Leu Trp Asp Lys Tyr Ser Ser Ser Leu Gly Ala Phe His1 5 10 15Ile67012PRTHomo sapiens 670Ala Arg Asn Gln Pro Gly Gly Arg Ala Phe Asp Phe1 5 1067117PRTHomo sapiens 671Ala Arg Lys Lys Gly Gly Tyr Gly Ser His Tyr Tyr Tyr Gly Met Asp1 5 10 15Val67212PRTHomo sapiens 672Gly Arg Thr Phe Thr Ser Ala Pro Phe Val Asp Gln1 5 1067312PRTHomo sapiens 673Ala Arg His Leu Pro Tyr Tyr Tyr Gly Met Asp Val1 5 1067418PRTHomo sapiens 674Ala Arg Gly Arg Arg Arg Ile Gln Gly Val Gly Glu Tyr Ser Gly Met1 5 10 15Asp Val67511PRTHomo sapiens 675Ala Ser His Asp Tyr Gly Gly Asn Phe Arg Val1 5 1067612PRTHomo sapiens 676Ala Arg Val Gly Gly Arg Val Trp Trp Phe Asp Pro1 5 1067715PRTHomo sapiens 677Ala Lys Tyr Arg Asp Leu Trp Ser Gly Tyr Asp Ala Phe Asp Ile1 5 10 156789PRTHomo sapiens 678Ala Thr Val Ile Arg His Phe Asp Asn1 567912PRTHomo sapiens 679Ala Lys Val Gln Thr Phe Val Gly Ala Phe Asp Leu1 5 1068013PRTHomo sapiens 680Ala Arg Asp Tyr Gly Asn Met Arg Tyr Gly Met Asp Gly1 5 1068112PRTHomo sapiens 681Ala Arg Gly Leu Arg Phe Leu Tyr Gly Met Asp Val1 5 1068224PRTHomo sapiens 682Ala Ser Glu Asn Leu Ile Ser Gln Gly His Cys Thr Gly Ala Ile Cys1 5 10 15Tyr Ser Thr Tyr Gly Met Asp Val 2068326PRTHomo sapiens 683Ala Arg Asp Ser Pro Tyr Tyr Tyr Asp Ala Thr Gly Ser Pro Leu Leu1 5 10 15Gly Pro Gly Thr Leu Val Thr Val Ser Ser 20 2568416PRTHomo sapiens 684Ala Asn His Trp Gly Ser Ala Val Met Val Thr Gly Tyr Phe Asp Tyr1 5 10 1568516PRTHomo sapiens 685Thr Arg Val Arg Trp Asp Gly Ile Glu Ser Thr Met Phe Phe Asp Ser1 5 10 1568616PRTHomo sapiens 686Ala Arg Val Lys Met Ala Asn Gly Ala Ile Pro Pro Tyr Phe Asp His1 5 10 1568716PRTHomo sapiens 687Val Arg Val Asn Arg Leu His Ser Gly Ser Tyr Phe Ser Phe Asp Tyr1 5 10 1568818PRTHomo sapiens 688Ala Arg Leu Gly Leu Ile Gln Ser Leu Arg Asn Tyr Tyr Tyr Gly Leu1 5 10 15Asp Val68911PRTHomo sapiens 689Thr Thr Ala Ile Arg Val Thr Gly Met Asp Val1 5 1069011PRTHomo sapiens 690Ala Arg Gly Trp Ser Asp Asn Ser Met Asp Val1 5 1069114PRTHomo sapiens 691Val Thr Leu Leu His Asp Tyr Gly Asp Tyr Ser Phe Asp Tyr1 5 1069215PRTHomo sapiens 692Ala Arg Gly Asn Ile Thr His Tyr Asp Leu Leu Pro Cys Asp Ser1 5 10 1569311PRTHomo sapiens 693Ser Leu Gly Arg Ile Asn Tyr Phe Phe Asp Tyr1 5 1069410PRTHomo sapiens 694Ala Arg Ala Ser Gln Leu Val Pro Asp Tyr1 5 1069514PRTHomo sapiens 695Ala Arg Gly Gly Pro Ile Asn Val Pro Leu Gly Phe Asp Pro1 5 1069622PRTHomo sapiens 696Ala Arg Asp Glu Gly Gly Pro Asn Cys Ser Gly Gly Asn Cys Tyr Tyr1 5 10 15Tyr Tyr Gly Met Asp Val 2069713PRTHomo sapiens 697Ala Asn Gly Gly Trp Gln Val Pro His Trp Phe Asp Pro1 5 1069815PRTHomo sapiens 698Ala Arg Ala Arg Ser Gly Tyr Ser Leu Gly Tyr Tyr Phe Asp Tyr1 5 10 1569915PRTHomo sapiens 699Ala Lys Val Ser Arg Pro Lys Gly Ala Gln Ala Ser Phe Asp Pro1 5 10 1570015PRTHomo sapiens 700Ala Thr Pro Lys Gly Gly Tyr Ser Gly Tyr Asp Gln Leu Asp Tyr1 5 10 1570118PRTHomo sapiens 701Ala Arg Pro Gly Tyr Thr Phe Gly Tyr His Ser Tyr Tyr Tyr Ala Met1 5 10 15Asp Val7026PRTHomo sapiens 702Ala Arg Gly Ile Asp Tyr1 570322PRTHomo sapiens 703Ala Arg Gly Ser Leu Arg Gly Thr Asn Gly Trp His Ser His Leu Gly1 5 10 15Tyr Tyr Gly Met Asp Val 2070415PRTHomo sapiens 704Ala Arg Ser Arg Leu Arg Tyr Ser Ser Ser Trp Tyr Phe Asp Tyr1 5 10 1570516PRTHomo sapiens 705Ala Arg Asp Ile Leu Pro His Gly Thr His Gly Trp Tyr Phe Asp Val1 5 10 1570612PRTHomo sapiens 706Ala Arg Ala Lys Gly Met Ile Ala Glu Leu Asp Tyr1 5 1070710PRTHomo sapiens 707Gln Ala Trp Asp Ser Ser Thr Ala Val Val1 5 1070811PRTHomo sapiens 708Gln Ser Ala Asp Thr Asn Gly Ser Ser Trp Ile1 5 107099PRTHomo sapiens 709Gln Gln Tyr Tyr Thr Thr Pro Gln Thr1 57109PRTHomo sapiens 710Gln Gln Ser Gly Ser Leu Pro Trp Thr1 571111PRTHomo sapiens 711Gln Ser Ala Asp Thr Asn Gly Ser Ser Trp Ile1 5 1071211PRTHomo sapiens 712Gln Ser Tyr Asp Ser Ser Leu Ser Gly Tyr Val1 5 107139PRTHomo sapiens 713Gln Gln Tyr Asn Asn Trp Pro Leu His1 571411PRTHomo sapiens 714Gln Glu Arg Asp Asn Trp Pro Leu Thr Trp Pro1 5 107159PRTHomo sapiens 715Gln Gln Asp Tyr Ser Leu Pro Thr Thr1 57169PRTHomo sapiens 716Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr1 57179PRTHomo sapiens 717Gln Gln Tyr Asn Asn Trp Pro Pro Thr1 571811PRTHomo sapiens 718Met Gln Ser Leu Gln Thr Pro Arg Ala Leu Thr1 5 107199PRTHomo sapiens 719Gln Gln Tyr Gly Ser Ser Pro Arg Thr1 57209PRTHomo sapiens 720Gln Gln Thr Tyr Ser Thr Pro Trp Thr1 57218PRTHomo sapiens 721Gln Gln Tyr Gly Ser Ser Leu Thr1 572210PRTHomo sapiens 722Gln Gln Tyr Asp Asn Leu Pro Gly Phe Thr1 5 1072311PRTHomo sapiens 723Gln His Tyr Asp Ser Leu Pro Leu Leu Ile Ser1 5 1072410PRTHomo sapiens 724Gln Gln Asn Asp Asp Ala Arg Ala Leu Thr1 5 107258PRTHomo sapiens 725Gln His Tyr Asp Ser Ser Ile Thr1 57269PRTHomo sapiens 726Gln Gln Ser Tyr Thr Val Pro Arg Thr1 57279PRTHomo sapiens 727Gln Gln Tyr Asn Ser Tyr Pro Arg Thr1 57289PRTHomo sapiens 728Gln Gln Tyr Tyr Ser Tyr Pro Arg Thr1 572912PRTHomo sapiens 729Ser Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val Val1 5 107309PRTHomo sapiens 730Gln Gln Leu Ile Ser Tyr Pro Pro Thr1 573110PRTHomo sapiens 731Cys Ser Tyr Ala Ala Gly Ser Thr Phe Val1 5 107329PRTHomo sapiens 732Gln Ala Trp Asp Ser Arg Ser Val Val1 57339PRTHomo sapiens 733Gln Ser Tyr Asp Ser Ser His Tyr Val1 57349PRTHomo sapiens 734Gln Gln Tyr Gly Ser Ser Pro Ile Thr1 57359PRTHomo sapiens 735Gln Gln Ser Ser Ser Ile Pro Tyr Thr1 57369PRTHomo sapiens 736Gln Gln Tyr Tyr Ser Thr Pro His Thr1 57379PRTHomo sapiens 737Gln Gln Leu Asn Ser Tyr Pro Leu Thr1 57388PRTHomo sapiens 738Gln Gln Arg Ser Asn Trp Leu Thr1 57399PRTHomo sapiens 739His Gln Tyr Val Ser Ser Pro Leu Thr1 57409PRTHomo sapiens 740Asn Asn Met Ile Leu Ser Leu Gln Leu1 57419PRTHomo sapiens 741Gln Gln Ser Tyr Ser Ile Pro Leu Thr1 57428PRTHomo sapiens 742Gln Gln Tyr Asp Asp Leu Leu Thr1 57439PRTHomo sapiens 743Leu Gln Asp Tyr Asp Tyr Pro Leu Ser1 57449PRTHomo sapiens 744Gln Gln Ser Tyr Asn Phe Pro Arg Thr1 57456PRTHomo sapiens 745Gln Gln Arg Ala Gly Thr1 57469PRTHomo sapiens 746Thr Gln Ala Thr Gln Phe Pro Trp Thr1 57479PRTHomo sapiens 747His Gln Ser Phe Ser Ser Pro Asp Thr1 574810PRTHomo sapiens 748Gln Gln Tyr Tyr Ser Thr Pro Arg Ile Thr1 5 1074910PRTHomo sapiens 749Gln His Arg Arg Asp Trp Pro Arg Tyr Thr1 5 1075010PRTHomo sapiens 750Gln Gln Tyr Arg Asp Thr Pro Ser Tyr Thr1 5 1075123PRTHomo sapiens 751Thr Thr Glu Ile Gly Leu Gly Gly Pro Asn Thr Pro Ser Ala Gln Leu1 5 10 15Tyr Tyr Tyr Gly Ile Asp Val 2075210PRTHomo sapiens 752Ala Ser Phe Arg Ser Gly Ala Phe Glu Ile1 5 1075320PRTHomo sapiens 753Ala Arg Val Arg Tyr Glu Tyr Asp Ser Gly Gly Tyr Tyr Tyr Val Tyr1 5 10 15Asp Phe Glu Tyr 2075419PRTHomo sapiens 754Ala Arg Val Ala Leu Ser Ser Ser Ser Phe Gly Glu His Tyr Tyr Gly1 5 10 15Val Asp Val75515PRTHomo sapiens 755Ala Arg Ala Gly Thr Val Phe Ala Gly His Tyr Gly Met Asp Val1 5 10 1575624PRTHomo sapiens 756Ala Lys Asp Pro Arg Arg Asp Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr1 5 10 15Pro Ser Arg Gly His Phe Asp Tyr 2075713PRTHomo sapiens 757Ala Arg Ile Ile Thr Arg Asn Gly Asp Ala Phe Asp Ile1 5 1075813PRTHomo sapiens 758Ala Lys Phe Gln Ser Ser Asn Trp Ser Pro Phe Asp Ser1 5 1075913PRTHomo sapiens 759Ala Arg Gly Val Trp Phe Gly Glu Phe Ala Val Gly Tyr1 5 1076013PRTHomo sapiens 760Ile Thr Gly Ile Phe Lys Ser Thr Trp Lys Thr Asp Tyr1 5 1076113PRTHomo sapiens 761Ala Arg Glu Ser Asp Phe Asn Tyr Gly Ala Val Asp His1 5 1076214PRTHomo sapiens 762Ala Lys Thr Gln Gly Tyr Asn Pro Asn Trp Pro His Asp Phe1 5 1076310PRTHomo sapiens 763Ala Lys Asp Gly Arg Gly Ser Ile Asp Tyr1 5 1076413PRTHomo sapiens 764Glu Arg Asp Ile Val Trp Gly Val Ala Gly Thr Asp Tyr1 5 1076511PRTHomo sapiens 765Ala Arg Glu Asn Ile Ala Val Phe Phe Asp Ile1 5 1076615PRTHomo sapiens 766Ala Arg Asp Lys Arg Tyr Ser Ser Gly Trp Tyr Tyr Phe Glu Ser1 5 10 1576712PRTHomo sapiens 767Val Lys Pro Ser Val Thr Thr His Tyr Phe Asp Tyr1 5 1076819PRTHomo sapiens 768Ala Arg Asp His Ser Pro Gly Thr Thr Trp Gly Asn Tyr Asn Tyr Gly1 5 10 15Met Asp Val76920PRTHomo sapiens 769Ala Arg Asp Ser Arg Tyr Tyr Asp Ser Arg Ser Ser Tyr Tyr Tyr Tyr1 5 10 15Gly Met Asp Val 2077015PRTHomo sapiens 770Ala Arg Val Ala Arg Pro Gly Gly Tyr Gly Arg Thr Phe Asp Glu1 5 10 1577115PRTHomo sapiens 771Ala Arg Val Arg Glu Arg Tyr Tyr Tyr Phe Tyr Gly Leu Asp Val1 5 10 1577212PRTHomo sapiens 772Ala Lys Gly Val Ala Ala Pro Gly Tyr Phe Glu Tyr1 5 1077311PRTHomo sapiens 773Val Ala Trp Asp Asp Ser Leu Ser Gly Arg Val1 5 107749PRTHomo sapiens 774Gln Gln Tyr Gly Ser Ser Ala Val Ser1 57758PRTHomo sapiens 775Cys Ser Tyr Ala Gly Ser Tyr Val1 577610PRTHomo sapiens 776Gln Gln Tyr Gly Gly Ser Pro Leu Phe Thr1 5 107779PRTHomo sapiens 777Gln Gln Tyr Lys Ser Tyr Pro Leu Thr1 577810PRTHomo sapiens 778Ser Ser Tyr Ala Gly Ser Arg Thr Trp Val1 5 107798PRTHomo sapiens 779Cys Ser Tyr Ala Gly Ser Tyr Thr1 57809PRTHomo sapiens 780Gln Gln Tyr Gly Asn Leu Pro Arg Thr1 578112PRTHomo sapiens 781Gln Gln Tyr Asn Asn Trp Pro Pro Arg Gly Ala Thr1 5 107828PRTHomo sapiens 782Gln Gln Arg Ser Asn Gly Trp Thr1 57839PRTHomo sapiens 783Gln Gln Tyr Asn Asn Trp Pro Tyr Thr1 57849PRTHomo sapiens 784Gln Gln Leu Asn Gly His Pro Arg Thr1 578510PRTHomo sapiens 785Met Gln Ser Ile Gln Leu Pro Pro Ile Thr1 5 107869PRTHomo sapiens 786Gln Tyr Tyr Gly Asp Ser Pro Arg Pro1 57879PRTHomo sapiens 787Gln Gln His Asp Asn Leu Gln Val Ile1 57888PRTHomo sapiens 788Gln His Arg Ala Asn Trp Pro Thr1 578910PRTHomo sapiens 789Gln Gln Arg Ser Asn Trp Pro Pro Phe Thr1 5 107909PRTHomo sapiens 790Gln Gln Ser Tyr Ser Thr Pro Gln Thr1 57919PRTHomo sapiens 791Met Gln Ala Leu Gln Thr Pro Lys Thr1 57928PRTHomo sapiens 792Gln Gln Ser Tyr Ser Asp Phe Ser1 57938PRTHomo sapiens 793Met Gln Ala Leu Gln Thr Phe Thr1 579410PRTHomo sapiens 794Gln Gln Arg Ser Asn Trp Pro Pro Ile Thr1 5 1079517PRTHomo sapiens 795Ala Arg Gly Asn Ser Tyr Gly Ser Gly Asn Leu Gly Tyr Tyr Leu Asp1 5 10 15Phe79616PRTHomo sapiens 796Ala Arg Gly Pro Asp Tyr Asn Asp Thr Pro Gly Tyr Tyr Gly Asn Tyr1 5 10 1579720PRTHomo sapiens 797Ala Arg Gly Ala His Tyr Tyr Asp Ser Ser Gly Tyr Arg Gln Leu Tyr1 5 10 15Gly Leu Asp Val 2079812PRTHomo sapiens 798Ala Arg Ala Asn Val Ala Thr Arg Tyr Phe Asp Tyr1 5 1079914PRTHomo sapiens 799Ala Arg Leu Arg Val Arg Gly Ala Gly Trp Ala Phe Asp Leu1 5 1080020PRTHomo sapiens 800Ala Lys Ser Asp Tyr Tyr Gly Ser Gly His Tyr Thr Thr Ile Pro Ser1 5 10 15Ser Phe Glu Asp 2080115PRTHomo sapiens 801Ala Arg His Pro Thr Gln Asn Tyr Ala Ser Gly Asp Tyr Tyr Thr1 5 10 1580214PRTHomo sapiens 802Ala Lys Gly Ala Arg Ile Thr Val Phe Gly Gly Leu Asp Val1 5 1080318PRTHomo sapiens 803Ala Arg Pro Tyr Phe Asp Gly Arg Ser Asn Ser Asn Leu Ile Phe Phe1 5 10 15Asp Tyr80420PRTHomo sapiens 804Ala Arg Val Ile Val Val Val Val Ala Ala Thr Ser Asp Leu Pro Val1 5 10 15Gly Phe Asp Pro 2080514PRTHomo sapiens 805Ala Arg Trp Leu Asp Asn Gly Ile Gln Gly Lys Tyr Asp Tyr1 5 1080616PRTHomo sapiens 806Ala Arg Gly Pro Val Trp Phe Gly Glu Tyr Gly Gly Ala Phe Asp Pro1 5 10 1580714PRTHomo sapiens 807Ala Arg Ala Lys Gly Arg Gly Leu Gln Asn Trp Phe Asp Pro1 5 1080825PRTHomo sapiens 808Ala Arg Val Ser Pro Leu Trp Asp Tyr Tyr Asp Ser Gly Pro Tyr Tyr1 5 10 15Asn Asp Phe Tyr Tyr Gly Met Asp Val 20 2580911PRTHomo sapiens 809Ser Thr Trp Asp Asp Ser Leu Asn Gly Pro Val1 5 108106PRTHomo sapiens 810His His Tyr Gly Arg Thr1 581110PRTHomo sapiens 811Gln Gln Arg Ala Asn Trp Pro Ala Leu Thr1 5 108129PRTHomo sapiens 812Gln His Leu Ser Thr Tyr Pro Ile Thr1 581311PRTHomo sapiens 813Gln Gln Arg Ser Asn Trp Pro Pro Ala Ile Thr1 5 108149PRTHomo sapiens 814Gln Gln Tyr Asn Asn Trp Pro Leu Thr1 58159PRTHomo sapiens 815Gln Gln Leu Thr Thr Tyr Pro Gly Thr1 58169PRTHomo sapiens 816Gln Gln Tyr Met Ser Leu Pro Tyr Ser1 581711PRTHomo sapiens 817Gln Gln Tyr Asn Thr Trp Pro Pro Ala Leu Thr1 5 108189PRTHomo sapiens 818Gln His Tyr His Ser Tyr Pro Trp Thr1 58198PRTHomo sapiens 819Gln Gln Arg His Glu Trp Pro Val1 58209PRTHomo sapiens 820Ser Asn Met Leu Gly His Arg Ser Pro1 582110PRTHomo sapiens 821Gln Gln Tyr Gly Ser Ser Pro Pro Ile Thr1 5 108226PRTHomo sapiens 822Gln Gln His Met Tyr Thr1 582316PRTHomo sapiens 823Ala Arg Gly Gly Asp Gly Tyr Thr Thr Arg Trp Phe Tyr Phe Asn His1 5 10 1582419PRTHomo sapiens 824Ala Arg Leu Gly Ala Glu Tyr Tyr Val Asp Ser Ser Gly Tyr Arg Gly1 5 10 15Ile Asp His82521PRTHomo sapiens 825Ala Arg Val Glu Arg Gly His Thr Tyr Gly Leu Asn Tyr Tyr Tyr Tyr1 5 10 15Tyr Gly Met Asp Val 2082618PRTHomo sapiens 826Ala

Arg Asp Ser Ser Asn Thr Phe His His Asp Ser Ser Gly Tyr Phe1 5 10 15Asp Asn82716PRTHomo sapiens 827Ala Arg Leu Ile Pro Gly Ser Gly Trp Arg Lys Gly Gly Phe Asp Tyr1 5 10 1582819PRTHomo sapiens 828Ala Arg Asp Ser Gly Trp Ser Gly Ile Thr Thr Val Arg Gly Val Pro1 5 10 15Pro Asp Phe82916PRTHomo sapiens 829Ala Arg Gly Tyr Phe Tyr Thr Ser Ser Asn Tyr Tyr Asn Thr Asp His1 5 10 1583020PRTHomo sapiens 830Ala Arg Asp Arg Phe Ser Arg His Tyr Gly Ser Gly Ser Leu His Tyr1 5 10 15Ala Met Asp Val 2083112PRTHomo sapiens 831Ala Thr Gly Tyr Gly Gly Asn Phe Ala Phe Asp Met1 5 1083212PRTHomo sapiens 832Ala Ser Gly Gly Tyr Gly Val Tyr Gly Phe Asp Tyr1 5 1083314PRTHomo sapiens 833Ala Arg Ala His Ser Tyr Tyr Val Tyr Tyr Tyr Met Asp Val1 5 1083421PRTHomo sapiens 834Val Arg His Gly Pro His Pro Gly Val Leu Val Trp Phe Gly Glu Gln1 5 10 15Ser Lys Ile Asp Tyr 2083522PRTHomo sapiens 835Ala Lys Asp Ile Gly Asn Ile Ala Gly Val Ala Gln Gly Ile Tyr Phe1 5 10 15Tyr Phe Gly Met Asp Val 2083612PRTHomo sapiens 836Ala Arg Lys Ser Tyr Gly Asp Pro Phe Phe Asp Tyr1 5 1083712PRTHomo sapiens 837Ala Ser Ser Val Met Val Val Ala Gln Phe Asp Ser1 5 1083814PRTHomo sapiens 838Ala Thr Gly Ala Gly Tyr Ser Tyr Pro Val Ala Met Asp Val1 5 1083913PRTHomo sapiens 839Ala Arg Ile Ile Ile Asn Arg Gly Gln Ser Phe Asp Tyr1 5 1084020PRTHomo sapiens 840Ala Arg Asn Ala Pro Lys Val Phe Gly Ser Gly Ser Tyr Tyr Ser Asn1 5 10 15Trp Phe Asp Pro 2084112PRTHomo sapiens 841Ala Arg Ser Tyr Ser Glu Val Leu Val Gly Tyr Asp1 5 108429PRTHomo sapiens 842Gln Gln Tyr Tyr Ser Ala Pro Leu Thr1 584310PRTHomo sapiens 843Met Gln Ala Leu Gln Thr Leu Ser Leu Thr1 5 1084412PRTHomo sapiens 844Ala Ala Trp Asp Asp Ser Leu Arg Gly His Trp Val1 5 108459PRTHomo sapiens 845Gln Thr Trp Gly Thr Gly Ile Arg Val1 58469PRTHomo sapiens 846Gln His Tyr Lys Asn Trp Pro Gly Thr1 584711PRTHomo sapiens 847Leu His Tyr Asn Asn Trp Pro Pro Arg Tyr Thr1 5 108489PRTHomo sapiens 848Gln Gln Tyr Lys Ser Tyr Pro Phe Thr1 584910PRTHomo sapiens 849Gly Ser Tyr Thr Ser Thr Ser Thr Cys Val1 5 108509PRTHomo sapiens 850Met Gln Ala Leu Gln Thr Pro Pro Thr1 58519PRTHomo sapiens 851His Gln Tyr Asn Ala Tyr Pro Trp Thr1 585210PRTHomo sapiens 852Gln Gln Tyr Asn Asn Trp Leu Pro Ile Thr1 5 108539PRTHomo sapiens 853Gln Gln Tyr Tyr Thr Thr Pro Leu Thr1 585410PRTHomo sapiens 854Gln Arg Leu Asn Ser Tyr Pro Arg Val Thr1 5 1085510PRTHomo sapiens 855Ser Ser Tyr Thr Ser Arg Ser Thr Trp Val1 5 108569PRTHomo sapiens 856Gln Gln Tyr Gly Asn Ser Pro Trp Thr1 58579PRTHomo sapiens 857Met Gln Ala Leu Gln Thr Pro Tyr Thr1 58588PRTHomo sapiens 858Cys Ser Tyr Ala Gly Lys Tyr Val1 58599PRTHomo sapiens 859Gln Gln Arg Leu Tyr Trp Pro Val Thr1 58608PRTHomo sapiens 860Gln Gln Arg Ser Asn Trp Leu Thr1 586117PRTHomo sapiens 861Ala Lys Asp Arg Thr Gly Asn Ile Gly Ala Gly Thr Gly Tyr Phe Asp1 5 10 15Lys86214PRTHomo sapiens 862Ala Arg Thr Pro Arg Glu Tyr Ile Ala Glu Tyr Phe Gln His1 5 1086317PRTHomo sapiens 863Ala Arg Val Lys Leu Arg Asp Gly Ser Ser Trp Tyr His Ala Phe Asp1 5 10 15Ile86417PRTHomo sapiens 864Ala Arg Trp Gly Leu Ser Ser Ala Trp Val Ala Pro Leu Gly Phe Asp1 5 10 15Tyr86521PRTHomo sapiens 865Ala Arg Glu Leu Leu Tyr Ser Gly Arg Gln Thr Tyr Tyr Tyr Ser Tyr1 5 10 15Tyr Gly Met Asp Val 2086619PRTHomo sapiens 866Ala Arg Arg Gln Gly Ala His Gly Arg Asp Leu Gly Phe His Tyr Ala1 5 10 15Met Asp Val86710PRTHomo sapiens 867Ala Arg Asp Gly Ala Ala Ala Gly Asp Tyr1 5 1086820PRTHomo sapiens 868Gly Asn Leu Ala Thr Val Gly Ala Thr Ala Pro Tyr Tyr Asn Tyr Tyr1 5 10 15Gly Met Tyr Val 2086911PRTHomo sapiens 869Ala Arg Gly Met Ala Thr Pro Ala Leu Leu Asn1 5 1087017PRTHomo sapiens 870Ala Arg Gly His Asn Lys Trp Leu Gln Leu Asn Phe Tyr Ala Met Asp1 5 10 15Val87118PRTHomo sapiens 871Leu Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu1 5 10 15Thr Leu87217PRTHomo sapiens 872Val Lys Gly Gly Tyr Asn Ser Val Trp Ser Asn Ser Tyr Gly Met Asp1 5 10 15Val87319PRTHomo sapiens 873Ala Arg Ala Leu Tyr Val Arg Gly Tyr Asn Tyr Gly Phe Leu Tyr Gly1 5 10 15Met Asp Val87419PRTHomo sapiens 874Ala Lys Gly Gly Pro Thr Ala Arg Val Leu Ser Gly Gln Leu Tyr Tyr1 5 10 15Phe Asp Tyr87528PRTHomo sapiens 875Ala Arg Gly Pro Ser Gly Leu Ala Val Ala Gly Thr Val Gly Glu Arg1 5 10 15Asp Arg Asn Tyr His Tyr Tyr Tyr Gly Met Asp Val 20 2587617PRTHomo sapiens 876Ala Arg Leu Gly Asp Ile Leu Thr Gly Tyr Val Asp Tyr Gly Met Asp1 5 10 15Val87713PRTHomo sapiens 877Ala Arg Ser Pro Ile Tyr Gly Asp Tyr Gly Phe Asp Pro1 5 1087817PRTHomo sapiens 878Ala Arg Thr His Cys Thr Gly Gly Ser Cys Phe Ser Ser Ser Phe Asp1 5 10 15Tyr87921PRTHomo sapiens 879Ala Arg Asp Arg Asp Tyr Gly Ser Gly Ser Gln Pro Leu Tyr Tyr Tyr1 5 10 15Tyr Ala Met Asp Val 2088011PRTHomo sapiens 880Ala Arg Val Leu Gly Asn Trp Gly Phe Asp Tyr1 5 1088120PRTHomo sapiens 881Ala Arg Gly Gly Lys Arg Leu Gly Glu Leu Ser Leu Phe His Tyr Tyr1 5 10 15Gly Met Asp Val 2088217PRTHomo sapiens 882Ala Arg His Arg Arg Gly Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Asp1 5 10 15Tyr88312PRTHomo sapiens 883Thr Arg Tyr Ser Tyr Gly Phe Ser Tyr Phe Asp Tyr1 5 1088414PRTHomo sapiens 884Ala Arg Ala Pro Thr Arg Ser Ile Gly His Gly Met Asp Leu1 5 1088518PRTHomo sapiens 885Ala Arg Glu Asn Asn Asn Ile Ala Leu Pro Tyr Tyr Tyr Tyr Gly Met1 5 10 15Asp Val88620PRTHomo sapiens 886Ala Arg Asp Ile Arg Tyr Thr Tyr Gly Pro Met Trp Gly Gly Asp Tyr1 5 10 15Gly Met Asp Val 2088719PRTHomo sapiens 887Ala Arg Arg Pro Pro Leu Leu Arg Ser His Asn Tyr Asn Tyr Leu Gly1 5 10 15Met Asp Val88820PRTHomo sapiens 888Ala Lys Ser Ser Gly Gly His Asn Trp Asn Tyr Val Asp Tyr Tyr Tyr1 5 10 15Gly Met Asp Val 2088910PRTHomo sapiens 889Ala Ser Thr His Leu Gly Gly Leu Asp Val1 5 1089011PRTHomo sapiens 890Ser Arg Ala Thr Asn Tyr Tyr Ala Leu Gly Tyr1 5 108919PRTHomo sapiens 891Ala Arg Asp Trp Pro Val Met Asp Val1 589213PRTHomo sapiens 892Ala Arg Val Val Gly Thr Thr Leu Tyr Ser Met Gly Tyr1 5 1089313PRTHomo sapiens 893Ala Arg Val Ala Ala Trp Tyr Ala Gly Ser Phe Asp Ser1 5 1089417PRTHomo sapiens 894Ala Lys Ala Gly Ala Tyr Cys Gly Gly Asp Cys Tyr Ser Tyr Leu Gln1 5 10 15Tyr8959PRTHomo sapiens 895Gln Gln Tyr Asn Asn Tyr Pro Trp Thr1 58969PRTHomo sapiens 896Gln Gln Tyr Asn Asn Trp Leu Ile Thr1 589710PRTHomo sapiens 897Gln Gln Tyr Tyr Thr Thr Pro Pro Trp Thr1 5 108989PRTHomo sapiens 898Gln Gln Tyr Tyr Thr Thr Pro Phe Thr1 589910PRTHomo sapiens 899Ser Ser Tyr Thr Ser Asp Asn Thr Arg Val1 5 1090010PRTHomo sapiens 900Cys Ser Tyr Ala Gly Ser Tyr Ser Trp Val1 5 109019PRTHomo sapiens 901Gln Gln Tyr Tyr Asp Tyr Pro Leu Thr1 590211PRTHomo sapiens 902Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val1 5 109039PRTHomo sapiens 903His Gln Tyr Asn Asn Trp Pro Leu Thr1 59049PRTHomo sapiens 904Gln Gln Arg Ile Asn Trp Pro Ile Thr1 59059PRTHomo sapiens 905Gln Gln Ser Tyr Ser Arg Pro Tyr Ser1 59069PRTHomo sapiens 906Gln Gln Tyr Asp Asn Val Pro Tyr Thr1 59079PRTHomo sapiens 907Gln Gln Tyr Asp Asn Ser Arg Phe Thr1 59088PRTHomo sapiens 908Met Gln Gly Ile His Leu Trp Thr1 59099PRTHomo sapiens 909Ser Ser Tyr Ala Gly Thr Ser Tyr Val1 591012PRTHomo sapiens 910Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Tyr Val1 5 109119PRTHomo sapiens 911Met Gln Ala Leu Gln Ile Pro Pro Thr1 59129PRTHomo sapiens 912Gln Gln Tyr Asn Ser Tyr Pro Pro Thr1 59139PRTHomo sapiens 913Gln Gln Ser Tyr Ser Thr Pro Tyr Ser1 59149PRTHomo sapiens 914Gln Gln Leu Asn Ser Tyr Pro Phe Thr1 59159PRTHomo sapiens 915Met Gln Ala Leu His Thr Pro Trp Thr1 591610PRTHomo sapiens 916Ser Ser Tyr Thr Arg Ser Ser Thr Val Val1 5 109179PRTHomo sapiens 917Gln Gln Arg Ser Asn Trp Pro Leu Thr1 591810PRTHomo sapiens 918Val Leu Tyr Val Gly Ala Ala Ile Ser Leu1 5 109199PRTHomo sapiens 919Gln Gln Ser Ser Asn Trp Pro Ile Thr1 59209PRTHomo sapiens 920Gln Gln Tyr Gly Gly Ser Pro Tyr Thr1 592110PRTHomo sapiens 921Gln Gln Tyr Gly Ser Ser Pro Leu Ile Thr1 5 109229PRTHomo sapiens 922Gln Gln Leu Asn Ser Tyr Pro Val Thr1 59239PRTHomo sapiens 923Met Gln Gly Thr His Trp Pro Leu Thr1 592410PRTHomo sapiens 924Ser Ser Tyr Thr Ser Ser Ala Thr Trp Val1 5 1092510PRTHomo sapiens 925Met Gln Gly Thr His Trp Pro Pro Trp Thr1 5 109268PRTHomo sapiens 926Gln Gln Tyr Tyr Asn Thr Trp Thr1 59279PRTHomo sapiens 927Ser Ser Tyr Thr Ser Thr Ser Ala Phe1 59289PRTHomo sapiens 928Gln Gln Tyr Gln Ser Asp Leu Phe Thr1 592919PRTHomo sapiens 929Ala Arg Leu Leu Ile Asp Tyr Thr Asn Tyr Lys Ser Val Ala Ser Ala1 5 10 15Phe Asp Ile93021PRTHomo sapiens 930Ala Ser Ser Pro Gly Tyr Asp Thr Arg Gly Tyr Tyr Ile Ala Gly Gln1 5 10 15Tyr Tyr Phe Val Asn 2093112PRTHomo sapiens 931Ala Arg Asp Gly Thr Ile Pro Gly Tyr Gly Asp Tyr1 5 1093216PRTHomo sapiens 932Ala Arg Met Pro Val Ala Ala His Tyr Phe Tyr Asp Gly Met Asp Val1 5 10 1593315PRTHomo sapiens 933Ala Lys Phe Pro His Arg Ser Thr Ser Trp Tyr Tyr Phe Asp Ser1 5 10 1593413PRTHomo sapiens 934Ala Arg Gly Leu Arg Val Glu Ile Pro Ile Phe Ala Tyr1 5 1093514PRTHomo sapiens 935Thr Arg Asp Thr Ile Val Gly Ala Thr Tyr Ala Phe Asp Ile1 5 1093619PRTHomo sapiens 936Ala Arg Glu Pro Asp Ser Ser Ser Trp Tyr Gln Asp Tyr Tyr Cys Ala1 5 10 15Met Asp Val93713PRTHomo sapiens 937Thr Arg Asp Leu Gly Asn Phe Ile Ala Tyr Met Asp Val1 5 1093824PRTHomo sapiens 938Ser Arg Gly Ser Tyr Tyr Tyr Asp Ser Arg Gly Tyr Tyr Phe Arg Pro1 5 10 15Pro Ser Ala Gly Pro Phe Asp Tyr 2093916PRTHomo sapiens 939Val Lys Ile Ala Val Gly Gly Ser Trp Ser Ser Glu Ala Leu Asp Tyr1 5 10 1594017PRTHomo sapiens 940Ala Arg Gly His Leu Val Gly Ala Thr Ser Tyr Tyr Tyr Gly Met Asp1 5 10 15Val94120PRTHomo sapiens 941Ala Arg Val Ser Leu Leu Trp Phe Gly Glu Leu Gly Ala Val Pro Tyr1 5 10 15Tyr Phe Asp Tyr 2094216PRTHomo sapiens 942Ala Arg Asp Arg His Arg Ala Gly Ala Leu Arg Tyr Gly Met Asp Val1 5 10 1594316PRTHomo sapiens 943Ala Lys Gly Gly Thr Ser Val Ala Ile Gly Trp Asn Trp Phe Asp Pro1 5 10 1594418PRTHomo sapiens 944Ala Arg Gly Tyr Arg Gly Asn Ile Leu Thr Gly Arg Leu Gly Tyr Phe1 5 10 15Asp Tyr94523PRTHomo sapiens 945Thr Thr Ala Gly Asn Tyr Tyr Asp Ser Arg Gly Tyr Tyr Phe Ser Arg1 5 10 15Pro Arg His Ser Phe Asp Tyr 2094619PRTHomo sapiens 946Ala Arg Ala Pro Gln Asn Tyr Tyr Gly Ser Gly Arg Tyr Tyr Ser Gly1 5 10 15Cys Asp Tyr94723PRTHomo sapiens 947Ala Arg Thr Ala Val Asp Arg Tyr Ser Ser Gly Trp Tyr Gly Glu Tyr1 5 10 15Tyr Tyr Tyr Ser Met Asp Val 2094821PRTHomo sapiens 948Ala Arg Arg Pro Leu Thr Ser Tyr Tyr Asp Ser Gly Ala Tyr Tyr Pro1 5 10 15Tyr Tyr Phe Asp Tyr 2094925PRTHomo sapiens 949Thr Arg Asp Thr Thr Tyr Phe Tyr Asp Asn Ser Gly Tyr Tyr Gly Trp1 5 10 15Ala Ser Lys Gly Gly Tyr Phe Asp Tyr 20 2595023PRTHomo sapiens 950Ala Arg Gln Pro Val Arg Gly Arg His Ser Ser Ser Gly Tyr Arg His1 5 10 15Tyr Tyr Tyr Gly Met Asp Val 2095123PRTHomo sapiens 951Ala Arg Val Glu Thr Tyr Asp His Val Trp Gly Ala Phe Arg Phe Gly1 5 10 15Glu Gly Gly Tyr Phe Asp His 2095221PRTHomo sapiens 952Ala Arg Gly Gly His Tyr Tyr Asp Ser Arg Gly Tyr Phe Thr Leu Ala1 5 10 15Gly Pro Ile Asp Tyr 2095311PRTHomo sapiens 953Gln Gln Tyr His Asn Trp Pro Pro Arg Leu Thr1 5 109548PRTHomo sapiens 954Gln Gln Tyr Asn Arg Tyr Val Ser1 595510PRTHomo sapiens 955Gln Gln Arg Ser Asn Trp Pro Pro Trp Thr1 5 109569PRTHomo sapiens 956Gln Gln Tyr Gly Ser Ser Pro Ile Thr1 595713PRTHomo sapiens 957Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Phe Tyr Val1 5 1095811PRTHomo sapiens 958Gln Gln Tyr Gly Gly Ser Pro Pro Arg Phe Thr1 5 109599PRTHomo sapiens 959Gln Gln His Tyr Ser Thr Pro Phe Thr1 596010PRTHomo sapiens 960Cys Ser Tyr Ala Gly Ser Arg Thr Arg Val1 5 1096111PRTHomo sapiens 961Ala Ser Trp Asp Asp Asn Leu Asn Ser Arg Val1 5 1096210PRTHomo sapiens 962Met Gln Gly Ile Ile Phe Pro Pro Ile Thr1 5 1096310PRTHomo sapiens 963Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val1 5 109649PRTHomo sapiens 964Gln Gln Leu Asn Ser Tyr Pro Glu Thr1 59659PRTHomo sapiens 965Leu Gln Val Asn Ser Tyr Pro Leu Thr1 596610PRTHomo sapiens 966Ser Ser Tyr Thr Thr Ser Thr Thr Val Ile1 5 1096711PRTHomo sapiens 967Cys Ser Tyr Gly Gly Thr Tyr Ser Pro Tyr Val1 5 109689PRTHomo sapiens 968Gln Gln Tyr Ala Lys Tyr Pro Leu Thr1 59699PRTHomo sapiens 969Gln Gln Tyr Ala Thr Ser Ser Leu Thr1 597011PRTHomo sapiens 970Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val1 5 1097111PRTHomo sapiens 971Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val1 5 1097210PRTHomo sapiens 972Gln Ser Phe Asp Ser Ser Asn Gln Glu Val1 5 1097312PRTHomo sapiens 973Gln Ser Tyr Asp Arg Ser Leu Ser Gly Ser Arg Val1 5 109749PRTHomo sapiens 974Gln Gln Phe Asn Ser Tyr Pro Gln Thr1 59757PRTHomo sapiens 975His His Tyr Asn Asn Trp Thr1 597610PRTHomo sapiens 976Gln Gln Tyr His Asp Trp Pro Leu Trp Thr1 5 1097748DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 977ctagtagcaa ctgcaaccgg tgtacattcc caggtgcagc tggtgcag 4897848DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 978ctagtagcaa ctgcaaccgg tgtacattcc gaggtgcagc tggtgcag 4897948DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 979ctagtagcaa ctgcaaccgg tgtacattcc caggttcagc tggtgcag 4898048DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 980ctagtagcaa ctgcaaccgg tgtacattcc caggtccagc tggtacag 4898148DNAArtificial

SequenceDescription of Artificial Sequence Synthetic primer 981ctagtagcaa ctgcaaccgg tgtacattct gaggtgcagc tggtggag 4898248DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 982ctagtagcaa ctgcaaccgg tgtacattct caggtgcagc tggtggag 4898348DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 983ctagtagcaa ctgcaaccgg tgtacattct gaggtgcagc tgttggag 4898448DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 984ctagtagcaa ctgcaaccgg tgtacattct caggtgcagc tggtggag 4898548DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 985ctagtagcaa ctgcaaccgg tgtacattct gaagtgcagc tggtggag 4898648DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 986ctagtagcaa ctgcaaccgg tgtacattcc caggtgcagc tgcaggag 4898750DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 987ctagtagcaa ctgcaaccgg tgtacattcc caggtgcagc tacagcagtg 5098848DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 988ctagtagcaa ctgcaaccgg tgtacattcc cagctgcagc tgcaggag 4898948DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 989ctagtagcaa ctgcaaccgg tgtacattcc caggtacagc tgcagcag 4899040DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 990ccgatgggcc cttggtcgac gctgaggaga cggtgaccag 4099142DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 991ccgatgggcc cttggtcgac gctgaagaga cggtgaccat tg 4299240DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 992ccgatgggcc cttggtcgac gctgaggaga cggtgaccag 4099341DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 993ccgatgggcc cttggtcgac gctgaggaga cggtgaccgt g 4199447DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 994gtagcaactg caaccggtgt acattctgac atccagatga cccagtc 4799548DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 995gtagcaactg caaccggtgt acattcagac atccagttga cccagtct 4899647DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 996gtagcaactg caaccggtgt acattgtgcc atccggatga cccagtc 4799747DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 997gtagcaactg caaccggtgt acatggggat attgtgatga cccagac 4799847DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 998gtagcaactg caaccggtgt acatggggat attgtgatga ctcagtc 4799947DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 999gtagcaactg caaccggtgt acatggggat gttgtgatga ctcagtc 47100047DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1000gtagcaactg caaccggtgt acattcagaa attgtgttga cacagtc 47100147DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1001gtagcaactg caaccggtgt acattcagaa atagtgatga cgcagtc 47100248DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1002gtagcaactg caaccggtgt acattcagaa attgtgttga cgcagtct 48100347DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1003gtagcaactg caaccggtgt acattcggac atcgtgatga cccagtc 47100446DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1004gaagacagat ggtgcagcca ccgtacgttt gatytccacc ttggtc 46100546DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1005gaagacagat ggtgcagcca ccgtacgttt gatctccagc ttggtc 46100646DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1006gaagacagat ggtgcagcca ccgtacgttt gatatccact ttggtc 46100746DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1007gaagacagat ggtgcagcca ccgtacgttt aatctccagt cgtgtc 46100848DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1008ctagtagcaa ctgcaaccgg ttcctgggcc cagtctgtgc tgackcag 48100948DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1009ctagtagcaa ctgcaaccgg ttcctgggcc cagtctgccc tgactcag 48101048DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1010ctagtagcaa ctgcaaccgg ttctgtgacc tcctatgagc tgacwcag 48101147DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1011ctagtagcaa ctgcaaccgg ttctctctcs cagcytgtgc tgactca 47101248DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1012ctagtagcaa ctgcaaccgg ttcttgggcc aattttatgc tgactcag 48101348DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1013ctagtagcaa ctgcaaccgg ttccaattcy cagrctgtgg tgacycag 48101437DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1014ggcttgaagc tcctcactcg agggygggaa cagagtg 37101528DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1015gttaagggat tttggacatg agattatc 28101628DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1016gataatctca tgtccaaaat cccttaac 28101723DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1017cttggttgag tactcaccag tca 23101820DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1018gaagactaca gcgtcgccag 20101923DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1019gttattgtct catgcgcgga tac 23102023DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1020gtatccgcgc atgagacaat aac 23102124DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1021cttcatgcaa ttgtcggtca agcc 24102223DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1022tgactggtga gtactcaacc aag 23102324DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1023aggagtcggg gcgaagaaga tcac 24102424DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1024gtgatcttct tcgccccgac tcct 24102524DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1025aggagtcggg gaggcgaaga tcac 24102624DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1026gtgatcttcg cctccccgac tcct 24102755DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1027acttggtcat gatactgctg attgccccgg catacagcat caggtgcata ggagt 55102853DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1028ttcgaaccgc ggctgggtcc tattaagcag agacagctgt ggataagaag atc 53102922DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1029cttgaccgac aattgcatga ag 22103044DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1030gtctttttcc gttggttgtt catagcctgc ttttttgtac aaac 44103144DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1031gtttgtacaa aaaagcaggc tatgaacaac caacggaaaa agac 44103250DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1032ttcgaaccgc ggctgggtcc tattacgcct gaaccatgac tcctaggtac 50103328DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1033caaagagtgg ttccatgaca tcccattg 28103428DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1034caatgggatg tcatggaacc actctttg 28103555DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1035acttggtcat gatactgctg attgccccgg catacagcat caggtgcata ggagt 55103653DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1036ttcgaaccgc ggctgggtcc tattaagcag agacagctgt ggataagaag atc 53103725DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1037tgaactcctg aggggaccgt cagtc 25103818DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1038ggtgctgggc acggtggg 18103921DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1039aacaaagccc gcccagcccc c 21104025DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1040ggagaccttg cacttgtact ccttg 25104121DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1041atgctccgtg ctgcatgagg c 21104218DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1042gagaagacgt tcccctgc 18104321DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1043gctctgcaca gccactacac g 21104420DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1044ctcatgcagc acggagcatg 20104555DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1045acttggtcat gatactgctg attgccccgg catacagcat caggtgcata ggagt 55104653DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1046ttcgaaccgc ggctgggtcc tattaagcag agacagctgt ggataagaag atc 53104728DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1047aggagtcggg gcggcgaaga tcacccac 28104828DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1048gtgggtgatc ttcgccgccc cgactcct 28104940DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1049ttgtcatagg agtcggggcg gcgaagatca cccaccactg 40105031DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1050cataggagtc ggggacaaga agatcaccca c 31105139DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1051gtcataggag tcggggagcg taagatcacc caccactgg 39105221DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1052acaaggagtg gttccatgac a 21105320DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1053ttttccgatg gtgctgccac 20105421DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1054gtatgcaggg acagatggac c 21105521DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1055accgcatctc gtttccttct t 21105621DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1056ggatgatcgt taatgacaca g 21105718DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1057accatcttcc caggcttg 18105821DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1058ggatcctgat ttgaaagctg c 21105920DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1059ttccacgaca ttccattacc 20106022DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 1060atctacgggg ggagtcagga tg 22106114PRTZika virus 1061Ile Val Ile Gly Val Gly Glu Lys Lys Ile Thr His His Trp1 5 10106214PRTZika virus 1062Ile Val Ile Gly Val Gly Asp Lys Lys Ile Thr His His Trp1 5 10106314PRTDengue virus 1 1063Ile Val Val Gly Ala Gly Glu Lys Ala Leu Lys Leu Ser Trp1 5 10106414PRTDengue virus 2 1064Ile Ile Ile Gly Val Glu Pro Gly Gln Leu Lys Leu Asn Trp1 5 10106514PRTDengue virus 3 1065Ile Val Ile Gly Ile Gly Asp Asn Ala Leu Lys Ile Asn Trp1 5 10106614PRTDengue virus 4 1066Ile Val Ile Gly Val Gly Asn Ser Ala Leu Thr Leu His Trp1 5 10106714PRTYellow fever virus 1067Ile Ile Val Gly Arg Gly Asp Ser Arg Leu Thr Tyr Gln Trp1 5 10106814PRTYellow fever virus 1068Ile Ile Val Gly Arg Gly Asp Ser Arg Leu Thr Tyr Gln Trp1 5 10106914PRTWest Nile virus 1069Ile Val Val Gly Arg Gly Glu Gln Gln Lys Asn His His Trp1 5 10107014PRTZika virus 1070Ile Val Ile Gly Val Gly Glu Arg Lys Ile Thr His His Trp1 5 10

Claims

1. An isolated or recombinant antibody comprising (Z021): a heavy chain comprising: a CDR1 comprising GGSIDTYY (SEQ ID NO:6), a CDR2 comprising FYYSVDN (SEQ ID NO:7), and a CDR3 comprising ARNQPGGRAFDY (SEQ ID NO:8) (a Z021 heavy chain); and a light chain comprising: a CDR1 comprising QSVSNY (SEQ ID NO:9), a CDR2 comprising DTS, and a CDR3 comprising QERNNWPLTWT (SEQ ID NO:10) (a Z021 light chain).

2. The antibody of claim 1 comprising at least one modification of its constant region, wherein the modification increases in vivo half-life of the antibody, or alters the ability of the antibody to bind to Fc receptors, or alters the ability of the antibody to cross placenta or to cross a blood-brain barrier or to cross a blood-testes barrier, or inhibits aggregation of the antibodies, or a combination of said modifications, or wherein the antibody is attached to a label or a substrate.

3. The antibody of claim 2, comprising the modification that increases in vivo half-life of the antibody.

4. The antibody of claim 2, comprising the modification that alters the ability of the antibody to bind to Fc receptors.

5. The antibody of claim 2, comprising the modification that increases in vivo half-life of the antibody and the modification that alters the ability of the antibody to bind to Fc receptors.

6. The antibody of claim 2, wherein the antibody is attached to the label or the substrate.

7. The antibody of claim 6, wherein the antibody is present in an enzyme-linked immunosorbent assay (ELISA) assay or an ELISA assay control.

8. The antibody of claim 7 wherein the ELISA assay is a direct ELISA assay, an indirect ELISA assay, a sandwich ELISA assay, or a competition ELISA assay.

9. The antibody of claim 1, wherein the heavy chain comprises the sequence of SEQ ID NO:13 and the light chain comprises the sequence of SEQ ID NO:14.

10. A method for prophylaxis or therapy of a viral infection comprising administering to an individual in need thereof an effective amount of the antibody of claim 1.

11. The method of claim 10, wherein the antibody comprises at least one modification of its constant region.

12. The method of claim 10, wherein the heavy chain comprises the sequence of SEQ ID NO:13 and the light chain comprises the sequence of SEQ ID NO:14.

13. The method of claim 10, wherein the individual is infected with or is at risk of being infected with a virus selected from the group consisting of Zika virus (ZIKV), dengue 1, 2, 3 or 4 viruses (DENV1-4), yellow fever virus (YFV), West Nile virus (WNV), or a combination thereof.

14. The method of claim 10, wherein at least two antibodies are administered, and wherein at least one of the antibodies comprises the Z021 antibody.

15. A polynucleotide encoding the heavy chain and the light chain of the antibody of claim 1.

16. The polynucleotide of claim 15, wherein the polynucleotide is in an expression vector.

17. The polynucleotide of claim 16, wherein the heavy chain comprises the sequence of SEQ ID NO:13 and the light chain comprises the sequence of SEQ ID NO:14.